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ABSTRACT
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder, 
characterised by progressive motoneuron degeneration in the spinal cord, motor cortex 
and brainstem. The pathogenic mechanisms underlying selective motoneuron 
degeneration are unclear and currently there is no effective treatment.
In this Thesis, strategies designed to prevent motoneuron degeneration are investigated 
in both in vivo and in vitro models of ALS. Furthermore, interaction between 
motoneurons and astrocytes is studied to examine the influence of astrocytes on disease 
progression.
In the SOD1G93a mouse model of ALS, the glial cell genotype influences the 
susceptibility of motoneurons to degeneration (Gong et al., 2000; Clement et al., 2003). 
In this Thesis, the effect of mutant SOD1 expression in astrocytes on motoneuron 
properties is examined in an in vitro co-culture system using confocal microscopy.
Cannabinoids exert anti-excitotoxic, anti-inflammatory and anti-oxidant actions, all of 
which may contribute to ALS pathogenesis. In these experiments, the potential 
neuroprotective effect of manipulating the endocannabinoid system is investigated in 
vivo in SOD 1093A mice. Augmentation of the endocannabinoid system, by 
pharmacological and genetic manipulation, ameliorates disease symptoms in SOD1G93a 
mice. Furthermore, genetic ablation of the CBi receptor significantly extends lifespan in 
SOD 1093A mice.
Finally, the effect of ablating the expression of mutant SOD1 protein in vitro in primary 
motoneurons using viral delivery of targeted small interfering RNA (siRNA) is
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assessed. The successful transfection and ablation of the mutant protein in vitro, as 
shown in this Thesis, has since been tested successfully in vivo.
The results of this Thesis show that manipulation of the endocannabinoid system and 
siRNA technology may be successful therapeutic approaches in ALS. The results also 
indicate that mutant SOD1 expression in astrocytes has a deleterious influence on 
mitochondrial function in motoneurons even under resting conditions. Therefore, 
specific targeting of astrocytes may also be an appropriate strategy to prevent 
motoneuron degeneration in ALS.
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CHAPTER 1
GENERAL INTRODUCTION
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In this Thesis, a series of experiments have been undertaken to investigate potential 
strategies to prevent the degeneration of motoneurons that occurs in diseases such as 
Amyotrophic Lateral Sclerosis (ALS). Therefore in the Introduction, the normal 
development of motoneurons, muscle fibres and the neuromuscular junction will be 
discussed to provide an understanding of the system that subsequently degenerates in 
ALS. Furthermore, the pathways by which motoneurons die and the pathological 
processes that are proposed to play a role in initiating the degeneration of motoneurons 
in ALS will also be discussed.
1.1. Development of the neuromuscular system
1.1.1. Motoneuron development
The vertebrate nervous system originates from the neural plate, which consists of a 
sheet of elongated neuroectodermal cells that form a group of multipotent proliferating 
progenitors. A thickening of the neural plate initiates folding and the subsequent fusion 
of the folds generates the neural tube (Briscoe & Ericson, 1999). The development of 
regional cell types in the neural tube occurs along both an anterior-posterior and dorsal- 
ventral axis. In the latter, the dorsal neurons are involved in the processing and relaying 
of sensory information and the ventrally located neurons are responsible for the co­
ordination and regulation of motor systems (Briscoe & Ericson, 1999).
In the ventral horn, neural progenitor cells are subdivided into five separate domains 
with defined locations, each of which differentiates into a separate neuronal subtype. 
The patterning of neuronal subtypes in the ventral horn occurs due to the secretion of 
Sonic Hedgehog (Shh) protein by the notochord and floor plate adjacent to the neural 
tube. This signal diffuses in a graded manner over a distance of several cell diameters 
and via specific concentration-dependent expression of different homeodomain
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transcription factors can establish segregated domains of neural progenitor cells in the 
ventral horn (Briscoe et al., 2000). The segregation of domains initiated in response to 
graded Shh signalling is further maintained by repressive interactions between the 
different classes of homeodomain proteins (Briscoe & Ericson, 2001). The distinct 
expression patterns of homeodomain proteins in progenitor cells will then activate 
neuronal subtype specific genes initiating the differentiation and development of each 
domain of progenitor cells into their appropriate post-mitotic neuronal subtypes. For 
example, the expression of motoneuron restricted 2 (MNR2) and homeobox 9 (HB9) 
homeodomain proteins, which induce post-mitotic motoneuron differentiation, is 
selective to the domain of progenitor cells destined to become somatic motoneurons and 
does not occur in neighbouring domains (Tanabe et al., 1998).
1.1.2. Motoneuron subtype specification
The graded signalling along the dorsal-ventral axis determines a single domain in which 
motoneurons are derived from progenitor cells. Differential signalling along the rostral- 
caudal axis however, classifies motoneurons according to their position in the spinal 
cord. Motoneurons are organised into distinct, longitudinally orientated columns 
depending on the target of their projected axons. Therefore, motoneurons innervating 
the limb musculature are arranged in the lateral motor column (LMC), whereas those 
innervating the axial musculature are arranged in the medial motor column (MMC; 
Price & Briscoe, 2004). Graded diffusion of fibroblast growth factor (FGF), produced 
by the paraxial mesoderm, regulates a rostrocaudal expression pattern of Hox-c 
homeodomain transcription factors in progenitor cells and post-mitotic motoneurons 
along the spinal cord (Dasen et al., 2003). This differential expression in motoneurons 
initiates subtype specific protein expression and determines their columnar and axon 
projectory fate (Dasen et al., 2003). Further subtype specification of LMC neurons into
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lateral and medial subtypes, innervating dorsally and ventrally derived limb muscles 
respectively, is dependent on a graded retinoid signalling cascade, regulating the 
expression of specific LIM homeodomain transcription factors in post-mitotic 
motoneurons (Sockanathan et al., 2003). A final level of columnar organisation is the 
grouping of motoneurons, innervating a single muscle, into motor pools. Although not 
yet fully defined, this organisation may be regulated by the differential expression of 
further homeodomain transcription factors, the ETS family (Lin et al., 1998; Price & 
Briscoe, 2004).
Motoneurons can be classified as either upper or lower motoneurons depending on their 
location in the CNS. Upper motoneurons are located in the motor cortex and synapse 
either directly or indirectly with lower motoneurons, which are located in the spinal 
cord. Lower motoneurons can be subdivided into somatic, innervating skeletal muscles, 
or autonomic, innervating cardiac and smooth muscles. Somatic motoneurons can be 
further classified as either a  or y motoneurons depending on the type of muscle fibre 
they innervate; a  motoneurons innervate the extrafusal muscle fibres, exerting muscle 
contraction and y motoneurons innervate the intrafusal fibres of the muscle spindle, 
controlling the stretch of the muscle. The a  motoneuron together with its axon and the 
muscle fibres it innervates constitutes a functional motor unit.
1.1.3. Skeletal muscle development
In vertebrates, skeletal muscles develop from muscle progenitor cells located in somites, 
which are formed from the segmentation of the paraxial mesoderm on either side of the 
neural tube. Somites are divided on a dorsal-ventral axis and it is the dorsal portion of 
the somite, the dermomyotome, in which the skeletal muscle progenitor cells are 
located. The dermomyotome is further divided along a medial-lateral axis, whereby
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muscle progenitors in the medial portion give rise to the deep back muscles and the 
remaining body musculature including the limbs, derives from progenitors located 
laterally. The dorsal-lateral and medial-lateral patterning of the somite, and therefore 
myogenesis, is regulated by signals from the neural tube and notochord, including Shh 
and Wnt proteins (reviewed in Christ & Brand-Saberi, 2002; Buckingham et al., 2003). 
Progenitor cells of the limb musculature detach from the epithelia of the lateral 
dermomyotome and migrate to the limb “buds”, a process regulated by transcription 
factor Pax3, where proliferation is ongoing (Epstein et al., 1996; Christ & Brand-Saberi, 
2002). The expression of muscle specific transcription factors such as MyoD and Myf5, 
induced by Shh and Wnt proteins in the dermomyotome, ensures muscle cell identity by 
inducing the cessation of proliferation and stimulating differentiation of muscle 
progenitors into committed myoblasts. Signals from the limb mesenchyme further 
contribute to the muscle patterning (Christ & Brand-Saberi, 2002).
In preparation for contractile activity, the metabolic activity of myoblasts increases 
(Schudt et al., 1975) and mononucleated myoblasts fuse to form multinucleated 
myotubes, in a calcium-dependent process (Holtzer et al., 1957). Subsequently, newly 
formed myotubes show an increase in expression of ion channels and incorporation of 
acetylcholine receptors (AChR) into the muscle membrane (Fambrough & Rash, 1971; 
Dryden et al., 1974; Gonoi et al., 1985; Gonoi & Hasegawa, 1988) that, with further 
development, form clusters independently of innervation (Peng et al., 1981). Contractile 
protein expression also increases (Allen & Pepe, 1965; Przybilski & Blumberg, 1966) 
and myotubes gain the ability to conduct electrogenic responses along the entire length 
of the fibre (Purves & Vrbova, 1974), with a corresponding increase in spontaneous 
contractions (Yaffe, 1969). At this stage in muscle development, there is evidence to 
suggest that primary myotubes can be characterised as either phasic (fast) or tonic
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(slow), indicating that early embryonic muscle patterning may occur independently of 
motoneuron innervation (Condon et al., 1990; Fredette & Landmesser, 1991). Further 
muscle development, including the formation of secondary myotubes, is however, 
dependent on functional motoneuron interaction (Ross et al., 1987; Wilson & Harris, 
1993).
1.1.4. Development of the neuromuscular junction
Motoneuron subtypes display distinct patterns of gene expression according to their 
position in the spinal cord, which ultimately determines their axonal projectories. 
However, cellular and extracellular matrix adhesion molecules and graded signalling of 
chemoattractants and chemorepellants can also influence axonal guidance (Colamarino 
& Tessa-Lavigne et al., 1995). Prior to contact with myotubes, spontaneous as well as 
evoked release of acetylcholine (ACh) from nerve terminals has been observed in vitro 
(Hume et al., 1983; Young & Poo, 1983). Consistent with these findings, expression of 
choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) increases in the 
axonal growth cone (Phelps et al., 1984). Myotube fusion occurs just at the time when 
motor axons are starting to make contact (embryonic day 12 in the mouse; Misgeld et 
al., 2002), accompanied by an up-regulation in AChR expression as previously 
described. Expression of AChE in myotubes is also elevated prior to the formation of 
the neuromuscular junction (Brzin et al., 1981).
1.1.4.1. Functional neurotransmission
Almost immediately upon contact between motor axons and myotubes synaptic 
transmission is initiated. Functional contact with myotubes induces an increase in the 
amplitude and frequency of spontaneous and evoked ACh release by the motor axon 
(Chow & Poo, 1985; Xie & Poo, 1986). This consequently induces the conductance of a
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larger current, the so-called endplate potential (EPP), by postsynaptic endplate channels, 
stimulating action potentials and subsequent muscle depolarisation. Accumulation of 
AChE at the synapse accompanies this elevation in ACh release, thereby providing a 
mechanism for the termination of transmitter action (Brzin et al., 1981). Initially the 
efficiency of transmission is low due to the lack of pre- and post-synaptic 
specialisations. Thus, the EPP has a slower rate of rise and smaller amplitude, compared 
to that generated at mature neuromuscular junctions, due to the low density of synaptic 
AChR and the limited release of ACh (Dennis et al., 1981; Takahashi et al., 1987).
1.1.4.2. Postsynaptic differentiation
The myonuclei at the postsynaptic endplate undergo transcriptional specialisation 
following innervation, including a secondary elevation in the expression of AChR, 
which subsequently cluster directly beneath the nerve terminal. Nerve-derived 
neuregulin initiates the localised up-regulation of AChR mRNA transcription, therefore 
ensuring a synapse specific effect (Martinou et al., 1991; Loeb & Fischbach, 1995). The 
synaptic clustering of AChR is subsequently induced by agrin, which is similarly 
synthesised and released by motoneurons and becomes incorporated into the basal 
lamina of the synaptic cleft (Nitkin et al., 1987). Activation of MuSK, the muscle- 
specific tyrosine kinase agrin receptor, recruits rapsyn, a MuSK effector protein, to the 
synapse, and this complex mediates the clustering and stabilisation of synaptic AChR 
(Anderson & Cohen, 1977; Gautam et al., 1995). Simultaneously, the degradation of 
‘extrajunctionaP AChRs is enhanced (Fambrough, 1979).
With further development, the postsynaptic membrane forms junctional folds, which lie 
directly across from the active zones in the nerve terminal, acting to optimise the action 
of neurotransmitters. Development of the postsynaptic membrane is accompanied by the
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replacement of the AChR y subunit by the s subunit, which confers a reduction in 
channel opening time (Merlie & Sanes, 1985), and further stabilisation of the AChR 
(Sanes & Lichtman, 1999). Maturation of the endplate is reflected by an increase in 
amplitude, frequency and size of EPPs, (Diamond & Miledi, 1962), accompanied by an 
elevation in ACh synthesis presynaptically (O’Brien & Vrbova, 1978). Therefore, with 
the specialisation of pre- (see below) and postsynaptic components and their increased 
integration, transmission efficiency at the synapse gradually improves.
1.1.4.3. Presynaptic differentiation
Differentiation of the presynaptic nerve terminal and the appearance of the active zone, 
is thought to be triggered by an elevation in intracellular calcium (Dai & Peng, 1993), 
mediated by an agrin-stimulated retrograde signal released from the muscle, possibly 
[32-laminin (Hoch, 2003). On myotube contact, the expression of synaptic vesicle 
proteins increases (Campagna et al., 1997) whereas expression of growth-associated 
proteins is down-regulated (Caroni & Becker, 1992). With the formation of active 
zones, synaptic vesicles and mitochondria accumulate at the terminal, at opposite poles 
(Sanes & Lichtman, 1999; Misgeld et al., 2002). Furthermore, the expression of 
voltage-gated calcium and potassium channels in the nerve terminal increases with 
development, to maximise calcium-dependent transmitter release (Funte & Haydon, 
1993; Robitaille et al., 1993). Target muscle contact is also required for the maturation 
of NMD A receptors located on motoneurons, elicited by a subunit change from NR2 to 
NR3B, to enable them to cope with more mature glutamatergic afferent inputs (Fukaya, 
2005).
40
1.1.4.4. Synapse elimination
Once innervation is established, successive axons follow the routes laid down by the 
initial pathfinder axons and each muscle fibre consequently becomes innervated by 
axons from several motoneurons. This ‘polyneuronal innervation’ is in contrast to the 
situation at the adult neuromuscular junction where each muscle fibre is innervated by a 
single motor axon, although each axon can branch to innervate many muscle fibres 
(reviewed in Gillingwater & Ribchester, 2003). Maturation of the neuromuscular 
junction involves the gradual elimination of synapses by retraction of axon branches and 
consequent reduction in the peripheral field of the motoneuron, rather than the death of 
motoneurons (Brown et al., 1976; Balice-Gordon & Thompson, 1988; Greensmith & 
Vrbova, 1996). The mechanisms mediating the preferential vulnerability of certain 
axons and therefore synapse elimination at the neuromuscular junction have not been 
fully elucidated. However, the correlation between the onset of synapse elimination and 
a general increase in locomotor activity, suggests that synaptic activity may play a role 
(Redfem, 1970). Indeed, experiments carried out to investigate the importance of 
neuromuscular activity to synapse elimination, demonstrate that paralysis of the target 
muscle delays synapse elimination (Duxson, 1982). In contrast, increasing 
neuromuscular activity via chronic stimulation of the nerve accelerates synapse 
elimination (O’Brien & Vrbova, 1978). More recently, it has been suggested that the 
synaptic efficacy of individual innervating axon branches is the determining factor 
underlying synapse elimination (Buffelli et al., 2003; Kasthuri et al., 2003). The 
efficacy of each axon branch is related to the amount of neurotransmitter released and 
therefore the ability of axons to excite postsynaptic muscle fibres. Therefore, amongst 
competing branches, the axon with the greatest efficacy will ‘outcompete’ weaker 
branches, which will subsequently detach from the neuromuscular junction and undergo 
protease-mediated degradation (Buffelli et al., 2003). A variety of possible proteases
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have been implicated in this process including cysteine proteases, for example calcium- 
activated neutral proteases (Connold et al., 1986; Tyc & Vrbova, 1995) and serine 
proteases such as thrombin (Zoubine et al., 1996).
1.1.4.5. Determination of motoneuron and muscle fibre phenotype
The elimination of polyneuronal innervation establishes the adult pattern of innervation, 
whereby each muscle fibre is innervated by a single axon terminal. The prevailing view 
is that the phenotype of each muscle fibre is subsequently determined by the activity of 
innervating motoneurons (Navarrete & Vrbova, 1984). Initially developing 
motoneurons are all tonically active with a low frequency of firing (Navarrete & 
Vrbova, 1983). However, during the first few weeks of postnatal development 
motoneurons differentiate, becoming either phasic, high frequency firing motor units 
(fast motoneurons) or remaining tonically active motor units but with an increased 
duration of low frequency firing (slow motoneurons). The firing pattern of motoneurons 
is determined by a combination of intrinsic electrophysiological properties and the 
descending and intemeuronal inputs onto motoneurons. Meanwhile the muscle fibres 
they innervate differentiate into fast (type II); either fast oxidative (type Ha) or fast 
glycolytic (type lib) depending on their oxidative capacity; and slow (type I) muscle 
fibres respectively (Navarrete & Vrbova, 1983). However, evidence also exists to 
suggest that muscle fibre phenotype may be predetermined to some extent, prior to 
innervation, and therefore mechanisms of target recognition may be involved in the 
guidance of motor axons to specific muscle fibre targets (reviewed in Sanes & 
Lichtman, 1999).
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1.1.4.6. Target dependence of motdoneurons
Once contact has been initiated, developing motoneurons and muscle fibres are highly 
dependent on functional interaction for their survival and maintenance. Interruption of 
this interaction at birth, for example by peripheral nerve injury, results in a loss of 
muscle function and the death of motoneurons (Romanes, 1946; Lowrie et al., 1987). 
However, this dependency declines rapidly during early postnatal development and 
following a similar injury in adults, no motoneurons die although some muscle force is 
still lost even after adult crush (Gutmann & Young, 1944). The functional dependence 
of motoneurons on their target during development may be related to neurotrophic 
support from muscles (Oppenheim, 1991). Alternatively, the critical period of 
motoneuron susceptibility to target withdrawal may represent their maturation from 
growing cells into target-independent fully transmitting neurons (as described in 
Chapter 1.1.4.3.; Greensmith & Vrbova, 1996). Therefore, in the absence of the target 
muscle this functional change may fail to occur, which will render motoneurons 
susceptible, for example to glutamate-induced cell death (Greensmith et al., 1994).
1.2. Motoneuron degeneration
Motoneuron degeneration occurs i) naturally during normal embryonic development as 
a consequence of programmed cell death, ii) pathologically, for example postnatally 
following injury, or as a consequence of normal aging and iii) during disease, for 
example in motoneuron diseases such as Amyotrophic Lateral Sclerosis. Motoneuron 
degeneration can occur via a number of mechanisms discussed in the following 
sections.
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1.2.1. Types of cell death
i) Apoptosis
Apoptosis, also known as programmed cell death, is a genetically controlled, ATP- 
dependent form of cell death characterised by an initial shrinkage of the cytoplasm and 
nucleus (pyknosis), chromatin condensation and blebbing of the plasma membrane. The 
cell then fragments into ‘apoptotic bodies’ that are phagocytosed by adjacent cells (Kerr 
et al., 1972; Wyllie et al., 1980). Depending on the initial ‘death’ signal, and cell type, 
apoptosis can proceed via two different, although interconnecting, pathways, as shown 
in Figure 1.1, either by ligation of ‘death’ receptors or activation of a mitochondria- 
dependent signalling pathway (Friedlander, 2003). Cell surface ‘death’ receptors 
include the p75NTR receptor, a member of the TNF family, or the Fas receptor, which 
initiates the activation of caspase 8 via the intermediary adaptor protein FADD. Caspase
8 subsequently activates caspase 3 as the final executioner in the cell death pathway.
The mitochondria-dependent pathway involves the translocation of pro-apoptotic 
molecules, Bax and Bid, to the mitochondria, which can stimulate the release and 
translocation of cytochrome c to the cytosol. Subsequently, cytochrome c can form an 
apoptosome by complexing with apoptosis activating factor-1 (Apaf-1) and procaspase
9 in an ATP-dependent manner, thus activating caspase 9 and initiating a cascade of 
protease activity resulting in apoptosis. The simultaneous release of Smac (second 
mitochondrial-derived activator of caspase)/Diablo from mitochondria potentiates this 
pathway by acting to inhibit endogenous caspase inhibitors (Friedlander et al., 2003). 
Permeabilisation of the outer mitochondrial membrane can be achieved by the Bax- 
induced formation of pores in the membrane (Eskes et al., 2000; Kuwana et al., 2002). 
Alternatively, opening of the mitochondrial permeability transition pore (mPTP),
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Figure 1.1 - Extrinsic receptor-mediated and intrinsic mitochondrial- 
dependent mechanisms of apoptotic cell death
EXTRINSIC
‘DEATH’RECEPTOR 
MEDIATED
e.g. Fas receptor
INTRINSIC 
DEATH STIMULUS
Bax
PLASMA
MEMBRANE
FADD
Caspase 8 activation
TRANSLOCATION
Cytochrome c
re ease
ATP
Smac/
Diablo
Caspase 3 
activation
Apoptosome 
formation 
(Cytochrome c - 
Apafl -  procaspase 9)
I
Apoptosis Endo- 
inducing nuclease 
factor G 
(AIF)
Inhibition 
of caspase 
inhibitors
i
Caspase 9 
activation
I
Caspase 3 
activation
Caspase -
independent
pathways
CELL DEATH
45
activated for example by high mitochondrial calcium and oxidative stress, will increase 
mitochondrial permeability and release cytochrome c to the cytosol, initiating apoptosis 
(reviewed in Duchen, 2004). There is evidence that these two mechanisms may be 
interrelated, as Bax can bind to the voltage dependent anion channel (VDAC) and 
adenine nucleotide transporter (ANT), which form part of the mPTP, and modulate their 
activity (Halestrap et al., 2002).
The main executors of cell death in both the extrinsic and intrinsic apoptotic pathways 
are the caspases, a family of cysteine-dependent, aspartate-specific proteases, present 
initially in the cell as inactive zymogens, procaspases, which once activated can cleave 
many cellular substrates and exert significant cellular damage (Guegan et al., 2003). 14 
caspases have been identified in mammals, which can be divided into two main groups: 
the initiator caspases and the effector caspases. The initiator caspases can be further 
subdivided according to their mechanism of activation, as shown in Figure 1.1, and 
their target: caspases 2, 8, 9 and 10 initiate apoptosis by activation of effector caspases, 
whereas caspases 1, 4, 5, 11, 12 and 13 are involved in cytokine maturation 
(Friedlander, 2003). Initiator caspases are activated by the binding of a regulatory 
molecule to a specific activation domain. In contrast, effector caspases (3, 6 and 7) 
require initiator caspase-mediated cleavage for their activation. Activation of effector 
caspases represents the final step in the apoptotic cascade, inducing degradation of 
cellular components and the fragmentation of DNA (Friedlander, 2003).
Caspase-independent apoptosis may be regulated by the release of apoptosis inducing 
factor (AIF) and endonuclease G from damaged mitochondria. Translocation of AIF to 
the nucleus may be involved in chromatin condensation, whereas endonuclease G is 
implicated in the nucleosomal fragmentation of DNA (Orrenius et al., 2003).
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ii) Necrosis
Necrosis, in contrast to apoptosis, is a passive form of cell death that occurs when cells 
are placed under extreme physiological stress. Necrosis is characterised by cellular 
oedema and swelling of organelles. Subsequently, chromatin condenses and the nucleus 
disintegrates. Ultimately, rupturing of the plasma membrane allows leakage of the 
cellular contents and the random degradation of nuclear DNA. Unlike apoptosis, 
necrotic cell death has a minimal ATP requirement and does not require protein 
synthesis. Instead, necrosis appears to be mediated by normal cellular mechanisms that, 
in response to altered homeostasis, mediate the degradation of cellular components and 
instigate cell death (Syntichaki & Tavemarakis, 2002, 2003).
It is now believed that the initial distinction between apoptosis and necrosis may have 
been an over-simplification. Indeed, another form of cell death, paraptosis has been 
described in which dying cells display characteristic features of both apoptosis and 
necrosis (Sperandio et al., 2000; Syntichaki & Tavemarakis, 2002). Furthermore, in 
response to different stimuli the same cells can undergo either apoptosis or necrosis. 
Therefore, the cellular decision to undergo apoptosis or necrosis appears to be 
dependent on the intensity of the insult and the energy state of the cell.
Various detrimental environmental factors or cellular mutations can trigger necrosis, by 
mediating alterations in ionic homeostasis, cellular acidification, oxidative stress and 
energy depletion (Syntichaki & Tavemarakis, 2003). Necrotic mediators include 
lysosomal and cytoplasmic proteases. The lysosomal membrane can be dismpted by 
either oxidative stress or by a family of calcium-activated cysteine proteases, the 
calpains. Cells have adapted to cope with an increase in intracellular concentrations of 
calcium, by sequestration in endoplasmic reticulum (ER) and mitochondria and
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extrudation via plasma membrane ATPases. However, calcium overloading, for 
example under excitotoxic conditions, can overwhelm the cellular buffering systems 
and activate calpains, which can rupture lysosomal membranes releasing numerous 
hydrolytic enzymes including cathespins. This combination of cellular proteases will 
consequently degrade cellular components, deplete energy and ultimately induce rapid 
necrotic cell death (Nicotera et al., 1999; Yamashima, 2000; Ferri & Kroemer, 2001).
1.2.2. Developmental motoneuron death
Programmed cell death (PCD) of motoneurons occurs at several distinct developmental 
stages, the timing and extent of which are tightly regulated (Oppenheim et al., 1991, 
1999). The reasoning behind the mass overproduction of motoneurons followed by their 
programmed death during development is unclear. The prevailing view is that PCD 
represents an important regulatory mechanism for the formation of optimally functional 
circuits by removing superfluous motor axons and matching the neuronal input to the 
target muscle size (Pettmann & Henderson, 1998). Motoneuron development is 
characterised by three distinct stages of PCD; i) during proliferation of precursor cells,
ii) at the onset of axon projection and iii) coincident with myotube innervation. Dying 
motoneurons display characteristic features of apoptotic morphology including 
organelle shrinkage and chromatin condensation. An increase in survival of 
motoneurons after caspase inhibition further implicates a role for caspases in PCD 
(Pettmann & Henderson, 1998).
The mechanisms that determine the selective degeneration of motoneurons in PCD, is 
however, not fully defined. The first two stages of PCD in the spinal cord are target- 
independent (Banks & Noakes, 2002). However, the PCD occurring coincidently with 
the onset of neuromuscular contact is under the influence of the target muscle, Schwann
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cells and potentially the motoneuron afferent inputs (reviewed in Oppenheim, 1991). 
Removal of the limb bud significantly enhances the developmental death of 
motoneurons (Hamburger, 1939), attributed to a dependence of motoneurons on a 
supply of survival-promoting neurotrophic factors from the target muscle. A limited 
supply of neurotrophins would initiate the PCD of unsupported motoneurons. However, 
it has subsequently been shown that motoneuron death is actually delayed by paralysis 
of the target muscle, which also increases target innervation (Oppenheim, 1987). Target 
muscle paralysis inhibits synaptic transmission and therefore the neuromuscular 
differentiation that occurs with development. Consequently, the inability of muscles to 
restrict the clustering of AChR, for example, enables the support of a greater number of 
motor axons. This suggests that competition between motoneurons for a limited number 
of target muscle contact sites may be the basis for PCD (Oppenheim, 1987). Upon 
innervation, motoneurons become dependent on their target muscles for differentiation 
and maturation into a fully transmitting neuron (as described in Chapter 1.1.4.6). 
Therefore, a lack of target contact may preserve motoneurons in a growth state and 
render them more vulnerable to apoptotic stimuli occurring in the maturing environment 
of the neuromuscular junction.
Potentially intrinsic properties of motoneurons may also increase the likelihood of their 
survival. Raoul et al, (2002) identified a cell death pathway specific to motoneurons that 
may be activated in PCD. Fas receptor-mediated activation of caspase 8 in combination 
with elevated nitric oxide (NO) production induces cell death specifically in 
motoneurons in culture. However, 50% of cultured motoneurons show resistance to Fas- 
mediated death following neurotrophin deprivation in vitro. Susceptible motoneurons 
up-regulate the Fas receptor ligand, FasL, whereas resistant motoneurons up-regulate an
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endogenous inhibitor of caspase 8 activation, implying intrinsic survival-promoting 
properties of subpopulations of motoneurons (Raoul et al., 1999).
1.2.3. Pathological motoneuron death - Amyotrophic Lateral Sclerosis
A number of neurodegenerative diseases are characterised by specific motoneuron 
degeneration, as listed in Table 1.1. Motoneuron degeneration is evident both in 
developmental and adult onset disorders. For example, spinal muscular atrophy (SMA), 
caused by mutations in the Survival of Motor Neuron 1 (SMN1) gene, is the most 
common genetic cause of infantile mortality. On the other hand, Kennedy’s disease, 
caused by a CAG repeat in the androgen receptor, manifests as late onset, progressive 
motoneuron degeneration, which affects predominantly males. However, the work in 
this Thesis focuses on Amyotrophic Lateral Sclerosis (ALS), which is characterised by 
a progressive loss of upper and lower motoneurons during the disease course (reviewed 
by Cleveland & Rothstein, 2001 and discussed in Chapter 1.3.). In transgenic mouse 
models of ALS, over 50% of motoneurons have died by disease end-stage (Kieran et al., 
2004; Sharp et al., 2005). Morphological identification of motoneurons as ‘apoptotic’ is 
complicated by the presumed low daily loss of motoneurons and the very transient 
detection period for apoptotic cells (Wyllie et al., 1980; Chiu et al., 1995). Furthermore, 
although some morphological characteristics of degenerating motoneurons in post­
mortem spinal cords of ALS patients are reminiscent of apoptosis, they cannot be 
definitely defined as apoptosis due to a lack of nuclear and chromatin condensation 
(Martin, 1999; Guegan et al., 2003). Therefore, alternative mechanisms of cell death, 
other than apoptosis, may also contribute to the death of motoneurons in ALS.
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Table 1.1 - Motoneuron diseases
Motoneuron disease Motoneurons affected
Amyotrophic Lateral Sclerosis Upper and lower motoneurons
Progressive Muscular Atrophy Lower motoneurons
Primary Lateral Sclerosis Upper motoneurons
Spinal Muscular Atrophy Lower motoneurons
Distal Hereditary Motor Neuropathy 
(Distal SMA)
Lower motoneurons
Hereditary Spastic Paraparesis Upper motoneurons
Spinal and Bulbar Muscular Atrophy 
(Kennedy’s Disease)
Lower motoneurons
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i) Evidence for apoptotic cell death in ALS
In approximately 20% of familial ALS cases, motoneuron degeneration occurs due to 
mutations in the Cu/Zn superoxide dismutase gene (SOD1; Rosen et al., 1993). In vitro, 
the expression of human mutant SOD1 in cell lines has been shown to induce apoptotic 
cell death (Rabizadeh et al., 1995; Durham et al., 1997; Cozzolino et al., 2005). 
Similarly, although rare, apoptotic motoneurons and glia have been identified in the 
spinal cord tissue from transgenic mutant SOD1 mouse models of ALS (a model of 
familial ALS in which the mutant human SOD1 gene is expressed, as described in more 
detail in Chapter 1.3.2.1; Pasinelli et al., 2000; Vukosavic et al., 2000). However, 
morphological studies of the motoneuron death that occurs in ALS are largely 
inconclusive. However, studies investigating the expression of molecular markers of 
apoptosis in post-mortem spinal cord tissue from ALS patients and from mutant SOD1 
mice have provided definitive evidence of an apoptotic involvement in ALS.
Coincident with the occurrence of mitochondrial defects in motoneurons in post-mortem 
spinal cord tissue from ALS patients and mutant SOD1 mice (described in detail in 
Chapter 1.3.4.3.), substantial evidence exists for the activation of the mitochondrial- 
dependent apoptotic cascade. Recently, an impaired association of cytochrome c with 
the inner mitochondrial membrane has been identified in the CNS of symptomatic 
SODlG93A mice, potentially increasing the susceptibility of mitochondria to apoptotic 
stimuli (Kirkinezos et al., 2005). Indeed, in early symptomatic S0D1G93A mice, 
cytosolic cytochrome c levels are elevated concurrently with reduced mitochondrial 
levels. Similarly, in post-mortem spinal cord tissue from sALS patients, the cytochrome 
c immunoreactivity in surviving motoneurons is diffusely distributed, indicating a 
cytosolic localisation (Guegan et al., 2001). Furthermore, the mitochondrial 
translocation of the pro-apoptotic molecule, Bax, and the expression of truncated Bid,
52
which potentiates the action of Bax, increase progressively during the disease course of
A
SOD1 mice. In fact, redistribution of Bax occurs just prior to the translocation of 
cytochrome c, perhaps serving as the initiating signal for permeabilisation of the outer 
mitochondrial membrane and release of cytochrome c (Guegan et al., 2001). Consistent 
with these findings, the expression of Bax mRNA is up-regulated and Bcl2 mRNA, an 
anti-apoptotic protein, is reduced in post-mortem spinal cord tissue from ALS patients 
(Martin, 1999). Interestingly, the anti-apoptotic function of Bcl-2 may be further down- 
regulated by its inclusion in mutant SOD 1-induced protein aggregates in spinal cord 
mitochondria that are found in post-mortem spinal cord tissue from ALS patients and in 
SOD 1093A mice (Pasinelli et al., 2004). Overexpression of Bcl-2 in SOD 1093A mice, 
however, significantly delays the degeneration of motoneurons, extending lifespan by 
approximately 15% (Kostic et al., 1997). Similarly, minocycline treatment, one action 
of which is to inhibit the release of cytochrome c, produces a 9% extension in lifespan 
(Zhu et al., 2002).
The functional significance of cytochrome c translocation to the cytosol is evident by an 
up-regulation in levels of the active initiator caspase 9 and a delayed increase in effector 
caspases 7 and 3 in symptomatic SOD 1093A mice, particularly in motoneurons (Guegan 
et al., 2001). Ablation of Apaf-1 in mutant SOD 1-expressing cell lines prevents the 
activation of caspase 3 and hence apoptosis, induced by mutant SOD1 (Cozzolino et al., 
2005). Activation of caspases 9 and 3 is also evident in motoneurons in post-mortem 
human ALS spinal cords (Martin, 1999; Inoue et al., 2003). In vitro, the expression of 
mutant SOD1 in N2a cells induces the activation of caspase 1, but only under conditions 
of oxidative stress (Pasinelli et al., 1998). In vivo, activation of caspase 1 occurs early in 
SOD 1093A mice, significantly preceding symptom onset, with sequential activation of 
caspase 3 occurring at the onset of symptoms in both motoneurons and glia (Pasinelli et
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al., 2000; Vukosavic et al., 2000). This suggests that caspase 1 may gradually induce 
cellular damage and on reaching a threshold activates caspase 3 as the final effector in 
the cell death pathway. The activation of caspase 1 is reflected by elevated levels of 
interleukin-lp in SODlG85R-expressing N2a cells (Pasinelli et al., 1998), which may 
subsequently initiate an inflammatory response. Indeed, a downstream consequence of 
caspase 1 activation may be microglial activation, which precedes symptom onset in 
mutant SOD1 mice (Hall et al., 1998; Weydt et al., 2004). Ablation of caspase 1 
significantly extends the lifespan of SOD1G93a mice, by 8% (Friedlander et al., 1997), 
whereas treatment of SOD1G93a mice with zVAD-fink, a broad-spectrum caspase 
inhibitor, produces a 22% extension in survival (Li et al., 2000).
Raoul et al, (2002) proposed the existence of a selective mechanism of apoptotic cell 
death for the induction of motoneuron degeneration. In primary motoneurons in culture, 
ligation of the death receptor, Fas, activates caspase 8 via binding of FADD adaptor 
protein. However, to induce cell death in cultured motoneurons, the simultaneous up- 
regulation of neuronal NOS transcription via a Daxx/ASK-l/p38 kinase-mediated 
pathway is also required. Caspase 8 activation in combination with peroxynitrite 
(derived from NO)-mediated cellular damage can induce the translocation of 
cytochrome c to the cytosol, the activation of caspase 3 and cell death (Raoul et al., 
2002). Mutant SOD 1-expressing motoneurons from mutant SOD1 mice show 
significantly greater susceptibility to NO-induced apoptotic death than that induced by 
excitotoxins or trophic factor deprivation (Raoul et al., 2002). The inflammatory 
processes known to occur in ALS, including microglial activation and reactive 
astrogliosis may therefore initiate apoptotic cell death via activation of this pathway. 
Interestingly, the activation of caspase 8 occurs near disease end-stage in SOD 1093A 
mice, suggesting this pathway may only be activated in the later stages of disease
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(Guegan et al., 2001). Further evidence for involvement of death receptors in 
motoneuron death in ALS comes from an elevation in expression of the p75NTR death
G93A.receptor in SOD1 mice and an increase in secretion of nerve growth factor, its 
endogenous ligand, by reactive astrocytes (Copray et al., 2003; Pehar et al., 2004).
ii) Evidence for necrotic cell death in ALS
The majority of degenerating motoneurons in transgenic mouse models of ALS have a 
non-apoptotic morphology, exhibiting swollen mitochondria, ER and golgi apparatus 
and condensed nuclei and cytoplasm (Dal Canto et al., 1995; Guegan et al., 2003). 
Indeed, a mechanism of necrotic death would be consistent with the excitotoxicity 
hypothesis of ALS. However, it is likely that a combination of both necrosis and 
apoptosis (and perhaps paraptosis) underlie motoneuron death in ALS.
1.3. Amyotrophic lateral sclerosis
1.3.1. Description of disease
Initially described in 1869 by French physician Jean-Martin Charcot, Amyotrophic 
Lateral Sclerosis (ALS) is the most common adult motoneuron disease in humans. ALS 
is characterized by a progressive degeneration of lower motoneurons in the spinal cord 
and brainstem, and large pyramidal neurons in the motor cortex and associated 
corticospinal tracts. The motoneurons of Onuf s nucleus, controlling pelvic floor 
musculature, and ocular motoneurons, controlling eye movement, are however, 
generally resistant in ALS. At an ultrastructural level, the neuropathology of 
degenerating motoneurons in ALS includes accumulations of intermediate filaments and 
ubiquitinylated intracellular aggregates in perikarya and proximal axons, abnormalities 
in mitochondrial structure and fragmentation of Golgi apparatus. Profound astrogliosis 
also accompanies motoneuron degeneration. Table 1.2 summarises the pathological
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Table 1.2 - Summary of the pathological features in human ALS
Disease stage Pathological changes Clinical manifestation References
Presenting
symptoms
Upper motoneuron 
degeneration
Muscle spasticity 
Hyperreflexia 
Extensor plantar 
reflexes
Rowland & 
Shneider, 2001
Lower motoneuron 
degeneration
Slurred speech 
Progressive decline in 
motor function and 
muscle wasting
Rowland & 
Shneider, 2001
Disease
progression
Upper motoneuron 
degeneration
Muscle spasticity 
Hyperreflexia 
Extensor plantar 
reflexes
Rowland & 
Shneider, 2001
Lower motoneuron 
degeneration
Muscle atrophy 
Fasciculation 
Muscle paralysis
Rowland & 
Shneider, 2001
Preservation of 
oculomotor neurons and 
neurons of the bladder
Rowland & 
Shneider, 2001
Degeneration of neurons 
in substantia nigra and 
dentate gyrus cells
Dementia Shaw, 2005
Death Degeneration of 
respiratory motoneurons
Respiratory difficulties Shaw, 2005
Degeneration of tongue 
and oesophageal muscles
Swallowing difficulties Rowland & 
Shneider, 2001
Post-mortem Significant degeneration 
of lower and upper 
motoneurons
Rowland & 
Shneider, 2001
Reactive gliosis Leigh & 
Swash, 1991
Mitochondrial
abnormalities
Borthwick et 
al., 1999
Fragmentation of golgi 
apparatus
Rowland & 
Shneider, 2001
Ubiquitinylated 
proteinaceous inclusions 
(Bunina bodies) in 
motoneuron soma
Leigh, 1991
Intermediate filament 
accumulations in 
motoneuron axons
Carpenter, 
1968; Hirano, 
1984
Loss of intemeurons in 
motor cortex and spinal 
cord
Cleveland & 
Rothstein, 
2001
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features of human ALS, which manifest either as clinical symptoms during disease 
progression or are observed in post-mortem tissue from ALS patients.
The worldwide incidence of ALS is on average 1-2 per 100,000, excluding high 
incidence foci, for example, Guam. Onset is normally within the fifth to sixth decade of 
life and clinical progression is variable, although generally limb weakness or slurred 
speech is the initial manifestation of disease. Degeneration of the large lower a  
motoneurons is reflected by a progressive decline in muscle function with 
accompanying muscle atrophy. Spasticity, hyperreflexia and extensor plantar reflexes 
are the clinical manifestations of upper motoneuron degeneration. Death ultimately 
occurs with the failure of respiratory muscles, often exacerbated by swallowing 
problems, on average 1-5 years after diagnosis.
ALS is a predominantly sporadic disorder (sporadic ALS; sALS), although 
approximately 10% of cases have a family history consistent with mendelian inheritance 
(familial ALS; fALS). Despite extensive research, the underlying pathogenic 
mechanisms of both sALS and fALS are still far from clearly understood, although it 
has been suggested that common pathogenic mechanisms are involved, as both forms 
are clinically indistinguishable. Therefore information gained from the study of fALS 
may be relevant to sALS pathogenesis (reviewed by Cleveland & Rothstein, 2001; 
Bruijn et al., 2004; Shaw, 2005).
1.3.2. fALS -  genetic linkage
i) ALSl/Cu/Zn superoxide dismutase (SOD1)
In 1993, mutations in the Cu/Zn superoxide dismutase (SOD1) enzyme, on chromosome 
21 q22.1, were identified in approximately 20% of fALS patients, (Deng et al., 1993;
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Rosen et al., 1993). The SOD1 enzyme is a ubiquitously expressed, predominantly 
cytoplasmic enzyme that acts as a cellular antioxidant by catalysing the conversion of 
superoxide radicals into hydrogen peroxide and water (Figure 1.2). The functional 
enzyme exists as a homodimer that requires copper and zinc binding for catalytic 
activity and stabilisation respectively (Shaw, 2005).
To date over 100 mutations have been identified in the SOD1 enzyme, which are 
scattered throughout the structure of the protein (www.alsod.org). Inheritance of ALS, 
induced by missense mutations in the SOD1 enzyme, is predominantly autosomal 
dominant with the exception of ALS induced by D90A, which can show recessive 
inheritance (Shaw, 2005). Initially, mutations in the SOD1 enzyme were suggested to 
reduce the dismutase activity and enhance oxidative stress, however, genetic ablation of 
endogenous SOD1 does not induce motoneuron disease in knock-out mice (Reaume et 
al., 1996). In contrast, transgenic mice expressing mutations in the human SOD1 
enzyme develop a motoneuron disease that resembles the human condition (Gurney et 
al., 1994; Ripps et al., 1995; Wong et al., 1995; Bruijn et al., 1997). Furthermore, 
neither expression of WT human SOD1 nor ablation of endogenous SOD1 affects
po cn
disease progression in SOD1 mice (Bruijn et al., 1998). Therefore, it is now widely 
recognised that the mutant SOD1 enzyme acquires a toxic gain of function, which is 
independent of activity levels (Borchelt et al., 1994; Dal Canto & Gurney, 1994; Ripps 
et al., 1995; Wong et al., 1995; Bruijn et al., 1997).
The generation of transgenic mice expressing mutations in the human SOD1 enzyme 
has provided an excellent research tool to investigate the pathogenesis of ALS. Indeed, 
mutant SOD1 mice demonstrate many of the pathological features seen in humans, 
including neurofilament inclusions, ubiquitinylated aggregates and selective
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Figure 1.2 -  The normal dismutase activity of the SOD1 enzyme
SOD1-Cu2+ + o 2' -------------- ►
SODl-Cu+ + O2 '  -------------- ►
SODl-Cu + 0 2
SOD1-Cu2+ + h 2o 2
Glutathione
peroxidase
Catalase
H20
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motoneuron loss (Gurney et al., 1994; Ripps et al., 1995; Wong et al., 1995; Bruijn et 
al., 1997). However, there are also limitations to the mutant SOD1 mouse model. For 
example, mutant SOD1 mice express mutant SOD1 at a level several fold higher than in 
ALS patients and as a consequence some mutant SOD1 mice express features that are 
not seen in spinal cord tissue from ALS patients, for example vacuolations (Bruijn et al.,
1997). Furthermore, the disease progression and severity is significantly influenced by 
the copy number of the transgene (Cleveland & Rothstein, 2001). Nevertheless, research 
using mutant SOD1 mice provides insight into the potential neurotoxic mechanisms that 
may contribute to ALS pathogenesis, as described in Chapter 1.3.4.
ii) ALS2/Alsin
The Als2 gene lies on chromosome 2q33 and was identified in 2001 as the causative 
gene for a slowly progressive, recessive form of juvenile ALS (Hadano et al., 2001; 
Yang et al., 2001). Two identified variants of the alsin protein are translated from 
alternative splicing of the Als2 gene, a long and short form (Hadano et al., 2001; Yang 
et al., 2001). Sequence analysis has revealed 3 putative guanine nucleotide exchange 
factor (GEF) domains of the alsin protein; RCC1 like domain, DH/PH domain and 
VPS9 domain, which can regulate the activity of small GTPases (Hadano et al., 2001; 
Yang et al., 2001). GTPases cycle between an inactive GDP bound state and an active 
GTP bound state and GEFs activate GTPases by stimulating GTP binding (Etienne- 
Manneville & Hall, 2002). In vitro, the VPS9 domain localises alsin on the cytoplasmic 
side of endosomal membranes (Otomo et al., 2003). Consistent with this finding, alsin 
acts as a functional GEF for Rab5 GTPase, which is involved in early endocytosis, and 
interacts directly with this GTPase through the VPS9 domain (Otomo et al., 2003; Topp 
et al., 2004). Alsin may also influence the organisation of the actin cytoskeleton due to 
GEF-mediated stimulation of Racl GTPase activity (Hall & Nobes, 2000).
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Nine different mutations from independent families have now been identified in the 
A Is 2 gene, which result in variable phenotypes that generally do not resemble typical 
ALS including juvenile ALS, juvenile primary lateral sclerosis and infantile-ascending 
hereditary spastic paralysis (Yang et al., 2001; Otomo et al., 2003). The position of each 
mutation is predicted to induce premature truncation of the ALS2 protein. In vitro 
expression of the predicted mutant proteins in cell lines results in an altered subcellular 
distribution and functional inactivation, potentially due to increased degradation (Otomo 
et al., 2003; Yamanaka et al., 2003). A loss of function may exert toxicity on 
motoneurons due to impaired membrane trafficking or alternatively it may interfere 
with motoneuronal development (Otomo et al., 2003; Tudor et al., 2005). However, the 
recent generation of an A Is2 knock-out mouse revealed no obvious motor phenotype, 
although motoneurons had an increased susceptibility to oxidative stress (Cai et al., 
2005). Interestingly, alsin can prevent mutant SOD 1-mediated toxicity in cell lines in 
vitro, although the physiological relevance of this direct interaction is still unclear 
(Kanekura et al., 2004).
iii) ALS4/sentaxin
Analysis of a large family with a rare early childhood/juvenile onset recessive form of 
slowly progressing ALS, mapped a genetic locus for ALS4 at chromosome 9q34 (Chen 
et al., 2004). The candidate gene was identified as sentaxin, a DNA/RNA helicase, 
thought to have a critical function in DNA repair and mRNA biogenesis (Chen et al., 
2004; Moreira et al., 2004). Potentially, missense mutations in sentaxin may render the 
helicase non-functional and impair the repair of mutated DNA/RNA, thus causing 
neuronal degeneration, although the reason for the underlying specificity for 
motoneurons remains unclear (Chen et al., 2004; Moreira et al., 2004).
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iv) ALS8/Vesicular Associated Membrane Protein (VAPB gene)
In 2004, an ALS locus was mapped at chromosome 20ql3.3 in a large Brazilian family 
with slowly progressive ALS, and was subsequently identified as the gene encoding 
vesicular associated membrane protein B (VAPB; Nishimura et al., 2004). A missense 
mutation has since been isolated in a highly conserved region of VAPB in the original 
family and six subsequent families. The presenting phenotype, from dominant 
inheritance of mutant VAPB, ranges from typical ALS to slowly progressive ALS or 
late-onset spinal muscular atrophy (Nishimura et al., 2004). Normally, VAPB is an 
intracellular membrane protein that has a critical function in cellular secretion and 
membrane transport (Soussan et al., 1999). However, the missense mutation in VAPB 
alters its subcellular distribution in vitro, inducing cytoplasmic aggregation and 
therefore disrupting normal VAPB function. The selective degeneration of motoneurons 
exposed to mutant VAPB may be related to critical threshold levels of VAPB required 
for intracellular trafficking (Nishimura et al., 2004).
v) Dynactin
Mutations in the gene encoding the pi 50 subunit of dynactin (DCTN1) on chromosome 
2pl3, have been discovered in families with a slowly progressing lower motoneuron 
disease. These mutations may affect the interaction of dynactin with both dynein and 
microtubules thus affecting axonal transport (Puls et al., 2003; Munch et al., 2004). 
Axonal transport deficits may have particularly serious consequences for motoneurons 
as some motoneuron axons can extend up to 1 metre in length (Shaw, 2005). In mutant 
SOD1 mice, deficits in axonal transport have been shown several months before 
symptom onset (Williamson & Cleveland, 1999).
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vi) Other genetic loci and genetic risk factors/modifiers
Another candidate gene for ALS is the angiogenin gene mapped to chromosome 
14ql 1.2 (Greenway et al., 2004). Other loci have been mapped to chromosome 9q21- 
22, 15ql5.1-21.1, 16ql2, 18q21 and 20ptel-pl3, although the candidate genes have not 
yet been identified (for review see Shaw, 2005). Finally, several genes proposed to be 
risk factors in SALS or modifier genes in fALS are summarised in Table 1.3.
1.3.3. ALS -  a non-cell autonomous disorder
1.3.3.1. Involvement of astrocytes in ALS
The degeneration of upper and lower motoneurons in ALS is accompanied by profound 
astrocytosis (Hirano, 1996; Schiffer et al., 1996; Hall et al., 1998). Reactive astrocytes 
assume a hypertrophic morphology that is associated with an increase in expression of 
glial fibrillary acidic protein (GFAP). Astrocyte activation is often accompanied by an 
up- regulation in production of cytokines, growth factors, matrix proteins, cell adhesion 
molecules, proteases and protease inhibitors (Ridet et al., 1997; John et al., 2003; 
Barbeito et al., 2004). In post-mortem spinal cord tissue from ALS patients, astrogliosis 
surrounds lower and upper motoneurons and can be found in the degenerating 
corticospinal tracts (Hirano, 1996; Schiffer et al., 1996). Furthermore, in ALS patients, 
the expression of the astrocyte transporter protein EAAT-2 is reduced in post-mortem 
spinal cord tissue, in association with a reduction in glutamate transport and an 
elevation in CSF glutamate levels, which indicates functional astrocyte deficits 
(Rothstein et al., 1991, 1992, 1995; Spreux-Varoquaux et al., 2002). Mutations in 
EAAT-2, as found in one sALS patient with a reduction in glutamate uptake capacity, 
may therefore represent a risk factor for the development of ALS (Trotti et al., 2002), 
although this may only have relevance for a small proportion of patients as in two large 
studies of familial and sporadic ALS patients no linkage has been found (Aoki et al.,
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Table 1.3 -  Potential genetic risk factors/modifiers in ALS
Proposed Risk
Factor/Modifier
Gene
Genetic loci Function Genetic
alteration
References
NF-H 22ql2.1-
ql3.1
Neuronal
intermediate
filament
KSP
deletion/insertion
Figlewicz et al., 
1994; Tomkins et 
al., 1998; Al 
Chalabi et al., 1999
NF-L 15pl2 Neuronal
intermediate
filament
Deletion Bergeron et al., 
1994
Peripherin 12ql2-ql3 Neuronal
intermediate
filament
Deletion Gros-Louis et al., 
2004
VEGF 6pl2 Growth factor Single nucleotide 
polymorphisms in 
promoter
Lambrechts et al., 
2003
CNTF 1 lql2.2 Growth factor Loss of function 
mutation
Giess et al., 2002
EAAT2 Ilpl3-pl2 Astroglial
glutamate
transporter
Reduced
expression
Trotti et al., 2001
AMPA receptor 
subunit GluR2
4q32-q33 Regulates
calcium
permeability of
AMPA/KA
receptors
Aberrant editing at 
Q/R site
Kawahara et al., 
2004
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1998; Jackson et al., 1999). In mutant SOD1 mice, reactive astrogliosis is evident from 
disease onset and increases steadily during disease progression (Hall et al., 1998; Levine 
et al., 1999; Alexianu et al., 2001; Elliott et al., 2001). Inclusions in astrocytes are one 
of the earliest pathological features seen in S0D1G85R mice, occurring before the 
appearance of symptoms, and are accompanied by reductions in GLT-1 expression by 
disease end-stage (Bruijn et al., 1997a). Therefore, alterations in non-neuronal cell 
functions are likely to contribute to ALS pathogenesis.
Astrocytes were once considered to be passive supporting cells, the ‘nerve glue’ 
(Virchow, 1958). However, there is now substantial evidence to suggest that astrocytes 
also provide metabolic and trophic support to neurons. Furthermore, evidence of 
bidirectional communication between neurons and astrocytes and their close spatial 
association indicates that astrocytes form an integral component of the synapse in that 
they act to modulate both neuronal activity and synaptic transmission (reviewed in 
Vemadakis, 1996; Kirchoff et al., 2001; described in more detail in Chapter 3.1.2.), 
However, considering the extensive functional interaction and close spatial association 
which is maintained between reactive astrocytes and degenerating motoneurons in 
SOD1G93a mice (Levine et al., 1999), it is perhaps not surprising that degenerative 
changes in astrocytes are seen in ALS. Indeed, the appearance of reactive astrocytosis 
coincident with symptom onset in mutant SOD1 mice suggests that the activation of 
astrocytes in ALS occurs in response to neuronal degeneration, as a significant 
proportion of motoneurons have already been lost by this disease stage (Chiu et al., 
1995; Levine et al., 1999; Sharp et al., 2005). Activation of astrocytes in ALS may 
occur as a consequence of the release of pro-inflammatory cytokines and free radicals 
from motoneurons and microglial cells (reviewed in Barbeito et al., 2004). Rao et al, 
(2003) suggested that reactive oxygen species (ROS) generated by damaged
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motoneurons could be released to exert oxidative damage on surrounding astrocytes. 
Indeed, peroxynitrite exposure is found to induce a phenotypic change that renders 
cultured astrocytes toxic to motoneurons (Cassina et al., 2002). However, although 
astrocytosis may occur secondarily to neuronal damage, there is increasing evidence to 
suggest that once activated, astrocytes may actively participate in the process of 
neuronal degeneration (Levine et al., 1999).
Evidence emerging from the study of transgenic mice supports the possibility that ALS, 
although a motoneuron-specific disorder, is not cell-autonomous. Expression of 
SOD1 under the control of the GFAP promoter produces significant astrocytosis in 
transgenic mice, although to a lesser extent than in S0D1G86R mice in which mutant 
SOD1 is ubiquitously expressed. Furthermore, the large motoneurons in the ventral horn 
display no significant morphological changes and do not undergo degeneration in these 
mice, therefore suggesting that mutant SOD 1-expressing astrocytes alone do not 
mediate disease (Gong et al., 2000). However, selective neuronal expression of 
SOD1 , using a NF-L chain promoter, similarly does not induce motoneuron 
degeneration in transgenic mice (Pramatarova et al., 2001), and a selective 2-fold 
elevation of mutant SOD 1093A expression in postnatal motoneurons also does not 
influence disease progression (Lino et al., 2002). This suggests that interaction between 
mutant SOD 1-expressing neurons and mutant SOD 1-expressing astrocytes is necessary 
for the development of ALS. Indeed, in an in vitro co-culture model, the expression of 
mutant SOD1 in both neuroblastoma and glioblastoma cells is necessary to induce 
neuronal apoptosis (Ferri et al., 2004). In 2003, the generation of chimeric mice with 
varying expression of mutant and endogenous SOD1 (WT) in motoneurons and non­
neuronal cells, further clarified the importance of the non-neuronal environment to 
disease progression (Clement et al., 2003). In these mice, the presence of WT non­
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neuronal cells significantly protects mutant SOD1 motoneurons from degeneration, 
whereas an environment of mutant SOD 1-expressing non-neuronal cells induces 
formation of ubiquitinylated intracellular aggregates in WT motoneurons (Clement et 
al., 2003). These results therefore provide definitive evidence that glial cells make a 
significant contribution to ALS pathogenesis.
1.3.4. Disease pathogenesis
Extensive research on mutant SOD1 mice in combination with analysis of post-mortem 
tissue from ALS patients has given some insight into several potentially neurotoxic 
mechanisms that may be involved in ALS pathogenesis. These mechanisms are 
discussed in detail in the following sections. These mechanisms may apply to the 
pathogenesis of both sALS and fALS, as evidence for their involvement exists in both 
forms of the disease.
1.3.4.1. Oxidative stress
Under normal conditions, superoxide radicals produced by cells are rendered harmless 
by conversion into water and hydrogen peroxide by the activity of the SOD1 enzyme, as 
shown in Figure 1.2. However, following the discovery that the mutant SOD1 enzyme 
acquires a toxic gain of function, it was proposed that alterations in structural 
conformation induce an aberrant protein chemistry. Improper folding of the mutant 
SOD1 protein may reduce the selectivity of the active site, allowing interaction with 
abnormal substrates, for example peroxynitrite, with subsequent nitration of tyrosine 
residues. Alternatively, the access of hydrogen peroxide to the active site will generate 
highly reactive hydroxyl radicals that can oxidise essential cellular components 
(Beckman et al., 1993; Wiedau-Pazos., et al., 1996; Figure 1.3).
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Figure 1.3 -  Proposed aberrant chemistry of the mutant SOD1 enzyme
a) Nitration of tyrosine
SOD1-Cu2+ +ONOO -------------- ►
SODl-CuO N 02+ + Tyr -----►
b) Generation of hydroxyl radicals
SOD1-Cu2+ + h 2o 2 -------------- ►
SODl-Cu+ + H20 2  ►
SODl-CuO N 02+
SOD1-Cu2+ + OH' + N 02-Tyr
SODl-Cu+ + 0 2’ + 2H+ 
SOD1-Cu2+ + OH + OH'
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An alternative hypothesis suggests that mutations in SOD1 alter the binding of copper 
or zinc ions to the enzyme. Crow et al, (1997) demonstrated that mutations in SOD1 
reduced the affinity of the enzyme for zinc by up to 30-fold in vitro. In the absence of 
zinc, the active copper atom could become reduced and catalyse the normal dismutase 
reaction in reverse, thus generating superoxide radicals. Subsequent reaction between 
superoxide and nitric oxide generates peroxynitrite, which can damage cellular 
components via tyrosine nitration (Estevez et al., 1999). Indeed, depletion of zinc from 
mutant SOD1 induces NO and copper-dependent toxicity in cultured motoneurons 
(Estevez et al., 1999). The susceptibility of motoneurons may be related to their high 
neurofilament content, which can compete with mutant SOD1 for zinc loading (Estevez 
et al., 1999).
The contribution of copper-induced toxicity in mutant SOD 1-mediated ALS is 
controversial. In mammals, the cellular copper concentration is low (Rae et al., 1999) 
and copper is loaded into SOD1 via a copper chaperone (CCS) protein (Wong et al.,
2000). However, ablation of CCS in mutant SOD1 mice does not affect disease 
progression despite a significant reduction in copper loading of mutant SOD1 
(Subramaniam et al., 2002). The possibility exists that the residual, CCS-independent 
copper loading of the mutant SOD1 enzyme may be sufficient to exert mutant SOD1- 
mediated toxicity in this model (Subramaniam et al., 2002). Subsequent ablation of the 
copper binding site of mutant SOD1, however, does not affect disease progression in 
mutant SOD1 mice, which suggests that copper-mediated toxicity does not significantly 
contribute to ALS pathogenesis (Wang et al., 2003). Furthermore, many mutations do 
not reduce the affinity of mutant SOD1 for zinc in transgenic mice in vivo, therefore 
zinc deficient SOD 1-mediated toxicity may not be physiologically relevant (Williamson 
et al., 2000). The downstream contribution of NO and peroxynitrite has also been
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further examined by eliminating either neuronal or inducible NOS from mutant SOD1 
mice, neither of which altered disease progression (Facchinetti et al., 1999; Son et al.,
2001). In contrast, however, treatment of mutant SOD1 mice with copper chelators does 
exert significantly beneficial effects (Hottinger et al., 1997).
In post-mortem spinal cord tissue from sALS and fALS patients, levels of 3- 
nitrotyrosine are elevated in motoneurons (Abe et al., 1997; Beal et al., 1997; Ferrante 
et al., 1997). Similarly, in mutant SOD1 mice, free 3-nitrotyrosine immunoreactivity 
and markers of lipid peroxidation are elevated from a presymptomatic stage (Bruijn et 
al., 1997a; Hall et al., 1998). Furthermore, evidence from mutant SOD1 mice suggests 
that oxidative damage occurs to both mitochondria (Mattiazzi et al., 2002) as well as 
GLT-1 glutamate transporter proteins (Trotti et al., 1999; Vanoni et al., 2004). In 
contrast, there is no evidence of protein bound nitrotyrosine in either mutant SOD1 mice 
or post-mortem tissue from ALS patients (Bruijn et al., 1997b). Similarly no increase in 
hydroxyl radical production can be detected in SOD 1G37R mice (Bruijn et al., 1997a). 
Therefore, the mechanism by which mutant SOD1 induces oxidative stress is 
controversial, although there is cellular evidence for oxidative damage. Furthermore, 
involvement of oxidative stress in both sALS and fALS suggests a common mechanism 
of motoneuron pathology.
I.3.4.2. Glutamate excitotoxicity
Glutamate is the most abundant excitatory neurotransmitter in the CNS (Heath & Shaw,
2002). However, there is substantial evidence to suggest that overactivation of 
glutamate receptors can induce neuronal damage, a process termed ‘excitotoxicity’. 
Elevated extracellular glutamate, either due to an increase in release or reduction in 
uptake, can activate calcium-permeable glutamate receptors on the postsynaptic cell,
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thus enhancing calcium influx. Excessive postsynaptic calcium can activate neurotoxic 
cascades, including the activation of calpains, endonucleases and phospholipases, 
ultimately leading to neuronal death (Choi, 1992).
Motoneurons receive glutamatergic inputs from the descending corticospinal tracts, 
from collaterals of the Aa fibres innervating muscle fibres and Golgi tendon organs and 
from excitatory intemeurons in the spinal cord (Heath and Shaw, 2002). Therefore 
abnormalities in glutamate neurotransmission may conceivably contribute to 
motoneuron degeneration in ALS. Indeed, an elevation in CSF glutamate levels occurs 
in approximately 40% of sALS patients (Rothstein et al., 1991; Spreux-Varoquaux et 
al., 2002) and transcranial magnetic stimulation studies in ALS patients reveal that 
cortical motoneurons are hyperexcitable (Zanette et al., 2002). Furthermore, an increase 
in firing frequency and reduction in action potential duration in embryonic SOD 1093A 
motoneurons in vitro is also indicative of an increase in excitability (Pieri et al., 2003; 
Kuo et al., 2004).
I.3.4.2.I. Glutamate uptake transporter, GLT-1
In most CNS regions, glutamate uptake by the astroglial glutamate transporter, GLT-1 
(EAAT-2) predominates (Tanaka et al., 1997). Therefore, any reduction in normal 
expression of this transporter may result in an elevation in extracellular glutamate and 
consequently may induce excitotoxicity. In 60-70% of sALS patients, there are 
reductions in EEAT-2 protein expression and glutamate transport in post-mortem tissue 
from the spinal cord and motor cortex (Rothstein et al., 1992, 1995). A mutation in 
EAAT-2 has also been identified in a sALS patient, with an associated reduction in 
glutamate uptake (Trotti et al., 2001). Similarly, glutamate uptake is diminished in 
symptomatic mutant SOD1 mice, which corresponds to reductions in GLT-1 expression
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(Bruijn et al., 1997a; Bendotti et al., 2001; Canton et al., 2001). Selective inhibition of 
the GLT-1 transporter protein in mice initiates a progressive paralysis in vivo (Rothstein 
et al., 1996). Furthermore, in organotypic spinal cord cultures, chronic inhibition of 
glutamate transport induces selective motoneuron degeneration (Rothstein et al., 1993), 
whereas restoration of GLT-1 activity either by pharmacological enhancement 
(Rothstein et al., 2005) or by the introduction of glial progenitor cells overexpressing 
GLT-1, significantly increases motoneuron survival in this model (Maragakis et al., 
2005).
Oxidative damage to GLT-1 transporter proteins and subsequent protein internalisation 
can disrupt glutamate uptake and reduce GLT-1 expression (Trotti et al., 1999; Vanoni 
et al., 2004). Indeed, peroxynitrite exerts a dose-dependent inhibition of glutamate 
transporter activity in reconstituted liposomes (Trotti et al., 1996). Similarly co­
expression of GLT-1 with mutant SOD1 in Xenopus oocytes inhibits glutamate 
transport (Trotti et al., 1999). Oxidative damage to glial glutamate transporters may be 
mediated by free radicals generated in and transferred from motoneurons in response to 
glutamate. Consequent inhibition of astroglial glutamate transport would therefore 
elevate extracellular glutamate and amplify any damage (Rao et al., 2003). Potentially, 
however, a loss of neuronal regulation of glutamate transporter expression, due to 
motoneuron loss in ALS, may also explain the down-regulation of GLT-1 (Swanson et 
al., 1997).
I.3.4.2.2. Calcium permeable AMPA/KA receptors
Glutamate excitotoxicity may be mediated through the activation of ionotropic, N- 
methyl-D-aspartate (NMDA) receptors and a-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA)/kainate (KA) receptors, and metabotropic glutamate receptors
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(reviewed in Heath & Shaw, 2002). Motoneurons are believed to be more susceptible to 
AMPA/KA receptor-mediated neurodegeneration (Rothstein et al., 1993; Vandenberghe 
et al., 1998; van den Bosch & Robberecht, 2000; van den Bosch et al., 2000). Indeed, 
activation of AMPA/KA receptors induces selective degeneration of cultured 
motoneurons in vitro (Rothstein et al., 1993; Carriedo et al., 1996) and in mice in vivo 
(Ikonomidou et al., 1996), an effect that is inhibited by selective AMPA/KA receptor 
antagonists (Vandenberghe et al., 1998; van den Bosch & Robberecht, 2000; van den 
Bosch et al., 2000, 2002; Van Damme et al., 2003). Furthermore, treatment of mutant 
SOD1 mice with AMPA/KA receptor antagonists significantly extends lifespan (Canton 
et al., 2001; Van Damme et al., 2003).
AMPA receptors mediate fast neurotransmission and are composed of 4 different 
subunits, GluRl-4, which confer different functional characteristics (Hollmann & 
Heinemann, 1994). The absence of the GluR2 subunit renders the receptor calcium 
permeable (Hollmann & Heinemann, 1994). The majority of studies indicate that 
motoneurons express GluR2-containing AMPA receptors (Morrison et al., 1998; Bar 
Peled et al., 1999; Vandenberghe et al., 2000a, 2000b; van den Bosch et al., 2000; Laslo 
et al., 2001; Heath et al., 2002), although there is evidence for the colocalisation of 
GluR2-containing and GluR2-lacking AMPA receptors on the same motoneurons 
(Vandenberghe et al., 2001). Recently, however, defective GluR2 editing, which would 
render the receptor calcium permeable, has been found selectively in motoneurons in 
post-mortem spinal cord tissue from ALS patients (Kawahara et al., 2004). The 
selective vulnerability of motoneurons may however, also be related to a higher density 
of calcium-permeable AMPA receptors which will result in an increase in agonist- 
induced calcium influx into these neurons (Carriedo et al., 1996; Vandenberghe et al., 
2000b; van den Bosch et al., 2000, 2002; Van Damme et al., 2003). Furthermore,
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following elevations in intracellular calcium, cultured motoneurons exhibit an increase 
in mitochondrial calcium buffering and free radical generation, which may inflict 
accumulative mitochondrial damage in comparison with other calcium-permeable 
AMPA/KA receptor expressing neurons (Carriedo et al., 2000).
Interestingly, reducing the calcium permeability of AMPA/KA receptors by crossing 
mice overexpressing the GluR2 subunit with SOD 1093A mice, significantly delays 
symptom onset and extends the lifespan of SOD1G93a mice by 14.3% (Tateno et al.,
2004). In contrast, an acceleration in disease course and shortening of lifespan is seen in 
SOD1 mice following either a 2-fold increase in calcium permeability or total 
ablation of the GluR2 subunit (Kuner et al., 2005; Van Damme et al., 2005). However, 
there is no motoneuron loss in GluR2 knock-out mice, suggesting that the absence of 
the GluR2 subunit alone is not sufficient to induce ALS (Jia et al., 1996).
I.3.4.2.3. Expression of calcium binding proteins
In addition to mitochondrial uptake, intracellular calcium can be buffered by calcium 
binding proteins. Electrophysiological studies in brain slices from WT mice, however, 
have demonstrated a lower calcium binding capacity in specific motoneuron populations 
vulnerable to degeneration in ALS, in contrast to those less vulnerable motoneuron 
populations such as oculomotor neurons and motoneurons of Onuf s nucleus (Lips et 
al., 1999; Vanselow et al., 2000). Furthermore, the calcium binding proteins, 
parvalbumin and calbindin-D28K, are not expressed in ‘vulnerable’ motoneurons, but 
are present in motoneurons less affected in ALS (Ince et al., 1993; Alexianu et al., 1994; 
Elliott & Snider, 1995). Motoneurons with a low expression of calcium binding proteins 
may therefore have to depend to a greater extent on mitochondrial calcium uptake in 
order to buffer excess calcium, and this may render their mitochondria more susceptible
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to damage. Indeed, as described in Chapter 1.3.4.3., mitochondrial abnormalities are a 
common pathological feature of ALS. In support of the proposal that a decrease in 
calcium buffering capacity contributes to the selective vulnerability of motoneurons in 
ALS, it has been found that overexpression of parvalbumin protects motoneurons in 
vitro against KA-induced calcium influx (van den Bosch et al., 2002), and protects 
neonatal motoneurons from injury-induced motoneuron death in parvalbumin 
overexpressing transgenic mice (Dekkers et al., 2003). Furthermore, the survival of 
SODlG93A mice crossed with parvalbumin overexpressing transgenic mice is also 
extended (Beers et al., 2001).
I.3.4.2.4. Riluzole
The role of excitotoxicity in ALS pathogenesis is demonstrated by the finding that 
treatment with the anti-glutamatergic agent Riluzole extends the lifespan of ALS 
patients. Indeed, Riluzole is the only therapy currently licensed for treatment of ALS 
patients. Riluzole acts to inhibit the presynaptic release of glutamate and may also 
modulate NMDA receptor activity (Doble et al., 1996). However, Riluzole only extends 
patients lifespan by 2 - 4 months (Bensimon et al., 1994; Miller et al., 2002; Traynor et 
al., 2003). In SOD1G93a mice, treatment with riluzole also delays disease onset and 
extends survival (Gurney et al., 1998). However, treatment combining riluzole with 
minocycline, a microglial inhibitor, plus nimodipine, a blocker of voltage-gated calcium 
channels, exerts significantly greater beneficial effects in mutant SOD1 mice on disease 
progression and lifespan than is achieved individually with these agents (Kriz et al.,
2003). This finding therefore supports a multifactorial ALS pathogenesis and highlights 
the benefits of targeting multiple pathways in the design of a suitable therapy.
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1.3.4.3. Normal mitochondrial function
Alterations in mitochondrial structure and function may be a critical factor contributing 
to ALS pathogenesis. Considering the critical role that mitochondria play in cellular 
physiology, it is not surprising that defects in mitochondrial function can result in 
disease. The primary function of mitochondria is to provide cellular ATP, although 
mitochondria also play significant roles in cellular calcium signalling and apoptotic cell 
death pathways. These functions are described in brief below (Sections I.3.4.3.I. -
1.3.4.3.3.).
I.3.4.3.I. Chemiosmotic theory -  the indirect coupling of electron transfer to ATP 
production
The primary function of mitochondria is to generate ATP and therefore provide cellular 
energy. In this process, acetyl coenzyme A, derived from respiratory substrates, is 
metabolised to carbon dioxide in the tricarboxylic acid cycle (TCA cycle). This also 
produces electrons that reduce NAD+ and FAD to provide reducing equivalents for the 
supply of electrons to complex I (NADH dehydrogenase) and II (succinate 
dehydrogenase) of the electron transport chain respectively. Electrons are transferred 
from complexes I and II to ubisemiquinone and then to complex III (ubiquinol 
cytochrome c reductase), which is covalently bonded to ubisemiquinone. Electrons are 
finally shuttled between complex III and IV (cytochrome c oxidase) and combine with 
two protons and oxygen to form water. The redox potential of each electron acceptor is 
greater than the previous acceptor in the chain. The transfer of electrons between 
complexes therefore generates a free energy that is proportional to the difference in 
redox potential between the acceptors. This energy is used by complexes I, III and IV to 
pump protons from the matrix to the intermembrane space. This consequently 
establishes an electrochemical potential gradient that consists of a mitochondrial
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membrane potential, approximately 150mV to 200mV negative to the cytosol, and a pH 
gradient between the cytosol and matrix (0.5 to 1.0 pH units). The coupling of electron 
transfer with proton translocation forms the basis of chemiosmotic theory.
The electrochemical proton gradient provides the driving force for the influx of protons 
through the F1F0 ATP synthase, a proton translocating ATPase, which is driven 
backwards by the proton gradient. Proton influx stimulates the phosphorylation of ADP 
to ATP. ATP is subsequently released from mitochondria via the ANT. Dissipation of 
the mitochondrial membrane potential may stimulate the ATPase to run in reverse, 
hydrolysing ATP and potentially depleting cellular energy.
I.3.4.3.2. Cellular calcium signalling
Another important role of mitochondria is the modulation of intracellular calcium 
signalling. In response to the elevation of cytoplasmic calcium above a certain ‘set 
point’ (Nicholls & Crompton, 1980), mitochondria will accumulate calcium. Under 
physiological conditions, mitochondrial calcium influx may provide a mechanism to 
couple cellular activity with ATP generation, since calcium up-regulates 3 rate limiting 
enzymes of the TCA cycle; pyruvate dehydrogenase, isocitrate dehydrogenase and 2- 
oxoglutarate dehydrogenase. Furthermore, it has been suggested that mitochondria are 
closely apposed to endoplasmic reticulum (ER) calcium release sites (Rizzuto et al.,
1998). Therefore following release of calcium from ER, mitochondria are exposed to 
high local calcium concentrations therefore stimulating uptake, which can modulate 
cellular calcium signalling. However, calcium overloading of mitochondria is also 
widely implicated in mechanisms of neuronal death (reviewed in Duchen, 2004).
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1.3.4.3.3. Apoptosis
In addition to the vital role that mitochondria play in ATP generation, they are also 
critical mediators in the initiation of apoptotic cell death. Release of cytochrome c from 
the intermembrane space and its translocation to the cytosol stimulates the activation of 
caspase 9 and subsequently initiates apoptosis, as described in Chapter 1.2.1.i. 
Furthermore, Smac/Diablo protein is also located in the intermembrane space and upon 
release acts to inhibit cellular inhibitors of apoptosis, therefore inducing PCD. Other 
intermembrane space proteins may include the pro-apoptotic molecules procaspase 9 
and AIF (Duchen, 2004). Permeability of the outer mitochondrial membrane can be 
achieved by translocation of Bax to mitochondria, which forms a pore in the membrane 
(Kuwana et al., 2002). Alternatively, opening of the mitochondrial permeability 
transition pore increases mitochondrial permeability and can induce the release of pro- 
apoptotic molecules (Zamzami et al., 1996).
1.3.4.3.4. Mitochondrial abnormalities in ALS
Irregularities in mitochondrial structure, including dilated cristae and mitochondrial 
swelling, are found in post-mortem spinal cord tissue from sporadic and familial ALS 
patients (Hirano et al., 1984; Fujita et al., 1996; Sasaki & Iwata, 1996; Siklos et al., 
1996). In mutant SOD1 mice, abnormalities in mitochondrial structure occur before the 
appearance of symptoms, and in SODlG93A and SODlG37R mice, symptom onset 
correlates with the appearance of membrane-bound vacuoles that derive from 
degenerating mitochondria (Dal Canto & Gurney, 1994; Wong et al., 1995; Kong & Xu 
et al., 1998; Bendotti et al., 2001; Jaarsma et al., 2001). These observations suggest that 
mitochondria may represent a primary target for mutant SOD 1-mediated damage and 
furthermore that in ALS, mitochondrial damage may be the trigger for motoneuron 
degeneration.
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Consistent with abnormalities in structure, alterations in mitochondrial function are also 
evident in ALS. Reductions in the activity of complexes I and IV in the electron 
transport chain are found in affected post-mortem tissue from sALS patients, 
symptomatic SOD1 mice and a SOD1 -expressing motoneuronal cell line (Fujita 
et al., 1996; Swerdlow et al., 1998; Weidemann et al., 1998; Borthwick et al., 1999; 
Vielhaber et al., 2000; Jung et al., 2002; Mattiazzi et al., 2002; Menzies et al., 2002b; 
Fukada et al., 2004). Evidence also suggests that mutant SOD1 mitochondria, isolated 
from spinal cords of SOD1 mice, have a lower maximal respiratory rate and 
reduced ATP generation (Mattiazzi et al., 2002). Moreover, under resting conditions the 
mitochondrial calcium buffering capacity of SOD1 motoneurons is impaired with a 
subsequent increase in cytosolic calcium levels (Carri et al., 1997; Swerdlow et al., 
1998; Kruman et al., 1999). Together with reductions in mitochondrial membrane 
potential and elevations in mitochondrial free radical production, this suggests that 
mitochondrial function is compromised in mutant SOD 1-expressing motoneurons (Carri 
et al., 1997; Kruman et al., 1999; Rizzardini et al., 2005). Interestingly, following 
chronic treatment with malonate, a complex II inhibitor that induces mitochondrial 
inhibition and eventually ATP depletion, motoneurons in organotypic cultures are 
selectively vulnerable compared to intemeurons (Kaal et al., 2000).
One source of superoxide production is the electron transport chain and the localised 
production of superoxide radicals therefore renders mitochondria highly susceptible to 
oxidative damage. Indeed, mitochondria from spinal cords of SOD1G93a mice show a 
significant increase in markers of protein and lipid oxidative damage (Mattiazzi et al.,
2002). Interestingly, although predominantly cytosolic, 1-5% of the SOD1 enzyme 
exists in both the mitochondrial intermembrane space (Okado-Matsumoto & Fridovich, 
2001; Sturtz et al., 2001; Higgins et al., 2002; Mattiazzi et al., 2002) and the matrix
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(Vijayvergiya et al., 2005), thus providing a mechanism by which mutant SOD1 in 
fALS can directly inflict damage on mitochondria. Moreover, selective targeting of 
mutant SOD1 to mitochondria rather than the cytoplasm, nucleus or endoplasmic 
reticulum was found to be essential for mutant SOD 1-induced toxicity in culture 
(Takeuchi et al., 2002). It has subsequently been shown that association of mutant 
SOD1 with mitochondria only occurs in the spinal cord in mutant SOD1 mice (Liu et 
al., 2004; Pasinelli et al., 2004; Vijayvergiya et al., 2005). This association prompts the 
formation of aggregates in mitochondria, which suggests that mutant SOD1 may exert 
mitochondrial damage by directly altering the function of mitochondrial proteins (Liu et 
al., 2004; Vijayvergiya et al., 2005). Indeed, it has been shown that Bcl2 is sequestered 
in such aggregates, therefore potentially reducing its anti-apoptotic function (Pasinelli et 
al., 2004).
Independently of mutant SOD1 involvement, mitochondrial calcium buffering may have 
a more significant role in motoneurons due to their low expression of calcium binding 
proteins, as discussed in Chapter 13.4.23.. Indeed, following AMPA/KA receptor 
activation and calcium influx, cultured motoneurons exhibit an increase in 
mitochondrial calcium buffering in comparison with other calcium permeable 
AMPA/KA receptor expressing neurons (Carriedo et al., 2000; Rao et al., 2003). An 
elevation in mitochondrial calcium uptake can subsequently stimulate free radical 
generation (Dykens, 1994; Castilho et al., 1995; Dugan et al., 1995) and therefore inflict 
mitochondrial damage. Indeed, a greater incidence of point mutations in mitochondrial 
DNA (mtDNA) is found in motoneurons in post-mortem spinal cord tissue from sALS 
patients (Wiedemann et al., 2002). Consistent with these findings, expression of sALS 
mtDNA in mtDNA-depleted neuroblastoma cells, replicates the ultrastructural changes 
in mitochondria seen in ALS patients (Swerdlow et al., 1998). Accumulated damage to
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mitochondria can then further increase the susceptibility of motoneurons to glutamate 
excitotoxicity (Kruman et al., 1999; Kanki et al., 2004).
Mitochondrial dysfunction will have serious cellular consequences due to their role in 
ATP generation as well as their calcium buffering functions. In addition, disruption of 
structure and function may initiate apoptosis. Interestingly, the association of 
cytochrome c with the inner mitochondrial membrane is impaired in mitochondria from 
the CNS of symptomatic SOD1 mice, perhaps due to accumulative damage, thereby
increasing the vulnerability of mitochondria to apoptotic stimuli (Kirkinezos et al.,
2005). Therapies that aim to protect mitochondria may therefore exert significant 
protection in ALS. Indeed, administration of creatine, which improves mitochondrial 
energy buffering, significantly delays disease progression and extends the lifespan of 
SOD 1093A mice by 17% (Klivenyi et al., 1999), whereas a 9% extension is seen after 
treatment with minocycline, one action of which is to inhibit the release of cytochrome 
c from mitochondria (Zhu et al., 2002).
1.3.4.4. Altered axonal transport
One of the pathological hallmarks of ALS is the presence of abnormal accumulations of 
intermediate filaments (IF) in the perikarya and axons of motoneurons from post­
mortem human tissue and mutant SOD1 mice (Carpenter, 1968; Hirano et al., 1996; Tu 
et al., 1996). These accumulations consist predominantly of neurofilaments and 
peripherin (Corbo & Hays, 1992; Migheli et al., 1993; Tu et al., 1996), and suggest that 
defects in axonal transport may contribute to ALS pathogenesis.
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1.3.4.4.1. Cytoskeletal abnormalities
i) Neurofilaments
Neurofilaments are the most abundant structural protein in large calibre axons including 
motoneurons and are involved in determining axonal calibre and maintaining axonal 
transport and structure. There are three neurofilament subunits: heavy (NF-H; 115kD), 
medium (NF-M; 95kD) and light (NF-L; 68kD), which are synthesised in the cell body 
and then co-assemble into neurofilament polymers. Similar to other structural proteins, 
neurofilaments are transported down the axon by slow anterograde transport and 
undergo progressive phosphorylation (Zhang et al., 1997).
However, the presence of neurofilament accumulations in degenerating motoneurons in 
post-mortem spinal cord tissue of both sALS and fALS patients and in mutant SOD1 
mice, suggests that slow anterograde transport may be defective in ALS. In addition, the 
formation of accumulations in proximal axons may act to hinder axonal transport 
further, therefore depriving the motoneurons of vital components necessary for normal 
cellular function (Collard et al., 1995; Zhang et al., 1997). Additionally these 
accumulations may also sequester organelles (Tu et al., 1997). In SOD1G93a mice the 
presence of accumulations correlates with symptom onset and increases during disease 
progression (Tu et al., 1996). Therefore, neurofilament accumulations may have a 
causal role in ALS. In fact it is suggested that the selective vulnerability of motoneurons 
in ALS is related to their high neurofilament content (Kawamura et al., 1981; Bruijn et 
al., 1997a). Underlying genetic alterations in neurofilament subunits may also 
contribute to their accumulation, by interfering with neurofilament assembly and 
increasing their propensity to aggregate, therefore representing a risk factor for ALS. 
Indeed, approximately 1% of ALS patients have missense mutations in the tail domain 
of the NF-H subunit (Figelwicz et al., 1994; Tomkins et al., 1998; Al Chalabi et al.,
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1999). Furthermore, a 60% reduction in levels of NF-L mRNA has been reported in 
ALS patients (Bergeron et al., 1994).
Interestingly, overexpression of either the human NF-L or NF-H subunits in WT mice 
induces an accumulation of neurofilaments in motoneurons, with accompanying 
motoneuron and skeletal muscle dysfunction (Cote et al., 1993; Xu et al., 1993). 
Disruption of neurofilament polymerisation by overexpression of the NF-L subunit 
carrying a point mutation similarly induces the formation of neurofilament aggregates 
and selective motoneuron degeneration in WT mice, similar to that seen in ALS (Lee et 
al., 1994). This therefore suggests that accumulations of neurofilaments, by 
neurofilament dysregulation, are sufficient to induce motoneuron dysfunction in ALS.
Ablation of the NF-L subunit in SODlG85R mice delays disease onset and extends 
lifespan by 15%, thus supporting the proposal that neurofilament accumulations are 
toxic (Williamson et al., 1998). However, perhaps surprisingly, the expression of a NF- 
H p galactosidase fusion protein, which acts by trapping neurofilaments in the cell body 
and preventing their transport into the axon, has no effect on disease progression in 
SODlG37R mice (Eyer et al., 1998). Even more surprising, overexpression of NF-H 
actually induces a 65% extension in the lifespan of SOD1 mice (Couillard-Despres 
et al., 1998). Consistent with these findings, a delay in disease progression is seen in 
SOD 1093A mice following overexpression of NF-H or NF-L subunits (Kong & Xu,
2000). Beneficial effects are also observed in S0D1G37R mice overexpressing NF-L 
(Couillard-Despres et al., 2000). Despite the apparently contradictory results achieved 
in mutant SOD1 mice, in each model the perikaryal accumulation of neurofilaments is 
increased, and it has been suggested that these accumulations in the perikarya rather 
than in axons are responsible for the protective effect seen. There is a correlation
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between axonal neurofilament content and the speed of axonal transport (Marszalek et 
al., 1996), therefore the protection mediated by perikaryal accumulation may be 
attributed to a reduction in axonal neurofilament content. This may relieve the burden 
on axonal transport, defects in which occur before disease onset in SODlG37R mice, 
thereby preventing ‘axonal strangulation’ (Williamson & Cleveland, 1999). 
Alternatively, the presence of multiple calcium binding sites and phosphorylation sites 
on neurofilaments suggests that perikaryal accumulations may buffer excess calcium or 
dysregulated kinase activity, such as the inappropriate activation of cyclin-dependent 
kinase 5 that occurs in SODlG37R mice (Nguyen et al., 2001). Recently however it has 
been shown that disease progression is significantly delayed and lifespan extended in 
SODlG37R mice in which the tail domain of NF-H and/or NF-M have been genetically 
replaced. These benefits are observed despite increased tau phosphorylation, which 
suggests that the restoration of axonal transport underlies the protective effects of 
neurofilament inclusions (Lobsiger et al., 2005).
ii) Peripherin
Peripherin, a 57kD intermediate filament, is expressed at low levels in motoneurons, 
although, expression is increased following neuronal injury (Troy et al., 1990) or in 
response to inflammatory cytokines (Stemeck et al., 1996). Indeed, in post-mortem 
spinal cord tissue from ALS patients and in spinal cord motoneurons in SOD1 mice 
the expression of peripherin is up-regulated (Robertson et al., 2003), and forms a 
component of the majority of IF accumulations seen (Migheli et al., 1993; Tu et al., 
1996). In WT mice, overexpression of peripherin induces the formation of toxic IF 
inclusions and selective motoneuron degeneration. This is enhanced by NF-L deficiency 
(Beaulieu et al., 1999), a situation that may occur in ALS patients (Bergeron et al., 
1994). Motoneuron death may therefore occur as a result of the association of peripherin
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with NF-M or NF-H subunits and the subsequent formation of toxic aggregates 
(Beaulieu et al., 1999), a mechanism that may be relevant in ALS. More recently, a 
toxic splice variant of peripherin, known to induce motoneuron death has been 
identified in motoneurons in post-mortem spinal cord tissue from ALS patients 
(Robertson et al., 2001, 2003). Furthermore, a truncation mutation in the peripherin 
gene, which disrupts the IF network, has been identified in a small proportion of ALS 
patients, which may represent a risk factor (Gros-Louis et al., 2004). However, 
contradictory to this toxic role of peripherin, neither overexpression nor ablation of 
peripherin affects disease progression or lifespan in SODlG37R mice, which suggests 
that abnormal peripherin expression and its accumulation may not actually influence 
ALS pathogenesis (Lariviere et al., 2003).
I.3.4.4.2. Altered axonal transport
The maintenance of efficient axonal transport is critical for motoneurons. Many 
motoneurons have extremely long axons, up to 1 metre in length, which places an 
enormous metabolic and structural demand on the cell. There are two main components 
of anterograde transport: fast transport mediated by kinesin motors, responsible for the 
movement of vesicles and mitochondria, and slow transport, mediated by dynein motors 
(Wagner et al., 2004), for the movement of the major structural proteins including 
neurofilaments (slow component a; 0.5mm/day), tubulin and actin (slow component b; 
l-2mm/day; Hoffman & Lasek, 1975, 1980). Motoneurons also rely on dynein- 
mediated retrograde transport for the provision of organelles and ligands such as 
neurotrophins from the neuromuscular junction to the cell body (Goldstein & Yang, 
2000).
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Defects in axonal transport are one of the earliest abnormalities seen in mutant SOD1 
mouse models of ALS (as discussed in Chapter 13.4.4.l.i). The appearance of 
neurofilament accumulations in degenerating motoneurons in ALS may be indicative of 
defects in slow anterograde transport, and may also act to further hinder axonal 
transport (Collard et al., 1995; Zhang et al., 1997). In support of this possibility, slow 
anterograde transport, particularly of tubulin, is reduced in SODlG37R and SODlG85R 
mice, several months before the onset of symptoms (Williamson & Cleveland, 1999). 
The discovery that the S0D1G37R enzyme is anterogradely transported in slow 
component b, suggests that the mutant enzyme may exert a direct toxic effect during its 
own transport (Borchelt et al., 1998). Significant reductions in fast anterograde transport 
have also been shown in proximal axons in post-mortem human ALS tissue (Sasaki & 
Iwata, 1996) and reductions in both fast and slow anterograde transport are also seen in 
symptomatic SOD1G93a mice (Collard et al., 1995; Zhang et al., 1997; Warita et al.,
1999). Furthermore, reductions in retrograde transport have recently been identified as 
early in motoneuron development as E l3, in motoneurons cultured from SOD 1093A 
mice (Kieran et al., 2005). Microarray technology on sALS post-mortem spinal cord 
tissue similarly revealed a reduction in dynactin expression at disease end-stage (Jiang 
et al., 2005).
Various transgenic mice have been generated to study the consequences of defective 
axonal transport on motoneuron function. Homozygous expression of a missense 
mutation in the dynein heavy chain (DNCHC1) gene in transgenic mice (Legs at odd 
angles; Loa) significantly reduces the rate of axonal transport in motoneurons and 
reduces motoneuron survival (Hafezparast et al., 2003). Similarly, targeted disruption of 
the dynein:dynactin complex by postnatal overexpression of the dynamitin (p50) 
subunit of dynactin in transgenic mice, induces a late-onset progressive motoneuron
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degeneration (LaMonte et al., 2002). Dynactin is a multiprotein complex believed to 
increase the efficiency of the dynein motor and is involved in the interaction of dynein 
with both microtubules and the substrate cargo to be transported (Karki & Holzbaur et 
al., 1995; Waterman-Storer et al., 1995, 1997; Muresan et al., 2001). Mutations in the 
gene encoding the p i50 subunit of dynactin (DCTN1) have subsequently been 
identified in families with a slowly progressing lower motoneuron disease (Puls et al., 
2003; Munch et al., 2004). Together these observations indicate that disruption of 
axonal transport can induce a motoneuron phenotype similar to that found in ALS.
Remarkably, it has recently been shown that the deficits in retrograde transport seen in
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embryonic SOD1 motoneurons could be reversed by crossing the SOD1 mice 
with the Loa mice, which express a dynein mutation that also reduces retrograde 
transport (Hafezparast et al., 2003). This manipulation increases the lifespan of
pQ<> i
SOD1 mice by 28%. The exact mechanism underlying this restoration of axonal 
transport is still unclear (Kieran et al., 2005), although these results suggest that 
correction of the defects in axonal transport may have beneficial effects in ALS.
1.3.4.5. Protein aggregation
Protein aggregation is a well-recognised pathological feature of several 
neurodegenerative disorders including ALS. Intracellular cytoplasmic aggregates, 
known as Bunina bodies, are present in the cell bodies and proximal axons of 
motoneurons in post-mortem spinal cord tissue from sALS and fALS patients and also 
in mutant SOD1 mice (Leigh et al., 1991; Bruijn et al., 1997a; Watanabe et al., 2001; 
Jonsson et al., 2003). However, as with the other neurodegenerative disorders their 
exact contribution to disease pathogenesis is unclear. These aggregates are believed to 
arise from misfolded proteins, which accumulate due to either inadequate refolding by
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chaperone proteins, or to reduced degradation as a result of inhibition of the proteasome 
(Kopito, 2000). Inclusions are generally immunoreactive for ubiquitin, suggesting that 
they have been targeted for proteasomal degradation (Bruijn et al., 1997a; Jaarsma et 
al., 2001; Watanabe et al., 2001), and molecular chaperones, such as heat shock proteins 
(hsps), are a common constituent of the inclusions (Shinder et al., 2001). Aggregations 
of misfolded proteins may exert toxicity by acquiring an aberrant chemistry, or through 
the sequestration of organelles or other essential proteins, and ultimately these 
aggregates may overburden the proteasome (Bruijn et al., 1998; Johnston et al., 2000). 
In contrast, it has been suggested that aggregates may also have a protective role by 
sequestering misfolded proteins that would otherwise exert toxic effects.
In mutant SOD 1-mediated ALS, disease-causing mutations occur throughout the 
structure of the SOD1 protein, rather than being localised, for example, to the active 
site. Therefore, it has been suggested that structural alterations may modify the protein 
conformation and increase its propensity to aggregate (Bruijn et al., 1997a; Durham et 
al., 1997; Johnston et al., 2000). Indeed, the stability of mutant SOD1 proteins is 
reduced compared to endogenous WT SOD1 (Johnston et al., 2000; Shinder et al., 
2001) and the expression of mutant SOD1 in primary motoneurons induces aggregate 
formation, and subsequently cell death (Durham et al., 1997). Interestingly, 
aggregations are not seen in cultured hippocampal cells or dorsal root ganglion cells 
following similar expression of mutant SOD1, therefore indicating that selective 
aggregate formation in motoneurons may underlie their vulnerability in ALS (Durham 
et al., 1997). In SODlG85R mice, one of the earliest abnormalities observed is the 
formation of astrocytic inclusions, which increase in abundance with disease 
progression, and by end-stage also occur in motoneurons (Bruijn et al., 1997a). 
Similarly, high molecular weight aggregates containing the mutant SOD1 protein are
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found in the spinal cord of presymptomatic SOD 1093A mice. As disease progresses, 
these insoluble protein complexes are sequestered into cytoplasmic inclusion bodies, 
which may interfere with axonal transport (Johnston et al., 2000). Delaying the 
appearance of aggregates in SOD1G93a mice delays the onset of symptoms, therefore 
indicating that protein aggregation does make a significant contribution to disease 
pathogenesis (Tateno et al., 2004).
Hsps act as molecular chaperones and associate with misfolded proteins to either 
promote their refolding or transfer to the proteasome for degradation (Shinder et al., 
2001). However, the presence of hsps in mutant SOD 1-containing aggregates in 
motoneurons suggests that this cellular defence mechanism is not sufficient to tackle the 
abundance of mutant SOD1 protein and this deficit in cellular chaperone proteins may 
underlie the presence of aggregates (Shinder et al., 2001). Surprisingly, cultured 
motoneurons have a high threshold for activation of HSF-1, the transcription factor that 
regulates the heat shock response (Batulan et al., 2003). Thus the expression of hsp70 in 
cultured motoneurons is unaltered in response to heat shock or exposure to glutamate, 
which is sufficient to elicit hsp70 up-regulation in other cell types in culture (Batulan et 
al., 2003). Consistent with these findings, in presymptomatic SODlG93A mice, hsp70 
levels are upregulated in unaffected tissues, whereas they are unchanged in spinal cord 
and brain (Bruening et al., 1999). Similarly hsp70 levels are unchanged in the post­
mortem spinal cord tissue from ALS patients (Batulan et al., 2003). In contrast, in 
symptomatic SOD1G93a mice, hsp27 and aB crystalline are upregulated in motoneurons 
and glia (Vleminckx et al., 2002). In support of the proposal that a deficient heat shock 
response in motoneurons contributes to aggregate formation and subsequent 
motoneuron degeneration, overexpression of hsp70, either alone or in combination with 
hsp40, reduces the formation of mutant SOD1 aggregates in cell lines in vitro and
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ameliorates cell death (Bruening et al., 1999; Takeuchi et al., 2002). Moreover, 
treatment of SOD 1093A mice with arimoclomol, which induces hsp expression by 
prolonging the activation of HSF1, delays disease progression and extends lifespan by 
22% (Kieran et al., 2004). However, a 10-fold increase in the expression of hsp70 does 
not affect disease progression in mutant SOD1 mice (Liu et al., 2005). These findings 
suggest that the expression of several hsps and their co-chaperones, which would result 
from the activation of HSF-1, may be required to ameliorate toxicity in mutant SOD1 
mice in vivo, rather than an increase in levels of specific hsps per se.
Therefore, the presence of protein aggregates in motoneurons of mutant SOD1 mice 
appears to contribute to disease pathogenesis, whereby the increasing formation of 
aggregates with disease progression exerts toxicity. The susceptibility of motoneurons 
to protein aggregation may be related to their reduced ability to induce a sufficient heat 
shock response and therefore to reduce the toxicity of abundantly misfolded mutant 
SOD1 proteins. Furthermore, the targeting of hsps to mutant SOD1 will reduce their 
cellular availability to chaperone other misfolded proteins, and this may also contribute 
to the toxicity of mutant SOD1 aggregates (Shinder et al., 2001). Recently, a specific 
reduction in proteasomal activities was shown in presymptomatic SODlG93A mice. A 
reduction in the capacity for the degradation of misfolded proteins may actually initiate 
aggregate formation and over the disease course may eventually overwhelm the 
proteasome (Kabashi et al., 2004). In sALS and mutant SOD 1-independent fALS, it is 
possible that proteins damaged by oxidative stress, for example, may aggregate and 
exert toxicity similar to mutant SOD 1-containing aggregates.
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1.3.4.6. Inflammation
In post-mortem spinal cord tissue from ALS patients there are substantial signs of 
inflammation including significant proliferation and accumulation of activated 
microglia, reactive astrocytes and CD4+ and CD8 + lymphocytes in areas of motoneuron 
degeneration (Troost et al., 1990; Engelhardt et al., 1993; Alexianu et al., 2001; McGeer 
& McGeer, 2002). Furthermore increases in mRNA and protein levels of inflammatory 
markers such as COX2 and PGE2 are also seen in post-mortem spinal cord tissue from 
ALS patients (Yasojima et al., 2001; Maihofiier et al., 2003). In S0D1G93A mice there is 
a correlation between disease progression and the intensity of inflammation (Hall et al., 
1998; Alexianu et al., 2001; Aimer et al., 2001; Elliott et al., 2001), so that reactive 
astrogliosis increases steadily from symptom onset. However, microglial activation is 
evident from a presymptomatic age and continues to increase in intensity during disease 
progression, paralleling the loss of motoneurons (Hall et al., 1998; Alexianu et al., 2001; 
Elliott et al., 2001; Olsen et al., 2001; Weydt et al., 2004). In fact, up-regulation of 
intracellular adhesion molecule-1 (ICAM-1) expression on microglia at 40 days is one 
of the earliest pathological changes in the SOD1G93a mice, and this up-regulation may 
be important in the induction of inflammatory processes (Kawasaki et al., 1993; 
Alexianu et al., 2001).
I.3.4.6.I. Microglial-mediated damage
In response to neuronal damage, microglia are activated, undergo rapid proliferation and 
migrate to the site of injury (Sargsyan et al., 2005). Activated microglia release a variety 
of neurotoxic mediators including pro-inflammatory cytokines, for example TNFa and 
IL-lp, as well as ROS and glutamate (Molina-Holgado et al., 1997; Waksman et al., 
1999; Tikka & Koistinaho, 2001; Facchinetti et al., 2003). These neurotoxic agents 
elicit cellular damage and initiate the recruitment and activation of further microglia,
91
thus propagating the inflammatory response (Puffenbarger et al., 2000; Facchinetti et 
al., 2003). Microglia from SOD1G93a mice have been shown to secrete significantly 
more TNFa than microglia from age-matched WT mice (Weydt et al., 2004) There is 
also an up-regulation of TNFa mRNA and protein in the CNS of S0D1G93A mice 
(Hensley et al., 2003). Pro-inflammatory cytokines can induce COX2 expression, via 
transcription factor NF-kB activation (Consilvio et al., 2004; Juttler et al., 2004). COX2 
activation will then increase production of prostaglandins, including PGE2 , which may 
actually contribute to excitotoxicity by stimulating the release of glutamate from 
astrocytes (Drachman & Rothstein, 2000). In addition, COX2 activation releases ROS, 
which may further propagate the inflammatory process (Consilvio et al., 2004).
I.3.4.6.2. Mechanisms of reactive astrocyte-induced neurotoxicity
i) Pro-inflammatory cytokines
Activated astrocytes, like microglia, release a variety of neurotoxic molecules including 
pro-inflammatory cytokines and ROS, which may also act to propagate the 
inflammatory reaction via further recruitment and activation of glial cells, and exert 
additional neuronal damage (Levine et al., 1999; reviewed in Barbeito et al., 2004). 
Indeed, there is an elevation in the expression of the inflammatory marker, COX2, and 
the transcription factor, NF-kB, in reactive astrocytes in post-mortem spinal cord tissue 
from ALS patients (Migheli et al., 1997; Maihofner et al., 2003).
ii) Nitric oxide (NO)
Under pathological conditions, the expression of inducible NOS is stimulated in 
activated astrocytes. Astrocyte viability is largely unaffected by NO. In contrast, NO 
can exert significant neuronal toxicity, via inhibition of mitochondrial respiration, the 
release of glutamate and subsequent depletion of cellular ATP (Bal-Price & Brown,
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2001). Furthermore, NO reacts with superoxide radicals to generate peroxynitrite, which 
can nitrate tyrosine residues exerting substantial cellular damage. Correspondingly, 
levels of 3-nitrotyrosine are elevated in motoneurons in post-mortem spinal cord tissue 
from sALS and fALS patients, (Beal et al., 1997; Ferrante et al., 1997). Interestingly, 
Raoul et al, (2002) have demonstrated that mutant SOD1 motoneurons in culture are 
selectively vulnerable to a subtype of Fas-mediated cell death that is enhanced by NO.
iii) Reduced glutamate uptake
Oxidative damage may also reduce the expression and function of the astrocytic GLT-1 
glutamate transporter protein (Trotti et al., 1996, 1999). Selective inhibition of the GLT- 
1 transporter in mice initiates motoneuron loss (Darman et al., 2004) and progressive 
paralysis in vivo (Rothstein et al., 1996). Reduced glutamate uptake will therefore 
elevate extracellular glutamate levels and potentially induce excitotoxic damage (Choi, 
1992).
I.3.4.6.3. Therapies targeting inflammation
Several therapies that aim to reduce inflammation in models of ALS have been 
examined. Minocycline and nordihydroguaiaretic acid, potent inhibitors of microglial 
activation, both exert beneficial effects in mutant SOD1 mice (Kriz et al., 2002; van den 
Bosch et al., 2002; Zhu et al., 2002; West et al., 2004). Furthermore, selective COX2 
inhibitors delay onset (Pompl et al., 2003) and extend the lifespan of S0D1G93A mice by 
25% (Drachman et al., 2002).
In summary, multiple mechanisms are proposed to play a role in the pathogenesis of 
ALS, and indeed substantial evidence exists for their individual involvement, as detailed 
in Chapters I.3.4.I. -  I.3.4.6. These neurotoxic mechanisms, however, appear to not be
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mutually exclusive, as shown in Figure 1.4, and may in fact interact, resulting in 
motoneuron degeneration via either apoptosis or necrosis.
1.4. Aims of this Thesis
The aim of this Thesis is to investigate potential strategies to prevent the degeneration 
of motoneurons in both in vivo and in vitro models of ALS. In particular, the 
neuroprotective potential of the endocannabinoid system is evaluated in the transgenic 
SOD1G93a mouse model of ALS. Furthermore, the development of a co-culture model
C*QT A  p Q i  aof SOD1 motoneurons and SOD1 astrocytes allows investigation into the 
interaction between motoneurons and astrocytes. This will increase our understanding 
of the influence astrocytes have on disease progression, and establish whether specific 
targeting of astrocytes may be an appropriate strategy to develop, to rescue 
motoneurons from degeneration in ALS.
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Figure 1.4 -  Summary of neurotoxic mechanisms proposed to contribute to ALS 
pathogenesis.
A variety of neurotoxic mechanisms, summarised in the diagram, are proposed to play a 
role in the pathogenesis of ALS, as described in Chapters 13.4.1. -  I.3.4.6.. The exact 
contribution of each mechanism to disease pathogenesis is unknown, although it is 
likely that interactions between multiple mechanisms occur. There is substantial 
evidence indicating that apoptosis is the final cell death pathway, however depending on 
the energy state of the cell necrosis may alternatively be initiated. This diagram is 
adapted from Shaw (2005).
[Ca ]c -  cytosolic calcium levels; GLT-1 -  astrocytic glutamate transporter -1;
#  glutamate neurotransmitter; I— I GLT-1; O  synaptic vesicle; 0 ^  AMPA
receptor; transported cargo;  intermediate filament.
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CHAPTER 2
MATERIALS AND METHODS
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2. METHODS
2.1. Breeding and maintenance of transgenic mouse colonies.
a) SOD1g,3a colony
Transgenic mice carrying a human SOD1 gene with a G93A mutation (TgN[SODl- 
G93A]lGur) were originally purchased from Jackson Laboratories (Bar Harbour, ME). 
The colony was maintained by breeding male heterozygous carriers with female 
(C57BL/6 x SJL) Fi hybrids. The SOD 1093A mice were originally generated and 
characterised by Gurney et al, (1994) and contain an estimated transgene copy number 
of 25.
b) SODl.Faa/i -/- and SODl.Girf -/- colony
The Cnrl -/- and Faah -/- mice (provided by C. Ledent, Belgium and B. Cravatt, USA, 
respectively; Ledent et al., 1999; Cravatt et al., 2001) were backcrossed at least seven 
generations on to the ABH mouse background. SOD1.Faah +/- and SODl.Cnrl +/- 
mice were obtained by breeding male heterozygous S0D1G93A carriers with female 
Faah or CBi receptor knock-out mice on the ABH background. Male heterozygous 
carriers for both genes were backcrossed again with female Faah or CBi receptor 
knock-out mice to obtain an F2 generation of SOD1.Faah -/- and SODl.Cwr/ -/- mice 
for use in the experiments described in this Thesis.
The animals were housed in a controlled temperature and humidity environment and 
maintained on a 1 2 -hour light/dark cycle with access to food and water provided ad 
libitum via an overhead rack. At the onset of paralysis, affected animals were provided 
with food pellets soaked in water to ensure sufficient nourishment and hydration. All 
experiments were carried out under license from the Home Office in accordance with
98
the Animals (Scientific Procedures) Act 1986 and following approval from the Institute 
of Neurology Ethical Review Committee.
2.2. Characterisation of SODlG93A mice
In these experiments, high copy expressing S0D1G93A mice were used (TgN[SODl- 
G93A]lGur). The disease progression in these mice has been investigated by several 
laboratories and Table 2.1 summarises the key pathological changes reported to occur 
during the progression of the disease. The first visible sign of disease in these mice is a 
fine hindlimb tremor at approximately 90 days of age, which progresses to hindlimb 
weakness and then complete hindlimb paralysis over the next month, coupled with an 
inability to groom, feed or drink from the overhead rack (Gurney et al., 1994). At 
disease end-stage, approximately 130 days, over 70% of ventral horn motoneurons have 
been lost and severe muscle atrophy and paralysis is observed. For the purpose of this
COT AThesis, disease in SODl mice was defined as 4 stages: 42 - 83 days of age 
(presymptomatic), 84 -  111 days of age (early symptomatic), 112 -  125 days of age 
(late symptomatic) and 126 -  153 days of age (end-stage disease). Although the term 
‘symptomatic’ may not be appropriate when referring to mice, in this Thesis the term 
‘symptomatic’ is used to describe the stage at which defects in motor function are first 
observed, with onset of disease signs occurring around 90 days of age.
2.3. Genotyping by polymerase chain reaction of purified DNA
The mice carrying the SODl093A transgene were identified by polymerase chain 
reaction (PCR) amplification of the transgene from genomic DNA. Tail snips (<0.5cm) 
were taken just after weaning, under ethyl chloride local anesthesia. To purify the 
DNA, the tails were digested for a minimum of 3 hours, with regular vortexing, in 
600pl lysis buffer (consisting of 484pl nuclei lysis solution [Promega UK,
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Table 2.1 -  Summary of the pathological changes observed in high copy expressing 
SOD1g,3A mice
Age of animal 
(disease stage)
Pathological change observed in 
SOD1gma mice
References
Embryonic Reduced rate of retrograde axonal 
transport
Increased excitability of motoneurons
Kieran et al., 2005
Pieri et al., 2003 
Kuo et al., 2004
0-39 days 
(presymptomatic)
Fragmentation of Golgi apparatus (3Id) 
Vacuolation of ventral horn 
motoneurons due to swelling of ER and 
mitochondria (37d)
Mourelatos et al., 1996 
Chiu et al., 1995
40-79 days 
(presymptomatic)
Loss of fast muscle fibre synapses 
(40d)
ICAM expression up-regulated (40d) 
40% of end-plates denervated (47d) 
Significant loss of gastrocnemious 
motor units (47d)
Significant loss of corticospinal, 
rubrospinal, bulbospinal neurons (60d) 
Protein aggregates in ventral horn 
motoneurons (60d)
Vacuolation of motor-related areas of 
the brain (69d)
Frey et al., 2000
Kawasaki et al., 1993 
Fischer et al., 2004
Kennel et al., 1996
Zang & Cheema, 2002
Johnston et al., 2000
Chiu et al., 1995
80-120 days 
(symptomatic)
Significant loss of motoneurons 
innervating the diaphragm (82d) 
Neurofilament inclusions in ventral 
horn motoneurons (82d)
Decline in constant rotarod 
performance (85d)
40% of ventral horn motoneurons lost 
(90d)
Reduction in GLT-1 expression (90d) 
Onset of reactive gliosis (90d)
Fine hindlimb tremor, muscle spasticity 
and hyperreflexia (9 Id)
Chiu et al., 1995 
Tu et al., 1996
Fischer et al., 2004
Sharp et al.,2005
Rothstein et al., 2005 
Olsen et al., 2001 
Chiu et al., 1995
End-stage Worsening of all disease signs 
>60% loss of ventral horn motoneurons 
Severe muscle atrophy 
Death -  approximately 130d
Gurney et al., 1994 
Chiu et al., 1995
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Southampton, UK] and 116pl 0.5mM EDTA [pH 8.0]) and 17.5pl proteinase K 
(20mg/ml; Invitrogen, Paisley, UK) at 55°C. Following digestion, 200pl of protein 
precipitation solution (Promega UK, Southampton, UK) was added to each digest and 
the sample vortexed vigorously for 20 seconds, before chilling on ice for 5 minutes and 
then centrifuging at 14,000g for 6  minutes at room temperature. The supernatant 
containing the DNA was removed and transferred to a clean eppendorf tube, to which 
isopropanol (0.7-1.Ox sample volume; VWR International Ltd, Poole, UK) was added 
and inverted gently several times. The samples were centrifuged at 14,000g for one 
minute at room temperature and the supernatant was decanted leaving a small DNA 
pellet. 600pl of 70% ethanol (VWR International Ltd, Poole, UK) was added and the 
DNA was rinsed by inverting the tube several times before the samples were 
centrifuged again at 14,000g for one minute at room temperature. The supernatant was 
decanted and discarded and the DNA pellet was rehydrated in 200pl sterile water.
2.5pl of each DNA sample was added to a reaction tube that contained 17.65pl sterile 
water, 2.5pl PCR buffer (10X), 0.75pl MgCk (50mM), 0.5pi dNTP solution (lOmM), 
0.25pi of both the forward and reverse primers for the endogenous SODl enzyme and 
human mutant SODl enzyme (lpg/pl), and 0.1 pi Taq polymerase (0.5 units) to make a 
final volume of 25pl. To identify the human SOD1G93a transgene, primers with the 
following sequences were used: 5’ CAT CAG CCC TAA TCC ATC TGA 3’ and 5’ 
CGC GAC TAA CAA TCA AAG TGA 3’. The samples were then temperature cycled 
as follows: 1 cycle of 3 minutes at 95°C; 36 cycles of 30 seconds at 95°C, 30 seconds at 
60°C, 45 seconds at 72°C; and one cycle of 2 minutes at 72°C. The PCR products were 
visualised by gel electrophoresis by running 20pl of each PCR product on a 4% agarose 
gel at 130mV for 40 minutes.
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2.4. Primary spinal cord astrocyte cultures
Primary astrocytes were prepared based on a procotol described by Robb & Conner 
(1998). Two working solutions were used, referred to as Solution A (comprising 50mls 
of Eagle’s Balanced Salt Solution [Invitrogen, Paisley, UK], supplemented with 
50units/ml penicillin, 50pg/ml streptomycin, 2.5jig/ml amphotericin B, 0.3% bovine 
serum albumin [BSA; dissolved in L-15 medium] and 20pg/ml DNase 1) and Solution 
B (comprising 20mls of Solution A further supplemented with 0.25mg/ml trypsin and 
0.15mg/ml DNAse 1), which was kept at 37°C until use.
P0-P2 transgenic mouse pups were decapitated and their spinal cords were dissected out 
and the meninges removed. The spinal cords were maintained in Hank’s balanced salt 
solution (HBSS; Invitrogen, Paisley, UK) supplemented with 50units/ml penicillin, 
50pg/ml streptomycin and 2.5pg/ml amphotericin B until genotyping was complete. A 
tail snip was taken from each pup to allow determination of its genotype prior to 
culturing, using PCR as described in Chapter 2.3.
The spinal cords were pooled according to genotype, either WT or SODl093A, and each 
genotype was cultured separately. Initially, the spinal cords were transferred into sterile, 
phenol red free, supplemented HBSS, and chopped into smaller pieces. Spinal cord 
pieces were then transferred to lOmls of Solution A and triturated until homogenous. 
The homogenate was centrifuged at 4°C for 5 minutes at 2000rpm, and the supernatant 
was discarded. The pellet was resuspended in lOmls of Solution B and incubated for 10 
minutes at 37°C in a 5% CO2 humidified incubator, before centrifugation for a further 5 
minutes at 2000rpm at 4°C. The supernatant was removed and the pellet resuspended in 
5mls of Solution A. The resuspension was centrifuged for a further 5 minutes at 4°C at 
2000rpm. Following the removal of supernatant, the final pellet was resuspended in 1ml
102
of Dulbecco’s Modified Essential Medium (DMEM; Invitrogen, Paisley, UK; 
supplemented with 50units/ml penicillin, 50pg/ml streptomycin, 2.5 pl/ml amphotericin 
B and 10% foetal calf serum). The resuspended pellet was passed through a 100pm 
mesh (Marathon, London, UK), and then the cell density determined using a 
haemocytometer. Cells were seeded onto O.lpg/ml poly-D-lysine coated 13mm 
coverslips in 24 well plates at a density of 1.5x105 cells/well, or 22mm coverslips in 6  
well plates at a density of 5x10s cells/well for survival assays and imaging experiments 
respectively. Cells were maintained in supplemented DMEM in a 37°C, 5% CO2 
humidified incubator for between 2 and 3 weeks until confluency was reached. 
Astrocytes were then placed in a 37°C, 5% CO2 environmental shaker and rotated at 
160rpm for 18 hours in order to dislodge 02A progenitor cells and microglia (Robb & 
Conner, 1998). The media was then rapidly exchanged for fresh media and the cultures 
were returned to the incubator for 7-10 days. At 3 weeks in vitro, mixed ventral horn 
cells were plated onto the enriched astrocyte layers, as described below.
To determine the percentage of astrocytes within the enriched astrocyte layer, glial 
cultures were immunostained for GFAP, a specific marker of astrocytes, and DAPI, a 
nuclear marker (0.01%, Molecular Probes, Paisley, UK), and the percentage of DAPI 
stained, GFAP positive cells were calculated.
2.5. Mixed ventral horn neuron cultures
Mixed motoneuron cultures were prepared using a protocol adapted from that described 
by Camu & Henderson (1994). Female (C57BL/6 x SJL) Fj hybrids were time-mated
p Q }  4
with male SODl mice. Pregnant females were terminally anaesthetised with 
pentobarbitone (140mg/kg) and embryos at gestational age E l2.5 were quickly removed 
by hysterectomy and placed in Dulbecco’s phosphate buffered saline (PBS; Invitrogen,
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Paisley, UK), supplemented with 50 units/ml penicillin (Invitrogen, Paisley, UK), 
50pg/ml streptomycin (Invitrogen, Paisley, UK) and 2.5pg/ml amphotericin B.
The spinal cords of individual embryos were isolated under a dissection microscope, 
using fine forceps to carefully separate the spinal cord from the surrounding tissue. The 
remaining meninges plus attached dorsal root ganglia were then carefully removed to 
avoid damaging the spinal cord. The dorsal horn was carefully detached from the 
ventral portion of the spinal cord using a fine ophthalmic scalpel blade and each 
individual ventral horn was collected in an eppendorf containing supplemented PBS, as 
described above. A tail snip was also taken from each embryo to allow determination of 
its genotype prior to culturing, using PCR as described in Chapter 2.3.
The spinal cords were pooled according to genotype, either WT or SODl093A, and each 
genotype was cultured separately. The tissue was incubated for 10 minutes at 37°C in 
HAM F10 modified medium (Invitrogen, Paisley, UK) containing 0.025% trypsin. The 
digest was transferred to complete medium (comprising LI 5 medium [Invitrogen, 
Paisley, UK] supplemented with 3.6mg/ml glucose, 0.2pM progesterone, 50units/ml 
penicillin [Invitrogen, Paisley, UK], 50pg/ml streptomycin [Invitrogen, Paisley, UK], 
5pg/ml insulin, lOOuM putrescine, 0.1 mg/ml conalbumin and 2% horse serum 
[Invitrogen, Paisley, UK]), containing 0.125mg/ml DNase 1 and 0.4% BSA and gently 
dissociated three times. The cell suspension was then centrifuged through a 4% BSA 
cushion for 5 minutes at 1500rpm. Then following removal of the supernatant, the pellet 
was resuspended in complete medium (as described above), further supplemented with 
0.02mg/ml DNase 1 and the cell density determined using a haemocytometer. Cells 
were seeded onto poly-omithine and laminin (Invitrogen, Paisley, UK) coated 13mm 
coverslips in 24 well plates at a density of 7.5 x 104 cells/well, or 22mm coverslips in 6
104
well plates at a density of 1.5 x 105 cells/well for survival assays and imaging 
experiments respectively.
In some experiments motoneuron:astrocyte co-cultures were prepared. In these co­
culture experiments, mixed ventral horn cultures were plated directly onto an enriched 
WT or SODl astrocyte layer at the densities indicated above. Cells were maintained 
in complete neurobasal medium ([Invitrogen, Paisley, UK] supplemented with 2% B-27 
supplement [Invitrogen, Paisley, UK], 0.5mM glutamine [Invitrogen, Paisley, UK], 
0.05% mercaptoethanol, 2% horse serum, O.lng/ml GDNF [Caltag, Silverstone, UK], 
0.5ng/ml CNTF [Caltag, Silverstone, UK], O.lng/ml BDNF [Caltag, Silverstone, UK], 
50 units/ml penicillin, 50pg/ml streptomycin and 2.5pg/ml amphotericin B) in a 37°C, 
5% CO2 humidified incubator for a minimum of 7 days in vitro (DIV) before 
undergoing any drug treatment or imaging protocol. The medium was replaced twice a 
week.
All reagents were obtained from Sigma-Aldrich, Poole, UK, unless otherwise stated.
2.6. Cellular fluorescence imaging
The cellular interaction between motoneurons and astrocytes was examined by 
fluorescent imaging technology using confocal microscopy and a cooled charge coupled 
device (CCD) camera.
2.6.1. Dye loading and drug application
Immediately prior to experimentation, coverslips of cultured cells (7-10 DIV) were 
removed from their culture medium and mounted in custom built imaging chambers. 
These chambers consisted of a circular base in which the 22mm coverslip was held
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secure by a slight indentation, and a threaded top that when screwed onto the base 
formed a watertight seal and allowed incubation of the cells in various experimental 
solutions. Furthermore, a rubber ring placed between the top and base prevented the 
leakage of recording medium from the chamber onto the objective lens.
Once mounted in imaging chambers, cells were incubated in Hepes buffered salt 
solution (referred to as recording medium, RM) composed of (mM): 156 NaCl, 3 KC1, 2 
MgS0 4 , 1.25 KH2PO4 , 2 CaCh, 10 glucose and 10 Hepes, and the pH was adjusted to 
7.35 with NaOH (all Sigma Aldrich, Poole, UK). Certain experiments required the use 
of RM with a high potassium concentration, which was based on the standard RM with 
an isotonic replacement of NaCl (109mM) with KC1 (50mM).
Cultures were loaded with various fluorimetric indicators that are listed in Table 2.2 (all 
Molecular Probes, Paisley, UK). Tetramethylrhodamine methyl ester (TMRM) is a 
highly lipid soluble cation and therefore is extremely membrane permeable. In contrast, 
the free acid moieties of the calcium indicators (fluo 4, fura-2FF and rhod 5N) are 
negatively charged and water-soluble and therefore their diffusion across cellular 
membranes is limited. Therefore, these fluorimetric indicators were loaded as their 
acetoxy-methyl (AM) esters, which are membrane permeant. Exposure to endogenous 
cellular esterases cleaves the AM esters and generates the fluorophore intracellularly. 
When required, a surfactant, Pluronic F-127 (0.005%) was added to the chambers to aid 
the dispersion of water insoluble molecules in the aqueous RM. After the loading 
period, cells were washed 3 times with RM to remove background dye and were then 
incubated in 0.5ml of fresh RM for the duration of the experiment. At least 3 
experiments were performed for each parameter studied, using cultures prepared on 
separate occasions.
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Table 2.2 -  Fluorophore loading conditions
Fluorophore Concentration 0.005% 
Pluronic 
required ?
Loading
conditions
Parameter
measured
Tetramethyl- 
rhodamine 
methyl ester 
(TMRM)
30nM Yes 30 mins at 
room
temperature
Mitochondrial
membrane
potential
Fluo 4 AM 
(fluo 4)
5pM Yes 30 mins at 
room
temperature
Cytosolic 
calcium levels 
(high affinity)
Fura 2-FF AM 
(fura 2-FF)
5pM Yes 30 mins at 
room
temperature
Cytosolic 
calcium levels 
(low affinity)
Rhod 5N AM 
(rhod 5N)
5pM Yes 30 mins at 
room
temperature
Mitochondrial 
calcium levels
Dihydroethidium
(HEt)
2pM Yes None Free radical 
generation
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Drugs applied during the course of the experiment were made up in 0.5ml aliquots of 
RM and applied by means of RM replacement. All experiments were performed at room 
temperature.
2.6.2. Fluorescence measurement
The majority of recordings were performed on a Zeiss 510 confocal laser scanning 
microscope (CLSM), however, the use of the ratiometric calcium indicator fura 2-FF 
required the use of a cooled charge-coupled device (CCD) camera. The general methods 
associated with confocal/CCD camera use are described in this section, however, details 
particular to one experiment are given in the individual Chapter.
i) Confocal imaging
Confocal images were produced using a Zeiss 510 CLSM (Oberkocken, Germany). This 
set-up comprised a Zeiss Axiovert 200M inverted microscope equipped with a quartz 
x40 and glass x63 plan-apochromat, oil immersion objective lenses (numerical aperture 
1.3 and 1.4 respectively). Four different laser types were available for the excitation of 
fluorescence: UV laser (lines at 351 and 364nm), laser diode 405nm (line at 405nm), 
Argon laser (lines at 458, 477, 488 and 514nm) and two helium-neon lasers (lines at 543 
nm and 633nm respectively).
A diagrammatic representation of the confocal microscope set-up is shown in Figure
2.1. The excitation wavelength provided by the laser is reflected, by means of a dichroic 
mirror, onto an objective lens, which focuses the illuminating light onto a small spot 
within the sample specimen. The diameter of the illuminated sample is determined by 
the numerical aperture of the objective lens. The excitation laser beam is rapidly moved 
across the sample area, under the control of the scan generator, which also rapidly scans
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Figure 2.1 - A diagrammatic representation of the experimental confocal
laser scanning microscope and the interline-transfer CCD camera set-up
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the emitted fluorescent light. Emitted fluorescence is reflected from the sample through 
the objective lens, the scan generator and the dichroic mirror, which separates the 
emitted fluorescent light from the excitation light. Emitted light passes through an 
appropriate bandpass (transmits emitted light within the indicated wavelength band) or 
longpass filter (transmits emitted light with wavelengths longer than the indicated 
threshold value) and is collected by a photomultiplier tube (PMT). The placing of a 
pinhole in front of the PMT detection system is the basis of confocal scanning. This 
pinhole limits the emitted light detected, so that only ‘in focus’ light originating from 
the sample specimen will pass through the pinhole. In contrast, light originating from 
‘out of focus’ planes will not be detected, therefore improving the quality of the images 
obtained. Photocathodes in the PMTs detect the light passing through the pinhole and 
release electrons that accelerate towards an electron multiplier, which consists of a 
series of dynodes. The current output from the electron multiplier is proportional to the 
number of electrons striking the photocathode. This analogue signal is then digitised to 
produce an image on the computer monitor.
Cells can be loaded with up to 4 fluorophores, allowing the measurement of multiple 
signals simultaneously and therefore permitting correlation between different responses 
of the cell. The optical configuration for individual fluorophores is detailed in Table
2.3. To avoid any cross talk between the excitation/emission spectra of different 
fluorimetric indicators, ‘multitracking’ was used, in which images at each optical 
configuration were collected successively, rather than simultaneously, on > 2  channels. 
The detector gain (PMT sensitivity), amplifier offset (black level setting) and amplifier 
gain (electronic post-amplification) were kept constant throughout the experimental 
series. Instead, the intensity of the laser (laser power) was the variable adjusted to 
optimise the signal. The linear relationship between laser power and fluorescent
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Table 2.3 -  The optical configurations for fluorophore use.
The optical configurations for each fluorophore are listed in the table. A dichroic mirror 
in the microscope separated the excitation from emission light. To prevent cross talk 
between the excitation/emission spectra of different fluorimetric indicators, images at 
each optical configuration were collected successively, rather than simultaneously, on 
two channels (multitracking). The emitted signal was passed through an appropriate 
bandpass or longpass filter and detected by a PMT.
I l l
Fluorophore Laser excitation 
wavelength (nm)
Microscope dichroic 
filter (nm)
Bandpass/ 
Longpass emission 
filter
TMRM 543 545 LP 560
Fluo 4 488 490 BP 505-550
Fura 2-FF 340/380 510 LP 515
Rhod 5N 543 545 LP 560
HEt 543 545 BP 560-615
NADH auto­
fluorescence
364 395 BP 435-485
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intensity allowed correction for changes in laser power. The presence of an acousto- 
optic tunable filter allowed the intensity of each laser line to be independently 
controlled and indeed this was maintained between 0.05% and 1% of the total laser 
output. The pinhole was set to give an optical slice of approximately 2pM to optimise 
light collection.
An image (an array of 512 x 512 pixels) was acquired every 30 seconds, to minimise 
photodamage. However, immediately after drug application continuous scanning was 
implemented for 5 minutes to allow a detailed analysis of the cellular response. For the 
analysis of mitochondrial membrane potential, a ‘z’ stack of images was taken 
throughout the culture. Images were acquired at a scan speed of 7.86 seconds and 
digitised to 12 bits, which provides 4096 grey levels, therefore improving resolution. 
Unless otherwise stated images were acquired using the x40 objective lens.
ii) Cooled charge coupled device (CCD) camera
The CCD camera was used in association with the ratiometric calcium indicator, fura 2- 
FF. Fluorescent measurements were obtained on a Nikon epifluorescence inverted 
microscope (Tokyo, Japan) equipped with a x20 fluorite objective lens (numerical 
aperture 0.7). Cells were placed on the microscope stage and fluorescence excited using 
a 75W xenon arc lamp, the beam passing sequentially through lOnm bandpass filters 
centred at 340 and 380nm housed in a stepping excitation filter wheel (Cairn Research, 
Faversham, UK) and controlled by Acquisition Manager software (Kinetic Imaging, 
Liverpool, UK; see Figure 2.1). Sequential excitation of cells at 340nm and 380nm, 
which corresponds to the excitation of calcium-bound and calcium-free fura 2-FF, 
allowed the ratiometric measurement of fura 2-FF fluorescence. Images were acquired 
every 1 0  seconds and cells were protected from phototoxicity by interposing a
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computer-controlled shutter in the light path between exposures. Excitation light was 
separated from emitted light by a dichroic mirror, and the emitted light was reflected 
through a 515nm longpass filter to a interline-transfer cooled CCD camera with a chip 
of 656 pixels x 494 pixels (pixel area 9.9 pm2) and digitised to 10 bit resolution (Orca 
ER; Hamamatsu 4880, Welwyn Garden City, UK). All data was collected using Kinetic 
Imaging software (Liverpool, UK). To reduce background noise, the CCD camera was 
cooled by a Peltier element to a temperature of 20°C below the ambient temperature.
Imaging using the interline-transfer CCD camera is based on the transfer of 
accumulated charge from each photodiode to an adjacent charge transfer channel. This 
occurs rapidly and efficiently therefore improving the acquisition rate. Data was 
digitised to 1 0  bits and acquisition speed further improved by ‘binning’ the pixels, 
whereby square arrays of 4 pixels were averaged to produce a single data point.
2.6.3. Image processing
Images were collected using Zeiss ‘LSM’ software or Kinetic Imaging ‘Acquisition 
Manager’ for confocal and CCD microscopy respectively. With the exception of 
experiments measuring mitochondrial membrane potential, all images were analysed 
using Lucida version 5.0 image analysis software (Kinetic Imaging, Liverpool, UK). 
Initially background fluorescence was subtracted from the acquired confocal image. 
Motoneurons and other cells of interest were selected and the change in signal 
differentiated over time. Subsequently, the change in digitised signal for each region of 
interest was corrected for laser power and plotted in Microcal Origin 7.1. (Northampton, 
MA, USA).
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Data acquired using fura 2-FF required an additional analysis step. Following 
subtraction of background fluorescence from the individual 340nm and 380nm images, 
the 340nm image was divided by the 380nm image to calculate the ratio of the signal 
generated. Subsequently the change in signal was differentiated over time and the 
change in digitised signal for each region of interest was plotted in Microcal Origin 7.1, 
as described above.
Experiments to investigate the resting mitochondrial membrane potential were analysed 
using Metamorph software (Universal Imaging Corporation, Downingtown, PA, USA). 
For each experiment a ‘z’ stack was taken through the culture, and this was compressed 
to a single image with each pixel representing the average intensity of that point through 
the sample. An image threshold was set at a point that represented the minimum 
fluorescence for that experimental culture. This threshold value was subtracted from the 
fluorescent signal to give a value corresponding to the mitochondrial membrane 
potential.
Single excitation wavelength fluorophores require extensive calibration to define the 
minimum and maximum fluorescence in each cell, due to the variability in fluorophore 
loading. The calibration takes into account the minimum fluorescence attained in the 
absence of calcium in the RM, and the maximum fluorescence attained in the presence 
of calcium and enables quantitative measurements to be made from the data acquired. 
However, the laborious nature of this calibration in combination with the potential risk 
of damaging the cultured cells warrants the representation of the fluorescence acquired 
from single wavelength fluorophores on an arbitrary scale, allowing only qualitative 
analysis. However, by averaging the data from at least 3 experiments, loading 
deviations should be minimised, therefore allowing quantitative analysis. The use of
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the ratiometric, low affinity calcium indicator fura 2-FF provides a more accurate 
quantitative measurement of the change in cytosolic calcium, compared to single 
wavelength indicator fluo 4. However, the fura 2-FF data has not been calibrated in 
terms of [Ca ]c because of the uncertainty arising from the use of different calibration 
techniques (Henke et al., 1996). Data are therefore presented as the ratio of the signal 
excited at 340nm and 380nm (representing calcium-bound and calcium-free 
respectively) for fura 2-FF.
For all experiments, the mean values or the slope of the fitted lines (depending on 
experiment) were compared using either a Mann Whitney U test or a one way ANOVA 
incorporating a Student Newman Keuls multiple comparison test (according to 
individual experiments) using Sigma Stat (version 2.03, Erkrath, Germany).
2.7. Motoneuron survival in vitro
To assess motoneuron survival in vitro, cultures (7-10 DIV) were divided into a treated 
group, the details of treatments are given in individual Chapters, or an untreated group. 
The effect of treatment on motoneuron survival was assessed using the Trypan Blue 
exclusion method. This method involves incubation of the cultured cells in 200pl trypan 
blue (Sigma-Aldrich, Poole, UK) for 10 minutes at 37°C. Subsequently, the trypan blue 
was removed and the cells were fixed in 4% paraformaldehyde (PFA; pH7.4; Tabb Ltd, 
Aldermaston, UK) in 0.1M PBS for 30 minutes then rinsed in PBS and stored at 4°C 
until processing. To assess the effect of pharmacological treatment on motoneuron 
survival, the cells were immunostained for MAP-2, a pan neuronal marker, using the 
protocol described below (Chapter 2.8). Motoneurons were identified according to the 
morphological criteria:
i) a cell body diameter > 15 pm
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ii) the presence of at least 3 neuritic processes
Random fields of neurons were counted and the number of surviving motoneurons was 
expressed as a percentage of the total number of motoneurons from an untreated culture 
prepared on the same occasion.
2.8. Immunocytochemistry
In the experiments described in this Thesis, immunocytochemistry was performed on 
both cultured motoneurons and spinal cord sections. Information regarding the specific 
primary antibodies used in individual experiments is detailed in the relevant Chapters.
The fixed cells or spinal cord sections were rinsed in PBS containing 0.1% Triton 
(Sigma-Aldrich, Poole, UK) for 15 minutes, and then incubated in a blocking solution 
consisting of 5% milk fat (Marvel, Premium Brands, Lines, UK) and 3% normal serum 
(Vector Laboratories, Burlingame, CA, USA) in PBS (pH 7.4), for 1 hour at room 
temperature. The blocking solution was then removed and the cells/sections were rinsed 
twice with PBS containing 0.1% Triton for 5 minutes and a final rinse in PBS only, for 
5 minutes. Cells/sections were then incubated overnight at 4°C in primary antibody 
solution made up in PBS. Following incubation, the primary antibody solution was 
removed and the sections were rinsed twice with PBS containing 0.1% Triton for 5 
minutes and a final rinse in PBS only, for 5 minutes. Cells/sections were next incubated 
in secondary antibody solution (dilution 1:100) in PBS for 2 hours at room temperature. 
Following removal of the secondary antibody, cells/sections were incubated for 1 hour 
at room temperature in Avidin-Biotin complex solution (ABC; Vector Laboratories, 
Burlingame, CA, USA), which was prepared thirty minutes before use, and then rinsed 
three times in PBS for 5 minutes each. Immunostaining was visualised using fast 3,3
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diaminobenzadine tablets (Sigma-Aldrich, Poole, UK), and then cells/sections were 
rinsed in PBS for 2 minutes, dehydrated through graded alcohols; 1 minute in 70% 
ethanol, 1 minute in 90% ethanol and 2 rinses in 100% ethanol for 1 minute each. 
Cells/sections were then cleared by incubation in histoclear for 2 minutes (2 rinses). 
Finally, the cultured cells plated on coverslips were removed from their 24 well plates, 
and mounted face down onto uncoated slides using DPX mounting solution. 
Alternatively, coverslips were mounted onto spinal cord sections using DPX mounting 
solution.
2.9. Mouse on mouse immunocytochemistry
The monoclonal antibody to the human SODl enzyme was raised in the mouse and 
therefore immunocytochemical detection of mutant SODl in cultured cells required the 
use of a mouse-on-mouse (MOM) immunodetection kit (Vector Laboratories, 
Burlingame, CA, USA). Cultured cells were incubated in MOM blocking reagent 
(consisting of 2 drops of MOM blocking reagent in 2.5ml PBS) for 1 hour at room 
temperature. The blocking solution was then removed and the cells were rinsed twice 
with PBS for 2 minutes each. Subsequently, cells were incubated in MOM diluent 
(consisting of 600pl of MOM protein concentrate stock solution diluted in 7.5ml PBS) 
for 5 minutes. The excess diluent was then removed and the primary antibody, diluted 
to the appropriate concentration in MOM diluent, was applied for 30 minutes. 
Following removal of the primary antibody, cells were rinsed twice in PBS for 2 
minutes each and then incubated in MOM biotinylated anti-mouse IgG reagent 
(consisting of lOpl stock MOM biotinylated anti-mouse IgG reagent diluted in 2.5mls 
MOM diluent) for 10 minutes. Cells were then twice rinsed in PBS and incubated in 
ABC solution (made up 30 minutes before application) for 1 hour at room temperature. 
Following removal of the ABC, the cells were rinsed three times in PBS for 5 minutes
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each. Immunostaining was visualised using fast 3,3 diaminobenzadine tablets (Sigma- 
Aldrich, Poole, UK), and then cells were rinsed in PBS for 2 minutes, dehydrated 
through graded alcohols; 1 minute in 70% ethanol, 1 minute in 90% ethanol and 2 rinses 
in 100% ethanol for 1 minute each. Cells were then cleared by incubation in histoclear 
for 2 minutes each (2 rinses). Finally, the cultured cells mounted on coverslips were 
removed from their 24 well plates and mounted face down onto uncoated slides using 
DPX mounting solution.
2.10. Physiological assessment of muscle function
Physiological assessment of hindlimb muscle force was assessed in vivo in 
anaesthetised mice at either 120 days of age (Chapter 4) or 90 days of age (Chapter 5). 
The animals were anaesthetised with 4% chloral hydrate (lml/lOOg body weight, 
injected intraperitoneally, i.p.; Sigma-Aldrich, Poole, UK) and once reflex action to 
painful stimuli was absent and the animals were deeply anaesthetised, they were 
prepared for assessment of hindlimb muscle function. The distal tendon of the tibialis 
anterior (TA) and extensor digitorum longus (EDL) muscle in both hindlimbs were 
exposed, dissected free from surrounding tissue and cut. The sciatic nerve was exposed, 
sectioned and all of its branches cut, apart from the deep peroneal nerve, which 
innervates the TA and EDL muscles. The hindlimbs of the animals were rigidly secured 
to the table with stainless steel pins and the distal tendons of the TA and EDL muscle 
attached to an isometric force transducer (Dynamometer UFI Devices, Welwyn Garden 
City, UK) via thread. Once attached, the length of each muscle was adjusted to obtain 
maximal twitch tension. Both muscles and nerves were kept moist with saline and 
experiments were carried out at room temperature.
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2.10.1. Muscle force
Muscle contraction was elicited by stimulation of the sciatic nerve using square wave 
pulses of 0 .0 2 ms duration at a supramaximal voltage ( 1 0  volts) via platinum electrodes. 
Maximal tetanic contraction and hence muscle force was assessed by stimulating the 
sciatic nerves of both hindlimbs with trains of stimuli at increasing frequencies of 40, 80 
and 100 Hz for a total duration of 450ms.
2.10.2. Motor unit number
To determine the number of functional motor units in each EDL muscle, stimuli of 
increasing intensity were applied to the sciatic nerve. This gradual increase in intensity 
resulted in stepwise increments in twitch tension due to the successive recruitment of 
motor axons. The motor unit traces were recorded on a storage oscilloscope (Tektronix, 
Beaverton, OR, USA) and a photograph was taken using a Tektronix oscilloscope 
camera (Beaverton, OR, USA). The number of increments was counted to give an 
estimate of the number of motor axons present in the nerve.
2.10.3. Fatigue test
At the end of the isometric tension recordings, the resistance of the EDL muscles to 
fatigue during repeated stimulation was tested. The EDL muscles were stimulated over 
a 3 minute period, at 40Hz for a duration of 250ms every second, and contractions were 
recorded on a pen recorder (Lectromed Multitrace 2, Letchworth Garden City, UK). The 
traces obtained illustrate the fatigue pattern of the muscle in response to sustained 
contraction. In addition, from such traces a fatigue index (F.I.), a measure of muscle 
fatigability, can be calculated. The F.I. represents the decline in EDL muscle force 
following repeated stimulation, thus quantifying the muscle fatigue, and is calculated as 
follows:
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Initial tetanic tension -  tetanic tension after 3 minute stimulation
F.I. = --------------------------------------------------------------------------------
Initial tetanic tension.
A muscle that is fatigue resistant will have an F.I. value close to 0, whereas a muscle 
that is fatiguable during sustained contraction will have an F.I. value close to 1.0.
2.10.4. Muscle histochemistry
Following the physiological recordings, the soleus, TA and EDL muscles were removed 
from both hindlimbs and weighed. The muscles were mounted in an upright position in 
tissue-tek (Agar Scientific, Stanstead, UK) on a piece of cork board, and snap-frozen in 
isopentane cooled in liquid nitrogen. Serial transverse sections (lOpM) were cut on a 
cryostat (Bright Instrument Company, Huntingdon, UK) and mounted onto poly-lysine 
coated slides (VWR International, Poole, UK). Muscle sections were stained for 
succinate dehydrogenase (SDH) activity to evaluate the oxidative capacity of the muscle 
fibres. According to the protocol detailed by Nachlas et al, (1957), a ‘working solution’ 
was prepared consisting of 0.1M phosphate buffer (pH 7.6), 1M sodium succinate, 
15mM nitroblue-tetrazolium, 0.1M potassium cyanide and lOmM phenazine 
methosulphate. This solution was filtered and stored in a darkly coloured bottle to 
protect the photosensitive elements from sunlight. To ensure maximal staining, the 
muscle sections and a small volume of the ‘working solution’ were incubated separately 
at 37°C for approximately 20 minutes. Subsequently the sections were exposed to the 
‘working solution’ and incubated at 37°C for a further 5 minutes to develop the SDH 
stain. Sections were then rinsed in 0.9% saline and dehydrated by washing in alcohol of 
increasing concentration (70% acetone for 1 minute, 90% acetone for 1 minute and then 
2 rinses in 100% ethanol for 2 minutes each). Finally, the sections were cleared in
121
histoclear ( 2  rinses for 2  minutes each) and then coverslips were mounted onto the 
sections using DPX mounting solution.
2.10.5. Motoneuron survival
In order to evaluate the survival of motoneurons as a consequence of the experimental 
conditions as detailed in this Thesis, the number of motoneurons in the sciatic pool of 
the lumbar spinal cord was counted. Animals were terminally anaesthetised with 
pentobarbitone (140mg/kg i.p.) and on cessation of reflex to painful stimuli were 
perfused transcardially with 0.9% NaCl and then 4% PFA. Once fixed, the spinal cords 
were removed and the lumbar regions (L2-L6) were post-fixed for 4-6 hours in the same 
fixative and then cryoprotected in sucrose (30% in PBS) overnight at 4°C.
Serial transverse sections (20pm) of lumbar spinal cord were cut on a cryostat, mounted 
onto poly-lysine coated slides and stained with gallocyanin, a Nissl stain (Cullings, 
1963). The sections were then dehydrated in increasing concentrations of alcohol, 
cleared in histoclear and then coverslips were mounted onto the slides using DPX as a 
mounting solution. The number of surviving motoneurons in the sciatic motor pool was 
assessed by counting the number of Nissl-stained motoneurons in every third spinal 
cord section in order to avoid counting the same cell twice in consecutive sections, 
using a light microscope (Leica DMR). For each animal, 60 spinal cord sections were 
assessed. Only large polygonal neurons with a distinguishable nucleus and nucleolus, 
visible at high magnification were included in the counts. This method of counting has 
previously been used to assess motoneuron survival (White et al., 2000).
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2.10.6. Statistical analysis
Statistical significance between the experimental groups was assessed either using a 
Mann-Whitney U test or a one-way analysis of variance (ANOVA), incorporating a 
Student Neuman Keuls multiple comparisons test using Sigma Stat (version 2.03, 
Erkrath, Germany). Significance was set at p < 0.05.
2.11. Transfection of primary cells using lentiviral vectors
The lentiviral vectors were generated at and supplied by Oxford Biomedica, Oxford, 
UK. At 1 DIV, mixed ventral horn cultures were incubated with VSV-G pseudotyped 
EIAV vectors encoding either GFP, lacZ, shRNA to mutant SOD1 or an empty vector. 
The volume of virus added to each well of a 24 well plate (5x105 cells), was calculated 
according to the following equation:
Multiplicity of infection (MOI) x Number of cells
Volume = -----------------------------------------------------------------
Titre
The viral titre ranged from 5 x l 0 8 - l x l 0 9 transducing units/ml, and was consistent 
within each viral batch. The MOI represents the average number of phage particles that 
infect a single cell. To optimise transfection, 6  different MOI: 0.25, 0.5, 0.75, 1, 2.5 and 
5; were tested using EIAV vectors encoding lacZ and the transfection efficiency for 
each MOI was calculated as described below in Chapter 2.12. The volume of virus 
required was diluted in complete neurobasal medium (as described in Chapter 2.5) and 
added to the cells via media replacement. Cells were incubated with virus for 5 hours at 
37°C in a 5% CO2 humidified incubator and then the media was replaced with fresh 
complete neurobasal media. Cells were left for a further 7DIV before processing.
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2.12. Calculation of transfection efficiency
Initially, primary mixed ventral horn cultures were transfected using lentiviral vectors 
encoding lacZ to calculate the transfection efficiency. Transfection efficiency was 
calculated by counting the number of motoneurons in which p-galactosidase (the lacZ 
gene product) had mediated the hydrolysis of an X-gal stain to form a blue product, 
therefore indicating successful transfection. Therefore at 7DIV, primary mixed ventral 
horn cultures were fixed in 4% PFA for 10 minutes and then rinsed twice in PBS. The 
cells were then incubated in a sufficient amount of staining solution (comprising 25 pi of 
400mM potassium ferricyanide, 25pl of 400mM potassium ferrocyanide, 25pl of 
200mM magnesium chloride and 125pi X-gal [20mg/ml] in a total volume of 2.5ml 
PBS) to cover the cells and left overnight at 37°C. Following removal of the staining 
solution, cells were fixed for 30 minutes in 4% PFA and then rinsed twice in PBS 
before mounting face down onto coverslips using citifluor as a mountant. The number 
of motoneurons successfully transfected was expressed as a percentage of the total 
number of motoneurons present.
2.13. Protein extraction
In order to evaluate the effect of the lentiviral vector encoding siRNA targeted to mutant 
SOD1, protein was extracted from transfected cells and a Western blot run to determine 
the levels of mutant SOD1 protein remaining. The protein extraction was performed at 
the Institute of Neurology and the protein samples sent to Oxford Biomedica where the 
Western blots were carried out.
To extract the protein from cultured mixed ventral horn cells, the media was first 
aspirated and the cells were rinsed in PBS. Following aspiration of the PBS, 200pl of 
lysis buffer (consisting of 20mM Tris-HCl pH7.5, lOmM EDTA, ImM EGTA, lOOmM
NaCl and 1% TritonX-100 in PBS), supplemented with 0.012pl proteinase inhibitor 
cocktail (all Sigma-Aldrich, Poole, UK), was added to each well of a 24 well plate for 
approximately 1 minute. The coverslips were then gently scraped to dislodge the lysed 
cells and the supernatant was collected into an RNAse free eppendorf and stored at 
-80°C prior to transfer to Oxford Biomedica. Equal amounts (lOpg) of each protein 
sample were fractionated by SDS-PAGE. Following transfer onto a nitrocellulose 
membrane (Amersham Biosciences, Buckinghamshire, UK) blots were probed with 
rabbit anti-human SOD1 antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) or rabbit polyclonal anti a-actin antibody (1:1000, Sigma-Aldrich, Poole, UK) 
followed by a horseradish peroxidase-conjugated secondary antibody (Dako, Glostrup 
Denmark). Blots were developed using ECL reagent (Amersham Biosciences, 
Buckinghamshire, UK) and band area quantified using Image J software (NIH, 
Bethesda, MA, USA).
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CHAPTER 3
THE INFLUENCE OF MUTANT SOD1 EXPRESSION IN 
ASTROCYTES ON MOTONEURON PROPERTIES IN AN
I N  V I T R O  MODEL OF ALS
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3.1. INTRODUCTION
3.1.1. Physiological function of astrocytes in the CNS
In the vertebrate CNS, glial cells are subdivided into two distinct classes: microglia and 
macroglia. Microglia are macrophage-like cells that are mobilised after injury, infection 
or disease and have a phagocytic function. Macroglial cells consist of oligodendrocytes, 
which, similar to Schwann cells that are present in the periphery, function to myelinate 
neurons, and astrocytes, the ‘supporting cells’ of the CNS, the functions of which will 
be discussed below.
In the mature CNS, astrocytes form an interconnecting network through gap junction 
communication. Gap junctions consist of two hemi-channels, each comprised of a 
hexagonal assembly of connexin proteins that are inserted in each glial membrane and 
form hydrophobic pores. Gap junctions allow the transport of ions and small molecules, 
including signalling molecules and various metabolites, between neighbouring cells 
(reviewed in Giaume & McCarthy, 1996). Astrocytic processes also make contact with 
both blood capillaries and numerous neurons, permitting additional intercellular 
trafficking (reviewed in Araque et al., 2001). Furthermore, direct contact with astrocytes 
is necessary for the formation of tight junctions between endothelial cells, which forms 
the basis of the blood brain barrier. Tight junctions occlude the intercellular spaces 
between endothelial cells rendering the brain capillaries highly impermeable (Tao- 
Cheng et al., 1987).
3.1.2. Neuronal-astrocyte interaction
Initially astrocytes were thought to be passive, supporting cells in the CNS, the so called 
nerve “glue” (Virchow, 1958). However, there is now substantial evidence to suggest 
that astrocytes provide metabolic and trophic support to neurons. Furthermore, evidence
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of bidirectional communication between neurons and astrocytes and their close spatial 
association indicates that astrocytes form an integral component of the synapse in that 
they act to modulate both neuronal activity and synaptic transmission (reviewed in 
Vemadakis, 1996; Kirchoff et al., 2001).
3.1.2.1. Neurite outgrowth
There is both in vitro and in vivo evidence to suggest that during development 
astrocytes are involved in axonal migration and neurite outgrowth. Astrocytes secrete a 
variety of growth factors, cytokines, proteases and protease inhibitors, with expression 
varying depending on developmental stage and the extracellular environment 
(Eddleston & Mucke, 1993; Mizuno et al., 1994). Furthermore, astrocytes express 
numerous cell adhesion molecules, including integrins, N-CAM, N-cadherin and LI 
glycoprotein (Tomaselli et al., 1988; Matsunaga et al., 1988; Doherty et al., 1990, 1991; 
Williams et al., 1992). Astrocytes also produce various extracellular matrix molecules, 
thereby encouraging specific cellular interactions (Sanes, 1989; Venstrom & Reichardt, 
1993; Letoumeau et al., 1994). However, there is also a subpopulation of astrocytes that 
are restrictive to neurite outgrowth and exert axonal guidance through the formation of 
inhibitory boundaries, which are impenetrable to axons (Steindler et al., 1990). This is 
achieved by the production of non-permissive extracellular matrix molecules, such as 
tenascin and chondroitin sulphate proteoglycan (Snow et al., 1990; reviewed in Powell 
et al., 1997).
3.1.2.2. Metabolic support
The contact of astrocytic processes with both neurons and blood capillaries makes 
astrocytes an ideal intermediate for the provision of nutrients and other essential 
substances to neurons. Furthermore, the selective expression of certain metabolic
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enzymes in astrocytes indicates a metabolic coupling between astrocytes and neurons. 
Indeed, in response to enhanced neuronal activity, glycogen stores in astrocytes are 
mobilised to provide glucose for neurons (Forsyth et al., 1996). Furthermore, the 
sodium-dependent uptake of glutamate by astrocytic transporters activates the Na+/K+ 
ATPase, stimulating glycolysis and the production of lactate, which can be used by 
neurons to maintain oxidative phosphorylation (Walz & Mukeiji, 1988).
Neurons also rely on astrocytes for the provision of several essential precursors. For 
example, following uptake by astrocytic transporters, glutamate is metabolised to 
glutamine by glutamine synthetase, an enzyme selectively found in astrocytes and 
oligodendrocytes (Norenberg & Martinez-Hemandez, 1979; Tansey et al., 1991). 
Released glutamine is subsequently taken up by neurons and recycled to glutamate by 
the enzyme glutaminase (Kirchoff et al., 2001). Astrocytes also supply neurons with 
cysteine and glycine, which, together with glutamine, are essential for the synthesis of 
glutathione, therefore enhancing the antioxidant capacity of neurons (Dringen et al., 
1999).
3.I.2.3. Modulation of neuronal activity and synaptic transmission
One of the primary functions of astrocytes is to maintain interstitial ionic homeostasis, 
in particular regulating the extracellular potassium concentration. Neuronal activity 
induces substantial alterations in the extracellular ionic concentration of potassium and 
protons, which can be detrimental to neuronal function if not regulated (Newman,
2003). Astrocytes are highly permeable to potassium and can therefore buffer changes 
in extracellular potassium in the synaptic cleft. Furthermore, cultured astrocytes express 
various ion channels and can therefore respond to changes in the extracellular ionic 
environment as a consequence of neuronal activity (Vemadakis, 1996).
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The expression of neurotransmitter receptors on their plasma membrane provides 
further evidence that astrocytes are not simply a passive structure at the synapse. 
Activation of astrocytic ionotropic and metabotropic glutamate receptors for example, 
evokes an elevation in intracellular calcium levels in isolated brain slices (reviewed in 
Araque et al., 2001). This occurs primarily by the release of calcium from intracellular 
ER stores. Local elevations in astrocytic calcium levels can initiate calcium oscillations 
within the same cell (Pasti et al., 1997; Carmignoto, 2000) or can initiate a calcium 
wave that propagates to neighbouring astrocytes either by diffusion of sufficient 
concentrations of IP3 through gap junctions or through the release of ATP, which can 
act on disconnected astrocytes (Comell-Bell et al., 1991; Bruner & Murphy, 1993; 
Guthrie et al., 1999). Neuronal activity and subsequent astrocytic calcium signalling can 
regulate astrocyte communication either by short-term modulation of gap junction 
activity or long-term regulation of the expression of connexin proteins (Giaume & 
McCarthy, 1996).
Interestingly, in response to elevated astrocytic calcium, adjacent neurons in vitro show 
a similar increase in cytosolic calcium, an effect that is susceptible to blockade by 
glutamate receptor antagonists (Nedergaard, 1994; Hassinger et al., 1995; Pasti et al., 
1997; Araque et al., 1998a). Indeed, cultured astrocytes have been shown to release 
glutamate in a calcium-dependent manner (Parpura et al., 1994). Therefore, astrocytes 
can potentially modulate the activity of distant synapses in addition to the active 
synapse through the propagation of calcium waves and the release of glutamate (Araque 
et al., 1999b). Astrocyte-mediated changes in neuronal calcium may influence calcium- 
dependent membrane transport mechanisms or the actions of metabolic or regulatory 
enzymes, with subsequent effects on ionic homeostasis or neurotransmitter metabolism 
and ultimately synaptic transmission (Araque et al., 2001).
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Astrocytes can modulate synaptic transmission directly via glutamate release, which can 
activate postsynaptic neurons in vitro, eliciting a depolarising slow inward current, 
consequently regulating neuronal excitability (Araque et al., 1998a, 1999). Furthermore, 
astrocyte-derived glutamate can activate presynaptic metabotropic or ionotropic NMDA 
receptors subsequently depressing or enhancing neurotransmitter release, respectively 
(Araque et al., 1998a, 1998b). Similarly, astrocyte-derived ATP can exert stimulatory or 
inhibitory effects on neuronal activity (Newman, 2003). Interestingly, the extent of the 
astrocytic calcium response appears to be dependent on the frequency of presynaptic 
neuronal activity. This suggests that neuronal activity can actually regulate the extent of 
astrocyte-mediated modulation of synaptic transmission (Pasti et al., 1997).
Indirect modulation of synaptic transmission mediated by astrocytes occurs through the 
uptake of neurotransmitters and neuromodulators at the synapse, including glutamate, 
GAB A and taurine. In most CNS regions, sodium-dependent glutamate uptake by the 
astroglial transporter, GLT-1 predominates (Tanaka et al., 1997), although the astroglial 
GLAST and the neuronal EAAC1 transporters also contribute (Rothstein et al., 1996). 
The uptake of glutamate into astrocytes provides a mechanism by which the action of 
glutamate is terminated, thereby preventing excess activation of synaptic glutamate 
receptors and further modulating synaptic transmission.
3.1.3. Role of astrocytes in neuronal injury
In response to a wide variety of neuronal insults, astrocytes proliferate and assume a 
hypertrophic morphology associated with alterations in gene expression, for example an 
increase in glial fibrillary acidic protein (GFAP) and vimentin expression (Ridet et al., 
1997; John et al., 2003; Barbeito et al., 2004). Reactive changes in morphology are 
often accompanied by increased production of cytokines, growth factors, matrix
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proteins, cell adhesion molecules, proteases and protease inhibitors (Ridet et al., 1997). 
The molecular signals that initiate reactive astrogliosis are largely undefined, although 
several cytokines have been implicated, including IL-lp, IFNy, TGFPi and TNFa (John 
et al., 2003). Indeed, injection of IL-ip into the CNS initiates reactive astrogliosis 
(Giulian et al., 1988), and in response to IL-lp astrocytes express various neurotoxic 
factors (Toulmond et al., 1996). Several growth factors are also implicated in the 
induction of reactive astrogliosis, including fibroblast growth factor-2 (FGF-2) and 
ciliary neurotrophic factor (CNTF), which promote morphological changes in cultured 
astrocytes and increase expression of GFAP (Perraud et al., 1988; Winter et al., 1995; 
Clatterbuck et al., 1996). However, the role of reactive astrocytosis is not fully clarified, 
therefore under certain circumstances reactive astrocytes may provide a permissive 
environment for regeneration. However, there is also evidence to suggest that 
astrocytosis plays an active role in neuronal degeneration (Ridet et al., 1997).
3.I.3.I. Evidence for a neuroprotective influence of reactive astrocytosis
Astrocytes have been shown to secrete various neurotrophins, including basic FGF, 
nerve growth factor, interleukin- 6  (IL-6 ), and epidermal growth factor, all of which 
promote neuronal survival. Therefore reactive astrocytosis may actually encourage 
neuronal regeneration. In support of this possibility, ablation of reactive astrocytes 
enhances neuronal degeneration in vivo in response to a CNS stab injury (Bush et al., 
1999). Furthermore, treatment with CNTF, an IL- 6  analogue that induces astrogliosis 
and GFAP overexpression, can promote motoneuron survival in vitro (Winter et al., 
1996; Albrecht et al., 2002). Similarly, induction of reactive astrogliosis via activation 
of the glial L-imidazoline receptor, protects motoneurons after axotomy, due to an 
associated up-regulation of GLT-1 and FGF-2 expression in astrocytes and 
motoneurons respectively (Casanovas et al., 2000). Indeed, functional astrocyte-induced
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FGF-2 expression may exert neuroprotection via NMD A receptor suppression (Mattson 
et al., 1993) and increased expression of antioxidant enzymes (Mattson et al., 1995). 
Moreover, the up-regulation of astrocytic cell adhesion and extracellular matrix 
molecules will provide a suitable environment for regeneration (reviewed in Ridet et al., 
1997). Indeed, following exposure to NO donors, astrocytes promote neuronal survival 
in vitro through a neurotrophic effect of the extracellular matrix molecules, fibronectin 
and laminin that maintain neuronal-astrocyte interaction (Tanaka et al., 1999).
Astrocytes have a higher oxidative capacity than neurons and therefore can scavenge 
ROS and other toxic metabolites produced by degenerating neurons (Slivka et al., 
1987), thereby minimising the spread of neurodegeneration. Astrocytes are able to 
rapidly detoxify hydrogen peroxide via glutathione peroxidase (Dringen et al., 1998) or 
catalase (Desagher et al., 1996), and in vitro astrocytes protect neurons from NO- 
mediated toxicity by a glutathione-dependent mechanism (Chen et al., 2001). Astrocytes 
may also enhance the endogenous ability of neurons to protect against neurotoxic 
insults, for example by increasing the provision of antioxidant precursors. Furthermore, 
astrocytes can augment the heat shock response of neurons via the release and transfer 
of the cytoprotective heat shock protein, hsp70, to neurons (Tytell et al., 1986; 
Hightower & Guidon, 1989). Indeed, overexpression of Hsp70 can protect motoneurons 
in vivo after sciatic nerve crush (Kalmar et al., 2002).
A consequence of astrocyte proliferation may be enhanced glutamate uptake from the 
synaptic cleft. This function is vital to protect neurons from the excitotoxic effects of 
glutamate and the activation of downstream neurotoxic cascades (Choi, 1992). Indeed, a 
neuroprotective role of astrocytes has been shown in response to various excitotoxic
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agents, an effect due at least partly to GLT-1-mediated uptake from the extracellular 
space (Sugiyama et al., 1989; Rosenberg et al., 1992; Rothstein et al., 1996).
3.I.3.2. Evidence for detrimental actions of reactive astrogliosis
There is, however, significant evidence to suggest that reactive astrocytes may actually 
play an active role in the induction of neuronal death. In vitro, resting astrocytes support 
neuronal growth in the absence of exogenous trophic factors. However, neuronal 
survival is reduced following the activation of astrocytes due to insufficient trophic 
support (Pehar et al., 2004). Moreover, ablation of GFAP-positive reactive astrocytes 
has been shown to enhance local neurite outgrowth in vivo following a CNS stab injury 
(Bush et al., 1999). Activation of astrocytes increases expression of the non-permissive 
molecules, GFAP and vimentin, suggesting a detrimental action of reactive astrocytes 
on neuronal regeneration (Emsley et al., 2004).
In addition to the trophic factors discussed in Chapter 3.I.3.I. activated astrocytes also 
release a variety of neurotoxic molecules. Pro-inflammatory cytokines, such as TNFa 
and IL-ip, can induce COX2 expression, via activation of the transcription factor NF- 
k B  (Consilvio et al., 2004; Juttler et al., 2004). COX2 activation generates 
prostaglandins, including PGE2, which may actually contribute to excitotoxicity by 
stimulating glutamate release (Drachman & Rothstein, 2000), and in addition releases 
reactive oxygen species (ROS), which may further propagate the inflammatory process 
(Consilvio et al., 2004).
Cytokine-mediated activation of inducible nitric oxide synthase (iNOS), the expression 
of which is restricted to astrocytes, may also contribute to neuronal degeneration. Under 
normal physiological conditions, NO functions as a neurotransmitter in the CNS
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(Garthwaite et al., 1991; Moncada et al., 1991). However, inappropriate production of 
NO can induce neurotoxicity, although astrocyte viability, in contrast, appears 
unaffected by NO (Bolanos et al., 1994; Stewart et al., 2000). High concentrations of 
NO can bind to complex IV and reversibly inhibit respiration (Brown & Cooper, 1994). 
Furthermore, peroxynitrite, generated via the reaction of NO with superoxide, can 
mediate irreversible inhibition of complexes I, II and II/III (Brookes et al., 1998; 
Stewart et al., 2000; Jekabsone et al., 2003). Inhibition of respiration induces 
mitochondrial depolarisation, which can subsequently lead to depletion of cellular ATP 
levels. NO may also initiate glutamate release, inducing excitotoxicity (Bal-Price & 
Brown, 2001). Furthermore, in models of NMD A receptor-mediated excitotoxicity, NO 
acts synergistically with elevated intracellular calcium to induce neuronal death in vitro 
(Hewett et al., 1994; Keelan et al., 1999; Comoletti et al., 2001; Solenski et al., 2003).
Glutamate uptake via astrocytic glutamate transporter proteins, GLT-1 and GLAST, 
represents another target for peroxynitrite-mediated damage (Trotti et al., 1996). 
Reduced expression or function of astrocytic transporters may have significant 
consequences for neuronal viability, as elevations in extracellular glutamate can mediate 
excitotoxic damage through sustained activation of neuronal glutamate receptors (Choi, 
1992).
3.1.4. Involvement of astrocytes in ALS
3.1.4.1. Evidence for the involvement of astrocytes in ALS
The degeneration of upper and lower motoneurons in ALS is accompanied by profound 
astrocytosis in post-mortem human ALS tissue (Hirano, 1996; Schiffer et al., 1996; Hall 
et al., 1998). In mutant SOD1 mice reactive astrogliosis is evident from disease onset 
and increases steadily with disease progression (Hall et al., 1998; Levine et al., 1999;
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Alexianu et al., 2001; Elliott et al., 2001). Reduced expression of the astroglial 
transporter protein GLT-1 in post-mortem spinal cord tissue from ALS patients, with an 
associated reduction in glutamate transport and corresponding elevation of CSF 
glutamate levels, indicates functional astrocytic deficits (Rothstein et al., 1991, 1992, 
1995; Spreux-Varoquaux et al., 2002). Furthermore, a mutation in GLT-1 has been 
identified in one sALS patient, which reduces plasma membrane expression and 
glutamate uptake by the transporter (Trotti et al., 2001). Inclusions in astrocytes are one
p o r n
of the earliest pathological features seen in SOD1 mice, occurring before the 
appearance of symptoms, and are accompanied by reductions in GLT-1 expression by 
end-stage disease (Bruijn et al., 1997b; Rothstein et al., 2005). Moreover, increased 
nitrotyrosine immunoreactivity (Sasaki et al., 2001) and expression of poly (ADP- 
ribose) polymerase (PARP), an enzyme activated by DNA damage, are evident in 
astrocytes from mutant SOD1 mice, indicating that oxidative damage to astrocytes is 
occurring in ALS (Kim et al., 2003). Therefore alterations in non-neuronal cell 
functions are likely to contribute to ALS pathogenesis.
The generation of transgenic mice with the selective expression of mutant SOD1 in 
either motoneurons or astrocytes supports the proposal that ALS is a non-cell
p o / ' n
autonomous disorder. Expression of mutant SOD1 under the control of the GFAP 
promoter produces significant astrocytosis in transgenic mice, although to a lesser
p o / ' n
extent than in SOD1 mice in which mutant SOD1 is expressed ubiquitously. 
Furthermore, large ventral horn motoneurons display no significant morphological 
changes and do not undergo degeneration in these mice, therefore suggesting that 
mutant SOD 1-expressing astrocytes alone do not mediate disease (Gong et al., 2000). 
However, selective neuronal expression of SOD 1093A, using a NF-L chain promoter, 
similarly does not induce motoneuron degeneration in transgenic mice (Pramatarova et
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al., 2001). A selective elevation of mutant S0D1G93A expression in postnatal 
motoneurons also has no influence on disease progression (Lino et al., 2001). This 
suggests that interaction between mutant SOD 1-expressing neurons and mutant SOD1- 
expressing astrocytes is necessary for the development of ALS. Indeed, Ferri et al, 
(2004) demonstrated that for the induction of neuronal apoptosis in an in vitro co­
culture model, the expression of mutant SOD1 in both neuroblastoma and glioblastoma 
cell lines is necessary. Moreover, the generation of chimeric mice, with varying 
expression of mutant and endogenous SOD1 (WT) in motoneurons and non-neuronal 
cells, further clarified the importance of the non-neuronal environment to disease 
progression (Clement et al., 2003). In these mice, the presence of WT non-neuronal 
cells significantly protects mutant SOD1 motoneurons from degeneration, whereas an 
environment of mutant SOD 1-expressing non-neuronal cells induces the formation of 
ubiquitinylated intracellular aggregates in WT motoneurons (Clement et al., 2003). 
Together these findings provide definitive evidence that glial cells make a significant 
contribution to ALS pathogenesis.
The appearance of reactive astrocytosis coincidently with symptom onset in mutant 
SOD1 mice suggests that in ALS astrocyte activation occurs in response to neuronal 
degeneration, as a significant proportion of motoneurons have already been lost by the 
onset of disease symptoms (Chiu et al., 1995; Levine et al., 1999; Sharp et al., 2005). 
Activation of astrocytes in ALS may occur through the release of pro-inflammatory 
cytokines and free radicals by motoneurons and microglial cells (reviewed in Barbeito 
et al., 2004). Rao et al, (2003) suggested that ROS generated by damaged motoneurons 
could be released to exert oxidative damage on surrounding astrocytes. Indeed, 
exposure of astrocytes to peroxynitrite induces a phenotypic change that renders 
cultured astrocytes toxic to motoneurons (Cassina et al., 2002). Furthermore, Levine et
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al, (1999) demonstrated that the processes of reactive astrocytes extend towards and 
wrap around degenerating motoneurons in SOD1G93a mice. This close spatial 
association combined with their extensive functional interaction provides a mechanism 
through which altered astrocytic function may actually actively participate in the 
process of neuronal degeneration (Levine et al., 1999).
3.1.4.2. Potential mechanisms of reactive astrocyte-induced toxicity in ALS
i) Production of pro-inflammatory molecules
In ALS, reactive astrocytes synthesise and secrete elevated levels of pro-inflammatory 
cytokines and ROS in vitro, which may act to propagate the inflammatory reaction via 
further recruitment and activation of astrocytes and microglia, thereby exerting neuronal 
damage (Levine et al., 1999; reviewed in Barbeito et al., 2004). Indeed, the expression 
of the pro-inflammatory marker COX2 and the transcription factor NF-kB are 
significantly increased in astrocytes in post-mortem spinal cord tissue from ALS 
patients (Migheli et al., 1997; Maihofner et al., 2003). COX2 activation induces the 
formation of prostaglandins such as PGE2 that can stimulate the release of glutamate 
from astrocytes. Consistent with these findings it has been shown that selective COX2 
inhibition protects motoneurons in organotypic spinal cord cultures from excitotoxic 
damage and extends the lifespan of SOD 1093A mice (Drachman & Rothstein, 2000, 
2002; Pompl et al., 2002).
ii) Inducible NOS
In SOD1G93a mice, the expression and activity of iNOS is upregulated in astrocytes 
from an early symptomatic stage of disease and may contribute to disease propagation 
(Aimer et al., 1999). Furthermore, the expression of mutant SOD1 induces activation of 
a glioblastoma cell line with an accompanying up-regulation of neuronal NOS (Ferri et
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al., 2004). Astrocytes are relatively resistant to the toxic effects of NO (Bolanos et al., 
1994). However, astrocyte-derived NO mediates motoneuron death in vitro (Cassina et 
al., 2002), possibly through irreversible damage to the mitochondrial electron transport 
chain (Brookes, et al., 1998; Stewart et al., 2000). Interestingly, Raoul et al, (2002) 
demonstrated that cultured motoneurons are selectively vulnerable to a subtype of Fas- 
mediated cell death that is enhanced by NO. Furthermore, expression of the p75NTR 
death receptor is upregulated in motoneurons in post-mortem spinal cord tissue from 
ALS patients (Seeburger et al., 1993) and activation, via NGF released by reactive 
astrocytes, initiates motoneuron death in a NO-dependent manner in vitro (Pehar et al.,
2004). NO-mediated toxicity may involve the generation of peroxynitrite, which can 
exert substantial cellular damage, via nitration of tyrosine residues. Correspondingly, 
levels of 3-nitrotyrosine are elevated in motoneurons in post-mortem spinal cord tissue 
from sALS and fALS patients (Beal et al., 1997; Ferrante et al., 1997).
Peroxynitrite also exerts a dose-dependent inhibition of glutamate transporter activity 
(Trotti et al., 1996) and in Xenopus oocytes co-expression of GLT-1 with mutant SOD1, 
which may induce oxidative stress, inhibits glutamate transport (Trotti et al., 1999). 
Selective inhibition of the astrocytic GLT-1 transporter protein initiates motoneuron 
loss (Damian et al., 2004) and progressive paralysis in mice in vivo (Rothstein et al., 
1996). Furthermore, in organotypic spinal cord cultures, chronic inhibition of glutamate 
transport induces selective motoneuron degeneration (Rothstein et al., 1993). 
Conversely, restoration of GLT-1 activity, either by pharmacological enhancement 
(Rothstein et al., 2005) or by introduction of glial progenitor cells overexpressing GLT- 
1, significantly increases motoneuron survival in this model (Maragakis et al., 2005). 
Elevated extracellular glutamate is hypothesised to contribute to ALS pathogenesis 
through the activation of neuronal glutamate receptors, as described in Chapter
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1.3.4.2., although it may also induce astrocytic glutamate release (Levi et al., 1992), 
which will further exacerbate neuronal injury (Parpura et al., 1994).
3.1.4.3. Potential neuroprotective actions of reactive astrocytes in ALS
In contrast, an increase in motoneuron survival in vivo following peripheral nerve injury 
is shown in the presence of activated astrocytes, which up-regulate motoneuron FGF-2 
expression (Casanovas et al., 2000). Furthermore, an increase in secretion of GDNF by 
reactive astrocytes exerts neuronal protection in co-cultures exposed to excitotoxic 
stimuli (Palantina et al., 2005).
3.1.5. Hypothesis to be tested
The majority of evidence suggests that the activation of astrocytes in the spinal cord 
contributes to motoneuron degeneration in ALS. To investigate the influence astrocytes 
may exert on motoneurons at a cellular level, a co-culture model was designed whereby 
WT or SOD1G93a motoneurons were co-cultured with WT or S0D1G93A astrocytes. The 
effect of expression of mutant SOD1 in astrocytes was then investigated on a variety of 
motoneuron responses under basal conditions and following excitotoxic stimuli, using 
confocal microscopy.
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3.2. METHODS
3.2.1. Primary cultures
Primary astrocyte and motoneuron cultures were prepared as detailed in Chapters 2.4 
and 2.5 respectively. The genotype of each pup or embryo was determined prior to 
culturing, using PCR as described in Chapter 2.3, and the spinal cords were pooled 
according to genotype, either WT or SOD 1093A, and each genotype was cultured 
separately. Astrocytes were maintained in a 37°C, 5% CO2 humidified incubator for 
between 2 and 3 weeks until confluency was reached. Astrocytes were then placed in a 
37°C environmental shaker and rotated at 160rpm for 18 hours in order to dislodge 02A 
progenitor cells and microglia (Robb & Conner, 1998). These cultures were then 
returned to the incubator for 7-10 days. After approximately 3 weeks in vitro, mixed 
ventral horn cells were plated onto the enriched astrocyte layers, as previously described 
in Chapter 2.5. Co-cultures were kept at 37°C in a 5% CO2 humidified incubator for a 
minimum of 7 DIV before undergoing any imaging protocol or drug treatment.
3.2.2. Immunocytochemistry
Co-cultures were immunostained with a primary antibody to the human SOD1 enzyme 
(1:500; Sigma-Aldrich, Poole, UK). This antibody was raised in the mouse and 
therefore the mouse on mouse immunocytochemistry protocol was used, as detailed in 
Chapter 2.9. To determine the percentage of astrocytes within the enriched astrocyte 
layer, glial cultures were immunostained for GFAP (according to the protocol detailed 
in Chapter 2.8; 1:100; Chemicon) and DAPI (0.01%) and the percentage of DAPI 
stained, GFAP positive cells were calculated.
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3.2.3. Dye loading
Co-cultured motoneurons (7-10 DIV) and astrocytes were mounted in custom built 
imaging chambers and bathed in standard recording medium (RM), as detailed in 
Chapter 2.6. Table 2.2 details the loading procedure for the fluorophores used in this 
chapter. All experiments were performed at room temperature.
3.2.4. Confocal imaging
Dye-loaded cells were placed onto the microscope stage and the microscope optics were 
configured according to the fluorophores used, as detailed in Table 2.3. Suitable 
dichroic mirrors were used for each fluorophore in order to separate the excitation from 
the emission signal. Detector gain, amplifier offset and amplifier gain were maintained 
constant throughout an experimental series. In contrast, the laser power was adjusted to 
optimise the signal, as the linear relationship between laser power and fluorescent 
intensity allowed correction for changes in laser power, which was maintained between 
0.05% and 1% of the total laser output. For the majority of experiments the pinhole was 
opened to a confocal thickness of approximately 2pM to optimise light collection. 
However, the pinhole was opened fully in experiments in which superoxide sensing 
fluorophore, HEt, was used or if NADH autofluorescence was measured.
Images were acquired every 30 seconds prior to drug addition, to minimise 
photodamage. Drugs were made up in 0.5ml aliquots of RM and applied by means of 
RM replacement. The drugs applied and their working concentrations are listed in 
Table 3.1. Following drug addition the scan interval was reduced to 0 seconds to allow 
detailed analysis of the response to drug addition. After 5 minutes of drug incubation, a 
30 second interval between scans was re-introduced to minimise photodamage. Each 
signal was detected by a photomultiplier tube, after passing through an appropriate
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Table 3.1 -  Concentrations of drugs used in imaging experiments
Drug used Concentration Drug Action
Kainate lOOpM Kainate receptor agonist
Glutamate 40pM Glutamate receptor agonist
Carbonyl cyanide p- 
trifluoromethoxyphenyl 
hydrazone (FCCP)
lpM Mitochondrial uncoupler (proton 
ionophore)
Cyanide ImM Inhibitor of complex IV
Rotenone 20pM Inhibitor of complex I
MK-801 20pM NMDA receptor antagonist
CNQX 20pM AMPA/KA receptor antagonist
MCPG ImM Metabotropic glutamate receptor 
antagonist
MK-801 - (5R,10S)-(+)-5-Methyl-10,ll-dihydro-5H-dibenzo [a,d] cyclohepten-5,10- 
imine hydrogen maleate
CNQX -  6-cyano-2,3-dihydroxy-7-nitro-qunioxaline.
MCPG - +(RS)-a-methyl-4-carboxyphenylglycine
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bandpass or longpass filter, as detailed in Chapter 2.6.2. Unless otherwise stated 
images were acquired using the x40 objective lens.
3.2.5. Imaging using the interline-transfer cooled CCD camera
Cells loaded with fura 2-FF according to Table 2.2 were imaged using an interline- 
transfer cooled CCD camera, as described in Chapter 2.6.2.ii. Sequential excitation of 
cells at 340nm and 380nm, which corresponds to the excitation of calcium-bound and 
calcium-free fura 2-FF, allows the ratiometric measurements of fura 2-FF fluorescence. 
Data were acquired every 10 seconds and cells were protected from phototoxicity by 
interposing a computer-controlled shutter in the light path between exposures.
3.2.6. Image analysis
Images were collected using Zeiss ‘LSM’ software or Kinetic Imaging ‘Acquisition 
Manager’ for confocal and CCD microscopy respectively, and analysed using Lucida 
version 5.0 image analysis software as described in Chapter 2.6.3. Experiments to 
investigate the resting mitochondrial membrane potential were analysed using 
Metamorph software (Universal Imaging Corporation, Downingtown, PA, USA), as 
described in Chapter 2.6.3. At least 3 experiments were performed for each 
experimental parameter, using co-cultures prepared on different days.
To calculate the extent of mitochondrial membrane potential (AvFm) depolarisation, the 
TMRM data was normalised, whereby the resting AvFm was given a value of 1 and the 
minimum AvFm attained after the addition of the mitochondrial uncoupler, FCCP, was 
given a value of 0. Normalisation was carried out to account for the variation in the 
resting A'Pm and allowed a more comprehensive evaluation of AT'm depolarisation.
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3.2.7. Motoneuron survival in vitro
At 7-10 DIV, cultured motoneurons were divided into five treatment groups: no 
treatment, lOOpM AMP A (excitotoxic agent), 200pM AMP A, lOOpM hydrogen 
peroxide (H2O2 ; inducer of oxidative stress) or 200nM staurosporine (STN; inducer of 
apoptosis). Treatment was implemented for 24 hours and the effect of treatment was 
assessed using the Trypan Blue exclusion method, as described in Chapter 2.7. The 
cultures were then fixed using 4% PFA and immunostained for MAP-2, a pan-neuronal 
marker. Motoneurons surviving were subsequently identified according to 
morphological criteria:
i) a cell body diameter > 15 pm
ii) the presence of at least 3 neuritic processes.
3.2.8. Statistical analysis
Statistical significance between mean values or the slope of the fitted lines (depending 
on experiment) was assessed using a Mann-Whitney U test in Sigma Stat (version 2.03, 
Erkrath, Germany). Significance between baseline cytosolic and mitochondrial calcium 
levels was assessed using one way repeated measures ANOVA. Values are expressed as 
mean ± standard error of the mean (S.E.M). Significance was set at p < 0.05.
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3.3. RESULTS
In this Chapter, a co-culture model of motoneurons and spinal cord astrocytes was 
developed to assess the influence of astrocytes on motoneuron degeneration in ALS. 
The effect of expression of mutant SOD1 in either motoneurons or astrocytes was 
evaluated on various cellular properties under both basal and excitotoxic conditions, 
using confocal microscopy in conjunction with a variety of fluorimetric indicators.
3.3.1. Co-culture immunocytochemistry
WT or SOD 1093A motoneurons were plated onto an enriched layer of either WT or 
S0D1G93A astrocytes and the identity of the cells in the differing co-culture conditions 
was confirmed by immunostaining at 7DIV. Figure 3.1 shows examples of co-cultures 
immunostained for the human SOD1 antibody: A, WT neurons cultured on WT 
astrocytes (WTnWTa), B, SODG93A neurons on WT astrocytes (SODnWTa), C, WT 
neurons on SOD1G93a astrocytes (WTnSODa) and D, SOD1G93a neurons on S0D1G93A 
astrocytes (SODnSODa). The glial layer consisted of approximately 99% astrocytes 
and the identity of astrocytes was confirmed by GFAP immunoreactivity (data not 
shown). Characterisation of the co-cultures revealed that approximately 48% of the 
neuronal cells were motoneurons, as determined by immunostaining with the pan 
neuronal marker MAP-2, and morphological criteria as described in Chapter 3.2.8..
3.3.2. The effect of expression of mutant SOD1 on resting cellular properties of 
motoneurons and astrocytes
A number of resting cellular properties were assessed at 7-10 DIV, in order to 
investigate the potential influence of astrocyte genotype, either WT or S0D1G93A, on the 
cellular properties of both motoneurons and astrocytes in co-culture.
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Figure 3.1 -  Immunostaining of co-cultures with primary antibody to human 
SOD1
The photomicrographs show examples of the 4 different co-cultures stained with a 
primary antibody to human SOD1: (A) WT motoneurons on WT astrocytes (WTnWTa), 
(B) SOD 1093A motoneurons on WT astrocytes (SODnWTa), (C) WT motoneurons on 
S0D1G93A astrocytes (WTnSODa) and (D) S0D1G93A motoneurons on SOD G93A 
astrocytes (SODnSODa). The arrow indicates a typical motoneuron identified according 
to the morphological criteria used in these experiments.
Scale bar = 50pm.
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3.3.2.1. Resting cytosolic and mitochondrial calcium levels in motoneurons
Co-cultures were loaded with fura 2-FF, a low affinity, ratiometric calcium indicator, 
and the effect of expression of mutant SOD1 on basal cytosolic calcium levels ([Ca2+]c)
94 -in motoneurons was assessed. Resting [Ca ]c was expressed as a ratio between the 
fluorescence excited at 340nm and the fluorescence excited at 380nm. The mean basal 
[Ca ]c under differing co-culture conditions is summarised in Table 3.2. Interestingly, 
motoneurons from SODnSODa co-cultures (n = 17) had a significantly lower resting 
[Ca2+]c compared to motoneurons from WTnWTa (n = 18), SODaWTn (n = 19) and 
WTnSODa (n = 22; p < 0.015) co-cultures. This finding was corroborated using fluo 4, 
a less quantitative, high affinity calcium indicator. The fluo 4 signal was also 
significantly lower, which was consistent with a lower resting [Ca2+]c, in motoneurons 
from SODnWTa and WTnSODa co-cultures than motoneurons from WTnWTa co­
cultures (p < 0.001). However, this finding was not confirmed using the more 
quantitative indicator, fura 2-FF. These results indicated that the expression of mutant 
SOD1 protein in both motoneurons and astrocytes was required to lower [Ca2+]c. There 
were no significant differences in the resting [Ca2+]c of astrocytes from any co-culture
(p > 0.2).
Resting mitochondrial calcium levels ([Ca2+]m) were assessed using rhod 5N, a calcium 
indicator that accumulates in mitochondria, using a x63 oil immersion objective lens. 
Rhod 5N is sequestered into the mitochondria due to the electrochemical gradient and is 
then retained in the mitochondria following cleavage of the AM ester by mitochondrial 
esterases. Resting [Ca2+]m values are summarised in Table 3.2. In contrast to the basal 
[Ca2+]c, resting [Ca2+]m was significantly elevated in motoneurons from SODnSODa co­
cultures (n = 14) compared to motoneurons from WTnWTa co-cultures (n = 7; p < 
0.005). Interestingly, the resting [Ca2+]m of motoneurons from SODnWTa (n = 9) and
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Table 3.2 -  Baseline levels of cytosolic and mitochondrial calcium in motoneurons
A i *
Cytosolic calcium levels ([Ca ]c) were assessed in WT and SOD1 motoneurons 
cultured with either WT or SOD1G93a astrocytes using the ratiometric, low affinity
^  I
calcium indicator, fura 2-FF. Resting [Ca ]c was expressed as a ratio between the 
fluorescence excited at 340nm and the fluorescence excited at 380nm and the mean 
values are summarised in the Table. The Table also shows the mean baseline [Ca2+]c 
measured with fluo 4, a less quantitative fluorophore. Basal mitochondrial calcium 
levels ([Ca ]m) were assessed using the cationic mitochondrial calcium indicator rhod
^  I
5N. The effects of expression of mutant SOD1 on the basal [Ca ]m in motoneurons are 
also summarised in the Table. Values represent the mean basal level ± standard error of 
the mean. *** p < 0.005 indicates a significant difference from WTnWTa. + p < 0.005 
indicates a significant difference from SODnWTa. p < 0.005 indicates a significant 
difference from WTnSODa.
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WTnWTa SODnWTa WTnSODa SODnSODa
Cytosolic
calcium
Motoneurons Fura 2-FF 
AM
± S.E.M.
0.483
± 0.002
0.475
± 0.003
0.481
± 0.005
0.455*** +n
± 0.002
n=  18 n = 19 n = 22 n=  17
Fluo 4 AM
(arbitrary
units)
± S.E.M.
2940
± 92.46
1756.4 ***
± 45.94
1113.2 ***
± 30.79
1216.1 ***
±32.2
n = 44 n = 30 n=  17 n = 34
Mitochondrial
Calcium
Motoneurons Rhod 5N 
AM
(arbitrary
units)
± S.E.M.
305.9
±4.55
437.9 ***
± 18.68
376.5 ***
± 10.18
497.3 ***+ 
±9.71
n = 7 n =9 n=  15 n = 14
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WTnSODa (n = 15) co-cultures was also significantly higher than in WTnWTa co­
cultures (n = 7; p < 0 .005). Furthermore, motoneurons from SODnSODa co-cultures
9 4 -had a significantly elevated resting [Ca ]m compared to motoneurons from SODnWTa 
co-cultures (p < 0.005), indicating that the expression of mutant SOD1 protein in both
y  I
astrocytes and neurons had a greater influence on resting [Ca ]m in motoneurons, 
although expression of mutant SOD1 protein in neurons alone did result in a significant
9+elevation in [Ca ]m at rest.
3.3.2.2. Spontaneous calcium activity in co-cultured cells
Co-cultured cells were loaded with fluo 4 and the spontaneous calcium activity of both 
motoneurons and astrocytes was recorded for a minimum period of 5 minutes. 
Examples of typical traces from SODnSODa co-cultures are shown in Figure 3.2 for
(A) motoneurons and (B) astrocytes. A motoneuron or astrocyte was determined to 
show spontaneous calcium activity if a transient intracellular calcium spike reached a 
minimum amplitude of 150 arbitrary units (a.u.) in fluo 4 intensity during the recording, 
to firmly distinguish spontaneous calcium activity from background noise. This allowed 
quantification of the percentage of cells that showed spontaneous calcium activity, as 
shown in Table 3.3. SOD 1093A motoneurons showed an increase in spontaneous 
calcium activity compared to WT motoneurons. In contrast, SOD 1093A astrocytes had 
reduced spontaneous calcium activity compared to WT astrocytes and this reduction
i  /*1Q ^  A
was enhanced if SOD1 astrocytes were cultured with SOD1 motoneurons.
3.3.2.3. Resting mitochondrial membrane potential
Co-cultures were loaded with TMRM, a highly lipid soluble, potentiometric indicator 
that has a single, delocalised positive charge and therefore becomes sequestered in 
mitochondria as a result of the electrochemical potential gradient between the cytosol
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Figure 3.2 -  Spontaneous calcium activity in co-cultured cells
Co-cultured were loaded with fluo 4 and the spontaneous calcium activity was recorded 
for a minimum period of 5 minutes. Typical traces from fluo 4 loaded (A) motoneurons 
and (B) astrocytes from SODnSODa co-cultures are illustrated. Each coloured trace 
represents the response from a single cell, 
s = seconds
153
A3000
2800 -
2600
2400 -  
^  2200- 
c  2000-
1800 -
1600 -
1400 -Ll_
1200 -
1000 -
800 -
600 -
400 0 50 100 150 200 250 300 350
Time (s)
B
2200
2000
1800 -
1600 -
1400 -
1200
1000 -
Ll_ 800
600
4 00 -
200 -
0 100 200 300 400 500
Time (s)
154
Table 3.3 - Spontaneous calcium activity in co-cultured cells
The spontaneous calcium activity of motoneurons and astrocytes from fluo 4 loaded co­
cultures was recorded for a minimum period of 5 minutes. The number of motoneurons 
or astrocytes from each of the 4 co-culture conditions that demonstrated spontaneous 
calcium activity, with an increase in fluo 4 intensity of 150 arbitrary units or more, to 
firmly distinguish between spontaneous calcium activity and background noise, during 
the recording was quantified, as shown in the table. It can be seen that S0D1G93A 
motoneurons had increased spontaneous calcium activity compared to WT 
motoneurons. In contrast, it appears that SODlG93A astrocytes had reduced spontaneous 
calcium activity compared to WT astrocytes and this reduction was enhanced if
  / ’" 'Q 'J  A  f - t Q ' j  *
SOD1 astrocytes were cultured with SOD1 motoneurons. Values represent the 
number of cells that show spontaneous calcium activity expressed as a percentage of the 
total number of cells from 3 different co-culture preparations, s = seconds.
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Motoneurons Astrocytes
WTnWTa 20.6% 71.4%
SODnWTa 31.1% 63.6%
WTnSODa 19.2% 69.6%
SODnSODa 36.8% 57.9%
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and mitochondria. Cells were imaged using a x63 oil immersion objective lens to obtain 
high spatial resolution, as shown in Figure 3.3. The mean resting mitochondrial 
membrane potential (AvFm), measured by TMRM signal, of motoneurons cultured under 
the different co-culture conditions is summarised in the bar chart shown in Figure 3.4A. 
Interestingly, both WT (n = 10) and SOD 1093A (n = 18) motoneurons co-cultured with 
S0D1G93A astrocytes had a significantly reduced resting AvFm compared to either WT (n 
= 19) or SOD1G93a (n = 18) motoneurons co-cultured with WT astrocytes (p < 0.005). 
Therefore the TMRM signal of motoneurons in SODnSODa and WTnSODa cultures 
was 453.6 a.u. (± 65.7 S.E.M.) and 587.1 a.u. (± 219.8 S.E.M.) respectively compared 
to 2147.6 a.u. (± 392.8 S. E.M.) and 2294.2 a.u. (± 401.5) in WTnWTa and SODnWTa 
co-cultures at rest, respectively. The basal AvFm of WT and S0D1G93A motoneurons 
cultured on WT astrocytes did not differ significantly (p > 0.3).
The resting AxFm of astrocytes from SODnSODa co-cultures was also significantly 
reduced (p < 0.01) compared to WTnWTa or SODnWTa co-cultures. Therefore, as 
illustrated in Figure 3.4B, astrocytes from SODnSODa cultures had a resting TMRM 
signal of 388.8 a.u. (± 53.7) compared to 2930.5 a.u. (± 482.1) and 2528.9 a.u. (± 582.8) 
in astrocytes from WTnWTa and SODnWTa cultures respectively.
3.3.2.4. NADH autofluorescence
The functional operation of complex I in the mitochondrial electron transport chain 
relies on the transfer of electrons and protons from the TCA cycle to complex I via the 
pyridine nucleotide carrier, nicotinamide adenine dinucleotide (NADH). The reduced 
carrier, NADH, has an intrinsic autofluorescence. However, the transfer of electrons and 
protons to complex I oxidises NADH to NAD+, which lacks autofluorescence. A change 
in fluorescence therefore indicates a shift in the balance between the reduced and
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Figure 3.3 -  Confocal image of a TMRM-loaded motoneuron cultured on an 
enriched astrocytic layer
The cationic fluorophore TMRM becomes partitioned into mitochondria due to the 
electrochemical potential gradient that exists between the cytosol and the mitochondria. 
The image was acquired on a Zeiss 510 CLSM confocal microscope using a x63 oil 
immersion objective lens. Scale bar = 8pm.
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Figure 3.4 -  The resting mitochondrial membrane potential of motoneurons co- 
cultured with astrocytes
The co-cultures were loaded with TMRM, a potentiometric indicator that becomes 
partitioned into mitochondria due to the electrochemical potential gradient that exists 
between the cytosol and the mitochondria. Images were acquired using a x63 oil 
immersion objective lens on a Zeiss 510 CLSM. A ‘z’ stack of images were taken 
thorough the co-culture and compressed to a single image with each pixel representing 
the average intensity of that point through the sample. The mean resting mitochondrial 
membrane potential (A'Fm) from motoneurons is shown in A, and B shows the mean 
resting astrocytic A'Fm- It can be seen that motoneurons cultured on SOD1G93a 
astrocytes had a significantly lower resting A'Fm compared to motoneurons cultured on 
WT astrocytes (A; p < 0.005). Similarly, the resting AxFm of astrocytes from 
SODnSODa co-cultures was significantly reduced compared to astrocytes from co­
cultures consisting of a WT astrocytic layer (B; p < 0.01). The values represent the 
mean resting ATV, measured by TMRM signal, ± standard error of the mean. ** p < 
0.01, *** p < 0.005 indicates a significant difference from motoneurons from both the 
WTnWTa and SODnWTa co-cultures.
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oxidised forms of the carrier. Manipulation of this system and measurement of the 
change in the redox state of NADH can give an indication of the metabolic state of the 
mitochondria.
Inhibition of complex IV, using sodium cyanide, will inhibit respiration and 
consequently prevent the oxidation of NADH to NAD+. Therefore, NADH 
autofluorescence will generally increase as NADH accumulates and the NADH to 
NAD+ ratio increases. A typical trace showing the increase in NADH autofluorescence
p A < J  A A
in SOD1 motoneurons co-cultured with SOD1 astrocytes in response to cyanide 
is illustrated in Figure 3.5A. The change in NADH autofluorescence of motoneurons 
cultured on an enriched astrocytic layer, in response to cyanide application is shown in 
Figure 3.5B. The mean values shown in the bar chart represent the peak increase in 
autofluorescence, corrected for baseline values. Addition of cyanide induced an increase 
in NADH autofluorescence from baseline values in all motoneurons. However, the 
increase in NADH autofluorescence in motoneurons from SODnSODa co-cultures (n = 
10) was significantly reduced compared to motoneurons from WTnWTa (n = 13) and 
SODnWTa (n = 14) co-cultures (p < 0.04). Therefore in response to cyanide, NADH 
autofluorescence in motoneurons from WTnWTa and SODnWTa co-cultures increased 
by 1092.7 a.u. (± 183.3 S.E.M.) and 1067.4 a.u. (± 205.3 S.E.M.) respectively, 
compared to an increase of only 463.4 a.u. (± 71.1 S.E.M.) in motoneurons from 
SODnSODa co-cultures. There was also a trend towards a lower increase in NADH 
autofluorescence in motoneurons from WTnSODa co-cultures (707.1 a.u. ± 177.0 
S.E.M.; n = 11), although this did not reach statistical significance (p > 0.1). Baseline 
values did not differ significantly between experimental groups (p > 0.1).
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Figure 3.5 -  The mean increase in NADH autofluorescence of co-cultured 
motoneurons and astrocytes in response to the complex IV inhibitor cyanide
A typical trace of the increase in NADH autofluorescence in SOD 1093A motoneurons 
co-cultured with SOD 1093A astrocytes in response to cyanide is shown in A. The bar 
chart summarises the mean peak increase in NADH autofluorescence from baseline 
values in (B) motoneurons and (C) astrocytes in co-culture, following treatment with 
cyanide. All motoneurons, regardless of their own genotype or the genotype of their 
astrocytic layer, showed an increase in NADH autofluorescence in response to cyanide
(B). However, the increase in NADH autofluorescence in motoneurons from 
SODnSODa co-cultures was lower compared to motoneurons co-cultured with WT 
astrocytes (p < 0.04). There was also a trend to a lower increase in NADH 
autofluorescence in motoneurons from WTnSODa co-cultures, but this did not reach 
significance. Similarly, in response to cyanide, the NADH autofluorescence was 
increased in all astrocytes (C). However, SOD 1093A astrocytes co-cultured with WT 
motoneurons demonstrated a lower increase following cyanide than astrocytes in the 
other co-cultures. Values represent the mean peak increase in NADH autofluorescence 
above baseline ± standard error of the mean. * p < 0.05.
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Astrocytes from WTnSODa (n = 13) co-cultures exhibited significantly less of an 
increase in NADH autofluorescence, in response to cyanide, in comparison to astrocytes 
from WTnWTa (n = 14), SODnWTa (n = 7) and SODnSODa (n = 11) co-cultures (p < 
0.05) as shown in Figure 3.5C. Therefore, astrocytes from WTnSODa co-cultures 
showed a cyanide-induced increase of 212.3 a.u. (± 76.9 S.E.M.) in NADH 
autofluorescence, from baseline, compared to 487.5 a.u. (± 92.9 S.E.M.), 808.7 a.u. (± 
275.5 S.E.M.) and 557.1 a.u. (± 163.2 S.E.M.) in astrocytes from WTnWTa, SODnWTa 
and SODnSODa co-cultures respectively. Again, baseline values were not different (p > 
0.08).
The mitochondrial inhibitor rotenone specifically inhibits complex I and therefore, 
similar to cyanide, the peak change in NADH autofluorescence in response to rotenone 
can be used to assess the metabolic state of the mitochondria. An example of a trace 
showing the increase in NADH autofluorescence in SOD1G93a motoneurons co-cultured 
with SOD1G93a astrocytes in response to rotenone is shown in Figure 3.6A. Application 
of rotenone, as shown in Figure 3.6B, induced an increase in NADH autofluorescence 
from baseline in motoneurons from all 4 co-culture conditions. However, consistent 
with the data recorded following exposure to cyanide, motoneurons from SODnSODa 
co-cultures (n = 10) responded with a significantly smaller increase in NADH 
autofluorescence compared to motoneurons from WTnWTa (n = 9), SODnWTa (n = 10) 
and WTnSODa (n = 8) co-cultures (p < 0.03). Thus, in response to rotenone, the NADH 
autofluorescence of motoneurons from SODnSODa co-cultures increased by 419.3 a.u. 
(± 131.4 S.E.M.) from baseline, which was significantly less than the response of 
motoneurons from WTnWTa (905.1 a.u. ± 125.6 S.E.M.), SODnWTa (1944.7 a.u. ± 
323.8) and WTnSODa (903.1 a.u. ± 136.9 S.E.M.) co-cultures. Interestingly, the 
increase in NADH autofluorescence of motoneurons from SODnWTa co-cultures was
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Figure 3.6 -  The mean increase in NADH autofluorescence of co-cultured 
motoneurons in response to the complex 1 inhibitor rotenone
An example of a trace showing the increase in NADH autofluorescence in SOD1G93a 
motoneurons co-cultured with SOD1G93a astrocytes in response to rotenone is shown in 
Figure 3.6A. The bar chart (B) summarises the mean peak increase in NADH 
autofluorescence from baseline values in motoneurons cultured under the 4 different co­
culture conditions, following treatment with rotenone. All motoneurons, regardless of 
their own genotype or the genotype of their astrocytic layer, showed an increased 
NADH autofluorescence in response to rotenone. However, the increase in NADH 
autofluorescence in motoneurons from SODnSODa co-cultures was significantly lower 
compared to motoneurons from all other co-cultures (p < 0.03). However, in contrast 
SOD1G93a motoneurons cultured with WT astrocytes showed a significantly greater 
increase in NADH autofluorescence in response to rotenone (p < 0.03). Values 
represent the mean peak increase in NADH autofluorescence above baseline ± standard 
error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.005.
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significantly greater than that of motoneurons from WTnWTa and WTnSODa (p < 
0.03) co-cultures. In contrast, there were no significant differences in the change in 
NADH autofluorescence in co-cultured astrocytes in response to rotenone (p > 0.3; data 
not shown).
3.3.2.5. Resting rate of superoxide generation
In these experiments, cells were loaded with dihydroethidium (HEt) a marker of 
superoxide generation. The stock HEt is non-fluorescent, however, oxidation of HEt 
generates the fluorescent ethidium and this fluorophore can therefore be used to 
compare rates of superoxide generation.
The basal rate of HEt oxidation in the different co-cultures was measured over a 15 
minute period. Figure 3.7A shows typical traces from motoneurons in WTnWTa co­
cultures taken from an experiment measuring the basal rate of superoxide production in 
motoneurons. The gradient of each slope was measured and taken to represent the basal 
rate, which was expressed in arbitrary fluorescent units (a.f.u.)/second. Figure 3.7B 
summarises the mean rate of superoxide generation in motoneurons and it can be seen 
that the basal rate of superoxide generation in motoneurons from SODnSODa cultures 
(n = 20) was significantly lower than the rate in motoneurons from WTnWTa co­
cultures (n = 14; p = 0.032). The basal rate of superoxide generation was 86.9 a.f.u./sec 
(± 9.8 S.E.M.) in motoneurons from SODnSODa compared to 119.0 a.f.u./sec (± 50.0 
S.E.M.) in motoneurons from WTnWTa c-cultures. The basal rate in motoneurons from 
SODnWTa (n = 17) and WTnSODa (n = 15) co-cultures did not differ significantly 
from WTnWTa (p > 0.2).
168
Figure 3.7 -  The basal rate of superoxide generation in both WT and SOD1G93a
A
motoneurons co-cultured with either WT or SOD1 astrocytes
The co-cultures were loaded with dihydroethidium (HEt), a non-fluorescent indicator 
that becomes fluorescent on oxidation to ethidium, and can therefore be used to 
compare rates of superoxide generation. The basal rate of superoxide generation was 
measured in motoneurons over a 15 minute period and a typical trace from WT 
motoneurons co-cultured with WT astrocytes is shown in A. The gradient of each slope 
was measured and taken to represent the rate of superoxide generation (expressed in 
arbitrary fluorescent units/second). The bar chart (B) summarises the mean rates of 
superoxide production under the different co-culture conditions. Motoneurons from 
SODnSODa co-cultures (n = 20) had a significantly reduced rate of superoxide 
generation under basal conditions (p = 0.032), compared to motoneurons from 
WTnWTa (n = 14) co-cultures, whereas the rate in motoneurons from SODnWTa (n = 
17) or WTnSODa (n = 15) co-cultures was unchanged. Values represent the mean basal 
rate ± standard error of the mean. * p < 0.05.
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Similar to motoneurons, the astrocytes from SODnSODa cultures also had a 
significantly reduced basal rate of superoxide generation compared to the astrocytes 
from WTnWTa co-cultures (p = 0.044). Therefore in astrocytes from SODnSODa the 
basal rate was 39.4 a.f.u./sec (± 8.5 S.E.M.) compared to 58.6 a.f.u./sec (± 29.6 S.E.M.) 
in astrocytes from WTnWTa co-cultures (data not shown).
3.3.3. The effect of expression of mutant SOD1 on the response to acute 
excitotoxicity
Excitotoxicity is one of the neurotoxic mechanisms proposed to contribute to the 
pathogenesis of ALS, as described in Chapter 1.3.4.2., Therefore in order to further 
evaluate the influence of astrocytes, the effect of expression of mutant SOD1 on the 
response of motoneurons under acute excitotoxic conditions was investigated next.
3.3.3.I. The change in cytosolic calcium ([Ca2+]c) in response to excitotoxic stimuli
Co-cultured cells were loaded with either the high affinity calcium indicator, fluo 4 (n = 
at least 27) or the low affinity, ratiometric calcium indicator, fura 2-FF (n = at least 11),
94 -and the change in [Ca ]c was evaluated in response to the sequential application of KA 
and glutamate. Figure 3.8 shows examples of images acquired during the application of 
excitotoxic stimuli to fluo 4-loaded co-cultured motoneurons and astrocytes: A, basal 
[Ca2+]c; B, the change in [Ca2+]c in response to KA. The mean fluo 4 trace of the [Ca2+]c 
response of motoneurons from WTnWTa co-cultures to excitotoxic stimuli is shown in
94 -Figure 3.9A. The mean peak increase in [Ca ]c, above baseline, in co-cultured 
motoneurons in response to KA is shown in Figure 3.9B, as measured by fluo 4 
intensity. Measurement of fluo 4 intensity revealed that there was no significant
94 -difference in the change in [Ca ]c in co-cultured motoneurons in response to KA (p > 
0.15). Similarly, Figure 3.9C demonstrates that there was no significant difference in
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Figure 3.8 -  The change in cytosolic calcium ([Ca2+]c) levels in fluo 4-loaded co­
cultures
The sequential images show representative images taken from an experiment to measure
2_j_
the change in [Ca ]c in fluo 4-loaded co-cultured cells, undertaken on the confocal 
microscope. A, represents the basal [Ca2+]c; B, illustrates the increase in [Ca2+]c in 
response to the addition of KA. Scale bar = 30pm.
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Figure 3.9 -  The change in cytosolic calcium ([Ca2+]c) in fluo 4-loaded motoneurons 
in response to excitotoxic stimuli
Cells were loaded with fluo 4 (n = at least 27), a high affinity calcium indicator, and the
94-change in fluo 4 intensity, corresponding to a change in [Ca ]c, was recorded in 
response to sequential stimulation with KA and glutamate. A shows the mean fluo 4 
trace from WT motoneurons co-cultured with WT astrocytes showing the change in 
[Ca ]c above baseline, in response to the addition of KA and then glutamate. The mean
9+change in the levels of [Ca ]c in co-cultured motoneurons in response to KA, are 
summarised in the bar chart shown in B. The fluo 4 response to glutamate is shown in
94-C, which summarises the mean change in [Ca ]c in motoneurons after the addition of
9 i
glutamate, above that achieved with KA. Values are the mean change in [Ca ]c ± 
standard error of the mean.
GLT = glutamate, s = seconds.
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the change in [Ca ]c in co-cultured motoneurons in response to the sequential addition 
of glutamate (p > 0.25). It can be seen that the addition of glutamate in some cases
^ I
actually reduced the [Ca ]c compared to the response achieved with KA. Similarly, no
94-differences were seen in the change in [Ca ]c between co-cultured astrocytes (p > 0.05; 
data not shown).
Fura 2-FF is a more quantitative calcium indicator because it is a low affinity, dual 
wavelength fluorophore. Therefore, to confirm the data acquired using fluo 4, the mean
9+change in [Ca ]c in co-cultured motoneurons, was measured using fura 2-FF on the
9 I
cooled CCD camera. The change in [Ca ]c was expressed as a ratio between the 
fluorescence excited at 340nm and the fluorescence excited at 380nm. The mean trace 
from WT motoneurons co-cultured with WT astrocytes is shown in Figure 3.10A. In 
contrast to the data acquired using fluo 4, there was a substantially larger increase in the 
fura 2-FF ratio in motoneurons in response to glutamate compared to KA. However,
9 +there was no significant difference in the change in [Ca ]c in co-cultured motoneurons 
in response to either KA (p > 0.4; n = at least 17) or glutamate (p > 0.3; n = at least 11), 
as shown in Figure 3.10B.
fT T | 2 * FThere was no significant difference in the change in [Ca ]c of co-cultured astrocytes to 
either KA or glutamate, as assessed using fura 2-FF (p > 0.55; data not shown).
3.3.3.2. The change in mitochondrial membrane potential (A^m) in response to 
excitotoxic stimuli
To examine the effect of excitotoxic stimulation on ATV co-cultures were loaded with 
TMRM, a potentiometric indicator, and sequentially exposed to KA and then glutamate. 
To evaluate the effect of expression of mutant SOD1, the rate of AT'™ depolarisation, as
176
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Figure 3.10 -The change in cytosolic calcium ([Ca ]c) in fura 2-FF loaded 
motoneurons in response to excitotoxic stimuli
Cells were loaded with fura 2-FF, a low affinity, ratiometric calcium indicator, and the
94-change in [Ca ]c in response to sequential stimulation with KA and glutamate was
9+recorded on the cooled CCD camera. The change in [Ca ]c was expressed as a ratio 
between the fluorescence excited at 340nm and the fluorescence excited at 380nm. The 
mean fura 2-FF trace from WT motoneurons co-cultured with WT astrocytes illustrating
9_i
the change in [Ca ]c in response to the addition of KA and then glutamate is shown in
9-4-A. The mean change in [Ca ]c in co-cultured motoneurons in response to both KA and
94-glutamate is summarised in the bar chart in B. Values are the mean change in [Ca ]c ± 
standard error of the mean.
GLT = glutamate, s = seconds.
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measured by the rate of decline of TMRM signal, in co-cultured motoneurons was 
calculated in response to both KA and glutamate. Figure 3.11 illustrates the change in 
TMRM signal in motoneurons from WTnWTa (n = 30), SODnWTa (n = 13), 
WTnSODa (n = 12) and SODnSODa (n = 14) co-cultures in response to excitotoxins. 
The rate of signal decline was calculated by measuring the gradient of the slope between 
the arrows marked in Figure 3.11. Table 3.4 summarises the mean rate of 
mitochondrial depolarisation in co-cultured motoneurons in response to KA and 
glutamate. There was no significant difference in the rate of A'Fm depolarisation in 
response to either KA or glutamate in co-cultured motoneurons (p > 0.06).
To evaluate the extent of mitochondrial depolarisation, the TMRM intensities were 
normalised, to account for the variation in resting AvFm between co-cultured 
motoneurons. Figure 3.12 shows the normalised TMRM traces for AT'm depolarisation 
in response to excitotoxic stimuli. It can be seen that the gradient of each trace, 
representing the rate of depolarisation, was very similar in all co-cultures. Table 3.5 
details the extent of KA and glutamate-induced mitochondrial depolarisation (the extent 
of depolarisation was calculated within the area marked by the arrows shown in Figure 
3.12), which occurred in motoneurons from each of the different co-cultures. Although 
the rates of AxPm depolarisation were not significantly different, the motoneurons from 
co-cultures containing either SOD1G93a neurons or astrocytes, and in particular 
SOD1G93a astrocytes, underwent a greater extent of mitochondrial depolarisation in 
response to KA, compared to WTnWTa co-cultures. Unfortunately due to the extensive 
depolarisation in response to KA, the true response to glutamate could not be evaluated 
from these experiments.
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Figure 3.11 -  Depolarisation of mitochondria in response to excitotoxic stimuli
Co-cultures were loaded with the potentiometric indicator, TMRM and the loss of A'Fm 
in co-cultured motoneurons, as measured by the loss of TMRM signal, was recorded in 
response to both KA and glutamate. The mean traces representing loss of AlFm in co- 
cultured motoneurons in response to excitotoxic stimulation are shown. The arrows 
mark the boundaries within which the rate of mitochondrial depolarisation was 
calculated from the gradient of the slope, in response to kainate and glutamate.
GLT = glutamate, s = seconds.
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Table 3.4 -  The rate of mitochondrial depolarisation in response to excitotoxic 
stimulation
The mean rate of mitochondrial depolarisation in co-cultured motoneurons in response 
to KA and glutamate is summarised in the Table (the gradient of the slope measured 
between the marked arrows shown in Figure 3.11 represented the rate of 
depolarisation). There was no significant difference in the rate of depolarisation 
between the motoneurons in the different co-cultures, in response to either KA or 
glutamate. Values represent the mean rate of depolarisation ± standard error of the 
mean.
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Kainate Glutamate
WTnWTa 44.7 5.3
± SEM ±6.2 ±1.7
SODnWTa 45.8 4.6
± SEM ±8.9 ±1.4
WTnSODa 58.7 4.6
± SEM ±13.0 ±3.0
SODnSODa 31.3 3.2
± SEM ±3.6 ±0.7
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Figure 3.12 -  Normalisation of the change in mitochondrial membrane potential 
(A'Fm) in co-cultured motoneurons in response to the sequential addition of KA 
and glutamate
To calculate the extent of mitochondrial depolarisation in response to excitotoxic 
stimuli, the change in TMRM signal was normalised, with the maximal intensity of 1 
representing the resting A'Fm, and the minimal intensity of 0 representing the remaining 
ATm after the addition of the mitochondrial uncoupler, FCCP. The traces show the 
mean normalised TMRM signals of co-cultured motoneurons in response to KA and 
glutamate. It can be seen that the rate of the mitochondrial depolarisation appeared 
similar in WTnWTa, SODnWTa, WTnSODa and SODnSODa, thus corroborating the 
data before normalisation as shown in Table 3.4. The arrows mark the boundaries 
within which the extent of mitochondrial depolarisation was calculated in response to 
KA and glutamate.
GLT = glutamate, s = seconds
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Table 3.5 - The extent of mitochondrial depolarisation in response to excitotoxic 
stimulation
The extent of mitochondrial depolarisation was calculated in response to KA and 
glutamate, within the respective areas as marked by arrows, as shown in Figure 3.12 
and the Table quantifies the mean extent of depolarisation in response to KA and then 
the further response to glutamate. Values represent the extent of mitochondrial 
depolarisation.
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KAINATE GLUTAMATE
WTnWTa -79.1% -90.8%
SODnWTa -81.8% -92.2%
WTnSODa -86.4% -93.1%
SODnSODa -87.6% -99.1%
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3.3.3.3. Superoxide generation in response to excitotoxic stimuli
To evaluate the effect of mutant SOD1 expression in either motoneurons or astrocytes 
on the generation of superoxide in response to excitotoxic stimuli, co-cultures were 
loaded with HEt, and the rates of free radical generation under different co-culture 
conditions compared. However, Budd et al, (1997) demonstrated that to acquire an 
accurate measurement of oxidation rates with HEt, it was necessary to use a low 
concentration, since at high concentrations (lOpM) oxidised ethidium could become 
sequestered in the mitochondria and upon depolarisation, the release of oxidised 
ethidium produced an unrepresentative increase in the fluorescent signal. Therefore, for 
these experiments, 2pM HEt was used, ensuring the increase in fluorescence was an 
accurate reflection of superoxide production. Furthermore, no increase in signal was 
seen upon addition of the mitochondrial uncoupler, FCCP, implying that excess 
oxidised ethidium was not being sequestered in the mitochondria.
Table 3.6 gives the rate of superoxide generation in motoneurons (A) and astrocytes (B) 
from WTnWTa, SODnWTa, WTnSODa and SODnSODa co-cultures under resting 
conditions, in response to KA and in response to glutamate. The rate of superoxide 
generation in WT motoneurons co-cultured with WT astrocytes (n = 16) in response to 
KA was not significantly different from the basal rate (p > 0.9). In contrast, there was a 
significant increase in the rate of superoxide generation in response to KA compared to 
the basal rate in motoneurons from SODnWTa (n = 15), WTnSODa (n = 17) and 
SODnSODa (n = 20) co-cultures (p < 0.03). In response to glutamate, with the 
exception of motoneurons from WTnWTa co-cultures, the rate of superoxide generation 
was reduced compared to the rate in response to KA (p < 0.04).
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Table 3.6 -  The rate of superoxide generation under resting conditions and in 
response to KA and glutamate
Table A summarises the rate of superoxide generation in motoneurons under basal 
conditions and also in response to KA and to glutamate. There was a significant 
increase in the rate of superoxide generation in response to KA compared to the basal 
rate in motoneurons from SODnWTa (n = 15), WTnSODa (n = 17) and SODnSODa (n 
= 20) co-cultures (p < 0.03), but not in WTnWTa co-cultures (p > 0.9; n = 16). In 
contrast, the rate of superoxide generation in response to glutamate in motoneurons 
from SODnWTa, WTnSODa and SODnSODa co-cultures was significantly lower than 
the rate in response to KA (p < 0.04), whereas the rate did not differ in motoneurons in 
WTnWTa co-cultures (p > 0.9). Table B summarises the rate of superoxide generation 
in astrocytes under basal conditions and also in response to KA and to glutamate. 
Astrocytes from SODnWTa (n = 16) co-cultures generated superoxide at a greater rate 
in response to KA (p < 0.001), and also glutamate (p = 0.011) compared to their basal 
rate of superoxide generation. In contrast, the rate of superoxide generation in astrocytes 
from WTnWTa (n = 23), WTnSODa (n = 19) and SODnSODa (n = 9) co-cultures did 
not differ in response to KA or glutamate compared to the baseline rate (p > 0.1). 
Values are the mean rate (a.f.u./sec) corrected for baseline ± standard error of the mean. 
* p < 0.05, ** p < 0.01, *** p < 0.005 indicates a significant difference in the observed 
rate compared to the rate before excitotoxin addition.
189
ABasal rate 
(a.f.u./sec)
Rate in response to 
KA 
(a.f.u./sec)
Rate in response to 
glutamate 
(a.f.u./sec)
WTnWTa 119.0 ±50.0 117.3 ±38.9 112.6 ±28.1
SODnWTa 73.6 ± 14.3 239.8 ±57.8** 103.9 ± 22.2 *
WTnSODa 68.1 ± 12.5 260.3 ±63.6 ** 133.5 ±31.2*
SODnSODa 86.9 ± 9.8 172.4 ±35.1 * 103.0 ±14.7*
B
Basal rate 
(a.f.u./sec)
Rate in response to 
KA 
(a.f.u./sec)
Rate in response to 
glutamate 
(a.f.u./sec)
WTnWTa 58.6 ± 29.6 29.8 ± 12.9 16.1 ±3.9
SODnWTa 5.3 ± 7.7 80.3 ± 15.6 *** 133.0 ±17.0*
WTnSODa 22.2 ± 5.3 61.2 ± 24.8 105.3 ±26.1
SODnSODa 39.4 ± 8.5 87.9 ± 49.3 62.4 ±21.1
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The bar chart in Figure 3.13A shows the rate of superoxide generation in co-cultured 
motoneurons in response to both KA and glutamate, corrected for basal rate. In response 
to KA, the rate of superoxide generation in motoneurons from SODnWTa co-cultures 
was significantly greater than in motoneurons from WTnWTa co-cultures (p = 0.027). 
Thus, in response to KA, the rate of superoxide generation in WTnWTa co-cultures was 
-1.7 a.f.u./sec (± 35.3 S.E.M.) compared to 166.2 a.f.u./sec (± 48.6 S.E.M.) in 
SODnWTa co-cultures. In addition, motoneurons from WTnSODa and SODnSODa co­
cultures also appeared to show a trend towards an increased rate of superoxide 
generation, although this did not reach statistical significance. Furthermore, analysis of 
the rate of superoxide generation in motoneurons in response to glutamate added 
sequentially to KA, revealed that there was no significant difference between 
SODnWTa, SODnSODa and WTnWTa co-cultures, whereas the rate in WTnSODa co­
cultures was significantly less than in WTnWTa co-cultures (p = 0.038).
The rate of superoxide generation in astrocytes from SODnWTa co-cultures was 
increased in response to KA compared to the rate in this co-culture under resting 
conditions (p < 0.001; Table 3.6B), and the rate was further increased in response to 
glutamate (p = 0.011). No other significant differences in the rate of superoxide 
generation were observed for astrocytes within a particular co-culture, between the three 
conditions. However, in response to KA, astrocytes from SODnWTa (n = 16) and 
WTnSODa (n = 19) co-cultures generated superoxide at a greater rate than astrocytes 
from WTnWTa co-cultures (n = 23; p < 0.002; Figure 3.13B). The rate of superoxide 
generation in response to glutamate was similarly increased in astrocytes from 
SODnWTa compared to WTnWTa co-cultures (p = 0.036), but no other significant 
differences were observed compared to WTnWTa co-cultures (p > 0.08).
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Figure 3.13 - The rate of superoxide generation in co-cultures in response to 
excitotoxic stimuli.
Co-cultures were loaded with HEt, a non-fluorescent dye that upon oxidation becomes 
fluorescent, and can therefore be used to compare the rate of superoxide generation 
between different co-culture conditions, in response to the sequential addition of KA 
and glutamate. The bar chart (A) illustrates the rate of superoxide generation that 
occurred, above baseline, in response to KA and glutamate in motoneurons from 
WTnWTa (n = 16), SODnWTa (n = 17), WTnSODa (n = 15) and SODnSODa (n = 20) 
co-cultures. There was a significant increase in the rate of superoxide generation in 
motoneurons from SODnWTa co-cultures in response to KA compared to motoneurons 
from WTnWTa co-cultures (p < 0.03). However, in response to glutamate, motoneurons 
from WTnSODa co-cultures showed a significantly reduced rate of superoxide 
generation compared to WTnWTa co-cultures (p < 0.04).
The bar chart in B illustrates the results from astrocytes. In contrast to motoneurons, 
astrocytes from SODnWTa (n = 16) and WTnSODa (n = 19) co-cultures generated 
superoxide at a significantly increased rate in response to KA, compared to astrocytes 
from WTnWTa (n = 23; p < 0.002) co-cultures. Similarly, astrocytes from SODnWTa 
co-cultures had a significantly increased rate of superoxide generation in response to 
glutamate compared to astrocytes from WTnWTa co-cultures (p < 0.035). Values are 
the mean rate (a.f.u./sec) above the basal rate of generation ± standard error of the 
mean. * p < 0.05.
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3.3.3.4. Correlation between cytosolic calcium ([Ca2+]c) influx, mitochondrial 
membrane potential (AT'm) and superoxide generation
For each of the 4 co-culture conditions, the change in [Ca2+]c, as measured by fluo 4, 
and the A^V as measured by TMRM, were plotted on the same graph to allow 
correlation between the timing of changes in each parameter (Figure 3.14). It can be 
seen that for (A) WTnWTa, (B) SODnWTa, (C) WTnSODa and (D) SODnSODa co­
cultures, there was a correlation between the peak of the [Ca2+]c response in response to 
KA and the onset of AvFm depolarisation. Furthermore, the time at which the rate of 
superoxide generation increased in motoneurons, relative to the basal rate, after KA 
exposure, was marked on the same graph (red line). Interestingly, in SODnWTa, 
WTnSODa and SODnSODa co-cultures, significant mitochondrial depolarisation had 
already occurred by the time point at which the rate of superoxide generation increased 
relative to the basal rate. This therefore implied that the generation of superoxide was 
not dependent on fully polarised mitochondria. In WTnWTa co-cultures, upon addition 
of KA, the rate of superoxide plateaued and then recovered to a rate that did not differ 
from the basal rate. However, it can be seen from the graph that at the time point when 
the rate increased back to the basal rate, some mitochondrial depolarisation had 
similarly occurred. The absence of a reduction in the rate in response to KA, however 
similarly implied that the generation of superoxide was not dependent on the AvFm.
3.3.3.5. The change in mitochondrial calcium ([Ca ]m) in response to excitotoxic 
stimuli
Co-cultured cells were loaded with the low affinity indicator, rhod 5N, which 
accumulates in mitochondria and can therefore be used to measure [Ca2+]m. An example 
of a typical trace from an experiment measuring changes in [Ca2+]c and [Ca2+]m in 
motoneurons in WTnWTa co-cultures is shown in Figure 3.15A. It can be seen that
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Figure 3.14 -  Temporal correlation between the change in cytosolic calcium 
([Ca2+]c), mitochondrial membrane potential (AT'm) and the rate of superoxide 
generation
9+The increase in [Ca ]c and the depolarisation of the AvFm were plotted on the same 
graph for (A) WTnWTa, (B) SODnWTa, (C) WTnSODa and (D) SODnSODa co­
cultures. In addition, the time at which the rate of superoxide generation changed 
relative to basal levels was marked (red line) to allow a correlation between the three
9-4-parameters. The peak increase in [Ca ]c, as measured by fluo 4, occurred 
simultaneously with the onset of mitochondrial depolarisation, as measured by TMRM, 
in each co-culture condition. Interestingly, in SODnWTa, WTnSODa and SODnSODa 
co-cultures at the time point at which the rate of superoxide generation increased above 
basal in response to KA, significant mitochondrial depolarisation had already occurred. 
This implied that AvFm was not necessary for the generation of superoxide in these 
conditions, 
s = seconds
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Figure 3.15 -  The change in mitochondrial calcium ([Ca2+]m) in co-cultured 
motoneurons in response to glutamate stimulation
Co-cultured cells were loaded with the low affinity, calcium indicator rhod 5N, which 
accumulates in mitochondria, and images were acquired using the x63 oil immersion 
objective lens on the confocal microscope. The trace in A is a typical example of the
y  I y  |
change in [Ca ]c and [Ca ]m in motoneurons in WTnWTa co-cultures in response to
y* y ,
glutamate, whereby the [Ca ]m signal initially lagged behind the [Ca ]c signal and then 
the [Ca2+]m actually exceeded the [Ca2+]c. The mean change in [Ca2+]m in co-cultured 
motoneurons in response to glutamate application, is shown in B. Values are the mean 
values of [Ca ]m ± standard error of the mean. ** p < 0.01. 
s = seconds
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sy, • •the change in [Ca ]m lagged behind that of the cytosol in response to excitotoxic 
stimuli, and then the elevation in [Ca2+]m actually exceeded that of the [Ca2+]c due to 
calcium loading of mitochondria.
Images of rhod 5N loaded cells were acquired on the confocal microscope and the mean 
change in [Ca2+]m in response to addition of glutamate was investigated under the 
differing co-culture conditions. The bar chart in Figure 3.15B shows the mean change 
in [Ca ]m of co-cultured motoneurons above baseline values in response to glutamate. 
Motoneurons from SODnSODa co-cultures (n = 28) showed a significantly lower
9-1-increase in [Ca ]m in response to the addition of glutamate compared to motoneurons 
from WTnWTa (n = 15; p = 0.006) co-cultures. Therefore in response to glutamate, the 
[Ca2+]m increased by 3386.8 a.u. (± 512.1 S.E.M.) in motoneurons from WTnWTa co­
cultures, whereas this response in motoneurons from SODnSODa co-cultures was 
significantly lower and [Ca2+]m only increased by 1800.7 a.u. (± 297.3 S.E.M.). 
Furthermore, there was a trend towards a lesser increase in [Ca2+]m in motoneurons 
from SODnWTa (n = 18) and WTnSODa (n = 33) in response to glutamate, compared 
to WTnWTa co-cultures, although these values did not reach significance (p > 0.1). 
Thus, the increase in [Ca2+]m in motoneurons from SODnWTa and WTnSODa co­
cultures was 2614.1 a.u. (± 395.4 S.E.M.) and 2387.2 a.u. (±310.0 S.E.M.) respectively.
3.3.4. The effect of plasma membrane depolarisation
Neuronal toxicity may be dependent on the route of calcium influx (‘source specificity’ 
hypothesis) rather than the extent of calcium influx (‘calcium load’ hypothesis). To test 
this, co-cultures were stimulated with recording medium (RM) containing depolarising 
concentrations of potassium (50mM), and the effects observed compared to those seen 
in response to KA.
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3.3.4.1. Evaluation of the effect of plasma membrane depolarisation on cytosolic 
calcium ([Ca2+]c) levels
Co-cultures were loaded with the high affinity calcium indicator, fluo 4, and stimulated 
with RM containing 50mM potassium. In addition, the RM contained the glutamate 
receptor antagonists MK-801 ((5R,10S)-(+)-5-Methyl-10,l l-dihydro-5H-dibenzo [a,d] 
cyclohepten-5,10-imine hydrogen maleate), CNQX (6-cyano-2,3-dihydroxy-7-nitro- 
qunioxaline) and MCPG (+(RS)-a-methyl-4-carboxyphenylglycine), to prevent 
activation of glutamate receptors subsequent to plasma membrane depolarisation and
94-the potential release of glutamate. The mean increase in [Ca ]c in motoneurons 
following the application of a high concentration of potassium is summarised in Table
9-4-3.7. The mean increase in [Ca ]c following application of KA is shown for comparison. 
The change in [Ca2+]c in motoneurons from WTnSODa and SODnWTa co-cultures was 
significantly less in response to potassium compared to KA application (p < 0.02).
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There was also a trend towards a lower [Ca ]c influx in motoneurons from WTnWTa 
and SODnSODa co-cultures in response to potassium compared to KA, although 
statistical significance was not reached (p > 0.05). Furthermore, in response to 
potassium, the [Ca2+]c influx in motoneurons in SODnSODa co-cultures (n = 13) was 
significantly greater than in motoneurons in SODnWTa (n = 19; p = 0.05) co-cultures.
3.3.4.2. Evaluation of the effect of plasma membrane depolarisation on 
mitochondrial membrane potential (AT'm)
TMRM loaded co-cultures were stimulated with RM containing 50mM potassium and 
the effect on the AT'm was investigated to determine if the calcium influx through 
voltage-gated calcium channels induced mitochondrial depolarisation. To control for the 
activation of glutamate receptors, subsequent to plasma membrane depolarisation and 
glutamate release, the RM contained MK-801, CNQX and MCPG. The rate of
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Table 3.7 -  Comparison of the change in cytosolic calcium ([Ca2+]c) in response to 
plasma membrane depolarisation and KA receptor activation
94-Co-cultures were loaded with fluo 4 and the mean change in [Ca ]c in response to RM 
containing high potassium concentrations (50mM) was evaluated by measuring the 
fluorescent intensity of fluo 4 using confocal microscopy. MK-801, CNQX and MCPG 
were included in the RM to prevent activation of glutamate receptors subsequent to 
plasma membrane depolarisation and glutamate release. The mean change in fluo 4
94-intensity, corresponding to levels of [Ca ]c, is summarised in the Table, and the mean
94-change in [Ca ]c in response to KA is provided for comparison. Values are the mean
94-change in [Ca ]c ± standard error of the mean. * p < 0.05, *** p < 0.005 indicates
94-significance between the increase in [Ca ]c in response to depolarising potassium 
compared to the change in response to KA. + indicates significance between 
motoneurons from SODnSODa and SODnWTa in response to potassium only.
K+ = potassium
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Depolarising K+ Kainate
WTnWTa 2344.2 5493.1
± S.E.M. ±582.9 ±988.7
SODnWTa 1425.8 *** 5192.0
± S.E.M. ± 409.0 ±785.8
WTnSODa 946.1 * 4150.3
± S.E.M. ± 549.3 ±643.2
SODnSODa 3581.5 + 4692.3
± S.E.M. ± 894.7 ± 1036.9
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mitochondrial depolarisation in response to potassium is summarised in Table 3.8A, 
and the data from KA-induced depolarisation is provided for comparison. Motoneurons 
from SODnWTa (n = 19) and WTnSODa (n = 7) co-cultures showed a significantly 
reduced rate of mitochondrial depolarisation in response to potassium than in response 
to KA (p < 0.015). There was also a trend towards a reduced rate of mitochondrial 
depolarisation in response to potassium in motoneurons from WTnWTa (n = 11) and 
SODnSODa (n = 8) co-cultures, although this did not reach significance (p > 0.4). 
Furthermore, motoneurons from SODnSODa co-cultures had a more rapid rate of 
mitochondrial depolarisation in response to potassium than motoneurons from 
WTnSODa co-cultures (p = 0.021).
To examine the extent of mitochondrial depolarisation, the TMRM intensities were 
normalised, to account for variation in resting ATm between co-cultures. Examples of 
the normalised traces are shown in Figure 3.16. From traces such as these, the extent of 
mitochondrial depolarisation, compared to baseline was calculated in motoneurons from 
each of the different co-cultures and the results are summarised in Table 3.8B. The data 
acquired with KA is provided for comparison. It appears that KA induced a greater 
extent of mitochondrial depolarisation than that induced by high concentrations of 
potassium, therefore indicating that the change in AvFm in response to KA was specific 
to glutamate receptor activation, rather than due to cellular depolarisation. Furthermore, 
in response to potassium, the extent of mitochondrial depolarisation was reduced in 
motoneurons from SODnWTa, WTnSODa and SODnSODa co-cultures compared to 
WTnWTa co-cultures.
203
Table 3.8 -  Mitochondrial membrane potential (AT'™) depolarisation in 
motoneurons in response to high concentrations of potassium
Co-cultures were loaded with the potentiometric fluorophore, TMRM, and the change in 
TMRM signal, which corresponded to a change in ATV in response to high 
depolarising concentrations of potassium was recorded. The mean rate of A'Fm 
depolarisation in motoneurons in response to potassium is shown in Table A, and the 
rate in response to KA is shown for comparison. Following normalisation of the TMRM 
signal, the extent of AT'™ depolarisation in response to potassium was calculated and 
Table B summarises the extent of A'Fm depolarisation in response to both potassium and 
KA. Potassium appeared to induce less AvPm depolarisation than KA. Values are the 
mean response ± standard error of the mean. * p < 0.05, *** p < 0.005 indicates a 
significant difference between the motoneurons of the same co-culture type in response 
to the two different treatments. + indicates a significant difference between motoneurons 
of SODnSODa and WTnSODa co-cultures in response to potassium only.
K+ = potassium, s = seconds
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ARate of WTnWTa SODnWTa WTnSODa SODnSODa
depolarisation
In response to K* 34.0 24.5* 7  ^ *** 28.1+
± SEM
±12.8 ±9.3 ±5.3 ±4.4
In response to KA 44.7 45.8 58.7 31.3
± SEM ±6.2 ±8.9 ±13.0 ±3.6
B
Extent of 
depolarisation
WTnWTa SODnWTa WTnSODa SODnSODa
Induced by K* 73% 58% 52% 65%
Induced by KA 79.1% 81.8% 86.4% 87.6%
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Figure 3.16 -  Mitochondrial membrane potential (ATm) depolarisation in 
motoneurons in response to high concentrations of potassium
To calculate the extent of AT'm depolarisation in motoneurons, the TMRM data was 
normalised. Examples of normalised traces from motoneurons under the different co­
culture conditions are shown. The arrows represent the points between which the extent 
of depolarisation was measured, 
s = seconds
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3.3.5. The effect of expression of mutant SOD1 on motoneuron survival following 
exposure to neurotoxic agents
At 7DIV, motoneurons in each of the four co-culture conditions were exposed to one of 
the following stressful stimuli for 24 hours: i) lOOpM AMP A (an excitotoxic agent), ii) 
200pM AMP A, iii) 200nM staurosporine (an inducer of apoptosis), iv) lOOpM 
hydrogen peroxide (an inducer of oxidative stress) or v) no treatment. At least 3 co­
cultures prepared on different occasions were exposed to each neurotoxic treatment and 
the number of surviving motoneurons was expressed as a percentage of the number of 
motoneurons in the untreated group prepared on the same occasion. Figure 3.17 shows 
examples of co-cultures stained for MAP-2 that received (A) no treatment, (B) 200pM 
AMPA or (C) 200nM staurosporine. Motoneurons treated with AMP A, staurosporine or 
H2 O2 showed morphological signs of cellular damage, such as damage to the 
motoneuron soma (shown by the arrowheads in Figure 3.17B) and neuritic blebbing 
(shown by the arrows in Figure 3.17C) compared to those in the control, untreated 
cultures. The effect of exposure to each of these stressful stimuli on motoneuron 
survival in each co-culture condition was assessed and the results are summarised in 
Figure 3.18. Exposure to each of the stressful stimuli resulted in the death of a 
significant proportion of motoneurons in each of the co-culture conditions. Surprisingly, 
there was no significant difference in the number of motoneurons surviving in 
WTnWTa, SODnWTa, WTnSODa and SODnSODa co-cultures following exposure to 
excitotoxic, apoptotic or oxidative insults (p > 0.1), suggesting that the presence of 
mutant SOD1 in either motoneurons or astrocytes had no effect on their vulnerability to 
acute cell death agents.
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Figure 3.17 -  MAP-2 immunostaining of co-cultured motoneurons
The photomicrographs show examples of MAP-2 immunostained motoneurons that 
were (A) untreated, or were treated with (B) 200pM AMPA for 24 hours or (C) 200nM 
staurosporine for 24 hours. A substantial proportion of motoneurons died following 
neurotoxic treatment and the motoneurons remaining following AMPA or staurosporine 
treatment showed morphological signs of cellular damage, such as damage to the 
motoneuron soma, as shown by the arrowheads in B, and neuritic blebbing, as shown by 
the arrows in C, compared to those in the control untreated co-cultures (A). Scale bar = 
50pm.
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Figure 3.18 -  The number of surviving motoneurons after exposure to stressful 
stimuli
Motoneurons in the various co-culture conditions were exposed to an excitotoxic 
(lOOpM or 200pM AMPA), apoptotic (200nM staurosporine) or oxidative (lOOpM 
hydrogen peroxide) insult for 24 hours. The number of surviving motoneurons was 
assessed using the trypan blue exclusion method and immunostained for MAP-2, a pan 
neuronal marker, for morphological identification. Exposure to each of the stressful 
stimuli induced the death of a substantial proportion of motoneurons compared to 
control, untreated co-cultures. However, there was no significant difference in the 
number of motoneurons surviving in WTnWTa, SODnWTa, WTnSODa and 
SODnSODa co-cultures exposed to any of the insults (p > 0.1). Values are the mean 
number of motoneurons surviving, from at least 3 different co-cultures, expressed as a 
percentage of the number of control motoneurons from the same preparation ± standard 
error of the mean.
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3.3.6. Summary of results
A number of physiological and cellular parameters of motoneurons and astrocytes under 
the various co-culture conditions were examined in this Chapter. The results of this 
Chapter are summarised in Figure 3.19, which illustrates the influence of mutant SOD1 
expression in astrocytes and also motoneurons to the response of motoneurons under 
basal conditions and in response to excitotoxic stimulation.
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Figure 3.19 -  Summary of the influence of mutant SOD1 expression in astrocytes 
and motoneurons under basal conditions (A) and in response to excitotoxic 
stimulation (B)
A) BASAL CONDITIONS
Mutant SOD1 expression Mutant SOD1 expression
in motoneurons in astrocytes
T spontaneous activity Impairment in mitochondrial
in motoneurons respiration in motoneurons
( J r  NADH autofluorescence)
i r
T mitochondrial calcium 
in motoneurons
Depolarisation of mitochondrial membrane potential in motoneurons
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B) EXCITOTOXIC CONDITIONS
Mutant SOD1 expression in either motoneurons or astrocytes
No change in [Ca2+]c influx in motoneurons
No change in rate of mitochondrial depolarisation in motoneurons
BUT
T in extent of mitochondrial depolarisation in motoneurons
f  rate of superoxide generation in motoneurons
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3.4. DISCUSSION
In this Chapter, the role that astrocytes play in ALS pathogenesis was investigated by 
studying the effect of differential expression of mutant SOD1 in either motoneurons or 
astrocytes. Several cellular properties of motoneurons and in some cases astrocytes were 
examined under both resting, basal conditions and in response to excitotoxic stimuli 
using fluorescent imaging. The key findings are summarised in Table 3.9, which 
illustrates the responses of motoneurons in which mutant SOD1 was expressed in either 
motoneurons, astrocytes or both cell types, compared with motoneurons from WTnWTa 
co-cultures. It can be seen that in motoneurons in SODnSODa co-cultures almost every 
parameter investigated is significantly different from the response obtained in WTnWTa 
co-cultures. Thus, expression of mutant SOD1 in both motoneurons and astrocytes has 
serious consequences, even in embryonic motoneurons. Furthermore, expression of 
mutant SOD1 in either astrocytes or in motoneurons also alters some motoneuron 
responses suggesting that expression of the mutant SOD1 protein in either neurons or 
non-neuronal cells alone is sufficient to induce alterations in the cellular homeostasis of 
motoneurons.
The co-culture system used in this study generates four different co-culture conditions; 
WTnWTa, SODnWTa, WTnSODa and SODnSODa. Spinal cords astrocytes are used, 
in preference over for example cortical astrocytes, in order to model the natural 
environment of spinal motoneurons that exists in vivo. Furthermore, it is important to 
use spinal cord astrocytes as deficits in glutamate transport have been reported in spinal 
cord astrocytes in both post-mortem tissue from ALS patients and mutant SOD1 mice 
(Rothstein et al., 1992; Bruijn et al., 1997). Despite the highly simplistic nature of this 
co-culture system compared to the in vivo spinal cord, it provides an excellent model to 
examine the effects of mutant SOD1 expression on a cellular basis. This system permits
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Table 3.9 -  Summary of the alterations in cellular properties of motoneurons 
induced by the expression of mutant SOD1, under basal conditions and in response 
to excitotoxic stimuli
The Table summarises the mean alterations in cellular properties of motoneurons from 
SODnWTa, WTnSODa and SODnSODa co-cultures in comparison to motoneurons 
from WTnWTa co-cultures, under basal conditions and in response to excitotoxic 
stimuli.
I ^  I
[Ca ]c = cytosolic calcium levels, [Ca ]m = mitochondrial calcium levels, = 
mitochondrial membrane potential.
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SO D nW Ta W TnSO D a SODnSODa
Basal Excitotoxic Basal Excitotoxic Basal Excitotoxic
[Ca2+]c -
fura 2-FF - - - - 4 -
fluo 4 4 - 4 - 4 -
[Ca2+]m
(rhod 5N) t - t - t 4
Spontaneous
[Ca2+]c (fluo 4) T - t
AWm (TMRM)
Basal - 4. 4
Rate - KA - - -
Extent - KA - t t
Superoxide
generation
(HEt)
Basal - - 4
KA t - -
GLT - 4 -
NADH
autofluorescence
Cyanide - - 4
Rotenone - - 4
High K+ (fluo 4)
[Ca2+]c - - -
A'Fm: Rate - - -
Extent 4 i 4
2 1 8
detailed analysis of the response of individual motoneurons to the extracellular 
application of a variety of agents. Furthermore, confocal imaging provides the high 
spatial and temporal resolution to perform such experiments.
3.4.1. The effect of expression of mutant SOD1 on basal cellular properties
3.4.1.1. Basal cellular calcium levels
Even under resting conditions, expression of mutant SOD1 in motoneurons and 
astrocytes alters several cellular properties compared to motoneurons in WT conditions. 
The results show that in motoneurons in SODnSODa co-cultures there is a reduction in 
[Ca2+]c, possibly due to enhanced mitochondrial calcium uptake, since [Ca2+]m is 
elevated. Selective expression of mutant SOD1 in either motoneurons or astrocytes also 
causes elevations in [Ca2+]m and lower [Ca2+]c at rest, although the cytosolic data, 
measured with fluo 4, is not observed with the more quantitative indicator fura 2-FF. 
However, it appears that expression of mutant SOD1 either in motoneurons or 
astrocytes, is sufficient to alter calcium homeostasis in motoneurons.
i) Elevated mitochondrial calcium levels ([Ca2+]m)
Calcium influx into mitochondria is dependent on the electrochemical potential
gradient, which in turn is determined by a combination of the AT^ and the [Ca2+]m
(Kapus et al., 1991). Therefore, mitochondrial hyperpolarisation may induce an
elevation in calcium loading of mitochondria. However, under basal conditions the ATm 
of motoneurons from SODnWTa co-cultures does not differ significantly from 
WTnWTa, whereas motoneurons from WTnSODa and SODnSODa co-cultures have a 
reduced AWm. This reduction in AvFm may be a consequence of the elevated [Ca ]m, as 
calcium influx into mitochondria, through the uniporter, will induce depolarisation of 
the AvFm. Mitochondrial depolarisation can subsequently inhibit the electrogenic
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Na /Ca exchanger consequently reducing calcium efflux (Montero et al., 2001).
94-Therefore, an elevated [Ca ]m influx may, via the induction of a slight mitochondrial 
depolarisation, slow the re-equilibration of calcium between the mitochondria and
94 -cytosol, thereby increasing resting [Ca ]m.
ii) Spontaneous calcium activity
Although mitochondrial hyperpolarisation may be the driving force for elevated [Ca2+]m 
uptake in mutant SOD 1-expressing co-cultures, it is more likely that the increase in
94-[Ca ]m is due to increased spontaneous calcium activity observed when mutant SOD1 
is expressed in motoneurons or in astrocytes but only when co-cultured with WT
9  I
motoneurons. Typically, transient elevations in [Ca ]c are reflected by more prolonged
94-changes in [Ca ]m and consequently changes in mitochondrial metabolism (Hajnoczky 
et al., 1995; Robb-Gaspers et al., 1998). Therefore, an increase in the frequency of
94-intracellular calcium transients may result in augmentation of [Ca ]m loading. Indeed, 
mutant SOD1 motoneurons, which show the greatest spontaneous calcium activity,
94-consistently have the highest [Ca ]m under basal conditions.
The increased spontaneous activity seen in mutant SOD1 motoneurons may be due to an 
increased persistent sodium conductance, which would induce motoneuron 
depolarisation and increase the probability of opening of voltage-gated calcium 
channels. Previous reports have found that mutant SOD1 motoneurons show an increase 
in spontaneous excitability (Pieri et al., 2003; Kuo et al., 2004). In mutant SOD1 mice 
this enhanced excitability of motoneurons may be further exacerbated by a reduction in 
the functioning of the Na+/K+ ATPase towards end-stage of disease (Ellis et al., 2003). 
As a result of the increased spontaneous excitability of mutant SOD1 motoneurons, the 
probability of opening of voltage-gated potassium channels is also likely to be
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increased, resulting in elevated extracellular potassium levels. Thus, in the presence of 
mutant SOD 1-expressing motoneurons, astrocytes may buffer excess potassium, which 
will reduce their spontaneous activity. In contrast, when co-cultured with WT 
motoneurons, the spontaneous activity of mutant SOD1 astrocytes will not be 
suppressed in this way. Since astrocyte calcium signalling can modulate neuronal 
activity (see Chapter 3.1.2.3), the increase in spontaneous activity of astrocytes may 
result in increased [Ca ]m in motoneurons, as observed in WTnSODa co-cultures.
iii) Consequences of elevated mitochondrial calcium levels ([Ca2+]m)
Under normal physiological conditions, the uptake of calcium by mitochondria provides 
a mechanism by which increased cellular activity is coupled with an up-regulation of
^  I
mitochondrial metabolism. However, elevated [Ca ]m has also been implicated in many 
pathological conditions. Indeed, inhibition of [Ca2+]m uptake has neuroprotective effects 
following exposure to excitotoxic levels of glutamate (Stout et al., 1998). There are 
several mechanisms by which elevated [Ca2+]m may be damaging to cellular function. 
Uptake of calcium may activate many calcium-dependent processes, particularly if high
9 +[Ca ]m is maintained. For example, a correlation between calcium uptake and NO 
production in endothelial cell mitochondria has been shown (Dedkova et al., 2004), 
which suggests that the calcium-dependent mitochondrial isoform of nitric oxide 
synthase (mtNOS) might be a target for the elevated [Ca2+]m. The high calcium affinity 
of mtNOS (Giulivi, 2003) coupled with elevated resting [Ca2+]m, implies that in the 
present study, mtNOS may be activated in the mutant SOD 1-expressing co-cultures 
even under basal conditions. NO may then damage both the respiratory chain (Stewart 
et al., 2000; Jekabsone et al., 2003), and the Na+/Ca2+ exchanger (Castilho et al., 1999), 
resulting in mitochondrial depolarisation (Ghafourifar & Richter, 1997). Elevated 
[Ca2+]m can also increase production of ROS (Dykens, 1994; Castilho et al., 1995;
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Dugan et al., 1995). If this occurs in combination with calcium-induced depletion of 
glutathione reductase and glutathione peroxidase activity, which has been shown to 
occur in isolated rat brain mitochondria (Zoccarato et al., 2004), subsequent damage to 
mitochondria will occur. Furthermore, high [Ca2+]m? under certain conditions can induce 
opening of the mPTP, which can initiate cell death pathways (Halestrap et al., 2002).
Therefore, elevated [Ca ]m in motoneurons even under basal conditions, may initiate a 
variety of potentially neurotoxic mechanisms that can inflict cumulative damage. In 
addition, these motoneurons will also have a reduced mitochondrial buffering capacity 
due to a reduced driving force for calcium uptake into mitochondria, which again may 
increase their susceptibility to further stressful stimuli. This is particularly important for 
motoneurons, which not only have a high metabolic demand but also rely to a greater 
extent on mitochondrial buffering, due to the reduced cytosolic expression of calcium 
buffering proteins (Ince et al., 1993; Alexianu et al., 1994; Elliott & Snider, 1995).
Previous studies have reported an elevation in [Ca2+]c as a consequence of mutant SOD1 
expression, which is proposed to be related to a reduced mitochondrial calcium 
buffering capacity (Carri et al., 1997; Kruman et al., 1999). However, culture 
differences, both in terms of cell types and culture conditions may explain the 
discrepancy between these studies and the present data.
3.4.I.2. Mitochondrial status under basal conditions
• • o  iIn addition to elevated [Ca ]m, motoneurons co-cultured with mutant SOD1 astrocytes
have a reduced AT'm under basal conditions. As discussed above, the elevation in basal
2+[Ca ]m may contribute to the observed mitochondrial depolarisation in motoneurons. 
However, the AT'm of motoneurons from SODnWTa co-cultures, which also display
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elevated [Ca ]m at rest, is the same as that of motoneurons in WTnWTa co-cultures. 
Therefore it appears that the expression of mutant SOD1 in astrocytes confers an 
additional property, which results in mitochondrial depolarisation in motoneurons under 
basal conditions.
i) Respiratory chain defects
Inhibition of respiration by cyanide or rotenone induces an increase in NADH 
autofluorescence as a consequence of an accumulation of NADH, due to the inability of 
complex I to oxidise NADH to NAD+. In motoneurons in SODnSODa co-cultures, there 
is a reduced change in NADH autofluorescence in response to cyanide or rotenone, 
inhibitors of complexes IV and I of the respiratory chain respectively. Furthermore, a 
smaller change in NADH autofluorescence in response to cyanide is also observed in 
motoneurons from WTnSODa co-cultures, although this does not reach statistical 
significance. The smaller increase in NADH autofluorescence in motoneurons from 
SODnSODa, and to some extent in WTnSODa co-cultures, suggests that expression of 
mutant SOD1 in astrocytes results in functional alterations in the electron transport 
chain, particularly in complex I. Reduced oxidation of NADH, possibly due to either a 
reduction in the availability of mitochondrial substrates or to a defect in the electron 
transport chain, would lower the pool of NAD+ available for reduction, and 
consequently reduce the change in NADH autofluorescence that is observed upon 
respiratory inhibition. Further experiments will be required to distinguish between these 
two possibilities, but both indicate a disruption in mitochondrial function.
Therefore, in motoneurons co-cultured with mutant SOD1 astrocytes the combination of 
elevated [Ca2+]m together with defects in the electron transport chain, perhaps in 
complex I, may induce mitochondrial depolarisation under basal conditions.
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Motoneurons from SODnWTa co-cultures demonstrate elevated resting [Ca2+]m but 
there is no indication of electron transport chain damage and consequently no reduction 
in A'f'm is observed.
Reductions in complex I and IV activities have been found in affected tissue from ALS 
patients, symptomatic SOD1G93a mice and a SODlG93A-expressing motoneuronal cell 
line (Fujita et al., 1996; Swerdlow et al., 1998; Weidemann et al., 1998; Borthwick et 
al., 1999; Vielhaber et ah, 2000; Jung et ah, 2002; Mattiazzi et ah, 2002; Menzies et ah, 
2002; Fukada et ah, 2004). Furthermore, mitochondria from the spinal cords of 
symptomatic S0D1G93A mice have a low maximal respiratory rate and reduced ATP 
generation, which will result in energy depletion (Mattiazzi et ah, 2002). Finally, a 
reduction in the AxPm of motoneurons due to mutant SOD1 expression under basal 
conditions has also been previously shown (Carri et ah, 1997; Kruman et ah, 1999; 
Rizzardini et ah, 2005). However, in those studies the reduction in AT'm is attributed to 
the expression of mutant SOD1 in motoneurons. The results of this Chapter, in contrast, 
suggest that the expression of mutant SOD1 in astrocytes is the critical factor that 
induces alterations in mitochondrial function in motoneurons.
ii) Astrocyte-mediated toxicity
In this study, expression of mutant SOD1 in astrocytes is sufficient to induce defects in 
the electron transport chain that, in combination with elevated [Ca2+]m, ultimately 
results in the mitochondrial depolarisation of co-cultured motoneurons. The expression 
of mutant SOD1 in a glioblastoma cell line is sufficient to induce cellular activation and 
the subsequent production of NO (Ferri et ah, 2004). Astrocyte-derived NO (via iNOS 
stimulation) can diffuse to neighbouring motoneurons and has been shown to inhibit 
mitochondrial respiration (Bal-Price & Brown, 2001). NO-mediated damage to the
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electron transport chain can occur via both a direct and indirect mechanism. NO can 
compete with molecular oxygen for binding to complex IV, and reversibly inhibit 
respiration (Brown & Cooper, 1994). However, the reaction of NO with superoxide 
generates peroxynitrite, which can mediate substantial cellular damage including 
irreversible inhibition of complexes I, II/III and IV (Brown & Cooper, 1994; Brookes et 
al., 1998; Stewart et al., 2000; Jekabsone et al., 2003). NO-mediated respiratory 
inhibition can induce mitochondrial depolarisation and subsequently increase ROS 
production, and furthermore may also stimulate the release of glutamate (Bal-Price & 
Brown, 2001; Votyakova & Reynolds, 2001). A contribution of mtNOS to 
mitochondrial damage is also possible, since this enzyme may be activated in response
94-to elevated [Ca ]m, and will generate NO inside the mitochondria, in close proximity to 
the electron transport chain (Giulivi, 2003).
Reactive astrocytes also release a variety of proinflammatory cytokines that can induce 
COX2 expression, via activation of the transcription factor NF-kB (Consilvio et al., 
2004; Juttler et al., 2004). COX2 activation will increase production of prostaglandins, 
including PGE2 , which may contribute to excitotoxicity by stimulating the release of 
glutamate from astrocytes (Drachman & Rothstein, 2000), and in addition releases 
ROS, which may further propagate the inflammatory process and exert neurotoxicity 
(Consilvio et al., 2004). Therefore, the data presented in this Chapter suggests that 
mutant SOD1 expression in astrocytes can have significantly detrimental effects on 
adjacent motoneurons.
However, under basal conditions, the mutant SOD 1-induced defect in respiration and 
elevation in [Ca2+]m, with resulting mitochondrial depolarisation, does not appear to 
affect motoneuron viability in vitro. Indeed, there is no difference in motoneuron
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survival in any of the 4 co-culture conditions. However, it is possible that over time the 
reduced efficiency of respiration in depolarised mitochondria may reduce ATP 
generation, therefore depleting cellular energy and eventually initiating necrosis.
3.4.I.3. Basal cellular superoxide production
The electron transport chain in mitochondria is regarded as the main cellular source of 
superoxide. The release of unpaired electrons from complexes I and III during oxidative 
phosphorylation, can react with oxygen to generate superoxide, which can subsequently 
exert cellular damage. A combination of highly susceptible mitochondrial components 
with the localised production of superoxide renders mitochondria highly vulnerable to 
oxidative damage.
In both motoneurons and astrocytes from SODnSODa co-cultures, the rate of 
superoxide generation under basal conditions is less than in WTnWTa co-cultures. This 
selective reduction in oxidation rates may be related to the increased expression of the 
mutant SOD1 enzyme in these co-cultures as the mutant S0D1G93A protein has been 
shown to retain full enzymatic activity (Gurney et al., 1994). In both SODnWTa and 
WTnSODa co-cultures, there is also a trend towards a reduced basal rate of superoxide 
generation, which may be related to the increased expression of the mutant SOD1 
enzyme. An alternative possibility is that the reduced rate of superoxide production is a 
consequence of the partial depolarisation of the mitochondria from both motoneurons 
and astrocytes in SODnSODa co-cultures. The generation of superoxide from complex I 
has a AvFm-dependent and independent component. Therefore the production of ROS via 
the succinate-driven transfer of electrons from complex II to I is highly A'Fm dependent, 
with mitochondrial depolarisation inhibiting superoxide production. In contrast, ROS
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production mediated by complex III is independent of (Votyakova & Reynolds, 
2001).
However, in contrast to the results that are presented in this Chapter, Kruman et al, 
(1999) reported an increased rate of superoxide production in primary SODlG93A 
motoneurons under basal conditions. However, this result is observed in motoneurons 
cultured without an enriched astrocyte layer. Furthermore, Swerdlow et al, (1998) 
reported an increase in the rate of free radical scavenging activity in platelets expressing 
mtDNA from sALS patients, which has been taken to imply a greater free radical 
production. However, if this assumption is correct then it applies to all free radicals and 
not just superoxide. Perhaps investigation into total free radical production may reveal 
an increase in the co-cultures.
3.4.2. The effect of expression of mutant SOD1 on the response of motoneurons to 
excitotoxicity
3.4.2.I. Cellular calcium levels
In these experiments the different co-cultures are exposed to excitotoxic stimuli, 
initially KA followed by glutamate, and the cellular response of motoneurons and 
astrocytes are assessed. KA is used as a specific glutamate receptor agonist since it has 
been proposed that motoneurons show a selective vulnerability to AMPA/KA receptor- 
mediated excitotoxicity, and the subsequent application of glutamate allows 
investigation into whether a secondary response is observed to a physiological agonist.
94-Expression of mutant SOD1 has no effect on the [Ca ]c influx into either motoneurons
2d-or astrocytes following exposure to KA and glutamate. Thus, the peak [Ca ]c influx 
induced by the sequential addition of KA and glutamate in both motoneurons and
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astrocytes is the same in all co-culture conditions. Thus, although there is considerable 
evidence to indicate that glutamate excitotoxicity plays a role in ALS, as discussed in 
detail in Chapter I.3.4.2., the current experiments do not detect any differential 
vulnerability of mutant SOD 1-expressing motoneurons to KA or glutamate compared to 
WT motoneurons. This implies that the expression of mutant SOD1 does not increase 
the selective vulnerability of motoneurons to excitotoxicity. In ALS, motoneurons, 
which have a number of characteristics that render them more susceptible to glutamate, 
including a reduction in expression of calcium binding proteins (Ince et al., 1993; 
Alexianu et al., 1994; Elliott & Snider, 1995) and an increased density of AMPA/KA 
receptors (Carriedo et al., 1996; Vandenberghe et al., 2000b; van den Bosch et al., 2000, 
2002; Van Damme et al., 2003), are exposed to greater levels of glutamate than 
motoneurons in normal spinal cord. The results of the experiments in this Chapter 
however, suggest that mutant SOD1 toxicity does not involve an elevated susceptibility 
to glutamate, at least in an acute, in vitro model. However, accumulative effects of the 
expression of mutant SOD1 over time on the vulnerability of motoneurons to 
excitotoxicity cannot be excluded.
As with some of the basal data obtained in experiments described in this Chapter, the 
data on glutamate-induced [Ca2+]c influx contrasts to that reported by Kruman et al, 
(1999), in which a given concentration of glutamate not only induces a greater [Ca2+]c 
influx, but also a greater production of ROS and an increased mitochondrial 
depolarisation in primary S0D1G93A motoneuron monocultures. However, Stout et al, 
(1998) demonstrated that increased [Ca2+]c itself might not be neurotoxic and suggest 
that the extent of [Ca2+]m loading determines toxicity since they found that inhibition of 
[Ca2+]m uptake, and the subsequent sustained elevation in [Ca2+]c, is neuroprotective. 
Alternatively, calcium-mediated neurotoxicity may be determined by the inability of the
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cell to return [Ca ]c to baseline due to defects in calcium extrusion. Mitochondrial 
depolarisation, induced by calcium uptake, may inhibit calcium extrusion mechanisms, 
since the Na+/Ca2+ exchanger and Ca2+/H+ pump are both ATP dependent (Montero et 
al., 2001). The contribution of such mechanisms to excitotoxicity-induced motoneuron 
toxicity requires further investigation.
3.4.2.2. Mitochondrial depolarisation in response to excitotoxicity
Expression of mutant SOD1 in motoneurons and astrocytes not only has no effect on
j
changes in [Ca ]c but also does not affect the rate of mitochondrial depolarisation in 
response to either KA or glutamate. Normalisation of the data to account for variability 
in the resting AvPm; however, reveals that in response to the same [Ca2+]c influx, 
mitochondria from motoneurons in WTnSODa and SODnSODa co-cultures depolarise 
to a greater extent in response to KA than in WTnWTa co-cultures. Previously, Kruman 
et al, (1999) have also shown a greater loss of AT'm in response to glutamate in 
SOD1G93a motoneurons.
The greater susceptibility of these mitochondria to depolarisation in response to 
excitotoxicity may be related to their underlying resting mitochondrial defects, 
including; elevated [Ca2+]m, possible defects in the electron transport chain complex 
activity and reduced AxFm. Therefore, the mitochondria from motoneurons co-cultured 
with mutant SOD 1-expressing astrocytes are already altered even under basal 
conditions, which suggests that they may have been less able to withstand an 
excitotoxic insult. The release of NO and proinflammatory cytokines by mutant SOD1
^ i
astrocytes, in combination with an elevation in [Ca ]m, may exert mitochondrial 
toxicity that underlies this selective vulnerability, as described in Chapter 3.4.1.2, 
Keelan et al, (1999) proposed that mitochondrial depolarisation following NMD A
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receptor activation, requires the combination of NO with an innocuous calcium load. 
Indeed, the [Ca2+]c influx in response to excitotoxicity may combine with NO derived 
from mutant SOD1 astrocytes to induce a greater extent of mitochondrial depolarisation 
in mutant SOD1 astrocyte containing co-cultures. The complete mitochondrial 
depolarisation in SODnSODa co-cultures following glutamate exposure may represent 
the opening of the mPTP, a large conductance pore that spans the inner and outer 
mitochondrial membranes. High [Ca ]m in combination with oxidative stress, ATP 
depletion, high inorganic phosphate and mitochondrial depolarisation can trigger the 
opening of the mPTP and ultimately mitochondrial death (Halestrap et al., 2002). The 
release of cytochrome c from the mitochondria may also stimulate apoptosis (De Giorgi 
et al., 2002), or alternatively, the resultant collapse of and ATP depletion may 
eventually initiate necrotic cell death (Sullivan et al., 2005).
3.4.2.3. Cellular superoxide production in response to excitotoxicity
In contrast to [Ca2+]c and mitochondrial membrane potential depolarisation, expression 
of mutant SOD1 in motoneurons, astrocytes or both cell types has a significant effect on 
the rate of superoxide generation following exposure to KA and glutamate. Thus, in 
response to stimulation with KA, the rate of superoxide generation is significantly 
increased in motoneurons from SODnWTa, WTnSODa and SODnSODa co-cultures 
compared to their individual basal rates, but not in WTnWTa co-cultures. However, 
when compared directly to WTnWTa co-cultures, the rate is only increased in response 
to KA in motoneurons from SODnWTa co-cultures, although there is a trend towards an 
increased rate of superoxide production in motoneurons from WTnSODa and 
SODnSODa co-cultures as well. Similarly in astrocytes, the rate at which superoxide is 
generated is increased in SODnWTa and WTnSODa co-cultures following KA 
exposure, compared to WTnWTa, although again a trend towards an increased rate is
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also observed in astrocytes in SODnSODa co-cultures. Thus, expression of mutant 
SOD1 appears to increase the rate of superoxide production in motoneurons and 
astrocytes in response to KA stimulation. However, these results may actually be an 
underestimation of the level of free radical production since HEt is an indicator of 
superoxide production alone. An elevated free radical generation in mutant SOD1 
motoneurons has been previously shown following glutamate stimulation (Kruman et 
al., 1999), consistent with these results. Similarly, markers of oxidative damage are 
increased in mitochondria isolated from the brain and spinal cord of symptomatic 
SODlG93Amice (Mattiazzi et al., 2002).
The increase in superoxide production together with further mitochondrial 
depolarisation in mutant SOD 1-expressing co-cultures is perhaps surprising due to the 
dependence of free radical production on AvFm. However, enhanced free radical 
generation has previously been associated with mitochondrial depolarisation induced by 
NMDA receptor (Solenski et al., 2003) and AMPA/KA receptor activation (Rao et al.,
2003). Furthermore, Lafon-Cazal et al, (1993) demonstrated an enhancement in free 
radical generation that is delayed in relation to mitochondrial depolarisation. More 
recently it has been suggested that a component of mitochondrial ROS generation 
occurs independently of the ATm. Votyakova & Reynolds, (2001) demonstrated that 
ROS production driven by complex I substrates glutamate and malate, occurs 
independently of AvFm. Furthermore, in the same study, the AvFm-independent 
production of ROS is enhanced in the presence of complex I inhibition (Votyakova & 
Reynolds, 2001). As described earlier, there appears to be a defect in mitochondrial 
respiration in motoneurons co-cultured with mutant SOD1 astrocytes, possibly mediated 
by iNOS activation. Therefore NO-mediated damage to the electron transport chain may 
induce an increased rate of superoxide generation in mutant SOD 1-expressing astrocyte
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co-cultures, despite depolarised mitochondria. Whereas in motoneurons in SODnWTa 
co-cultures, elevated [Ca ]m and mtNOS activation may be responsible for increased 
superoxide production (Dykens, 1994; Castilho et al., 1995; Dugan et al., 1995). Indeed, 
the increase in superoxide generation despite a significant reduction in AWm implies that 
under these co-culture conditions, a significant proportion of AxFm-independent 
superoxide production occurs. Potentially, the production of free radicals from 
arachidonic acid metabolism, xanthine oxidase and NADPH oxidase, which are 
mitochondrial-independent sources, may also contribute to the observed increase in 
superoxide generation.
In motoneurons in mutant SOD 1-expressing co-cultures, the rate of superoxide 
generation in response to glutamate is significantly reduced compared to the rate in 
response to KA. This may be indicative of reduced mitochondrial viability. Indeed, the 
almost complete loss of AxFm in motoneurons in SODnSODa co-cultures in response to 
glutamate may reflect the opening of the mPTP. Calcium extrusion mechanisms are 
sensitive to ROS-induced damage. Therefore, enhanced ROS production may impair the 
cellular clearance of calcium, further increasing intracellular calcium concentrations, so 
that the combination of ROS and calcium can induce mPTP opening (Castilho et al., 
1999; reviewed in Duchen, 2004).
3.4.2.4. Mitochondrial calcium levels
• • 94-In all co-culture conditions, glutamate stimulation induces significant [Ca ]m loading. 
However, the loading of [Ca2+]m in motoneurons from SODnSODa co-cultures is less 
than that in motoneurons in WTnWTa co-cultures. This is in contrast to the results
obtained under basal conditions, which show that motoneurons in SODnSODa co-
2+
cultures have significantly elevated [Ca ]m. However, there may be a causal link
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7-4-between the two values as increased [Ca ]m at rest can induce partial mitochondrial 
depolarisation and reduce the subsequent driving force for calcium influx into
7 -4-mitochondria, which is dependent on both the A ^m and the [Ca ]m (Kapus et al., 1991). 
Therefore, in response to glutamate stimulation, the mitochondria of motoneurons in 
SODnSODa co-cultures will have a reduced capacity for calcium influx. The resting
7  I
[Ca ]m in motoneurons in SODnWTa and WTnSODa co-cultures are also elevated, and
7 -4-there is a tendency for a lower [Ca ]m influx in motoneurons in these co-cultures in 
response to glutamate.
7 -hThese observations may at first appear to contradict the prevailing view that [Ca ]m
7 4-overloading is associated with neuronal death and conversely that inhibition of [Ca ]m 
uptake has neuroprotective effects (Stout et al., 1998; Rodrigo et al., 2002). Therefore,
7 +the fact that mutant SOD1 motoneurons have a reduced [Ca ]m loading in response to 
glutamate in the co-culture set up in this study may be considered surprising. However, 
as discussed above, mutant SOD1 motoneurons co-cultured with mutant SOD1 
astrocytes exhibit several mitochondrial defects even under basal, resting conditions. 
This suggests that they might have a particular vulnerability to further insults. Indeed a 
greater extent of mitochondrial depolarisation and increased superoxide production are 
observed in motoneurons in SODnSODa co-cultures in response to excitotoxicity. It is 
possible that a toxic threshold for [Ca2+]m exists in motoneurons and once reached, 
calcium-dependent deleterious processes are activated. Therefore, the pre-existing 
mitochondrial defects in combination with only a reduced [Ca2+]m influx in response to 
excitotoxicity, may be sufficient to induce mitochondrial depolarisation resulting in 
cytochrome c release and apoptosis, or energy depletion and necrotic cell death.
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3.4.2.5. Response to depolarisation of the plasma membrane
A critical factor influencing the effects of [Ca2+]c influx may be the source through 
which the calcium enters the cell (‘source specificity’ hypothesis; Sattler et al., 1998), 
rather than the extent of the calcium influx (‘calcium load’ hypothesis; Lu et al., 1996). 
The basis of the ‘source specificity’ hypothesis is that distinct neurotoxic signalling 
pathways may be activated in response to calcium influx via a specialised route (Sattler 
et al., 1998), for example AMPA/KA receptors in motoneurons. In contrast, an 
equivalent calcium influx through an alternative pathway, for example voltage-gated 
calcium channels, may lack neurotoxic actions. Therefore in this study, the change in
2_j_
[Ca ]c and extent of mitochondrial depolarisation is also investigated in response to 
high concentrations of potassium, which acts to depolarise the plasma membrane.
The results show that there is a greater [Ca2+]c influx and rate of mitochondrial 
depolarisation in motoneurons in response to KA compared to potassium in all co­
culture conditions, although in homogeneous WT or SOD1G93a co-cultures these results 
do not reach significance. However, the extent of mitochondrial depolarisation in 
motoneurons is greater in response to KA compared to potassium in all co-cultures. 
This suggests that both mutant SOD 1-expressing and WT motoneurons have an 
increased vulnerability to KA over potassium-induced depolarisation. However, 
potassium does induce prolonged mitochondrial depolarisation in motoneurons. This is 
in contrast to mitochondria in hippocampal neurons that have been shown to not 
depolarise in response to potassium, despite a significant elevation in [Ca2+]c (Keelan et 
al., 1999). Previously, Roy et al, (1998) reported that calcium influx via voltage-gated 
calcium channels contributes to the toxicity of SOD 1093A expression.
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3.4.2.6. Survival assay
In addition to fluorescent imaging of motoneurons in co-cultures the effect of 
expression of mutant SOD1 in astrocytes on the susceptibility of motoneurons to a 
number of toxic insults is also examined. In contrast to the data acquired by fluorescent 
imaging, 24 hour exposure to neurotoxic agents, reveals no differences in motoneuron 
survival in any of the co-culture conditions. These results imply that the expression of 
mutant SOD1 in motoneurons or astrocytes does not increase vulnerability of 
motoneurons to cell death. However, it is more likely that such cell death assays are too 
crude to identify subtle but significant changes in motoneurons that may accumulate 
over time, to gradually increase the vulnerability of motoneurons to cell death.
3.5. Overall summary of results
3.5.1. Susceptibility of motoneurons to mitochondrial damage
The results of this Chapter indicate that mutant SOD1 astrocytes exert a deleterious 
influence on the mitochondrial function of mutant SOD1 motoneurons, inducing defects 
in several mitochondrial parameters even under basal conditions. However, following 
acute excitotoxic stimulation, the influence of mutant SOD 1-expressing astrocytes is 
less clear, although it appears that expression of mutant SOD1 in either motoneurons or 
astrocytes is sufficient to induce the observed changes.
Motoneurons have a very high metabolic rate and are therefore particularly vulnerable 
to mitochondrial inhibition. Interestingly, irregularities in mitochondrial structure, 
including dilated cristae and mitochondrial swelling, have previously been identified in 
motoneurons in post-mortem tissue from sporadic and familial ALS patients (Hirano et 
al., 1984; Fujita et al., 1996; Sasaki & Iwata, 1996; Siklos et al., 1996). In mutant SOD1 
mice, one of the earliest pathological signs are abnormalities in mitochondrial structure
235
associated with altered function, occurring even before the appearance of symptoms (as 
discussed in Chapter I.3.4.3.; Dal Canto & Gurney, 1994; Wong et al., 1995; Kong & 
Xu et al., 1998; Bendotti et al., 2001; Jaarsma et ah, 2001). Moreover, there is some 
evidence to suggest that mutant SOD1 may specifically associate with mitochondria in 
the spinal cord of mutant SOD1 mice (Liu et al., 2004; Pasinelli et al., 2004). 
Furthermore, proteomic analysis of NSC34 cells reveals significant mitochondrial 
deficits induced by mutant SOD1 expression (Kirby et al., 2005). Thus, together with 
the results of the present study, an increasing body of evidence now suggests that 
mitochondria may be a primary target in ALS. The results shown here provide a 
functional basis for the morphological and proteomic changes previously reported by 
other authors.
3.5.2. The contribution of astrocytes to ALS pathogenesis
The evidence presented in this Chapter supports a toxic role of mutant SOD1 astrocytes 
on mutant SOD1 motoneurons under basal conditions. These findings are consistent 
with increasing evidence that suggests that ALS is a non-cell autonomous disorder. In a 
series of elegant experiments, Clement et al, (2003) generated chimeric mice that have 
varying expression of mutant SOD1 and endogenous WT SOD1 in motoneurons and 
non-neuronal cells. In these mice, mutant SOD1 expressing non-neuronal cells are 
found to exert detrimental effects on WT motoneurons. In contrast, an environment of 
WT non-neuronal cells protects mutant SOD1 motoneurons from degeneration. 
Similarly, it has also been shown that the selective expression of mutant SOD1 in either 
motoneurons or astrocytes in vivo is not sufficient to induce motoneuron pathology, 
indicating that interaction between mutant SOD 1-expressing neurons and astrocytes is 
required for the development of ALS (Gong et al., 2001; Pramatarova et al., 2001; Lino 
et al., 2 0 0 2 ).
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Considering the close spatial association and extensive functional interaction between 
neurons and astrocytes, which is maintained in ALS (Levine et al., 1999), it is perhaps 
not surprising that degenerative changes are also seen in astrocytes. Rao et al, (2003) 
demonstrated that free radicals generated through the activation of AMPA/KA receptors 
in motoneurons could be released to exert oxidative damage on neighbouring astrocytes. 
Furthermore, activated astrocytes release a variety of neurotoxic molecules, including 
pro-inflammatory cytokines and NO, which can exert neuronal damage (reviewed in 
Barbeito et al., 2004). This may initiate a self-propagating cycle of damage between 
motoneurons and astrocytes.
3.6. CONCLUSION
In ALS, significant astrocytic pathology accompanies motoneuron degeneration in the 
spinal cord. Recently it has been suggested that alterations in non-neuronal cell 
functions are likely to contribute to ALS pathogenesis. The data presented in this 
Chapter suggest that the expression of the mutant SOD1 enzyme, particularly in 
astrocytes, appears to exert potentially deleterious effects on the mitochondrial function 
of both motoneurons and astrocytes under basal conditions. Alterations in cellular 
homeostasis induced by activated astrocytes may therefore increase the intrinsic 
vulnerability of motoneurons and astrocytes to the neurotoxic mechanisms thought to 
play a role in ALS pathogenesis.
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CHAPTER 4
THE NEUROPROTECTIVE EFFECTS OF 
CANNABINOIDS IN THE SODlG93A MOUSE MODEL OF
ALS
238
4.1. INTRODUCTION
In the experiments described in this Chapter the neuroprotective potential of 
cannabinoids was investigated in an in vivo model of ALS, by treatment of S0D1G93A 
mice with a synthetic cannabinoid.
4.1.1. Cannabinoids
Cannabis is a widely used illicit recreational drug recognised for its ability to induce a 
mildly euphoric relaxation with associated alterations in perception, cognition, memory 
and motor skills (Kumar et ah, 2001). However, for centuries cannabis sativa has also 
been used as a treatment for epilepsy (reviewed in Mechoulam & Lichtman, 2003). 
More recently the therapeutic potential of cannabis has been further recognised by its 
use as an analgesic, an anti-emetic and an appetite stimulant for AIDS and cancer 
patients (Kumar et al., 2001). Cannabis sativa is composed of over 60 cannabinoid 
compounds that are responsible for the induction of its therapeutic and psychoactive 
effects. The main psychoactive component, A9-tetrahydrocannabinol (A9-THC), was 
isolated and synthesised in 1964 (Gaoni & Mechoulam). Other derivatives such as 
cannabidiol (CBD), the main non-psychoactive component, may modulate the response 
to A9-THC (Wade et al., 2004) and indeed may also have therapeutic potential (Zuardi 
et al., 1991).
The prescriptive use of cannabis is banned in the UK under the 1971 Misuse of Drugs 
Act. However illegal self-medication has continued with reports of beneficial effects, 
particularly the alleviation of muscle spasticity by multiple sclerosis (MS) patients. As a 
result, several clinical trials have been initiated. An oromucosal spray combining A9- 
THC and CBD under a self-titrating dosing regimen significantly reduces spasticity 
according to the Visual Analogue Scale (Wade et al., 2004). In contrast, synthetic oral
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A9-THC (Marinol) does not affect spasticity as assessed by the Ashworth score of 
spasticity (Zajicek et al., 2003). However, the patients involved in this trial did report 
reduced pain levels following cannabinoid treatment (Zajicek et al., 2003). Furthermore, 
clinical trials testing the analgesic capacity of cannabinoid extracts in conditions of 
acute and chronic pain report significant cannabinoid-mediated pain relief (Kumar et al., 
2001; Berman et al., 2004). Thus, as a consequence of several successful clinical trials it 
is now apparent that cannabinoids may have an even greater therapeutic potential than 
previously thought.
4.1.2. Cannabinoid receptor pharmacology and modulation of neuronal activity
Until the late 1980s A9-THC was believed to exert its effects via incorporation into 
biological membranes due to its high lipophilicity. However, Devane et al, (1988) 
demonstrated specific binding of CP 55,940, a synthetic cannabinoid, to rat brain 
membranes in a dose-dependent, saturable and enantioselective manner, all 
characteristic features of receptor interaction. Indeed, following identification of 
specific binding sites for CP 55,940 throughout the CNS (Herkenham et al., 1990), the 
CBi receptor was isolated and cloned (Matsuda et al., 1990). Subsequently a second 
cannabinoid receptor, the CB2 receptor (with 6 8 % homology to the CBi receptor) was 
identified (Kaminski et al., 1992) and cloned from peripheral immune cells (Munro et 
al., 1993). Due to the relatively recent discovery of cannabinoid receptors, 
developments in this research area are still ongoing and as a consequence there may be 
other, as yet unidentified cannabinoid receptors. Indeed a putative ‘CB3 ’ receptor has 
been described in the brains of mice lacking the CBi receptor (Di Marzo et al., 2000; 
Breivogel et al., 2001; Monory et al., 2002).
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Cannabinoid receptors are coupled to inhibitory GTP binding proteins, G j /0 (Matsuda et 
al., 1990; Schatz et al., 1992). Therefore activation of CBi and CB2 receptors inhibits 
adenylate cyclase activity in a pertussis toxin sensitive manner (Howlett & Fleming, 
1984, 1985; Bidaut-Russell et al., 1990; Vogel et al., 1993). This reduction in cAMP 
levels, and subsequent inhibition of protein phosphorylation, may inhibit neuronal 
activity by activation of A-type potassium channels (Deadwyler et al., 1995). In 
addition, CBi, but not CB2 , receptor coupled Gj proteins mediate inhibition of voltage 
gated N- and P-/Q- type calcium channels (Caulfield & Brown, 1992; Mackie & Hille, 
1992; Mackie et al., 1995; Twitchell et al., 1997; Shen & Thayer, 1998a) and activation 
of inwardly rectifying potassium channels (Mackie et al., 1995), independent of 
adenylate cyclase inhibition. Thus activation of CBi receptors can reduce neuronal 
excitability and may suppress neurotransmitter release. Indeed cannabinoids have been 
shown to inhibit the release of neurotransmitters in vitro (Shen et al., 1996; Gessa et al., 
1998; Levenes et al., 1998; Nicholson et al., 2003). Furthermore, the endogenous ligand 
anandamide and synthetic cannabinoid receptor agonist WIN55,212-2 have been shown 
to directly interact with, and inhibit, sodium channels and T-type calcium channels, 
actions which would also reduce neuronal excitability and further hinder action 
potential propagation (Chemin et al., 2001; Nicholson et al., 2003).
However, there is increasing evidence that cannabinoids may also have a stimulatory 
influence on neuronal activity. Under conditions in which G j /0 proteins are inhibited or 
indeed absent, CBi receptors have been shown to couple to Gs proteins, stimulatory 
GTP binding proteins, increasing intracellular cAMP levels (Felder et al., 1998; Maneuf 
& Brotchie, 1997; Hampson et al., 1998a). Coupling to Gs proteins and consequential 
cAMP elevation is theorised to underlie an observed stimulatory effect of cannabinoids 
on calcium influx (Sugiura et al., 1996; Rubovitch et al., 2002; Bash et al., 2003).
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Activation of protein kinase A (PKA), by cAMP, phosphorylates and activates L-type 
calcium channels inducing a calcium influx (Rubovitch et al., 2002). Alternatively, 
protein kinase C-mediated phosphorylation of mitogen activated protein kinases 
(MAPK) may also modulate activation of L-type calcium channels, inducing calcium 
influx via a CBi receptor-coupled, Gj/ 0 protein-mediated mechanism (Rubovitch et al.,
2004). Furthermore, an interaction between CBi receptors and phospholipase C (PLC) 
can induce calcium release from inositol (1,4,5) tris-phosphate (IP3) regulated stores 
(Netzeband et al., 1999). Enhanced calcium influx may underlie the reported stimulation 
of neurotransmitter release mediated by cannabinoids (Acquas et al., 2000; Ferraro et 
al., 2001). The ability of CBi receptors to couple to more than one G protein may have 
relevance under pathological conditions. Indeed, elevated cAMP during reperfusion is 
believed to improve functional outcome after ischaemic injury (Block et al., 1997).
Several other signalling pathways may also contribute to the effects of CBi receptor 
activation. Induction of mRNA expression of immediate early genes (IEGs), such as c- 
fo s , involved in neuroprotection against excitotoxicity (Marsicano et al., 2003), and 
Krox 24, a growth related gene (Bouaboula et al., 1995a), by CBi receptor activation is 
mediated by Gi protein-dependent activation of extracellular signal regulated kinase 
(ERK; Marsicano et al., 2003) and MAPK respectively (Bouaboula et al., 1995b). ERK 
activation via CBi receptor stimulation also plays a more direct role in the control over 
cell fate when induced by ceramide synthesis. In cultured astrocytes, brief exposure to 
cannabinoids induces a transient increase in ceramide generation through the coupling 
of the adaptor protein FAN (factor associated with neutral sphingomyelinase activation) 
to the CBj receptor, resulting in sphingomyelin hydrolysis in a Gj protein independent 
manner (Sanchez et al., 2001). Ceramide production is involved in the stimulation of 
glucose metabolism and glycogen synthesis (Sanchez et al., 1998). However, prolonged
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cannabinoid exposure initiates de novo synthesis and accumulation of ceramide, which 
induces sustained ERK activation, and under such circumstances apoptosis can be 
induced (Galve-Roperh et al., 2000; Guzman et al., 2001). Figure 4.1 summarises the 
cellular consequences of cannabinoid receptor activation.
4.1.3. Endocannabinoid synthesis
The discovery of a receptor based signalling cascade activated by cannabinoid agonists 
added further weight to the hypothesised existence of endogenous metabolites capable 
of activating cannabinoid receptors. Indeed, displacement of radiolabelled cannabinoid 
ligands by fractions extracted from porcine brain and canine gut led to the identification 
of two endocannabinoids, arachidonyl ethanolamide (anandamide; AEA) and 2- 
ararachidonylglycerol (2-AG) respectively (Devane et al., 1992; Mechoulam et al., 
1995; Sugiura et al., 1995). Three further substances, homo-y-linolenylethanolamide 
and docosatetraenylethanolamide, both structurally related to AEA (Hanus et al., 1993) 
and 2-arachidonyl glyceryl ether (Hanus et al., 2001) have subsequently been identified 
as endocannabinoids. Meanwhile in 2002, O-arachidonoyl ethanolamine (virhodamine), 
another structural analogue of AEA was discovered. However, virhodamine has been 
shown to have antagonistic properties at CBj receptors, in contrast to AEA, although it 
acts as a full agonist at CB2 receptors similarly to AEA (Porter et al., 2002).
Endocannabinoids are synthesised in a calcium-dependent manner (Di Marzo et al., 
1994; Cadas et al., 1996). Confirmation of their activity at cannabinoid receptors (CBi 
and CB2 receptors; Devane et al., 1992; Felder et al., 1993; Vogel et al., 1993; Felder et 
al., 1995; Slipetz et al., 1995), and identification of uptake transporters and degradation 
mechanisms (Di Marzo et al., 1994) have confirmed their status as neurotransmitters 
(discussed in more detail in Chapter 5.1.2. -  5.1.4.). However, there is also evidence
243
Figure 4.1 -  The cellular pathways of cannabinoid receptor activation
Activation of cannabinoid receptors 1 and 2 (CBi and CB2) by either endogenous or 
exogenous cannabinoids stimulates many cellular pathways that are summarised in the 
flow diagram. Each pathway is described in more detail in Chapter 4.1.2.
FAN -  factor associated with neutral sphingomyelinase activation; MAPK -  mitogen 
activated protein kinase; ERK -  extracellular activated protein kinase; A.C. -  adenylate 
cyclase; PKA -  protein kinase A; PKC -  protein kinase C; PLC -  phospholipase C; 
DAG -  di acyl glycerol; IP3 -  inositol (1,4,5) tris-phosphate.
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that suggests that the endocannabinoid system may be involved in neuroprotection 
under pathological conditions. Indeed, elevated levels of AEA and 2-AG are reported in 
several animal models of neurodegeneration, occurring both in response to neurotoxic 
stimuli and as a consequence of pathological disease mechanisms (Sugiura et al., 2000; 
Baker et al., 2001; Hansen et al., 2001; Panikashvili et al., 2001; Marsicano et al., 2003; 
Witting et al., 2004), which suggests that this up-regulation may form part of an 
adaptive response against neuronal damage (discussed in further detail in Chapter
5.1.6.). Administration of exogenous cannabinoids may therefore be a successful 
therapeutic approach in neurodegenerative diseases.
4.1.4. Cannabinoid receptor-mediated neuroprotection
Investigation of the therapeutic potential of cannabinoids to date has been concentrated 
primarily on their ability to provide symptom relief in MS and chronic pain syndromes. 
Despite the ambiguity of the results from human clinical trials in MS patients (Zajicek 
et al., 2003; Wade et al., 2004), in an autoimmune mouse model of MS, the chronic 
relapsing experimental allergic encephalomyelitis (CREAE) model, cannabinoids 
alleviate muscle spasm and tremor (Baker et al., 2000, 2001). Furthermore, 
cannabinoid-mediated analgesia is widely documented in animal models of both acute 
and chronic pain (reviewed in Kumar et al., 2001). However, recently a number of in 
vivo and in vitro studies have directly explored the potential neuroprotective properties 
of cannabinoids in animal models of neurodegeneration. Cannabinoids acting via the 
CBi and CB2 receptors have been shown to be neuroprotective in a number of 
experimentally-induced situations including excitotoxicity (for example, Shen & 
Thayer, 1998a, 1998b; Abood et al., 2001; van der Stelt et al., 2001a; Marsicano et al., 
2003; Molina-Holgado et al., 2003; Pryce et al., 2003), ischaemia (Nagayama et al., 
1999), and inflammation (Molina-Holgado et al., 1997, 2003; Puffenbarger et al., 2000;
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Baker et al., 2001; Klegeris et al., 2003; Pryce et al., 2003) and following acute brain 
trauma (Panikashvili et al., 2001). These neuroprotective effects of cannabinoids can be 
mediated either via the CBi or the CB2 receptor.
4.I.4.I. CBi receptor-mediated neuroprotection
In the CNS, the predominant cannabinoid receptor subtype is the CBi receptor (Matsuda 
et al., 1990). Autoradiographical studies reveal a widespread distribution of the CBi 
receptor in the CNS with the highest densities found in areas including the basal 
ganglia, the molecular layers of the cerebellum and in portions of the hippocampus 
(Herkenham et al., 1990, 1991). This localisation in the CNS correlates with the 
observed effects of cannabis on movement, cognition and memory (Herkenham et al., 
1991). Neuronal expression of CBi receptors occurs on both the cell soma and neurites 
(Westlake et al., 1994; Twitchell et al., 1997; Tsou et al., 1998; Ong & Mackie, 1999). 
Cultured astrocytes and microglial have also been shown to express CBj receptors 
(Molina-Holgado et al., 2002; Facchinetti et al., 2003; Walter et al., 2003).
Activation of CBi receptors on presynaptic terminals will act to reduce neuronal 
excitability by inducing alterations in calcium and potassium permeability, as discussed 
in Chapter 4.1.2. (Caulfield & Brown, 1992; Mackie & Hille, 1992; Mackie et al., 
1995; Twitchell et al., 1997; Shen & Thayer, 1998a). This raises the threshold for 
neurotransmitter release, consequently reducing presynaptic release (Shen et al., 1996; 
Gessa et al., 1998; Levenes et al., 1998; Nicholson et al., 2003). Therefore under 
conditions of excitotoxicity, which is suggested to contribute to the pathogenesis of 
many neurodegenerative diseases, activation of CBi receptors may reduce presynaptic 
glutamate release. In addition, activation of postsynaptic CBj receptors may also reduce 
excitotoxicity-induced postsynaptic calcium influx via inhibition of voltage gated N-
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and P/Q- type calcium channels (Caulfield & Brown, 1992; Mackie & Hille, 1992; 
Mackie et al., 1995; Twitchell et al., 1997; Hampson et al., 1998a; Abood et al., 2001). 
Interestingly, due to the activity-dependent nature of their synthesis, it is possible that 
endocannabinoid synthesis will be increased under excitotoxic conditions (Di Marzo et 
al., 1994; Cadas et al., 1996). Indeed following injection of excitotoxins into the CNS of 
mice, levels of the endocannabinoids, AEA and 2-AG, are increased (Sugiura et al., 
2000; Hansen et al 2001; Panikashvili et al., 2001; Marsicano et al., 2003), suggesting a 
role for endocannabinoids in protection against excitotoxicity.
In support of a CBj receptor-mediated neuroprotective effect, results have shown that 
injection of kainate (KA) into the CNS of CBj receptor knock-out mice produces a 
more extreme behavioural reaction and greater mortality than in wild-type (WT) mice 
(Marsicano et al 2003; Pryce et al., 2003). More specifically, Marsicano et al, (2003) 
generated a conditional knock-out mouse model in which only CBi receptors on 
glutamatergic neurons of the forebrain were deleted. Administration of KA to these 
mice induces seizures that are significantly worse in than in mice with a full 
complement of CBi receptors. In addition to the immediate benefits, CBi receptor 
activation under excitotoxic conditions also induces an up-regulation of IEGs, c-fos and 
Krox-24, which may be involved in the initiation of long-term adaptive changes 
(Bouaboula et al., 1995; Marsicano et al., 2003). These results imply that CBi receptors, 
particularly those located on glutamatergic neurons, play a role in endogenous 
protection against excitotoxicity and represent a system that may be suitable for 
therapeutic manipulation by administration of exogenous cannabinoid agonists.
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4.1.4.2. CB2 receptor-mediated neuroprotection
CB2 receptors are primarily regarded as peripheral cannabinoid receptors (Howlett et 
al., 2002) and under normal healthy circumstances, CB2 receptors are not detected in the 
CNS (Walter & Stella, 2004). However, CB2 receptors have recently been identified on 
the plasma membrane of cultured rodent microglial cells (Facchinetti et al., 2003; 
Walter et al., 2003; Carrier et al., 2004), and cultured human microglia cells have been 
found to express CB2 receptor mRNA and protein (Klegeris et al., 2003).
Microglia have a dual and conflicting role in neurodegeneration. Following neuronal 
damage, microglia become activated and undergo rapid proliferation and migration to 
the site of injury (Sargsyan et al., 2005). Activated microglia release a variety of 
neurotoxic mediators including reactive oxygen species (ROS), pro-inflammatory 
cytokines, such as TNFa and IL-ip, and glutamate (Molina-Holgado et al., 1997; 
Waksman et al., 1999; Facchinetti et al., 2003). Such mediators are involved in 
phagocytosis, to remove degenerating neurons and thus potentially aid recovery. 
However, they can also play a role in the propagation of inflammatory processes, which 
would hinder protective mechanisms (McGeer and McGeer, 2002; Consilvio et al., 
2004; Sargsyan et al., 2005). Microglia can therefore have a neuroprotective or 
neurotoxic influence, the outcome of which is likely to be dependent on many 
interacting factors (Sargsyan et al., 2005).
The anti-inflammatory action of cannabinoids is based on their ability to reduce the 
release of neurotoxic mediators from microglia. Stimulation of microglia in vitro with 
lipopolysaccahride induces an up-regulation of TNFa and IL-ip mRNA expression in 
microglia (Puffenbarger et al., 2000; Facchinetti et al., 2003). Treatment with 
cannabinoid receptor agonists, however, dose-dependently reduces the expression and
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release of pro-inflammatory cytokines (Puffenbarger et al., 2000; Facchinetti et al., 
2003) via a CB2 receptor-mediated mechanism (Klegeris et al., 2003). Indeed, 
cannabinoids actually reduce microglial activation (Arevalo-Martin et al., 2003), thus 
limiting propagation of the inflammatory response. In the CREAE autoimmune model 
of MS, WIN55,212-2, a synthetic cannabinoid agonist, reduces tremor and spasticity, 
whereas a CB2 receptor antagonist worsens such symptoms (Baker et al., 2000, 2001). 
Meanwhile, in the Theiler’s virus MS autoimmune model, various cannabinoid agonists 
reduce both microglial and T-lymphocyte activation in the spinal cord with concomitant 
reduction in CNS mRNA for TNFa and II-ip (Croxford & Miller, 2003).
4.1.5. Cannabinoid receptor independent neuroprotection
Cannabinoid receptor agonists may also act by receptor-independent anti-oxidant 
actions. Hampson et al., (1998b) reported a potent anti-oxidant capacity of A9-THC and 
CBD, comparable to the anti-oxidant butylated hydroxytoluene. Furthermore CBD, a 
non-receptor binding cannabinoid, exerts greater neuronal protection than that achieved 
with vitamin E, a known antioxidant, in response to an excitotoxic insult (Hampson et 
al., 1998b). Meanwhile, A9-THC and CP 55,940 show receptor-independent anti­
oxidant activity in vitro, in response to oxidative stress mediated by serum deprivation 
or hydrogen peroxide exposure respectively (Chen & Buck, 2000; Marsicano et al., 
2002).
4.1.6. Evidence supporting the use of cannabinoid therapy in ALS
The discovery of endocannabinoid up-regulation in response to pathological conditions 
and the identification of mechanisms by which cannabinoids can exert neuroprotective 
effects in a receptor-dependent and independent manner, suggests that the cannabinoid 
system may be a therapeutic target in ALS. In summary, CBi receptor activation may
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inhibit glutamate release from presynaptic nerve terminals and reduce the postsynaptic 
calcium influx in response to glutamate receptor stimulation. Meanwhile, CB2 receptors 
may influence inflammation, whereby receptor activation will reduce microglial 
activation and subsequently inhibit their secretion of neurotoxic mediators. Lastly, 
cannabinoid agents may also exert anti-oxidant actions by a receptor-independent 
mechanism. Although the pathogenic mechanisms in ALS are still not fully understood 
there is significant evidence, as described in Chapter 1.3.4, which indicates that 
excitotoxicity, inflammation and oxidative stress may all contribute to disease 
pathogenesis.
4.I.6.I. CBj receptor involvement -  potential anti-excitotoxic action
Motoneurons receive glutamatergic inputs from the descending corticospinal tracts, 
from collaterals of the Aa fibres innervating muscle fibres and Golgi tendon organs and 
from excitatory intemeurons in the spinal cord (Heath and Shaw, 2002). Elevated 
synaptic glutamate, due to increased release or reduced uptake, will enhance 
postsynaptic calcium influx via activation of calcium-permeable glutamate receptors 
and subsequent depolarisation-induced activation of voltage-gated calcium channels. 
Excessive calcium can then activate neurotoxic cascades in the postsynaptic cell 
ultimately resulting in neuronal death (Choi et al., 1992).
CBi receptors are expressed on the cell soma and neurites of motoneurons cultured from 
the spinal cord (Abood et al., 2001), although the levels of expression in the ventral 
horn of the spinal cord are relatively low compared to the basal ganglia (Herkenham et 
al., 1991). However, following peripheral nerve injury in WT mice, expression of CBi 
receptors in the spinal cord increases (Lim et al., 2003). Furthermore, the finding that 
CBi receptors are expressed on microglia also suggests that during disease progression,
251
overall CBi receptor density in the spinal cord may increase due to the influx of 
microglia to areas affected in ALS.
In the spinal cord, pre- and postsynaptic CBj receptors may be activated either by 
endocannabinoids, the synthesis of which is elevated under excitotoxic conditions 
(Sugiura et al., 2000; Hansen et al 2001; Panikashvili et ah, 2001; Marsicano et al., 
2003), or alternatively by the administration of exogenous cannabinoids. This may then 
provide neuroprotection via dual modulation of neuronal excitability. CBi receptor- 
mediated presynaptic regulation of calcium and potassium permeability may inhibit 
glutamate release from the nerve terminal. In addition, inhibition of postsynaptic 
voltage-gated calcium channels will reduce the calcium influx into the postsynaptic cell 
(Caulfield & Mackie 1992; Mackie & Hille, 1992; Mackie et al., 1995; Twitchell et al., 
1997; Hampson et al., 1998a; Shen & Thayer, 1998a; Abood et al., 2001), as described 
in greater detail in Chapter 4.1.2. An inhibitory effect of cannabinoids on non-neuronal 
cells, via CBi receptors, may similarly act to reduce glutamate release, contributing to 
an anti-excitotoxic effect (Tikka et al., 2002). In models of ALS, there is evidence to 
suggest that cannabinoids may be neuroprotective. Indeed, treatment of mouse mixed 
spinal cord cultures with A9-THC exerts neuroprotection against direct KA-induced 
toxicity (Abood et al., 2001). Furthermore, treatment of S0D1G93A mice with A9-THC 
delays disease progression (Raman et al., 2004).
4.I.6.2. CB2 receptor involvement -  potential anti-inflammatory action
In the post-mortem spinal cords of ALS patients there are substantial signs of 
inflammation including significant proliferation and accumulation of activated 
microglia, reactive astrocytes and CD4+ and CD8+ lymphocytes in areas of motoneuron 
degeneration (Troost et al., 1990; Engelhardt et al., 1993; Alexianu et al., 2001; McGeer
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& McGeer, 2002). Furthermore increased mRNA and protein levels of inflammatory 
markers such as COX2 and PGE2 are seen in the post-mortem spinal cords of ALS 
patients (Yasojima et al., 2001; Maihofner et al., 2003). Similar neuroinflammatory 
changes are seen in the mutant SOD1 mouse models of ALS where a correlation 
between the intensity of inflammation and disease progression is reported (Hall et al., 
1998; Alexianu et al., 2001; Aimer et al., 2001; Elliott et al., 2001).
Recent studies using immunocytochemistry have demonstrated the expression of CB2 
receptors on microglia (Facchinetti et al., 2003; Klegeris et al., 2003; Walter et al., 
2003; Carrier et al., 2004). Interestingly, in response to peripheral nerve injury there is a 
simultaneous increase in the presence of activated microglia and the expression of CB2 
receptors in the rat spinal cord (Zhang et al., 2003). In mutant SOD1 mice, the presence 
of activated microglia increases from a presymptomatic stage (Hall et al., 1998; 
Alexianu et al., 2001; Aimer et al., 2001), therefore it is likely that CB2 receptor 
expression will also increase. Activated microglia can exert either protective or toxic 
effects depending on various interacting factors (Sargsyan et al., 2005). However, it is 
unlikely that microglia exert a neuroprotective effect in ALS, as in S0D1G93A mice 
there is a concurrent increase in the presence of activated microglia with the loss of 
motoneurons (Hall et al., 1998; Alexianu et al., 2001; Weydt et al., 2004). Upon 
activation, microglia release a variety of pro-inflammatory cytokines, including TNFa 
and IL-lp, that cause neuronal damage and the recruitment of further microglia 
(Puffenbarger et al., 2000; Facchinetti et al., 2003). However, cannabinoids can limit the 
propagation of this inflammatory response by inhibiting microglial activation (Arevalo- 
Martin et al., 2003) and subsequently reducing the expression and release of pro- 
inflammatory cytokines (Puffenbarger et al., 2000; Facchinetti et al., 2003) via a CB2 
receptor-mediated mechanism (Klegeris et al., 2003). Furthermore, CB2 receptor
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activation will also inhibit the release of ROS from microglia, consequently reducing 
oxidative damage (Tikka & Koistinaho, 2001).
Previously, minocycline and nordihydroguaiaretic acid (NDGA), potent inhibitors of 
microglial activation, have been shown to exert beneficial effects in mutant SOD1 mice 
(Kriz et al., 2002; van den Bosch et al., 2002; Zhu et al., 2002; West et al., 2004). 
Furthermore, selective inhibitors of the COX2 enzyme, which act to inhibit 
inflammation, have been shown to delay disease onset and extend survival in mutant 
SOD1 mice (Drachman et al., 2002; Pompl et al., 2002). Therefore, cannabinoids, 
acting via the CB2 receptor, may have therapeutic effects in ALS by inhibiting 
microglial activation and reducing inflammation.
4.I.6.3. Cannabinoid receptor-independent involvement -  potential anti-oxidant 
action
Mutations in the SOD1 enzyme structure may increase aberrant interactions with 
abnormal substrates such as peroxynitrite or hydrogen peroxide, or alternatively impede 
the binding of copper or zinc ions to the enzyme. A consequence of the gain of function 
acquired by the mutant SOD1 enzyme may therefore be to increase oxidative stress as 
discussed in Chapter I.3.4.I.. Therefore anti-oxidant agents targeted at reducing 
oxidative stress may be an effective therapy in ALS. Cannabinoids, including A9-THC 
and CP 55,940, can exert anti-oxidant actions, via a cannabinoid receptor-independent 
mechanism, in models of oxidative stress in vitro (Chen & Buck, 2000; Marsicano et 
al., 2002). Furthermore, treatment of S0D1G93A mice with CBD significantly delays 
disease progression, although does not increase lifespan (Weydt et al., 2005).
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4.1.7. Hypothesis to be tested
In ALS, multiple pathways are believed to contribute to disease pathogenesis (reviewed 
in Bruijn et al., 2004). Previous studies have shown that cannabinoids can exert 
neuroprotection under conditions of excitotoxicity, inflammation and oxidative stress. 
Therefore in this study the effect of R(+)-WIN55,212-2, a synthetic aminoalkylindole 
that acts as a full agonist at CBi and CB2 receptors (D’ambra et al., 1992), was 
investigated in the SODG93A mouse model of ALS. The therapeutic potential of R(+)- 
WIN55,212-2 was examined in terms of its ability to delay disease progression, as 
assessed by effects on muscle function and motoneuron survival, and ultimately to 
extend the lifespan of SOD 1093A mice.
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4.2. METHODS
4.2.1. Breeding and maintenance of transgenic mouse colonies
Transgenic mice carrying a human SOD1 gene with a G93A mutation (TgN[SODl- 
G93A]lGur) were maintained as described in Chapter 2.1a. Individual animals were 
genotyped by PCR using DNA extracted from tail snips, as described in Chapter 2.3.
4.2.2. Analysis of endocannabinoid levels with disease progression in SOD1G93a 
mice
This analysis was performed in collaboration with Professor Vincenzo Di Marzo’s 
group at the Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, 
Naples, Italy, on tissue extracted from S0D1G93A mice at the Institute of Neurology, 
UK.
The levels of endocannabinoids in the spinal cords of WT and SOD1G93a mice were 
assessed at 40, 90 or 120 days of age (n = at least 3 in each group). The mice were 
killed by overdose of pentobarbitone anaesthetic (Fort Dodge Animal Health, 
Southampton, UK) and their spinal cords rapidly dissected and immediately frozen in 
liquid nitrogen. Post-mortem delay between onset of dissection and freezing of 
dissected tissue in liquid nitrogen was estimated to be between 5 and 10 minutes. 
Tissues were dounce-homogenized with chloroform/methanol/Tris-HCl 50 mM, pH 7.4 
(1/1/1 by volume) containing 5 pmol of octa-deuterated (d8)-anandamide and 50 pmol 
of d8-2-arachidonoylglycerol (Cayman Chemicals, Ann Arbor, MI, USA) as internal 
standards. Lipid-containing organic phase was dried down, weighed and pre-purified by 
open-bed chromatography on silica gel, and analyzed by liquid chromatography- 
atmospheric pressure chemical ionization-mass spectrometry (LC-APCI-MS) using a 
Shimadzu high-performance liquid chromatography (HPLC) apparatus (LC-10ADVP)
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coupled to a Shimadzu quadrupole mass spectrometer (LCMS-2010) via a Shimadzu 
APCI interface (Kyoto, Japan). Mass spectrometry analyses were carried out in the 
selected ion-monitoring mode. Temperature of the APCI source was 400°C; HPLC 
column was a Phenomenex (i.d.= 3pm, length 150mm, section 4.5 mm) reverse phase 
column. AEA (retention time of 14.5 min) and 2-AG (retention time of 17.0 min) quasi- 
molecular ions were quantified by isotope dilution with the above-mentioned deuterated 
standards and their amounts in pmols and nmols respectively, normalized per mg of 
lipid extract. The endocannabinoid extraction and quantification was performed by 
Professor Vincenzo Di Marzo and colleagues.
4.2.3. WIN55,212-2 preparation and treatment protocol
The synthetic cannabinoid receptor agonist R(+)-WIN55,212-2 (Tocris, Bristol, U.K.) 
was dissolved in a vehicle which consisted of ethanol, cremaphor (Fluka Biochemika, 
Buchs, Switzerland), DMSO and PBS (ratio 1: 1 : 1 : 17). WT and S0D1G93A mice of 
both sexes were divided into four treatment groups:
1. Treatment with 0.1 ml WIN55,212-2 (5mg/kg) injected i.p. once daily from 40 
days of age (presymptomatic; n = 15);
2. Treatment with 0.1 ml WIN55,212-2 (5mg/kg) i.p. once daily from 90 days of 
age (early symptomatic; n = 19);
3. Treatment with 0.1ml vehicle i.p. from 40 days of age (n = 11);
4. No treatment to serve as untreated controls (n = 32).
Each of the treatment groups were further subdivided into 2 subgroups in order to study
i) disease progression and ii) lifespan.
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4.2.4. Assessment of disease progression
The progression of disease in S0D1G93A mice in this study was evaluated by repeated 
assessment of body weight and spontaneous locomotor activity over the course of 
disease. In addition the effect of treatment with WIN55,212-2 on disease progression 
was also assessed at 120 days of age, a relatively late stage of the disease, by 
examination of muscle force and phenotype, motor unit and motoneuron survival as 
described in Chapters 2.10.1 -  2.10.5.
4.2.4.1. Body weight
Experimental animals were weighed on a weekly basis until disease onset at which 
point the mice were weighed twice a week and a weekly average taken to monitor the 
loss of body weight with disease progression. At the onset of body weight decline, mice 
were weighed on a daily basis.
4.2.4.2. Spontaneous locomotor activity
Locomotor activity was evaluated by monitoring the experimental animals in an activity 
chamber. After an initial equilibration period of 5 -  10 minutes, the distance travelled 
(cm) over a further 5 minutes in a 27 x 27 cm open-field activity monitor (Med 
Associates, Georgia, VT, USA) was recorded.
Assessment of locomotor activity was undertaken at least 24 hours after the previous 
injection of WIN55,212-2 or vehicle to ensure no residual drug effects were observed.
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4.2.5. Lifespan analysis
The lifespan of SOD1G93a mice was determined as the number of days the animals 
survived for before reaching an end-point that agreed with Home Office guidelines, 
namely when the animal:
i) had lost > 20% of its maximal body weight
ii) was unable to perform the righting reflex in less than 30 seconds (unable to right 
itself when placed on its side). WT mice are able to complete this task in < 2 
seconds.
The effect of WIN55,212-2 treatment on the lifespan of SOD1G93a mice was assessed 
under the same criteria, and the animals were culled when they reached this end-point, 
and lifespan recorded.
4.2.6. Statistical analysis
Statistical significance between the experimental groups was assessed using a Mann- 
Whitney U test. Spontaneous locomotor activity assessments were compared by one­
way analysis of variance (ANOVA) repeated measures, incorporating a Student 
Neuman Keuls multiple comparisons test. Endocannabinoid levels were compared by 
one-way ANOVA, incorporating a Student Neuman Keuls multiple comparisons test. 
Values are expressed as mean ± standard error of the mean (S.E.M). Significance was 
set at p < 0.05.
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4.3. RESULTS
In this Chapter levels of endocannabinoids in SODlG93A and WT littermates were 
assessed in order to establish any changes in endocannabinoid levels associated with 
disease progression. Furthermore, the therapeutic potential of WIN55,212-2 in 
SOD 1093A mice was assessed by examining disease progression, muscle function and 
motoneuron survival after treatment from a presymptomatic (40 days) or symptomatic 
(90 days) age.
4.3.1. Endocannabinoid levels in SO D lG93A mice during disease progression
In order to assess whether endocannabinoid levels varied during disease progression in 
the colony of S0D1G93A mice used in these experiments, we measured levels of 
endocannabinoids in both WT and SOD 1093A mice at various ages. The levels of the 
endocannabinoids, AEA and 2-AG, were measured in the spinal cord of WT and 
SOD1G93a mice at 40 days (presymptomatic), 90 days (early symptomatic) and 120 days 
of age (end-stage). There was no significant difference in the levels of AEA and 2-AG 
in the spinal cord between WT and S0D1G93A mice at 40 days (p > 0.1). However, as 
shown in Figure 4.2, levels of AEA in the spinal cord of SODlG93A mice at 90 and 120 
days of age were significantly elevated over 2 fold in comparison to WT mice (p < 0.05; 
18.1±2.3 pmol/g and 14.9±2.4pmol/g compared to 8.0 ±2.3 pmol/g and 6.9±1.7pmol/g 
respectively). Spinal cord levels of 2-AG were only elevated towards the end-stage of 
disease, and were significantly higher in 120 day old S0D1G93A mice compared to WT 
(p = 0.003; 6.7±0.7 nmol/g compared to 4.4±0.5 nmol/g respectively). Thus, as 
previously shown (Witting et al., 2004), there was a clear increase in the levels of 
endocannabinoids in the spinal cord of SODlG93A mice during the symptomatic phase of 
disease.
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Figure 4.2 - Levels of endocannabinoids in spinal cords of WT and SODlG93Amice
Levels of the endocannabinoids (A) anandamide (AEA) and (B) 2-arachidonoylglycerol 
(2-AG) were analyzed in spinal cord extracts from WT and SOD 1093A mice at 40, 90 
and 120 days of age (n = at least 3 in each case). Levels were expressed as the 
concentration of endocannabinoid per gram of tissue. There was a clear increase in the 
levels of AEA in symptomatic SODlG93A mice. Levels of 2-AG appeared to increase in 
S0D1G93A mice only during the late stages of disease (120 days). Prior to the onset of 
disease symptoms, levels of AEA and 2-AG were no different from WT. Error bars 
represent standard error of the mean. * p < 0.05, *** p < 0.005.
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4.3.2. Assessment of disease progression in SO D lG93A mice.
SOD1G93a mice treated with WIN55,212-2 from 40 or 90 days of age and their 
untreated littermates were monitored on a daily basis and various parameters checked 
regularly to assess disease progression.
4.3.2.1. Body Weight.
The body weight of the SODlG93A mice used in this study was recorded from 70 days of 
age until disease end-point, and the data is summarised in Figure 4.3. Weight 
measurements were expressed as a percentage of the maximal body weight for each 
individual mouse, the maximal weight being recorded between 105 and 111 days of age 
(15 weeks) in untreated S0D1G93A mice. Treatment with WIN55,212-2 from 40 days of 
age was found to significantly delay the decline in body weight that usually occurs in
y -iQ -J a A
SOD1 mice during disease progression. In untreated SOD1 mice (n = 9) the 
onset of body weight decline was evident from 112 days of age (16 weeks) and by 133- 
146 days of age (19-20 weeks or end-stage) body weight had declined by approximately 
20%. However, from Figure 4.3 it can be seen that treatment with WIN55,212-2 from 
40 days of age (n = 9) delayed the onset of decline in body weight by 1 week, with the 
onset occurring between 119 and 125 days of age (17 weeks; p < 0.05). In untreated 
SOD1g93A mice by 133-146 days of age (19-20 weeks) body weight had declined by > 
20% and these mice had therefore reached the defined ‘end-point’ of disease. In 
contrast, in S0D1G93A mice treated with WIN55,212-2 from 40 days of age, body 
weight did not drop below 20% of the maximum until 140 days of age (20 weeks), and 
even when the mice were unable to right themselves within 30 seconds (the second 
definition of ‘end-stage’) they still maintained significantly more body weight than 
untreated SOD 1093A mice, which were culled one week earlier. In contrast, treatment
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Figure 4.3 -  The effect of WIN55,212-2 on the decline in body weight of SO DlG93A 
mice
The body weight of SODlG93A mice treated from 40 and 90 days of age with 
WIN55,212-2 and their untreated SOD1G93a littermates was recorded weekly from 70 
days of age (10 weeks) until disease end-point, as shown in the graph. Body weight was 
expressed as a percentage of the maximal weight of each individual animal. As a 
consequence of disease progression the body weight of untreated SOD 1093A mice (n = 
9) declined from 112 days of age (16 weeks) onwards. However, treatment with 
WIN55,212-2 from 40 days of age (n = 9) significantly delayed the decline in body 
weight of SOD 1093A mice. In contrast, treatment with WIN55,212-2 from 90 days of 
age (n = 8) had no effect on the loss of weight observed in SOD 1093A mice. Error bars = 
standard error of the mean. * p < 0.05.
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with WIN55,212-2 from 90 days of age (n = 8), had no effect on the decline in body 
weight seen with disease progression in SODlG93A mice (p > 0.05). Similarly, treatment 
of SOD1G93a mice with vehicle had no effect on the decline of body weight (p > 0.05; 
data not shown).
4.3.2.2. Locomotor activity
The spontaneous locomotor activity of WT and SODlG93A mice was measured twice a 
week from the time at which treatment with WIN55,212-2 was initiated, at either 40 or 
90 days of age. Comparison with WT animals allowed an assessment of any change in 
locomotor activity of untreated SOD1G93a animals as a measure of disease progression. 
Figure 4.4 shows the mean spontaneous locomotor activity, during a 5-minute period, 
of untreated WT and SOD 1093A animals from 40 days of age until end-stage disease in 
the SOD1G93a mice. The data was pooled into four time points according to defined 
disease stages in the SODlG93A mice: 42 - 83 days of age (6-11 weeks; 
presymptomatic), 84 -  111 days of age (12 -  15 weeks; early symptomatic), 112 -  125 
days of age (16 -  17 weeks; late symptomatic) and 126 -  153 days of age (18-21 weeks; 
end-stage disease). It can be seen in Figure 4.4 that there was no significant difference 
in spontaneous locomotor activity between WT and SOD1G93a mice until 111 days of 
age (15 weeks). By 112 -  125 days of age (16-17 weeks), a late symptomatic stage of 
disease, S0D1G93A mice showed a significant reduction in locomotor activity (343.0 ± 
61.0cm; n = 12) compared to age-matched WT mice (676.8 ± 95.3cm; n = 8; p = 0.005). 
Similarly at the disease end-stage, as may be expected from the progressive paralysis 
that occurs, the spontaneous locomotor activity of SOD1G93a mice was significantly less 
than that of WT mice (p < 0.001). Whereas WT mice travelled 744.2cm (± 102.8 
S.E.M.) in 5 minutes, SODlG93A mice between 126-153 days of age (18 -  21 weeks) 
only travelled 152.8cm (± 28.2 S.E.M.).
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Figure 4.4 -  The spontaneous locomotor activity of WT and SOD1G93a mice
As a measure of disease progression, the locomotor activity (centimetres travelled) of 
untreated WT and SOD1G93a mice was recorded over a 5 minute period in an activity 
chamber from 6 weeks of age until the disease end-point of the SOD l 093A mice. The 
graph shows a comparison of WT and S0D1G93A activity grouped according to the 
disease stage of the S0D1G93A mice: 42 - 83 days of age (presymptomatic), 84 -  111 
days of age (early symptomatic), 112 -  125 days of age (late symptomatic) and 126 -  
153 days of age (end-stage disease). It can be seen that WT mice (n = 8) showed no 
significant change in locomotor activity with increasing age. In contrast, within the 
duration of the study there was a progressive decline in the spontaneous locomotor 
activity of untreated SOD 1093A mice (n = 12) during disease progression, as paralysis of 
the hindlimb muscles increased. Values are the mean response ± standard error of the 
mean, cm = centimetres. * p < 0.05, *** p < 0.005.
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The effect of treatment with WIN55,212-2 from 40 days of age on locomotor activity in 
WT mice was assessed next. Locomotor activity did not differ significantly in WT mice 
(n = 8) during the study period, as shown in Figure 4.4. Therefore all activity 
recordings were pooled, and the effect of treatment with WIN55,212-2 or vehicle was 
assessed and the results are summarised in Figure 4.5. It can be seen that treatment with 
WIN55,212-2 significantly reduced locomotor activity in WT animals from 718cm (±
52.8 S.E.M.; n = 8) on average in untreated WT animals over a 5 minute period, to 
406cm (± 35.0 S.E.M.; n = 6 ) in WIN55,212-2 treated WT animals (p < 0.001). This 
finding is consistent with previous reports that show that cannabinoid receptor agonists 
induce hypomotility (Sulcova et al., 1998; Sanudo-Pena et al., 2000; Wiley et al., 2003; 
Drews et al., 2005). Treatment with vehicle had no effect on the locomotor activity of 
either WT or SODlG93A mice (p > 0.06; n = 6). In all experiments, locomotor activity 
was assessed 24 hours after the previous treatment with WIN55,212-2, therefore 
avoiding measurement of the immediate drug effects on activity levels, rather than the 
overall effect of WIN55,212-2 on locomotor activity of the mice.
SOD 1093A mice treated with WIN55,212-2 from 40 days of age showed reduced 
spontaneous locomotor activity between the ages of 46 and 111 days (6 -1 1  weeks) 
compared to untreated S0D1G93A littermates, as shown in Figure 4.6. Whereas 
untreated presymptomatic and early symptomatic SOD1G93a mice travelled 761.3cm (± 
64.0 S.E.M.; n = 12) and 589.6cm (± 54.4 S.E.M.; n = 12) respectively, over a 5 minute 
period, S0D1G93A mice treated with WIN55,212-2 from 40 days of age, travelled 
541.9cm (± 61.2 S.E.M.; n = 12 ; p = 0.016) and 398.3cm (± 37.4 S.E.M.; n = 12; p = 
0.047) respectively. However, from 112 days of age (16 weeks; a late symptomatic 
disease stage) there was no significant difference in spontaneous locomotor activity 
between treated and untreated SOD1G93a littermates (p > 0.5). Therefore the significant
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Figure 4.5 -  The effect of WIN55,212-2 treatment on the spontaneous locomotor 
activity of WT mice
The spontaneous locomotor activity of WT mice was recorded from 40 days of age until 
the maximal survival time of SODlG93A littermates (approximately 140 days). 
Locomotor activity did not differ significantly in WT mice (n = 8) during the study 
period, as shown in Figure 4.4. Therefore all activity recordings were pooled, and the 
effect of treatment with WIN55,212-2 or vehicle was assessed and the results are 
summarised in the bar chart. Treatment with WIN55,212-2 significantly reduced the 
spontaneous locomotor activity of WT mice (n = 6). In contrast, treatment with vehicle 
had no effect on the activity levels of WT mice even over a prolonged period of time (n 
= 6). Values are the mean response ± standard error of the mean, cm = centimetres. *** 
p < 0.005.
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Figure 4.6 - The effect of treatment with WIN55,212-2 from 40 days of age on the 
spontaneous locomotor activity levels of SODlG93A mice
As a measure of disease progression the locomotor activity (in centimetres travelled) of 
SOD1G93a mice over a 5 minute period in an activity chamber was recorded from 42 
days of age (6 weeks) until disease end-point. Furthermore the effect of treatment with 
WIN55,212-2 from 40 days of age on the spontaneous activity levels of SOD1G93a mice 
was investigated. The bar chart shows a comparison of the activity of SOD1G93a mice 
and their WIN55,212-2 treated SOD1G93a littermates, grouped according to the disease 
stage of the SOD1G93a mice: 42 - 83 days of age (presymptomatic), 84 -  111 days of 
age (early symptomatic), 112 -  125 days of age (late symptomatic) and 126 -  153 days 
of age (end-stage disease). It can be seen that during presymptomatic and early 
symptomatic stages of disease the WIN55,212-2 treated SOD1G93a mice had 
significantly reduced locomotor activity compared to untreated SOD1G93a littermates. 
However, this hypomotile effect was lost with further disease progression. Values are 
the mean response (n = 12) ± standard error of the mean. * p < 0.05.
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hypomotile effect induced by WIN55,212-2 on SOD 1093A mice appeared to be lost at a 
late symptomatic stage of the disease, when hindlimb dysfunction was becoming 
prevalent. However, from the results observed in WT mice treated with WIN55,212-2 it 
was possible that at a late symptomatic stage of disease, the spontaneous locomotor 
activity recorded in WIN55,212-2 treated SOD1G93a mice represented a combination of 
the hypomotile effect induced by the cannabinoid receptor agonist, in addition to the 
effects of disease progression. The cannabinoid-mediated hypomotility seen prior to 
disease onset and early in disease progression may actually have had a protective role as 
certain aspects of hindlimb function, as shown later, were better preserved in 
WIN55,212-2 treated SOD1G93a mice at 120 days of age. At the time of locomotor 
assessment, 24 hours had passed since the last treatment with WIN55,212-2, therefore 
avoiding measurement of the immediate drug effects on activity levels, rather than the 
overall effect on locomotor activity of the SOD1G93a mice.
The effect of treatment with WIN55,212-2 from 90 days of age, a symptomatic stage of 
disease, on locomotor activity was also examined. The spontaneous locomotor activity 
of SOD1G93a mice treated with WIN55,212-2 from 90 days of age (n = 6) did not differ 
significantly from untreated SOD 1093A mice (n = 12) at any stage (p > 0.2), as shown in 
Figure 4.7. In this study SODlG93A mice were already symptomatic by the time 
treatment was initiated. Thus no reduction in activity was observed in SOD1G93a mice 
treated with WIN55,212-2 after symptom onset compared to untreated SOD1G93a 
littermates.
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Figure 4.7 -  The effect of treatment with WIN55,212-2 from 90 days of age on the 
spontaneous locomotor activity of SODlG93A mice
The spontaneous locomotor activity of SOD 1093A mice treated with WIN55,212-2 from 
90 days of age and their untreated SOD 1093A littermates was recorded from the onset of 
treatment until the disease end-point. The graph shows a comparison of the activity of 
SOD1G93a mice (n = 12) and their WIN55,212-2 treated SOD1G93a littermates (n = 6), 
grouped according to the disease stage of the SOD 1093A mice: 90 -  111 days of age 
(early symptomatic), 112 -  125 days of age (late symptomatic) and 126 -  153 days of 
age (end-stage disease). It can be seen that treatment with WIN55,212-2 had no 
significant effect on the locomotor activity of SODlG93A mice over this time period. 
Values are the mean response ± standard error of the mean, cm = centimetres.
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4.3.3. Hindlimb muscle function in SOD1G93a mice at 120 days of age
The effect of treatment with WIN55,212-2 from 40 or 90 days of age on the function of 
the hindlimb TA and EDL muscles of SOD1G93a mice was assessed at 120 days of age, 
a relatively late stage of disease, by in vivo physiological recordings of muscle 
contractions.
4.3.3.1. Isometric tension recordings
Twitch and tetanic contractions of TA and EDL muscles in both hindlimbs of WT, 
untreated SOD1G93a and WIN55,212-2 treated S0D1G93A littermates, were recorded at 
120 days of age. In order to take into account the reduction in muscle weight in 120 day 
old SOD 1093A mice, in these experiments the maximal force recorded was expressed per 
1 OOmg muscle weight.
i) Twitch force
The mean twitch tension of TA muscles elicited by stimulation of the sciatic nerve of 
WT, SODlG93A and WIN55,212-2 treated S0D1G93A littermates is summarised in 
Figure 4.8. By 120 days of age, the mean twitch tension of TA muscles from SOD1 
mice was significantly reduced compared to WT littermates. Thus TA muscles from 
WT mice produced a mean twitch force of 68.4g (± 5.3 S.E.M. per lOOmg TA muscle; n 
= 10), whereas in SOD1G93a mice this was reduced to 34.4g (± 5.8 S.E.M. per lOOmg 
TA muscle; n = 14; p < 0.001). This represented a 49.7% reduction in maximal twitch 
tension in SOD1G93a TA muscles compared with WT at 120 days of age. Treatment 
with WIN55,212-2 significantly reduced the loss in twitch force in TA muscles of 
SOD1G93a mice. Thus, following treatment from 90 days of age the twitch force of TA 
muscles of SODlG93A mice was 51.13g (± 6.5 S.E.M. per lOOmg TA muscle; n = 16; p 
= 0.026), representing a loss of only 25.2% of the twitch response attained in WT mice.
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Figure 4.8 -  The twitch tension of TA muscles from WT, untreated SOD1G93a and 
WIN55,212-2 treated SOD1G93a mice at 120 days of age
The maximal twitch tension of TA muscles was elicited by stimulation of the sciatic 
nerve by a single square pulse of 0.02ms duration at a supramaximal voltage. The mean 
twitch tension of TA muscles from WT (n = 10), S0D1G93A (n = 14) and WIN55,212-2 
treated SOD1g93A mice (40 days, n = 9; 90 days, n = 16) are summarised in the bar 
chart. Force was expressed per lOOmg muscle weight to take into account the reduction 
in muscle weight in 120 day old SOD1G93a mice. At 120 days, the twitch tension of TA 
muscles was substantially reduced in SODlG93A mice compared to WT. However, 
treatment with WIN55,212-2 from 90 days of age significantly prevented this decline in 
twitch tension. Treatment from 40 days, in contrast, had no effect on twitch tension, g = 
grams. Values represent the mean response ± standard error of the mean. * p < 0.05, ** 
p < 0.01, ***p< 0.005.
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Therefore the twitch response of TA muscles from SOD1G93a mice treated with 
WIN55,212-2 from 90 days of age was 49% greater than in untreated S0D1G93A 
littermates. Surprisingly, treatment with WIN55,212-2 from 40 days of age had no 
significant effect on the twitch force of TA muscles (41.49g ±7.1 S.E.M. per lOOmg 
TA muscle; n = 9; p > 0.2). Treatment with WIN55,212-2 from either 40 or 90 days of 
age had no effect on the maximal twitch force of EDL muscles of S0D1G93A mice (p > 
0.07; data not shown).
ii) Maximal tetanic tension
The maximal tetanic tension (MTT) of TA and EDL muscles at 120 days of age was 
examined next. The results showed that the MTT of TA and EDL muscles was 
significantly reduced in SODlG93A mice compared to TA and EDL muscles from WT 
mice, as shown in Figure 4.9 and Figure 4.10 respectively (p < 0.005). TA muscles 
from 120 day old WT mice produced a MTT of 276.6g (± 12.0 S.E.M. per lOOmg TA 
muscle; n = 9), whereas TA muscles from S0D1G93A mice produced a maximal force of 
only 90.7g (± 15.0 S.E.M. per lOOmg TA muscle; n = 14), a reduction of 67.2%. The 
MTT of EDL muscles in untreated SOD1G93a mice at this stage was also significantly 
reduced compared to WT littermates. Therefore WT EDL muscles produced a MTT of 
305.94g (± 16.8 S.E.M. per lOOmg EDL muscle; n = 10), whereas in S0D1G93A mice 
the MTT of EDL muscles was just 175.68g (± 14.8 S.E.M. per lOOmg EDL muscle; n = 
13), a reduction of 42.6%. Treatment with WIN55,212-2 from 90 days, however, 
significantly prevented the decline in hindlimb muscle force so that the MTT of TA and 
EDL muscles at 120 days was 157.0g (± 19.8 S.E.M.; p = 0.005; n = 16) and 243.4g (±
27.8 S.E.M.; p = 0.044; n = 16), a reduction of only 43.2% and 20.4% respectively 
compared to WT muscles. Thus the MTT of S0D1G93A TA and EDL muscles treated 
with WIN55,212-2 (from 90 days) was significantly greater than in the untreated
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Figure 4.9 -  Maximal tetanic force of TA muscles from WT, untreated SOD1G93a 
and WIN55,212-2 treated SOD1G93a mice at 120 days of age
Maximal tetanic tension (MTT) of TA muscles was elicited by increasing the frequency 
of stimulation of the sciatic nerve (40, 80 and 100Hz). The bar chart summarises the 
results of the MTT of TA muscles from WT (n = 9), SOD1G93a (n = 14) and 
WIN55,212-2 treated SOD1G93a mice (n = 16) at 120 days of age. Force was expressed 
per lOOmg muscle weight to take into account the reduction in muscle weight in 120 
day old SOD1G93a mice. As a function of disease progression the MTT of TA muscles 
from untreated SOD 1093A mice was significantly less than in WT littermates. However, 
treatment with WIN55,212-2 from 90 days of age prevented the decline in muscle force 
and TA muscles in treated SOD1G93a mice were significantly stronger than in their 
untreated SOD1G93a littermates. In contrast, treatment with WIN55,212-2 from 40 days 
of age had no effect on muscle force, g = grams. Values are the mean MTT of TA 
muscles ± standard error of the mean. * p < 0.05, ** p< 0.01, *** p < 0.005.
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Figure 4.10 -  The effect of treatment with WIN55,212-2 on the maximal tetanic 
tension of EDL muscles from SOD1G93a mice
Maximal tetanic tension (MTT) of EDL muscles was elicited by increasing the 
frequency of stimulation of the sciatic nerve (40, 80 and 100Hz). The MTT of EDL 
muscles in WT (n = 10), untreated SOD1G93a (n = 13) and SODlG93A treated with 
WIN55,212-2 from 40 (n = 7) and 90 days of age (n = 16) is summarised in the bar 
chart. Force was expressed per lOOmg muscle weight to take into account the reduction 
in muscle weight in 120 day old SOD 1093A mice. The MTT of SOD 1093A EDL muscles 
was significantly reduced at 120 days compared to WT EDL muscles. Treatment with 
WIN55,212-2 from 90 days of age, however, maintained EDL force in SOD1G93a mice. 
In contrast, treatment with WIN55,212-2 from 40 days of age had no effect on the force 
of EDL muscles in SOD1G93a mice, g = grams. Values are the mean MTT of EDL 
muscles ± standard error of the mean. * p< 0.05, *** p< 0.005.
283
Te
ta
ni
c 
fo
rc
e 
(g
) 
11
00
m
g 
ED
L 
m
us
cl
e
400 
350 H 
300 
250  ^
200 
150 
100 
50 H 
0
WT SOD SOD1 + WIN 
(40 days)
SOD1 + WIN 
(90 days)
284
SOD1G93a mice. Indeed muscle force was improved by 73.1% and 38.5% in TA and 
EDL muscles respectively, compared to muscles in untreated SOD 1093A mice. 
Surprisingly treatment with WIN55,212-2 from 40 days of age did not significantly 
affect the MTT of SOD1G93a TA and EDL muscles (p > 0.25). Twitch and tetanic 
tensions of SOD1G93a TA and EDL muscles were also unaffected by treatment with 
vehicle (p > 0.05; data not shown).
4.3.4. Motor unit survival
The number of functional motor units in the EDL muscles of WT, SOD1G93a and 
WIN55,212-2 treated SOD1G93a mice was assessed at 120 days of age. Representative 
examples of traces from (A) WT, (B) untreated SODlG93A and S0D1G93A mice treated 
with WIN55,212-2 from (C) 40 and (D) 90 days of age are shown in Figure 4.11, and 
the mean motor unit survival is summarised in the bar chart (E). At 120 days of age WT 
EDL muscles had on average 29 (± 0.9 S.E.M., n = 10) motor units compared to only 12 
(± 0.9 S.E.M.; n = 18) in untreated SOD1G93a mice. Treatment with WIN55,212-2 
significantly improved motor unit survival and in 120 day old SOD1G93a mice 16 (± 1.7 
S.E.M.; n = 9; p = 0.04) and 20 (± 0.9 S.E.M.; n = 16; p<0.001) motor units survived 
following treatment from 40 and 90 days of age respectively.
4.3.5. Muscle fatigue characteristics
In SOD1G93a mice alterations in the contractile characteristics of EDL muscles are 
known to occur as disease progresses (Derave et al., 2003; Sharp et al., 2005). The 
effect of treatment with WIN55,212-2 on these disease related changes in muscle 
phenotype were examined next. Repeated stimulation of the sciatic nerve to the EDL 
muscle over a 3 minute period elicits a characteristic fatigue trace as shown in Figure 
4.12. The Figure shows examples of the fatigue traces of EDL muscles from (A) WT,
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Figure 4.11 -  The number of motor units in EDL muscles of WT, untreated 
SOD1G93a and WIN55,212-2 treated SODlG,3A mice at 120 days of age
Stimulation of the sciatic nerve with increasing intensity produces stepwise increments 
in twitch tension of EDL muscles that corresponds to the successive recruitment of 
motor axons. Representative motor unit traces from EDL muscles from (A) WT, (B) 
untreated S0D1G93A and S0D1G93A mice treated with WIN55,212-2 from (C) 40 and 
(D) 90 days of age are shown. The number of functional motor units was determined by 
counting the increments in twitch tension and the mean values are summarised in the 
bar chart (E). Horizontal scale bar =10 milliseconds, g = grams. Values shown are the 
mean ± standard error of the mean. * p < 0.05, *** p < 0.005.
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Figure 4.12 -  Fatigue traces from WT, untreated SODlG93A and WIN55,212-2 
treated SODlG93A mice at 120 days of age
Repeated stimulation of the EDL muscle via the sciatic nerve over a 3 minute period 
elicits a fatigue trace. Representative examples of fatigue traces from (A) WT, (B) 
untreated SODlG93A and SODlG93A mice treated with WIN55,212-2 from (C) 40 and 
(D) 90 days of age are shown. EDL is a fast fatigable muscle in WT mice. However, 
with disease progression EDL muscles in SOD 1093A mice became fatigue resistant with 
no significant reduction in tetanic force over the period of stimulation. This change in 
the fatigue characteristics of EDL muscles in SODlG93A mice did not occur to the same 
extent in EDL muscles from SOD1G93a mice treated with WIN55,212-2. Thus in 
WIN55,212-2 treated S0D1G93A mice, EDL muscles fatigued following repeated 
stimulation, although to a lesser extent than in WT EDL muscles. The scale of force is 
not indicated as the size of the initial tetanic recording was adjusted to maximally 
occupy the trace paper, to allow changes in contraction with time to be more easily 
visible.
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(B) SOD1G93a and SOD1G93a mice treated with WIN55,212-2 from (C) 40 and (D) 90 
days. EDL is normally a fast muscle that fatigues rapidly when subjected to repeated 
stimulation, as seen in Figure 4.12A. In contrast, in untreated S0D1G93A mice in the 
late stages of disease, EDL muscles were largely fatigue resistant (Figure 4.12B). 
However, in SOD1G93a mice treated with WIN55,212-2, EDL muscles showed fatigue 
characteristics that resembled those of normal EDL muscles, as shown in Figures 
4.12C and D.
4.3.6. Muscle histochemistry
The changes in the fatigue characteristics of EDL muscles of SOD1G93a mice were 
reflected in the histochemical properties of the muscle fibres. EDL muscles from WT, 
SODlG93A and WIN55,212-2 treated SOD1G93a mice were sectioned and stained for 
SDH activity, an indicator of oxidative metabolic capacity, as shown in Figure 4.13. 
SDH staining of WT EDL muscle sections from 120 day old mice revealed a mosaic 
pattern of lightly and darkly stained muscle fibres, with the majority of fibres staining 
lightly for SDH, indicating a low oxidative capacity (Figure 4.13A). In EDL muscles of 
120 day old SOD 1093A mice, however, a greater proportion of fibres were more 
intensely stained, indicating an increased oxidative capacity of these fibres (Figure 
4.13B). EDL muscles from 120 day old SOD1G93a mice treated with WIN55,212-2 from 
40 (Figure 4.13C) and 90 (Figure 4.13D) days of age, in contrast, showed a pattern of 
SDH staining more characteristic of WT EDL muscles, so that a greater proportion of 
fibres were lightly stained than in the untreated S0D1G93A EDL muscle.
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Figure 4.13 -  Succinate dehydrogenase staining of EDL muscle sections from WT, 
untreated SODlG93A and WIN55,212-2 treated SOD1C93a mice
EDL muscle sections from (A) WT, (B) untreated SODlG93A and SODlG93A mice 
treated with WIN55,212-2 from (C) 40 and (D) 90 days of age were sectioned on a 
cryostat and stained for succinate dehydrogenase (SDH) activity, an indicator of 
oxidative capacity. WT EDL muscles showed a mosaic pattern of SDH activity, with 
the majority of fibres staining lightly. A greater proportion of untreated SODlG93A EDL 
muscle fibres, however, had an increased oxidative capacity, reflected by more intense 
staining for SDH activity. In contrast, EDL muscles from 120 day old SOD1G93a mice 
treated with WIN55,212-2 showed a pattern of SDH staining that was more 
characteristic of WT EDL muscles, with a greater proportion of fibres lightly stained. 
Scale bar = 200pm.
291
292
4.3.7. Motoneuron survival
The effect of treatment with WIN55,212-2 on motoneuron survival was assessed in 120 
day old SOD1G93a mice, by counting the number of motoneurons in the sciatic pool in 
each ventral horn. Figure 4.14 shows examples of Nissl - stained spinal cord sections 
from (A) WT, (B) SOD1093a and S0D1G93A treated with WIN 55,212-2 from (C) 40 
and (D) 90 days of age. The improvement in motor unit survival observed in 
WIN55,212-2 treated S0D1G93A mice was reflected in an increase in motoneuron 
survival, and the results are summarised in the bar chart (E). At 120 days of age a 
significant number of motoneurons in the sciatic pool had already died in untreated 
S0D1G93A mice, so that only 140 (± 6.7 S.E.M.; n = 12; p < 0.001) motoneurons 
survived compared to 369 (± 12.9 S.E.M.; n = 8) in the spinal cords of WT littermates, a 
reduction in motoneuron survival of 62.1%. However, treatment with WIN55,212-2 
from both 40 and 90 days of age rescued a significant proportion of motoneurons so that 
271 (± 7.5 S.E.M.; n = 8 ; p < 0.001) and 199 (± 10.2 S.E.M.; n = 16; p < 0.001) 
motoneurons survived, a loss of only 26.6% and 46.1% respectively, compared to WT 
littermates. Thus treatment with WIN55,212-2 protected motoneurons from cell death in 
SOD 1093A mice, and 93% and 42% more motoneurons survived following treatment 
from 40 and 90 days respectively, compared to their untreated SODlG93A littermates.
In addition, the number of motoneurons surviving in the sciatic pool at the end-stage of 
disease was also assessed (Figure 4.15). The number of motoneurons surviving in the 
spinal cord of end-stage SOD1G93a mice treated with WIN55,212-2 from 40 days of age 
was significantly greater than in untreated SOD 1093A littermates. Thus, 122 
motoneurons (± 6.9 S.E.M.; n = 12; p = 0.035) survived in end-stage spinal cord of 
SOD1G93a mice treated with WIN55,212-2 from 40 days of age, compared to 96 
motoneurons (± 7.6 S.E.M.; n = 12) in untreated SODlG93A littermates, representing a
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Figure 4.14 -  Motoneuron survival in WT, untreated SOD1G93a and WIN55,212-2 
treated SOD1G93a mice at 120 days of age
Motoneuron survival at 120 days of age was assessed by counting the number of Nissl- 
stained motoneurons in the sciatic motor pool (dotted areas) of (A) WT, (B) untreated 
S0D1G93A and S0D1G93A mice treated with WIN55,212-2 from (C) 40 and (D) 90 days 
of age. The mean motoneuron survival is summarised in the bar chart (E). At 120 days 
of age SOD1G93a mice (n = 12) had lost a substantial proportion of their sciatic 
motoneurons compared to WT mice (n = 8 ). However, treatment with WIN55,212-2 had 
neuroprotective effects and significantly more motoneurons survived in treated 
SOD1G93a mice at 120 days of age. Indeed, WIN55,212-2 treatment from 40 (n = 8 ) and 
90 (n = 16) days rescued 93% and 42% of motoneurons respectively. Values are the 
mean ± standard error of the mean. Scale bar = 100pm. *** p <0.005. There was a 
significant difference between the mean values of each of the experimental groups.
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Figure 4.15 -  Motoneuron survival in end-stage untreated SOD1G93a mice and 
SODlG93A mice treated with WIN55,212-2
Motoneuron survival was assessed by counting the number of Nissl-stained 
motoneurons in the sciatic pool of untreated SOD1G93a and WIN55,212-2 treated 
SOD1G93a mice at the end-stage of disease. It can be seen that even at the end-stage of 
disease, treatment with WIN55,212-2 from 40 days of age rescued a significant 
proportion of sciatic motoneurons in SODlG93A mice. However, no increase in 
motoneuron survival was seen in the group treated with WIN55,212-2 from 90 days of 
age. Values are the mean ± standard error of the mean. * p < 0.05.
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27.9% increase in motoneuron survival. However the improvement in motoneuron 
survival seen at 120 days following treatment with WIN55,212-2 from 90 days of age, 
was not maintained and only 103 motoneurons (± 7.5 S.E.M.; n = 6 ; p > 0  .4) survived at 
the end-stage.
4.3.8. The effect of WIN55,212-2 treatment on the lifespan of SODlG93A mice
The lifespan of WIN55,212-2 treated SOD1G93a mice was recorded to determine 
whether the significant delay in disease progression, as shown by an improvement in 
muscle function and motoneuron survival at 1 2 0  days of age, was reflected in an 
increased lifespan of SODlG93A mice. Untreated S0D1G93A mice on the C57BL/6 x SJL 
Fi hybrid background lived on average for 131 days (± 1.4 S.E.M.; n = 23), as shown in 
Figure 4.16. Lifespan in this study was determined as the age when the mice have lost > 
20% of their body weight or when they can no longer right themselves within 30 
seconds when placed on their sides. Treatment with WIN55,212-2, from either 40 or 90 
days of age, had no significant effect on lifespan and treated SODlG93A mice had an 
average lifespan of 131 days (± 3.4 S.E.M.; n = 10; p > 0.5) and 134 days (± 2.3 S.E.M.; 
n = 1 0 ; p > 0  .1 ) respectively, although at each time point examined, except end-stage, 
more treated SOD 1093A mice survived.
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Figure 4.16 -  The effect of WIN55,212-2 treatment on the lifespan of SOD1G93a
mice
The effect of treatment with WIN55,212-2 on the lifespan of SOD1G93a mice was 
investigated. At weekly time intervals, the number of animals surviving in each 
experimental group was expressed as a percentage of the total number of animals in that 
group, as shown in the graph. Although there is a slight shift to the right in the lifespan 
curve of SOD1G93a mice treated with WIN55,212-2 from 40 or 90 days of age, there 
was no significant increase in survival. The value at each time point represents the mean 
survival of each group of experimental mice.
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4.4. DISCUSSION
The availability of transgenic mice expressing mutations in Cu/Zn SOD1 enzyme has 
enabled considerable research into the disease pathogenesis of ALS (Gurney et al., 
1994; Ripps et al., 1995; Wong et al., 1995; Bruijn et al., 1998). These mice also 
provide a useful model in which to test potential therapeutic agents. Indeed, the results 
of this Chapter show that administration of the exogenous cannabinoid WIN55,212-2, 
even after symptom onset, significantly delays disease progression in the SODlG93A 
mouse model of ALS. Surprisingly however, the dramatic improvements in disease 
progression observed in SOD 1093A mice following pharmacological enhancement of the 
cannabinoid system, are not reflected in an increased lifespan.
There is substantial evidence implicating excitotoxicity as a contributing factor to ALS 
pathogenesis (reviewed in Heath & Shaw, 2002; Bruijn et al., 2004). A number of 
therapies aimed at reducing excitotoxicity have previously been shown to have 
beneficial effects in animal models of ALS (Gurney et al., 1998; Canton et al., 2001; 
Van Damme et al., 2003). However, in ALS patients’, treatment with the anti -  
glutamatergic agent Riluzole has only limited effects, with patient lifespan extended by 
only 2-4 months (Bensimon et al., 1994; Riviere et al., 1998; Miller et al., 2002; 
Traynor et al., 2003). Cannabinoids have been shown to reduce excitotoxicity in a 
number of models of neuronal death via a CBi receptor-dependent mechanism (for 
example Hampson et al., 1998a; Shen & Thayer, 1998b; Abood et al., 2001; Marsicano 
et al., 2003; Pryce et al., 2003). However, they also exhibit other potentially beneficial 
effects. For example they are known to have anti-inflammatory (reviewed in Walter & 
Stella, 2004) and anti-oxidant properties (Hampson et al., 1998b; Chen & Buck, 2000; 
Marsicano et al., 2002), which in view of the role of these pathogenic mechanisms in 
ALS, may be particularly relevant. This combination of potential neuroprotective
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mechanisms, against inflammation and oxidative stress in addition to excitotoxicity, 
suggest that cannabinoids may have a greater impact on disease progression in ALS 
than therapies that target excitotoxicity alone. Indeed, the combination of riluzole, 
minocycline, an inhibitor of microglial activation, and nimodipine, a blocker of voltage- 
gated calcium channels, delays disease onset and extends survival in SODlG37R mice to 
a greater extent than achieved individually with these agents, thus highlighting the 
benefits of targeting multiple pathways (Kriz et al., 2003).
4.4.1. Up-regulation of endocannabinoids in symptomatic SOD1G93a mice
The results of this study show an increase in levels of the endocannabinoids, AEA and 
2-AG, in the spinal cord of S0D1G93A mice during the symptomatic stages of disease in 
contrast to presymptomatic stages. This is consistent with the observations of Witting et 
al, (2004), who also reported elevated levels of endocannabinoids in the spinal cord of 
symptomatic S0D1G93A mice. It is possible that this is an adaptive response aimed at 
counteracting excitotoxicity, similar to that observed in the hippocampus of mice 
treated with KA (Marsicano et al., 2003). However, such an endogenous response is 
clearly not sufficient to counteract the progression of disease. Administration of an 
exogenous cannabinoid may therefore act to boost this endogenous protective 
mechanism, and the results presented in this Chapter show that treatment with 
WIN55,212-2 significantly delays disease progression in the S0D1G93A mice, 
maintaining muscle function and delaying motoneuron degeneration. It is interesting to 
note that in response to peripheral nerve injury, both CBj and CB2 receptors are up- 
regulated in the spinal cord, on neurons and microglial respectively (Lim et al., 2003; 
Zhang et al., 2003). This suggests that the pool of cannabinoid receptors available for 
activation in areas affected in ALS may actually increase with disease progression, at 
least initially.
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4.4.2. The effect of WIN55,212-2 treatment on hindlimb muscle force
Treatment of S0D1G93A mice with WIN55,212-2 from 40 or 90 days of age, a 
presymptomatic and early symptomatic stage respectively, has significantly beneficial 
effects on muscle force. In 120 day old SOD1G93a mice, muscle force is substantially 
reduced compared to WT mice. Indeed, the maximal tetanic force of TA and EDL 
muscles of SOD1G93a mice is reduced by 67% and 43% respectively, compared to WT 
muscle force. Sharp et al, (2005) similarly reported a greater vulnerability of TA 
muscles in SODlG93A mice. This increased vulnerability of TA muscles may be related 
to the larger peripheral field of motoneurons innervating the TA muscle compared to 
EDL, which therefore may render these motoneurons more vulnerable to pathogenic 
mechanisms, for example oxidative stress. A previous study reported an increased 
vulnerability of fast twitch EDL muscles, compared to slow twitch soleus muscles in 
SOD1G93a mice (Derave et al., 2003). This further supports the link between motor unit 
susceptibility in ALS and their functional size and perhaps phenotype.
Treatment with WIN55,212-2 from 90 days of age prevents the reduction in muscle 
force in S0D1G93A mice. Thus, the twitch force of TA muscles is 49% greater than in 
untreated SOD 1093A littermates and tetanic force is 73% greater. Similarly the maximal 
tetanic force of EDL muscles in SOD1G93a mice treated with WIN55,212-2 from 90 
days of age, is 39% greater than EDL muscles in untreated S0D1G93A mice. Since TA 
muscles of SOD1g93A mice are affected earlier and to a greater extent than EDL 
muscles, any beneficial effects of WIN55,212-2 may have a comparatively greater 
impact on TA than EDL muscles.
Treatment with WIN55,212-2 from 40 days has no effect on the decline in force of 
either TA or EDL muscles in SODlG93A mice. In view of the positive effects of
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treatment from 90 days, this is a surprising finding, although WIN55,212-2 treatment 
from 40 days does exert beneficial effects on other muscle characteristics.
4.4.3. The effect of WIN55,212-2 treatment on muscle contractile characteristics
Treatment with WIN55,212-2 from either 40 days or 90 days prevents the appearance of 
disease-induced changes in the fatigue characteristics of EDL muscles. EDL muscles 
are normally fast muscles that fatigue rapidly when repeatedly stimulated due to the low 
oxidative capacity of the muscle fibres. However, as a consequence of disease 
progression in S0D1G93A mice, EDL muscle fibres undergo a phenotypic change and 
become fatigue resistant (Derave et al., 2003; Sharp et al., 2005). Histochemical 
staining for SDH activity reveals an increased proportion of more intensely stained 
muscle fibres in EDL muscles from SODlG93A mice. This indicates that these muscle 
fibres have a higher oxidative capacity than normal, a characteristic more typical of 
slow muscle fibres, which have the capability to maintain contraction for extended 
periods of time (Navarrete & Vrbova, 1983).
Muscle fibre phenotype is normally determined by the activity of innervating 
motoneurons (Navarrete & Vrbova, 1984). During development, all motoneurons are 
initially tonically active with a low frequency of firing (Navarrete & Vrbova, 1983). 
However, during the first few weeks of postnatal development motoneurons 
differentiate, becoming either phasic, high frequency firing motor units (fast 
motoneurons) or remaining tonically-active motor units, but with an increased duration 
of low frequency firing (slow motoneurons). As a consequence of this change in 
motoneuron firing pattern, the muscle fibres these motoneurons innervate differentiate 
into fast and slow muscle fibres respectively (Navarrete & Vrbova, 1983). Interruption 
of this nerve-muscle interaction during early postnatal development, for example by
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peripheral nerve injury, has been shown to have more severe consequences for fast 
muscles than slow muscles. Therefore as a result of injury, fast muscles generate 
significantly less force than normal and also become fatigue resistant, with a fatigue 
pattern more typical of slow muscles. In contrast, following neonatal nerve injury, 
although significantly weaker than normal, slow muscles remain virtually unchanged 
(Lowrie et al., 1982, 1987). This injury-induced change in fast muscle phenotype may 
be the result of a change in the activity pattern of those motoneurons that survive injury, 
since fast motoneurons that survive become more active (Navarrete & Vrbova, 1984). In 
contrast, muscle fibres during the period of separation remain unchanged. Therefore 
upon reinnervation there will be a large mismatch in the characteristics of fast muscles 
and motoneurons innervating them, which may be detrimental to the muscles (Navarrete 
& Vrbova, 1984).
It is possible that in S0D1G93A mice, as a consequence of motoneuron degeneration, the 
remaining motoneurons also become more active, as observed following nerve injury 
(Navarrete & Vrbova, 1984). Such a change in motoneuron activity would directly 
affect muscle fibre phenotype. Alternatively, there may be a selective loss of 
motoneuron subtypes. Indeed, Frey et al, (2000) demonstrate a selective loss of fast 
neuromuscular synapses in SODlG93A mice from as early as 40 days of age, suggesting 
a preferential degeneration of fast motoneurons. Furthermore, Atkin et al, (2005) show a 
preferential vulnerability of fast twitch muscle fibres by analysis of single muscle fibre 
contractile properties in S0D1G93A mice at the end-stage of disease. Such selective 
degeneration of fast motoneurons would also explain the change in EDL muscle 
phenotype observed here in SOD1G93a mice, as remaining muscle fibre innervation 
would be from slow motoneurons. Another possibility for the observed change in 
muscle fibre phenotype in S0D1G93A mice may be that during the
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denervation/reinnervation that occurs in S0D1G93A mice (Sharp et al., 2005), EDL 
muscle fibres become selectively reinnervated by fatigue resistant motoneurons, as a 
result of collateral sprouting of slow motoneuron axons, thus altering muscle phenotype.
Alternatively, independent of motor unit activity, it is possible that biochemical changes 
in the skeletal muscles may also be involved in the change in muscle fibre phenotype in 
SOD1G93a mice. Overexpression of uncoupling protein 1 in skeletal muscle has been 
shown to result in a reduction in muscle mass and also induces a change in muscle fibre 
phenotype from fast glycolytic fibres to slow oxidative fibres as a result of the chronic
p o r n
uncoupling of mitochondria (Couplan et al., 2002). In presymptomatic SOD1 mice, 
the levels of uncoupling protein 3 are up-regulated in skeletal muscle, resulting in the 
functional uncoupling of mitochondria in these muscles, and this may contribute to the 
changes seen in muscle fibre phenotype with disease progression (Dupuis et al., 2003).
In EDL muscles from S0D1G93A mice treated with WIN55,212-2 from either 40 or 90 
days, repeated stimulation produces fatigue characteristics that resemble those of 
normal EDL muscles, indicating that WIN55,212-2 treatment has delayed the 
deleterious changes in muscle fibre phenotype in SOD1G93a mice. Similarly, SDH 
staining reveals that EDL muscle fibres from S0D1G93A mice treated with WIN55,212-2 
retain the mosaic pattern of lightly and darkly stained fibres, with a predominance of 
light staining, characteristic of WT EDL muscle fibres. Therefore, in WIN55,212-2 
treated SODlG93A mice, EDL remains a fast, fatigable muscle with a relatively low 
oxidative capacity. This observation may be a direct consequence of increased 
motoneuron survival in these SODlG93A mice.
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4.4.4. The neuroprotective effect of WIN55,212-2 treatment in SOD1G93a mice
The results show that in S0D1G93A mice at 120 days of age, more than 60% of motor 
units and the same proportion of motoneurons have already died. This is in agreement 
with previous reports (Kieran et al., 2004; Sharp et al., 2005). However, treatment with 
WIN55,212-2 rescues a significant proportion of motor units. Thus following treatment 
with WIN55,212-2 from 40 or 90 days of age only approximately 43% and 30% of 
motor units are lost respectively. This increase in motor unit survival is reflected in a 
dramatic increase in motoneuron survival in WIN55,212-2 treated SOD1G93a mice, 
particularly following treatment from 40 days of age. Thus only 27% of motoneurons 
die in S0D1G93A mice treated with WIN55,212-2 from 40 days and only 46% of 
motoneurons die in mice treated from 90 days of age.
4.4.5. The effect of WIN55,212-2 treatment on locomotor activity
It is interesting that S0D1G93A mice treated with WIN55,212-2 from 40 days of age are 
significantly less active at a presymptomatic and early symptomatic stage of disease 
than untreated SOD1G93a mice. Cannabinoid-induced inhibition of movement is a 
widely recognised effect (Baker et al., 2003). However, reports suggest that there is 
actually a biphasic locomotor response to cannabinoids, with low doses stimulating 
locomotor activity and high doses exhibiting an inhibitory action (Sulcova et al., 1998; 
Sanudo-Pena et al., 2000; Wiley et al., 2003; Drews et al., 2005). Although it has been 
shown that repeated administration of A9-THC can actually stimulate locomotor activity 
(Wiley, 2003), this study was only carried out over a period of 5 days, in contrast to the 
1 -3 months duration in the experiments described in this Chapter.
The relationship between ALS and general exercise, both prior to and after disease
onset, remains controversial. Several studies claim to link excessive vigorous exercise,
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both occupational and recreational, with an increased risk of developing ALS (Scarmeas 
et al., 2002; Piazza et al., 2004). In contrast, it has also been proposed that physical 
exercise may be a therapy for ALS patients in an attempt to increase/preserve muscle 
strength (Drory et al., 2001). The present data suggests that reduced activity levels after 
disease onset may be protective by preserving hindlimb muscle function, whereas 
reduced activity levels before disease onset may actually have deleterious effects. 
Treatment from 90 days of age significantly improves all aspects of muscle function 
even at a late stage of disease (120 days of age). Cannabinoid-induced inhibition of 
neurotransmitter release may reduce the input firing frequency from motoneurons to 
muscle fibres, which consequently would reduce their activity and induce hypomotility. 
As discussed earlier, increased motoneuron activity due to disease progression may be 
the process underlying the increased fatigue resistance of EDL muscles in SOD 1093A 
mice, therefore the hypomotility induced by WIN55,212-2 may delay such deleterious 
changes. Reduced input to motoneurons may also help to prevent excitotoxic damage 
and may contribute to the neuroprotective effects observed here. However, treatment 
from 40 days did not affect muscle force despite exerting beneficial effects on the 
fatigue characteristics of EDL muscles in S0D1G93A mice. This suggests that prolonged 
hypomotility induced by WIN55212,2 may actually prevent the preservation of muscle 
force seen following treatment from 90 days.
4.4.6. The effect of WIN55,212-2 treatment on the lifespan of SOD1G93a mice
Surprisingly, the significant improvements seen in muscle function and motoneuron 
survival at 120 days of age, following treatment with WIN55,212-2, are not reflected in 
an increase in lifespan of SOD1G93a mice. The failure of WIN55,212-2 to affect lifespan 
is particularly surprising considering the significant increase in motoneuron survival at 
end-stage disease in mice treated from 40 days of age. These results are however
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consistent with previous studies in which A9-THC and cannabinol delay the onset of 
disease in S0D1G93A mice but do not significantly extend lifespan (Raman et al., 2004; 
Weydt et al., 2005). However the present study extends these observations to confirm 
that cannabinoid treatment preserves body weight, muscle function and motoneuron 
survival at a late stage of disease, thereby significantly increasing the “quality of life” of 
S0D1G93A mice. Therefore, treatment of SODlG93A mice with WIN55,212-2, a synthetic 
cannabinoid, significantly delays the disease progression, via the maintenance of muscle 
force and the preservation of motoneuron survival. However, these improvements are 
not reflected by an increase in lifespan of the SODlG93A mice.
4.4.7. Mechanism of cannabinoid-mediated neuroprotection
4.4.7.I. CBi receptor-mediated neuroprotection
Cannabinoids exert their effects primarily by activation of CBi and CB2 receptors, 
located predominantly in the CNS (Herkenham et al., 1991) and on cells of the immune 
system (Howlett et al., 2002) respectively. Cannabinoid receptor agonists have been 
shown to inhibit neurotransmitter release via activation of presynaptic CBi receptors 
(Shen et al, 1996; Gessa et al., 1998; Levenes et al., 1998; Nicholson et al., 2003). 
Furthermore, activation of postsynaptic CBi receptors may reduce excitotoxicity- 
induced postsynaptic calcium influx via inhibition of voltage gated N- and P-/Q- type 
calcium channels (Caulfield & Brown, 1992; Mackie & Hille, 1992; Twitchell et al., 
1997; Shen & Thayer, 1998a; Abood et al., 2001; Hampson & Grimaldi, 2001). It was 
therefore hypothesised that exogenous WIN55,212-2 may act via the CBi receptor to 
inhibit glutamate neurotransmission and thus limit excitotoxicity in the S0D1G93A 
model of ALS. Indeed, many in vivo and in vitro studies have shown neuroprotective 
actions of cannabinoids under excitotoxic conditions, via a CBi receptor-dependent 
mechanism (for example, Shen & Thayer, 1998a, 1998b; Abood et al., 2001; van der
309
Stelt et al., 2001a; Marsicano et al., 2003; Molina-Holgado et al., 2003; Pryce et al., 
2003). Furthermore, injection of KA into the CNS of CBi receptor knock-out mice 
elicits a more severe response than in WT mice (Marsicano et al., 2003; Pryce et al., 
2003). In addition, Parmentier -  Batteur et al (2002) reported an increase in 
neurological damage in CBi receptor knock-out mice after either middle cerebral artery 
occlusion or NMD A injection, therefore highlighting the role of this receptor in 
neuroprotection.
4.4.7.2. CB2 receptor-mediated neuroprotection
Other studies have demonstrated neuroprotective effects of cannabinoids in the presence 
of CBi receptor antagonism, indicating a non-CBj receptor-mediated effect (Nagayama 
et al., 1999; Klegeris et al., 2003; van der Stelt et al., 2001b). CB2 receptors were 
initially thought to be located only in the immune system (reviewed in Howlett et al.,
2002). However, CB2 receptors have recently been localised to rodent microglia in vitro 
(Facchinetti et al., 2003; Walter et al., 2003; Carrier et al., 2004) and to human 
microglia (Benito et al., 2003; Klegeris et al., 2003). Therefore, CB2 receptor activation 
may also contribute to the effects of cannabinoids in the CNS. Indeed, microglial 
expression of CB2 receptors has been shown to be up-regulated in the lumbar spinal 
cord of rats following peripheral nerve injury (Zhang et al., 2003).
Several lines of evidence indicate that inflammation may also play a role in ALS 
(McGeer & McGeer, 2002). In the post-mortem spinal cords of ALS patients there are 
abundant signs of inflammation, with reactive astrocytes, activated microglia and CD4+ 
and CD8 + T-lymphocytes present in areas of motoneuron degeneration (Troost et al., 
1990; Engelhardt et al., 1993; Alexianu et al., 2001; Yasojima et al., 2001; McGeer & 
McGeer, 2002; Zhang et al., 2005). Furthermore, increased mRNA and protein levels of
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inflammatory markers such as COX2, PGE2 and TNFa are also seen in the post-mortem 
spinal cords of ALS patients (Poloni et al., 2000; Yasojima et al., 2001; Maihofher et 
al., 2003).
In SOD1G93a mice there is a correlation between disease progression and the intensity of 
inflammation (Hall et al., 1998; Alexianu et al., 2001; Aimer et al., 2001). Reactive 
astrogliosis increases steadily from disease onset, whereas microglial activation is 
evident from a presymptomatic age of 60 days and continues to increase in intensity 
with disease progression, paralleling the loss of motoneurons (Hall et al., 1998; 
Alexianu et al., 2001; Elliott et al., 2001; Olsen et al., 2001; Weydt et al., 2004). The 
contribution of glial cells to disease progression in ALS is highlighted by studies in 
which in vivo expression of the mutant SOD1 protein under the control of a neuronal 
promoter does not result in development of motor neuron disease (Pramatarova et al., 
2001; Lino et al., 2002). This indicates that expression of the mutant SOD1 protein is 
required in both motoneurons and glial cells for disease to manifest. The up-regulation 
of intracellular adhesion molecule-1 (ICAM-1) expression on microglia at 40 days is in 
fact one of the earliest pathological changes seen in the S0D1G93A mice (Alexianu et al., 
2001). Such up-regulation may be important in the induction of inflammatory processes 
(Kawasaki et al., 1993; Alexianu et al., 2001). Microglia are also implicated in the 
propagation of inflammation, whereby microglial activation induces the release of pro- 
inflammatory cytokines, ROS and glutamate which initiate the recruitment and 
activation of further microglia, and in addition can also elicit cellular damage (Molina- 
Holgado et al., 1997; Tikka & Koistinaho, 2001). Microglia from SOD1G93a mice have 
been shown to secrete significantly more TNFa than age-matched WT microglia 
(Weydt et al., 2004) and there is a significant up-regulation of TNFa mRNA and 
protein in the CNS of S0D1G93A mice (Hensley et al., 2003). Pro-inflammatory
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cytokines, such as TNFa and IL-lp, can induce COX2 expression, via activation of the 
transcription factor NF-kB (Consilvio et al., 2004; Juttler et al., 2004). Activation of 
COX2 will then increase production of prostaglandins, including PGE2, which may 
actually contribute to excitotoxicity by stimulating the release of glutamate from 
astrocytes (Drachman & Rothstein, 2000), and in addition releases ROS, which may 
further propagate the inflammatory process (Consilvio et al., 2004).
Minocycline, a potent inhibitor of microglial activation, has been shown to inhibit 
neuronal death induced by exposure to cerebrospinal fluid from ALS patients (Tikka et 
al., 2002) and also delay onset and extend survival by 9-16% in mutant SOD1 mice 
(Kriz et al., 2002; van den Bosch et al., 2002; Zhu et al., 2002). Similarly, NDGA, an 
inhibitor of 5-lipoxygenase, which acts to suppress microglial activation by reducing 
TNFa release, extended the lifespan of SOD1G93a mice by 32% (West et al., 2004). 
Other inhibitors of inflammation have also been shown to have beneficial effects in 
ALS models. In a model of chronic motoneuron degeneration the selective COX2 
inhibitor SC236 prevents motoneuron loss (Drachman & Rothstein, 2000), whereas in 
vivo, selective COX2 inhibitors delay onset (Pompl et al., 2003) and extend the lifespan 
of SOD1G93a mice by 25% (Drachman et al., 2002). However, recently a clinical trial 
using celebrex (a selective COX2 inhibitor) failed to have any significant effect on 
muscle function in ALS patients. At this stage it is not clear whether the lack of effects 
observed are actually due to poor bioavailability of the drug, an incorrect dosage 
regimen or even a inappropriately designed trial and also whether this negative result is 
solely related to celebrex or to all COX2 inhibitors (www.alsa.org).
Cannabinoids have also been shown to reduce microglial activation (Arevalo-Martin et 
al., 2003) and reduce both mRNA expression and release of pro-inflammatory cytokines
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from microglia (Puffenbarger et al., 2000; Croxford & Miller, 2003; Facchinetti et al.,
2003) via a CB2 receptor-mediated mechanism (Klegeris et al., 2003). Furthermore, 
Molina-Holgado et al, (2003) suggest that cannabinoids antagonise the actions of the 
pro-inflammatory mediator IL-ip via a CBi or CB2 receptor-induced increase in II-1 
receptor antagonist, thus reducing inflammation. There is also evidence to suggest that 
cannabinoids can inhibit activation of the transcription factor NF-kB, in a CBi receptor- 
dependent manner, which may also suppress inflammation by reducing the expression 
of the COX2 enzyme, nitric oxide and expression of pro-inflammatory cytokine TNFa, 
for example (Waksman et al., 1999; Juttler et al., 2004). In addition to these anti­
inflammatory actions, an inhibitory effect of cannabinoids on microglia may also limit 
their release of glutamate and ROS, thus lowering the potential contribution of 
excitotoxicity and oxidative stress to disease pathogenesis (Molina-Holgado et al., 1997, 
2002; Waksman et al., 1999; Tikka et al., 2002).
4.4.7.3. Other potential targets
Another possible target mediating the effect of WIN55,212-2 in nervous tissue is the as 
yet unidentified, G protein coupled cannabinoid “CB3” receptor that has been 
pharmacologically characterised in the brain of CBi receptor knock-out mice (Di Marzo 
et al., 2000; Breivogel et al., 2001; Monory et al., 2002). This receptor is activated to 
the same extent by AEA and WIN55,212-2, but not by other synthetic cannabinoids or 
A9-THC. It is insensitive to CBi and CB2 receptor antagonists and is not coupled to the 
inhibition of adenylate cyclase (Monory et al., 2002), unlike the existing cannabinoid 
receptors. There is, however, evidence to suggest that this receptor may be selectively 
coupled to the inhibition of glutamate release in the mouse hippocampus (Hajos et al., 
2001).
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Cannabinoids have also been shown to act via receptor-independent mechanisms. A9- 
THC and CBD have been ascribed an anti-oxidant capacity equivalent to that of 
butylated hydroxytoluene, a known anti-oxidant (Hampson et al., 1998b; Chen & Buck, 
2000). Indeed, CBD, a non-receptor binding cannabinoid, exerts significant 
neuroprotection in models of serum deprivation and hydrogen peroxide-induced 
oxidative stress (Chen & Buck, 2000; Marsicano et al., 2002) and NMDA/AMPA- 
mediated excitotoxicity (Hampson et al., 1998b). A9-THC achieves similar levels of 
neuroprotection in these models but these effects are insensitive to CBi receptor 
antagonism, are not stereoselective and are achieved at concentrations significantly 
higher than that required for receptor binding (Chen & Buck, 2000). Meanwhile, the 
synthetic cannabinoid, CP 55,940, exerts an equivalent degree of neuroprotection in WT 
and CBi receptor knock-out cerebellar granule neurons, suggesting that CBi receptors 
are not involved (Marsicano et al., 2002). However, it is unlikely that anti-oxidant 
activity contributes to the neuroprotection mediated by WIN55,212-2 in this ALS 
model, as the anti-oxidant mediated neuroprotection of CBD, A9-THC and CP 55,940 
has been shown to be dependent on the presence of a phenol ring in their structure and 
WIN55,212-2, an aminoalkylindole, lacks a phenol ring.
4.5. CONCLUSION
Treatment with WIN55,212-2, from either 40 or 90 days, a presymptomatic or 
symptomatic age respectively, delays disease progression in SOD 1093A mice. At 120 
days of age, a relatively late stage of disease, muscle function and motoneuron survival 
are significantly improved in WIN55,212-2 treated SODlG93A mice compared to their 
untreated SODlG93A littermates. However, despite these significant improvements, no 
increase in lifespan is observed. These results may have relevance for the treatment of
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ALS, as the clear increase in muscle function induced by WIN55,212-2 may translate to 
a significant improvement in patient “quality of life”.
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CHAPTER 5
THE EFFECTS OF GENETIC MANIPULATION OF THE 
ENDOCANNABINOID SYSTEM IN THE SOD1G93a 
MOUSE MODEL OF ALS
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5.1. INTRODUCTION
The results presented in Chapter 4 demonstrated that administration of an exogenous 
synthetic cannabinoid receptor agonist, WIN55,212-2, to symptomatic SOD1G93a mice 
has significant neuroprotective effects, but no impact on lifespan. Therefore the effect of 
genetically enhancing endocannabinoid levels in SOD1G93a mice was examined next, in 
order to establish whether this would have a greater impact on disease than 
pharmacological treatment. Furthermore, in order to elucidate the mechanism by which 
cannabinoids exert their neuroprotective capabilities, the CBi receptor was genetically 
ablated in SOD1G93a mice and the effect of this manipulation on disease progression 
was assessed.
5.1.1. Endocannabinoids
The discovery of cannabinoid receptors in the early 1990s (Matsuda et al., 1990; Munro 
et al., 1993) initiated extensive research into the existence of endogenous modulators of 
the cannabinoid system. In 1992, arachidonoyl ethanolamine (anandamide; AEA), the 
first endocannabinoid, was identified (Devane et al., 1992), followed by 2-arachidonoyl 
glycerol (2-AG), 2-arachidonoyl glycerol ether, homo-y-linolenylethanolamide, 
docosatetraenylethanolamide and O-arachidonoyl ethanolamine, comprising a family of 
lipid-derived neurotransmitters (Devane et al., 1992; Hanus et al., 1993, 2001; 
Mechoulam et al., 1995; Sugiura et al., 1995; Porter et al., 2002). In animal models, 
administration of synthetic AEA or 2-AG reproduces the characteristic behavioural 
effects of plant-derived and synthetic cannabinoids for example, hypomotility, analgesia 
and hypothermia (Fride & Mechoulam, 1993; Di Marzo et al., 1998). Two further 
endocannabinoids, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), have 
also been characterised although they do not activate the known cannabinoid receptors 
(Freund et al., 2003).
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The ability of AEA and 2-AG to displace [3H]HU-243, a specific cannabinoid receptor 
agonist, demonstrates their efficacy at both CBj and CB2 receptors (Devane et al., 1992; 
Felder et al., 1993; Vogel et al., 1993; Felder et al., 1995; Slipetz et al., 1995). The 
functional coupling between endocannabinoid-mediated cannabinoid receptor binding 
and the activation of Gi/ 0 proteins is shown by significant inhibition of adenylate cyclase 
activity in a pertussis toxin sensitive manner (Vogel et al., 1993; Pertwee et al., 1994; 
Felder et al., 1995; Slipetz et al., 1995). CNS levels of 2-AG are elevated approximately 
200 fold over AEA concentrations (Sugiura et al., 1995; Stella et al., 1997). 
Furthermore, 2-AG can fully activate both G j  and G0 binding proteins. AEA can 
similarly activate G j  proteins fully, but in contrast mediates only partial activation of G0 
proteins (McAllister & Glass, 2002). This differential regulation of G protein activation, 
together with differing CNS concentrations, may permit some control over the effects 
exerted by endocannabinoids in different cell types (McAllister & Glass, 2002).
5.1.2. Endocannabinoid synthesis
The cellular synthesis of endocannabinoids occurs on demand, in response to neuronal 
depolarisation and the subsequent increase in intracellular calcium (Di Marzo et al., 
1994; Cadas et al., 1996). The synthetic pathways of AEA and 2-AG are summarised in 
Figure 5.1 and Figure 5.2 respectively. In contrast, the biosynthetic pathways of the 
other identified endocannabinoids are not yet fully understood (De Petrocellis et al.,
2004).
AEA and other N-acyl ethanolamines (NAEs) are derived from phospholipid 
precursors, the N-acyl phosphatidylethanolamines (NAPEs), by the action of an N-acyl 
phosphatidylethanolamine-selective phospholipase D (NAPE-PLD), a member of the
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Figure 5.1 -  Synthetic and degradation pathways of anandamide
The diagram details the pathways and enzymatic reactions involved in the synthesis and 
degradation of anandamide (AEA). AEA is derived from its corresponding N -  acyl 
phosphatidylethanolamine (NAPE) precursor, N-arachidonoyl
phosphatidylethanolamine, by calcium-dependent hydrolysis of the NAPE 
phosphodiester bond, a reaction catalysed by NAPE-phospholipase D (Di Marzo et al., 
1994; Cadas et al., 1997; Okamoto et al., 2004). This forms N-arachidonoyl 
ethanolamine (AEA) and phosphatidic acid. The NAPE precursor of AEA is in turn 
generated by the N-acyl transferase mediated transfer of a fatty acid group from sn-1 
phosphatidylcholine to the amino group of phosphatidylethanolamine (Cadas et al., 
1997; Di Marzo et al., 2004). Following the release of AEA and its subsequent re­
uptake by the putative endocannabinoid membrane transporter (Di Marzo et al., 1994), 
AEA is hydrolysed by fatty acid amide hydrolase to form ethanolamine and arachidonic 
acid (Di Marzo et al., 1994; Cravatt et al., 1996).
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Pathways of anandamide synthesis and degradation
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N-arachidonoyl ethanolamine (AEA) + phosphatidic acid TERMINATION
Intracellular uptake
Fatty acid amide hydrolase (Faah)
Ethanolamine + Arachidonic acid
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zinc metallohydrolase enzyme family (Okamoto et al., 2004). NAPE-PLD catalyses the 
calcium-dependent hydrolysis of the NAPE phosphodiester bond to generate the 
corresponding NAE and phosphatidic acid (Di Marzo et al., 1994). The action of 
NAPE-PLD is not specific to one NAPE and this enzyme is therefore responsible for 
the generation of all NAEs, including N-arachidonoyl ethanolamine (AEA), N- 
palmitoyl ethanolamine, N-stearoyl ethanolamine and N-oleoyl ethanolamine (Cadas et 
al., 1997; Okamoto et al., 2004). Generation of NAPEs is also calcium-dependent, 
therefore to avoid depletion, synthesis of the precursor pool of NAPEs occurs under the 
same conditions that stimulate endocannabinoid synthesis. NAPEs are synthesised by 
the calcium-dependent transfer of a fatty acid acyl group from phosphatidylcholine to 
the amino group of a phosphatidylethanolamine, catalysed by an uncharacterised N-acyl 
transferase enzyme (Cadas et al., 1997; Di Marzo et al., 2004).
In contrast, there are two possible mechanisms by which 2-AG may be synthesised, as 
shown in Figure 5.2. The calcium-dependent hydrolysis of sn-1 -acyl-2-arachidonoyl 
glycerol (di acyl glycerol; DAG) by the action of membrane bound diacyl glycerol lipases 
(DAGL), isoforms a  and p, can generate 2-AG (Bisogno et al., 2003; Di Marzo et al., 
2004). DAG in turn is generated, along with inositol (1,4,5) tris-phosphate ( I P 3 ) ,  by 
phospholipase C (PLC) mediated hydrolysis of a particular subset of membrane 
phospholipids, the phosphatidylinositols (Stella et al., 1997). Alternatively, 
phosphatidylinositols may be hydrolysed by phospholipase Ai to generate 2 - 
arachidonoyl lysophospholipid, which can be subsequently hydrolysed to 2-AG by the 
action of lyso-PLC (Freund et al., 2003; Piomelli, 2003). Evidence for this pathway 
occurring in vivo, however, is lacking.
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Figure 5.2 -  Synthetic and degradation pathways of 2-arachidonoyl glycerol
This diagram represents the synthetic and degradation pathways of 2-arachidonoyl 
glycerol (2-AG). 2-AG can be derived from the calcium-dependent hydrolysis of sn-1- 
acyl-2-arachidonoyl glycerol (DAG), catalysed by diacylglycerol lipases (DAGL; 
Bisogno et al., 2003; Di Marzo et al., 2004). DAG is generated from phospholipase C- 
mediated breakdown of phosphatidylinositols, phospholipid components of cellular 
membranes, along with inositol (1,4,5) tris-phosphate (IP3 ; Stella et al., 1997). 
Alternatively, 2-AG can be synthesised by phospholipase Ai-mediated hydrolysis of 
phosphatidylinositols to generate 2 -arachidonoyl lysophospholipid, which can be 
subsequently broken down to form 2-AG by the action of lyso-phospholipase C (Freund 
et al., 2003; Piomelli, 2003). Following the release of 2-AG and its re-uptake by the 
putative endocannabinoid membrane transporter (Di Marzo et al., 1994), 2-AG is 
hydrolysed by the action of monoacylglycerol lipase to form glycerol and arachidonic 
acid (Karlsson et al., 1997; Dinh et al., 2002).
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Pathways of 2-AG synthesis and degradation
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The existence of different biosynthetic pathways for AEA and 2-AG suggests that these 
endocannabinoids may operate independently of each other and may actually be 
responsible for the regulation of different physiological functions. This possibility is 
supported by the fact that calcium entry through ionotropic glutamate receptors is 
sufficient to initiate the synthesis of 2-AG, whereas the synthesis of AEA and other 
NAEs requires the activation of both ionotropic glutamate and acetylcholine receptors 
(Stella & Piomelli, 2001), which again suggests a differential regulation of 
endocannabinoid synthesis under certain conditions.
Endocannabinoids can also be synthesised in a calcium-independent manner through the 
activation of postsynaptic metabotropic glutamate receptors (Cadas et al., 1996; 
Maejima et al., 2001). Activation of group I metabotropic glutamate receptors, coupled 
to G q / n ,  stimulates the activation of PLCps subunits, thus producing DAG from 
membrane phospholipids and subsequently forming 2-AG (Maejima et al., 2001). 
Furthermore, the production of IP3 via PLC activity will induce calcium release from 
intracellular stores, potentially stimulating the calcium-dependent synthesis of both 
AEA and 2-AG (Freund et al., 2003). There is also evidence suggesting that group I 
metabotropic glutamate receptors are coupled to the activation of protein kinase A 
(PKA) though adenylate cyclase stimulation and the subsequent elevation in cAMP 
levels (Cadas et al., 1996). This transduction pathway may potentiate the activity of N- 
acyl transferase, enhancing AEA formation (Azad et al., 2004).
5.1.3. Endocannabinoid reuptake
In the CNS, endocannabinoids are synthesised by neurons, astrocytes and microglia (Di 
Marzo et al., 1994; Walter et al., 2003). Following synthesis, in contrast to most other 
neurotransmitters, endocannabinoids are released by a non-vesicular mechanism into the
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extracellular space, permitting activation of cannabinoid receptors (Di Marzo et al.,
1994). However, subsequent reuptake and hydrolysis of endocannabinoids occurs 
rapidly, so that for example, the biological action of AEA is less than 5 minutes in 
duration (Di Marzo et al, 1994; Willoughby et al., 1997; Cravatt et al., 2001). Initially it 
was thought that termination of the actions of endocannabinoids occurred by simple 
diffusion across plasma membranes, with intracellular hydrolysis acting as the driving 
force for diffusion (Glaser et al., 2003). However, AEA accumulation has been shown 
to be identical in WT neurons and in neurons lacking fatty acid amide hydrolase (Faah), 
the enzyme responsible for AEA hydrolysis, indicating that internalisation is not driven 
by hydrolysis (Fegley et al., 2004). Furthermore, endocannabinoid uptake has 
characteristics typical of carrier-mediated uptake: selectivity, saturation at 37°C, rapid 
action and temperature dependency (Di Marzo et al., 1994; Beltramo et al., 1997; 
Hillard et al., 1997). Uptake, however, is not dependent on cellular ATP suggesting a 
mechanism of facilitated diffusion rather than active uptake (Hillard et al., 1997), with 
the direction of transport depending on the endocannabinoid concentration gradient. 
Alternatively, it has been suggested that the binding of endocannabinoids to a lipid 
binding protein may act as the driving force for cellular uptake (Fegley et al., 2004; 
Ortega-Gutierrez et al., 2004). In 1997, AM404, a competitive inhibitor of 
endocannabinoid uptake, was developed based on the structure of AEA (Beltramo et al., 
1997). Administration of AM404 potentiates the effects of AEA in both in vitro and in 
vivo studies and provides pharmacological evidence for the existence of an endogenous 
endocannabinoid membrane transporter (EMT; Beltramo et al., 1997; Calignano et al., 
1997) that is believed to be involved in the release as well as reuptake of 
endocannabinoids (Hillard et al., 1997). However, despite substantial evidence for its 
existence, no transporter protein has ever been isolated.
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5.1.4. Endocannabinoid hydrolysis
Termination of endocannabinoid action occurs by intracellular hydrolysis that follows 
cellular reuptake (as shown in Figures 5.1 & 5.2; Di Marzo et al., 1994; Goparaju et al., 
1999; Dinh et al., 2002). The Faah enzyme, identified and cloned from rat liver 
microsomes in 1996 (Cravatt et al., 1996), is responsible for the hydrolysis of AEA into 
ethanolamine and arachidonic acid (Di Marzo et al., 1994; Cravatt et al., 1996). 2-AG in 
contrast, is hydrolysed by monoacylglycerol lipase (MAGL; Dinh et al., 2002) into 
glycerol and arachidonic acid (Karlsson et al., 1997).
Regional CBi receptor expression in the CNS co-localises with that of both the Faah 
and MAGL enzymes, although the two degradative enzymes show a complementary 
neuronal distribution (Dinh et al., 2002; Gulyas et al., 2004). The Faah enzyme is found 
predominantly postsynaptically with a somatodendritic localisation (Egertova et al., 
2003). At an ultrastructural level Faah is associated with smooth endoplasmic reticulum 
and the outer membranes of mitochondria (Gulyas et al., 2004). Faah activity has also 
been demonstrated in glial cells (Di Marzo et al., 1994). Meanwhile, MAGL has an 
almost exclusive presynaptic location (Gulyas et al., 2004). This segregation of the main 
endocannabinoid hydrolysing enzymes again suggests differential functions for AEA 
and 2-AG (Gulyas et al., 2004).
The generation of Faah -/- mice in 2001, as described by Cravatt et al, allowed further 
examination of the physiological role of AEA and other Faah-hydrolysed NAEs, such as 
OEA and PEA. Hydrolysis rates in Faah -/- mice are reduced by between 5 0 -  100 fold 
and levels of AEA and the other Faah-hydrolysed NAEs are consequently elevated 10 - 
15 fold in the CNS (Cravatt et al., 2001). Faah -/- mice are viable, fertile and display 
normal cage behaviour and lifespan (Cravatt et al., 2001). Importantly in the Faah -/-
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mice the CBj receptor system is functionally equivalent to that in WT mice (Lichtman 
et al., 2002). Indeed, administration of exogenous AEA to Faah -/- mice induces CBj 
receptor-mediated analgesia, hypomotility, catalepsy and hypothermia (Cravatt et al.,
2001). Furthermore, Faah -/- mice actually demonstrate a reduced basal sensitivity to 
pain following thermal and chemically noxious stimuli, an effect partially reversed by 
CBi receptor antagonism. This demonstrates the CBi receptor-mediated effect of AEA 
in the endogenous response to pain and also highlights the regulatory role of Faah in 
this response (Cravatt et al., 2001; Lichtman et al., 2004).
Clement et al, (2003) however, demonstrated an increased susceptibility of Faah -/- 
mice to kainate (KA) induced seizures, which was ascribed to AEA-mediated inhibition 
of GABA release in the hippocampus. This is in contrast to the generally accepted anti­
convulsant properties of cannabinoids (reviewed in Mechoulam & Lichtman, 2003) and 
in addition also contradicts their implicated role in an endogenous neuroprotective 
mechanism against excitotoxicity (Sugiura et al., 2000; Hansen et al 2001b; 
Panikashvili et al., 2001; Marsicano et al., 2003). However, the overall neuroprotective 
influence of endocannabinoids will also depend on the contribution of those not 
hydrolysed by Faah, for example, 2-AG. In addition, the final outcome may actually 
depend on the regional distribution of endocannabinoid synthesis in the CNS (Cravatt & 
Lichtman, 2003).
5.1.5. The physiological role of endocannabinoids
Since endocannabinoids have only been relatively recently discovered, their 
physiological functions are not yet fully understood. However, the use of selective 
pharmaceutical inhibitors and the availability of animal models in which the
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cannabinoid system has been genetically manipulated have provided some insight into 
the physiological significance of endocannabinoids.
5.I.5.I. Endocannabinoid sites of action
Endocannabinoid-mediated activation of CBi and CB2 receptors, as described in 
Chapter 4.1.2., will exert, in brief, the following effects:
i) Inhibition of adenylate cyclase activity with consequent reduction in cAMP 
levels
ii) Activation of A- type potassium channels
iii) CBi receptor-mediated inhibition of voltage gated N-, P- and Q- type calcium 
channels and stimulation of inwardly rectifying potassium channels
iv) CBi receptor-mediated activation of MAPK
v) CBi receptor-induced up-regulation of immediate early genes, for example c-fos
vi) Potential stimulatory effects on calcium mobilisation dependent on elevated 
cAMP levels, and a combination of PKA/PKC and PLC activation that may 
occur under certain circumstances (as described in more detail in Chapter
4.1.2.),
There is also increasing evidence for other, uncloned, cannabinoid receptors that may 
account for several of the effects exerted by endocannabinoids. The “CB3” receptor has 
been pharmacologically characterised in the brains of CBi receptor knock-out (Cnrl -/-) 
mice (Di Marzo et al., 2000; Breivogel et al., 2001; Monory et al., 2002). This receptor 
subtype is activated only by AEA and WIN55,212-2 and has been suggested to be 
responsible for mediating cannabinoid-induced inhibition of glutamatergic 
neurotransmission (Hajos et al., 2001; Hajos & Freud, 2002). Furthermore, this receptor 
subtype, or alternatively an unidentified receptor subtype, may underlie the selective
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ability of AEA to inhibit gap junction permeability in striatal astrocytes and 
consequently reduce calcium propagation within this astrocytic network (Venance et al.,
1995).
Jarai et al, (1999) identified a potential endothelial cannabinoid receptor subtype in rat 
mesenteric arteries, activated by AEA and abnormal-cannabidiol, a non-cannabinoid 
receptor binding cannabinoid. AEA-mediated mesenteric vasodilation was maintained 
in Cnrl -/- Cnr2 -/- mice, which implicates a currently unidentified receptor subtype in 
this effect (Jarai et al., 1999). However, it has been suggested that AEA-mediated 
vasodilation is in fact mediated by activation of the vanilloid receptor, VR1 (or TRPV1) 
receptor and subsequent release of calcitonin gene related peptide (CGRP; Zygmunt et 
al., 1999). AEA has been identified as an endogenous ligand for the VR1 receptor and 
may in fact exert a number of cannabinoid receptor-independent effects, through this 
receptor (Zygmunt et al., 1999; Smart et al., 2000). VR1 receptors are calcium 
permeable, non-selective cation channels (Zygmunt et al., 1999; Smart et al., 2000), 
activation of which will induce an intracellular calcium influx, neuronal depolarisation 
and subsequently increase excitability (Smart et al., 2000). However, VR1 channels also 
undergo rapid desensitisation and therefore AEA-mediated activation may in fact induce 
their desensitisation and paradoxically reduce neuronal excitability (Veldhuis et al., 
2003). Indeed, arvanil, a potent CBj and VR1 receptor agonist has neuroprotective 
effects in an animal model of ouabain-mediated excitotoxicity, acting through both CBj 
and VR1 receptors (Veldhuis et al., 2003). Meanwhile, capsazepine, a VR1 receptor 
antagonist, also had direct neuroprotective effects in this model (Veldhuis et al., 2003).
Furthermore, AEA interacts with several ion channels providing a receptor-independent 
mechanism through which endocannabinoids can modulate neuronal function. For
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example, AEA directly inhibits TASK-1, a background potassium channel that is 
involved in setting the neuronal resting membrane potential (Maingret et al., 2001). 
Somatic motoneurons and cerebellar granule neurons express high levels of TASK-1 
and inhibition of this current induces depolarisation and increases neuronal excitability 
(Maingret et al., 2001). AEA can also directly inhibit sodium channels and T-type 
calcium channels, which may reduce neuronal excitability (Chemin et al., 2001; 
Nicholson et al., 2003).
Prior to enzymatic hydrolysis, the arachidonoyl moiety of endocannabinoids is subject 
to oxidation by enzymes of the prostaglandin system, for example, COX-2, and 
lipoxygenases (Kozak et al., 2000; Veldhuis et al., 2003). Interestingly some of these 
oxidative products have activity at molecular targets distinct from the cannabinoid 
receptors. For example, the 15-(S)-hydroxy derivative of 2-AG, formed by 2-AG 
lipoxygenation, can activate peroxisome proliferation activator receptor-a (Kozak et al.,
2002). Furthermore, 12-Hydroxy-N-arachidonoylethanolamine (12-HAEA), an 
oxygenation product of AEA, reduces oedema in a model of excitotoxicity via a CBi 
receptor-independent mechanism, and 15-HAEA actually potentiates the protective 
effects of AEA in this model (Veldhuis et al., 2003). These metabolites may contribute 
to the recognised actions of endocannabinoids.
5.I.5.2. Physiological functions of endocannabinoids
The endocannabinoid system is highly conserved within vertebrates, and is also present 
in invertebrates, indicating the physiological importance of endocannabinoids (De 
Petrocellis et al., 2004). The generation of knock-out mice in which the CBj and CB2 
receptors have been ablated, has enabled a more thorough evaluation of the 
physiological role of endocannabinoids (Ledent et al., 1999; Zimmer et al., 1999;
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Buckley et al., 2000). Cnrl -/- mice are healthy, viable and fertile, however, they show 
an increased rate of spontaneous mortality therefore highlighting the physiological 
importance of the CBi receptor (Zimmer et al., 1999). Furthermore, Cnrl -/- mice 
demonstrate a reduction in locomotor activity, lower analgesic sensitivity and a 
reduction in addictive behaviours (Ledent et al., 1999; Zimmer et al., 1999 Pryce et al.,
2003), suggesting that such behaviours are under the control of the CBi receptors. Cnr2 
-/- mice appear normal and have demonstrated a role for the CB2 receptor in the 
inhibitory action of cannabinoids on T lymphocyte activation (Buckley et al., 2000). 
Limited research has been performed on mice deficient in both CBj and CB2 receptors. 
However, they appear to display no gross defects and are healthy and fertile (Jarai et al., 
1999). The physiological functions of endocannabinoids characterised thus far are 
summarised in Table 5.1.
5.I.5.3. Entourage effects
In vivo and in vitro studies of 2-AG have shown that the action of 2-AG is greatly 
enhanced when it is combined with 2 -linoleoyl-glycerol and 2 -palmitoyl-glycerol, two 
2-acyl-glycerol esters lacking cannabinoid receptor activity. However, when applied in 
combination with 2-AG they enhance the hypomotile, hypothermic and analgesic 
effects of 2-AG in vivo, partially due to the inhibition of 2-AG hydrolysis (Ben-Shabat 
et al., 1998). Lipoxygenase metabolism of AEA generates 12-HAEA and 15-HAEA 
(Veldhuis et al., 2003) and 15-HAEA has been shown to potentiate the actions of AEA 
in an ouabain model of excitotoxicity (Veldhuis et al., 2003). Furthermore, OEA 
competes with AEA for Faah-mediated hydrolysis thus prolonging the actions of AEA 
(Mechoulam et al., 1997).
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Table 5.1 -  A summary of the main physiological functions of endocannabinoids.
Physiological
actions
Endo­
cannabinoid
involved
Functions References
Neuro­
modulation
2-AG Presynaptic inhibition of 
neurotransmitter release via 
CBi receptor activation 
(DSI/DSE)
Kreitzer & Regehr, 2001. 
Maejima et al., 2001 
Ohno-Shosaku et al., 2001 
Wilson & Nicoll, 2002
LTP AEA/2-AG Inhibition of LTP via CBi 
receptor-mediated inhibition 
of glutamate release
Ameri et al., 1999 
Reibaud et al., 1999 
Auclair et al., 2000 
Slanina et al., 2005
Induction of LTP via CBj 
receptor-mediated inhibition 
of GABA release
Wigstrom & Gustafsson, 
1985
Wilson & Nicoll, 2001
Aversive
memories
AEA/2-AG Abolition of memory 
associated fear via CBi 
receptor-mediated inhibition 
of GABA release
Marsicano et al., 2003
Movement AEA Activation of CBj receptors 
in basal ganglia
Herkenham et al., 1991
Hypomotility mediated via 
VR1 receptor activation
Sulcova et al., 1998 
De Lago et al., 2004
Hypermotility mediated via 
TASK-1 channel inhibition
Maingret et al., 2001 
Ledent et al., 1999 
Zimmer etal., 1999
Anti­
nociception
AEA Analgesia via CBi receptor- 
mediated modulation of 
neurotransmission in the 
descending tracts from PAG 
to spinal cord
Walker et al., 1999 
Zimmer et al., 1999 
Cravatt et al., 2001 
Freund et al., 2003
Brain
development
2-AG Axonal guidance or growth 
of developing neurons
Femandez-Ruiz et al., 
2000
Bisogno et al., 2003 
Williams et al., 2003
AEA/2-AG Neurogenesis via CBj 
receptor-mediated ERK 
activation
Femandez-Ruiz et al., 
2000
Jin et al., 2004
AEA/2-AG Developmental elimination 
of climbing fibre synapses
Maejima et al., 2001
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Feeding AEA/2-AG Stimulation of feeding via 
CBi receptor-mediated 
alteration in expression of 
hypothalamic neuropeptides
Williams et al., 1998 
Di Marzo et al., 2001 
Cota et al., 2003 
Ravinet Trillou et al., 
2004
Gamber et al., 2005
AEA/2-AG Stimulation of lipogenesis 
via CBi receptor activation
Cota et al., 2003
Ravinet Trillou et al.,
2004
OEA Satiety via PPARa activation 
and up-regulation of lipid 
metabolism genes
Rodriguez de Fonseca et 
al., 2001 
Fu et al., 2005
Sleep AEA Sleep induction via CBi 
receptor activation
Santucci et al., 1996 
Cravatt et al., 1995 
Mechoulam et al., 1997
Blood
pressure
AEA/2-AG Vasodilation via CBi 
receptor-mediated inhibition 
of NE release
Varga etal., 1995
AEA Vasodilation via VR1 
receptor-mediated release of 
CGRP
Jarai et al., 1999 
Wagner etal., 1999
Inflammation AEA/2-AG Immunosuppression via CB2 
receptor activation
Molina-Holgado et al., 
1997
Buckley et al., 2000 
Baker et al., 2001
PEA Anti-inflammatory action Skaperetal., 1996
Bone density AEA/2-AG Control of bone density via 
CBi receptor-mediated 
stimulation of osteoclast 
formation
Idris et al., 2005
Addiction AEA Susceptibility to addiction 
due to Faah enzyme 
polymorphism
Sipe et al., 2002
Abbreviations: DSI -  depolarisation-induced suppression of inhibition, DSE -
depolarisation-induced suppression of excitation, LTP -  long term potentiation, GABA 
-  gamma amino butyric acid, PAG -  periaqueductal grey matter, PPARa - peroxisome 
proliferator-activated receptor-alpha, NE -  norepinephrine.
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5.1.6. The pathophysiological role of endocannabinoids
There is increasing evidence to suggest that endocannabinoids may contribute to an 
endogenous protective response, initiated under pathological conditions. In the post­
mortem brain of rodents there is a rapid accumulation of both NAPEs and NAEs 
(Hansen et al., 2001a, 2001b; Sugiura et al., 2001). Furthermore, levels of AEA and 2- 
AG are up-regulated following injection of excitotoxins into the CNS of rodents 
(Sugiura et al., 2000; Hansen et al., 2001b; Marsicano et al., 2003), following induction 
of ischaemia (Muthian et al., 2004) and after traumatic brain injury (Panikashvili et al., 
2001; Hansen et al., 2001a). Additionally, as shown in Chapter 4 and also by Witting et 
al, (2004), the levels of AEA and 2-AG are increased in late symptomatic SOD1G93a 
mice, and spastic mice in the CREAE model of MS also have elevated endocannabinoid 
levels (Baker et al., 2001). Therefore, following various pathological stimuli and in 
several models of neurodegenerative disease, endocannabinoid levels are up-regulated. 
This up-regulation may therefore be regarded as an adaptive response aimed at 
counteracting ongoing pathogenesis and exerting a neuroprotective effect.
5.1.7. Hypothesis to be tested
Endocannabinoids levels are elevated in response to various pathological conditions, 
which suggests that they form the basis of an endogenous neuroprotective mechanism. 
Therefore in this study, the effect of elevating endogenous AEA levels was investigated 
in SOD 1093A mice via genetic ablation of the Faah enzyme, which elevates AEA levels 
in the CNS between 10 and 15 fold (Cravatt et al., 2001). Furthermore, to further 
examine the neuroprotective mechanisms exerted by cannabinoids, the contribution of 
the CBi receptor was investigated by genetically ablating the CBi receptor in S0D1G93A 
mice. The therapeutic effect of this genetic manipulation of the endocannabinoid system 
on disease progression and lifespan in SODlG93A mice was examined.
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5.2. METHODS
5.2.1. Breeding and maintenance of transgenic mouse colonies
Transgenic mice carrying a human SOD1 gene with a G93A mutation (TgN[SODl- 
G93A]lGur) were maintained as described in Chapter 2.1a. Individual animals were 
genotyped by PCR using DNA extracted from tail snips for both the expression of the 
human SOD 1093A transgene, as described in Chapter 2.3, as well as for either the 
presence of a disrupted Faah allele or the neo cassette inserted to disrupt the CBj 
receptor gene. The Faah -/- and Cnrl -/- PCR amplifications were undertaken by Mr 
Gareth Pryce in the Department of Inflammation at the Institute of Neurology.
To identify Faah -/- mice the primers used were 5’ 
TAACTAGGCAGTCTGACTCTAG 3’, and 5’ TTTGTCACGTCCTGCACGACG 3’. 
The samples were then temperature sampled as follows: 1 precycle for 2 minutes at 
94°C, and then 35 cycles of 1 minute at 94°C, 1 minute at 50°C and 30 seconds at 72°C. 
The primers used for Cnrl -/- mice were 5’GATCCAGAACATCAGGTAGG 3’ and 5’ 
AAGGAAGGGTGAGAACAGAG 3’. The samples were then temperature cycled as 
follows: 1 precycle for 2 minutes at 94°C and then 30 cycles of 30 seconds at 55°C, 1 
minute at 55°C and 30 seconds at 72°C. The PCR products were visualised by gel 
electrophoresis by running 20pl of each PCR product on a 2% agarose gel at 130mV for 
40 minutes.
The mice lacking the fatty acid amide hydrolase gene {Faah -/-) and mice lacking the 
CBi receptor gene {Cnrl -/-) were obtained from Professor David Baker, Institute of 
Neurology, for use in this project (originally donated by Dr. B. Cravatt, La Jolla, CA 
and Dr. C. Ledent, Brussels, Belgium, respectively). The generation of Faah -/- and 
Cnrl -/- mice has been previously described in detail by Cravatt et al, (2001) and
335
Ledent et al, (1999) respectively. Briefly, Faah -/- mice were generated by insertion of a 
PGK-Neo cassette (consisting of a phosphoglycerate kinase promoter driving the 
neomycin phosphotransferase gene) between iscoRI and EcoRV  sites located 2.3kb 
apart, replacing the first FAAH exon (encoding amino acids 1-65) and approximately 
2kb of upstream sequence. For the generation of the Cnrl -/- mice, a PGK-Neo cassette 
was inserted between Avrll and Sfil sites located 1073 base pairs apart on the single 
coding exon, replacing the first 233 codons of the gene.
Faah -/- and Cnrl -/- mice were backcrossed for at least seven generations onto the 
ABH mouse background to minimise genetic heterogeneity. SQDX.Faah +/- and 
SOD1 .Cnrl +/- mice were obtained by breeding male heterozygous SOD 1093A carriers 
with female Faah or CBi receptor knock-out mice (Fi generation). Male heterozygous 
carriers for both genes were backcrossed again with female Faah or CBi receptor 
knock-outs to obtain a F2 generation of SOD1 .Faah -/- and SO D l.C nrl -/- mice for use 
in this study. For these breeding experiments we also crossed the control SODlG93A 
mice onto the ABH background of the ABH .Faah -/- and ABH. Cm*/ -/- mice. Male Fi 
generation ABH. SOD 1093A mice were then backcrossed with female ABH mice to 
generate an F2 generation of ABH.SOD1G93a mice. Therefore in these experiments 
described here, all mice were from an F2 generation irrespective of genotype.
5.2.2. Experimental groups
To examine the effect of Faah or CBi receptor ablation on the disease progression in 
SOD1G93a mice, animals were divided into two experimental groups to study disease 
progression, by analysis of either:
a) hindlimb muscle function and motoneuron survival at 90 days of age, as described in 
Chapters 2.10.1 -  2.10.5., or
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b) lifespan of the SOD 1093A mice.
In this study, disease progression was assessed at an early symptomatic stage of disease, 
at 90 days of age, which enabled us to observe any positive or negative effects of Faah 
or CBj receptor ablation on disease progression.
5.2.3. Assessment of body weight
As a measure of disease progression, in this study a record of body weight of each 
animal was kept from 70 days of age. Each animal was weighed twice a week and a 
weekly average was taken to monitor the loss of body weight over time. At the onset of 
body weight decline, mice were weighed on a daily basis.
5.2.4. Spinal cord immunocytochemistry
Cross sections of spinal cord were immunostained with primary antibodies to GFAP 
(1:100; Chemicon) according to the protocol detailed in Chapter 2.8.
5.2.5. Lifespan analysis
The lifespan or disease end-point, of ABH.SODlG93A (F2 generation) mice was 
determined as the number of days the animals lived for before reaching an end-point 
that met Home Office guidelines, namely when the animal:
a) had lost > 20% of its maximal body weight
b) was unable to perform the righting reflex in less than 30 seconds.
The effect of Faah or CBi receptor ablation on the lifespan of S0D1G93A mice was 
assessed under the same criteria, and the animals were culled when they reached this 
end-point, and lifespan recorded.
337
5.2.6. Statistical analysis
Statistical significance between the experimental groups was assessed by one-way 
analysis of variance (ANOVA) incorporating a Student Neuman Keuls multiple 
comparisons test. Values are expressed as mean ± standard error of the mean (S.E.M.). 
Significance was set at p < 0.05.
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5.3. RESULTS
In this Chapter, the effects of raising the levels of the endocannabinoid, AEA, in 
SOD1G93a mice were assessed by breeding SOD1G93a mice with mice lacking the fatty 
acid amide hydrolase enzyme {Faah Faah is normally responsible for the hydrolysis 
of AEA, and in Faah -/- mice, brain AEA levels are elevated between 10 and 15 fold 
(Cravatt et al., 2001). In addition in a separate set of experiments, to further elucidate 
the neuroprotective mechanism of action of endogenous and exogenous cannabinoids 
on disease progression in S0D1G93A mice, we bred S0D1G93A mice with mice lacking 
the CBi receptor gene {Cnrl
For these breeding experiments we crossed the control S0D1G93A mice onto the ABH 
background of the ABH .Faah -/- and ABH .Cnrl -/- mice. Disease progression, 
including muscle function and motoneuron survival, in SOD1 .Faah -/- and SODl.CwT 
-/- mice was assessed at an early symptomatic stage of disease, at 90 days of age, rather 
than a late stage of disease, to enable us to observe any positive or negative effects of 
Faah or CBi receptor ablation on disease progression. The SODl.Faah -/- and 
SODl.Cnrl -/- mice used in this study were all F2 generation offspring and were 
therefore compared to F2 generation ABH.SOD1G93a (ABH.SOD1) and ABH.WT mice. 
However, the data acquired from in vivo physiological assessment of both Fi and F2 
generation ABH.SOD 1 or ABH.WT mice revealed that there were no significant 
differences between generations and this data was therefore pooled.
5.3.1. Assessment of body weight decline in SOD1G93a mice
SOD 1093A mice, in which either the Faah enzyme or the CBj receptor had been ablated, 
were monitored on a daily basis and their body weight was measured regularly to assess 
the progression of disease.
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The body weight of the SOD 1093A mice bred onto the ABH background was recorded 
weekly from 70 days of age until disease end-point and the data is summarised in 
Figure 5.3. Body weight measurements were expressed as a percentage of the maximal 
body weight for each individual mouse, the maximal weight being recorded between 85 
and 91 days of age (13 weeks) in the control ABH.SOD 1 mice. The onset of body 
weight loss in the ABH.SOD1 mice (n = 5) occurred between 105 and 111 days of age 
(15 weeks) and by 119 -  125 days (17 weeks) body weight had declined by 
approximately 20%. From Figure 5.3. it can be seen that ablation of the Faah enzyme 
had no effect on the rate of decline in body weight. Therefore, in SOD1 .Faah -/- mice 
(n = 8) the onset of body weight loss occurred between 105 and 111 days of age (15 
weeks) and the rate of weight loss was rapid, similar to ABH.SOD 1 mice, with 
approximately 20% of body weight being lost by 119 -  125 days of age (17 weeks). 
However, ablation of the CBi receptor (n = 8) significantly delayed the loss in body 
weight that occurred in ABH.SOD 1 mice with disease progression. Therefore, a 
significant reduction in body weight did not occur in SOD\.Cnrl -/- mice until 119 — 
125 days of age (17 weeks) and body weight did not decline by > 20% until 147 -  153 
days of age (21 weeks). In fact, from 112 days of age onwards, the body weight of 
SODl.C«r7 -/- was significantly greater than in SOD1 .Faah -/- mice (p < 0.025).
5.3.2. Hindlimb muscle function in SO D lG93A mice at 90 days of age
The effect of genetically ablating either the Faah enzyme or the CBj receptor in 
SOD1G93a mice on the ABH background was assessed on hindlimb muscle function at 
90 days of age, an early symptomatic stage of disease.
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Figure 5.3 - The effect of Faah and CBj receptor ablation on the decline in body
weight of ABH.SOD1 mice
The body weight of ABH.SOD1, SOD1 .Faah -/- and SOD1.Cnrl -/- mice was recorded 
weekly from 70 days of age (10 weeks) until disease end-point, as shown in the graph. 
Body weight was expressed as a percentage of the maximal body weight of each 
individual animal. As a consequence of disease progression, the body weight of 
ABH.SOD1 mice (n = 5) declined from 105 days of age (15 weeks) onwards. Genetic 
ablation of the Faah enzyme had no significant effect on the decline in body weight of 
SOD 1093A mice (n = 8). In contrast ablation of the CBi receptor significantly delayed 
the loss of body weight observed in SOD1G93a mice (n = 8). Values are the mean body 
weight at each age ± standard error of the mean. * p < 0.05.
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5.3.2.1. Isometric tension recordings
Twitch and tetanic contractions of TA and EDL muscles in both hindlimbs of ABH.WT, 
ABH.SOD1, SODX.Faah -/- and SODl.C«r7 -/- mice, were recorded at 90 days of age. 
All forces were expressed per 1 OOmg muscle weight to take into account any reduction 
in muscle weight in 90 day old SOD 1093A mice.
i) Twitch force
At this early symptomatic stage of disease the hindlimb muscles of ABH.SOD 1 mice 
were already significantly affected compared to their ABH.WT littermates. In 90 day 
old ABH.WT mice the mean TA twitch tension was 76.29g (± 4.2 S.E.M. per lOOmg 
TA muscle; n = 16), as shown in Figure 5.4. In contrast in ABH.SOD1 mice, TA 
generated only 26.05g (± 2.6 S.E.M. per lOOmg TA muscle; n = 18; p < 0.001) of twitch 
force, a reduction of 65.9% compared to the WT control. In contrast, the twitch force of 
TA muscles from SOD1 .Faah -/- mice was less affected. Thus in SOD1 .Faah -/- mice 
at 90 days of age, TA generated 62.63g (± 3.9 S.E.M. per lOOmg TA muscle; n = 9; p < 
0.02) of twitch force, representing a reduction of only 17.8%. However, the twitch 
tension of TA muscles from SOD1 .Cnrl -/- mice at 90 days of age was very similar to 
that in ABH.SOD1 mice, generating only 33.Og (± 4.3 S.E.M. per lOOmg TA muscle; n 
= 10) of force, a reduction of 56.7% compared to ABH.WT (p < 0.001).
ii) Maximal tetanic tension
The maximal tetanic tension (MTT) of TA and EDL muscles from ABH.SOD1 mice at 
90 days of age was significantly reduced (p < 0.005) compared to ABH.WT mice, as 
shown in Figures 5.5 and 5.6 respectively. Thus by 90 days of age, the MTT of TA 
muscles from ABH.WT mice was 286.8g (± 11.7 S.E.M. per lOOmg TA muscle; n = 
16), compared to 118.4g (± 12.8 S.E.M. per lOOmg TA muscle; n = 16) in ABH.SOD 1
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Figure 5.4 -  The twitch tension of TA muscles from ABH.WT, ABH.SOD1, 
SOD1 .Faah -/- and S O D l.O ir/ -/- mice at 90 days of age
The maximal twitch tension of TA muscles was elicited by stimulation of the sciatic 
nerve by a single square pulse of 0.02ms duration at a supramaximal voltage. The mean 
twitch tension of TA muscles from ABH.WT (n = 16), ABH.SOD1 (n = 18), 
SOD1 .Faah -/- (n = 9) and SODl.Cwi -/- mice (n = 10) are summarised in the bar 
chart. Force was expressed per lOOmg muscle weight to take into account the reduction 
in muscle weight in 90 day old ABH.SOD1 mice. At 90 days of age, the twitch tension 
of TA muscles from ABH. SOD 1 mice was substantially reduced compared to ABH.WT 
TA muscles. However, the reduction in twitch force in SOD1 .Faah -/- mice was 
significantly less than in ABH.SOD 1 mice. Ablation of the CBi receptor, however, had 
no significant effect on the reduction in twitch tension in SOD1G93a mice by 90 days of 
age. g = grams. Values represent the mean response ± standard error of the mean.
* p < 0.05, *** p < 0.005 .
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Figure 5.5 -  Maximal tetanic force of TA muscles from ABH.WT, ABH.SOD1, 
SOD\.Faah -/- and SODl.CWrf -/- mice at 90 days of age
Maximal tetanic tension (MTT) of TA muscles was elicited by increasing the frequency 
of stimulation of the sciatic nerve (40, 80 and 100Hz). The bar chart summarises the 
MTT of TA muscles from ABH.WT (n = 16), ABH.SOD1 (n = 16), SOD1 .Faah -/- (n = 
9) and SOD1 .Cnrl -/- (n = 9) mice at 90 days of age. Force was expressed per lOOmg 
muscle weight to take into account the reduction in muscle weight in 90 day old 
ABH.SOD 1 mice. As a consequence of disease progression the MTT of TA muscles 
from ABH.SOD1 mice was significantly less than in ABH.WT littermates at 90 days of 
age. However, ablation of the Faah enzyme in SODlG93A mice preserved the MTT of 
TA muscles at this early disease stage. In contrast, ablation of the CBi receptor did not 
prevent the reduction in the MTT of TA muscles and a significant reduction in the MTT 
of SODl.Cwi -/- TA muscles was seen compared to ABH.WT littermates at 90 days of 
age. g = grams. Values are the mean MTT of TA muscles ± standard error of the mean. 
* * * p <  0.005.
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Figure 5.6 -  The effect of genetic ablation of either the Faah enzyme or the CBi 
receptor on the maximal tetanic tension of EDL muscles from ABH.SOD1 mice
Maximal tetanic tension (MTT) of EDL muscles was elicited by increasing the 
frequency of stimulation of the sciatic nerve (40, 80 and 100Hz). The MTT of 
ABH.WT (n = 16), ABH.SOD1 (n = 16), SOD1 .Faah -/- (n = 9) and SOD1 .Cnrl -/- (n 
= 9) mice is summarised in the bar chart. Force was expressed per lOOmg muscle 
weight to take into account the reduction in muscle weight in 90 day old ABH.SOD1 
mice. The MTT of EDL muscles from ABH.SOD1 mice was significantly reduced at 90 
days of age compared to EDL muscles from ABH.WT mice. Ablation of the Faah 
enzyme in SOD1G93a mice preserved the MTT of EDL muscles at this stage of disease. 
In contrast, ablation of the CBi receptor did not prevent the reduction in EDL force in 
ABH.SOD1 mice and in SOD1 .Cnrl -/- the MTT of EDL muscles was significantly 
lower than in ABH.WT mice, g = grams. Values are the mean MTT of EDL muscles ± 
standard error of the mean. * p < 0.05, *** p < 0.005.
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mice, a reduction in maximal force of 58.7%. EDL muscles of 90 day old ABH.SOD1 
mice were less affected than TA muscles, as observed in Chapter 4.3.3. in 120 day old 
SOD1G93a mice. Whereas EDL muscles in ABH.WT mice generated 300.4g (± 16.9 
S.E.M. per lOOmg EDL muscle; n = 16) of force, this was reduced to 213.6g (± 16.9 
S.E.M. per lOOmg EDL muscle; n = 16; p < 0.005) in EDL muscles from ABH.SOD1 
mice at 90 days of age, a reduction of 28.9%.
Surprisingly, the MTT of both TA and EDL muscles from SOD1 .Faah -/- mice was not 
significantly different from ABH.WT mice at 90 days of age (p > 0.1). Thus the MTT of 
TA muscles from SOD1 .Faah -/- mice was 244.8g (± 11.1 S.E.M. per lOOmg TA 
muscle; n = 9) and that of EDL muscles was 292.4g (± 15.6 S.E.M. per lOOmg EDL 
muscle; n = 9), a reduction of only 14.6% and 2.7% compared to TA and EDL muscles 
from ABH.WT mice respectively. Thus at this stage, EDL muscles in SOD l.EWz -/- 
mice were as strong as EDL muscles in ABH.WT mice. Muscle force in SOD1 .Cnrl -/- 
mice, however, was significantly reduced at 90 days of age. The MTT of TA muscles 
from SODl.Ozr/ -/- mice was only 40.6% of that in ABH.WT mice, generating only 
113.4g (± 9.4 S.E.M. per lOOmg TA muscle; n = 9; p <0.005) of force. Similarly, EDL 
muscles were significantly weaker with an MTT of 179.7g (± 14.3 S.E.M. per lOOmg 
EDL muscle; n = 9; p < 0.005), a reduction of 40.2% compared to EDL muscles in 
ABH.WT mice. Interestingly, the MTT of SOD.Ozr/ -/- hindlimb muscles did not 
differ significantly from muscles in ABH.SOD1 mice (p > 0.1), suggesting that ablation 
of the CBi receptor had no effect on the progression of hindlimb paralysis. In contrast, 
ablation of the Faah enzyme completely delayed the decline in muscle function and 
indeed the muscle force of SODl.Faah  -/- mice was indistinguishable from ABH.WT, 
suggesting that elevation of endocannabinoid levels exerted significant beneficial 
effects at this early stage of disease.
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5.3.3. Motor unit survival
The number of functional motor units in each experimental group was assessed at 90 
days of age. Figure 5.7 shows representative traces from (A) ABH.WT, (B) 
ABH.SOD1, (C) SOD1 .Faah -/- and (D) SOD1 .Cnrl -/- mice, and the mean number of 
surviving motor units are summarised in the bar chart (E). At 90 days of age ABH.WT 
mice had, on average, 31 motor units (± 0.9 S.E.M.; n = 16) compared to only 21 (± 1.2 
S.E.M.; n = 19; p < 0.005) in ABH.SOD1 mice. Ablation of the Faah enzyme resulted 
in a significant increase in survival of motor units in S0D1G93A mice, so that 27 (± 1.5 
S.E.M.; n = 10) motor units survived, a value not significantly different from the 
ABH.WT mice (p > 0.1). However, in SODlG93A mice in which the CBi receptor had 
been ablated, a significant number of motor units were already lost by 90 days of age. 
Thus EDL muscles from SODl.CwrZ -/- mice had only 19 (± 1.4 S.E.M.; n = 10) 
functional motor units, which was significantly less than the number of motor units in 
EDL muscles of ABH.WT mice (p < 0.005).
5.3.4. Muscle fatigue characteristics
Repeated stimulation of the nerve innervating the EDL muscle produces a fatigue trace 
as shown in Figure 5.8 for (A) ABH.WT, (B) ABH.SOD1, (C) SOD1 .Faah -/- and (D) 
SODl.Cwr/ -/- EDL muscles. The bar chart, shown in Figure 5.9, summarises the 
fatigue index (F.I.), which gives a measure of the fatigability of the EDL muscles. EDL 
muscles are normally fast muscles that fatigue rapidly when subjected to repeated 
stimulation (Figure 5.8A) and in this study ABH.WT EDL muscles had a F.I. of 0.62 (± 
0.02 S.E.M.; n = 16). In contrast, the EDL muscles from ABH.SOD1 mice at 90 days of 
age, an early symptomatic age, were largely fatigue resistant (Figure 5.8B) and had a 
F.I. value of 0.33 (± 0.05 S.E.M.; n = 18; p = 0.005), indicating that significant changes
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Figure 5.7 -  The number of motor units in EDL muscles of ABH.WT, ABH.SOD1, 
SODl.Faah -/- and SODl.Cnrl -/- mice at 90 days of age
Stimulation of the sciatic nerve with increasing intensity produced stepwise increments 
in twitch tension of EDL muscles that corresponded to the successive recruitment of 
motor axons. Representative motor unit traces from EDL muscles from (A) ABH.WT (n 
= 16), (B) ABH.SOD1 (n = 19), (C) SOD1 .Faah -/- (n = 10) and (D) SO D l.C nrl -/- (n 
= 10) mice are shown. The number of functional motor units was determined by 
counting the number of increments in twitch tension and the mean values are 
summarised in the bar chart (E). Horizontal scale bar =10 milliseconds. Vertical scale 
bars = 1 gram, g = grams. Values shown are the mean ± standard error of the mean. *** 
p < 0.005.
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Figure 5.8 -  Fatigue traces from ABH.WT, ABH.SOD1, SOD1 .Faah -/- and 
SOD1.C nrl -/- mice at 90 days of age
Repeated stimulation of the EDL muscle over a 3 minute period elicited a fatigue trace. 
Representative examples of fatigue traces from (A) ABH.WT, (B) ABH.SOD1, (C) 
SOD1.Faah -I- and (D) SODl.C/zr7 -/- mice at 90 days of age are shown. In WT mice, 
the EDL is a fast fatigable muscle. However as a consequence of disease progression, 
EDL muscles from ABH.SOD1 mice became fatigue resistant with no significant 
reduction in tetanic force over the duration of stimulation. This change in the fatigue 
pattern of EDL muscles from ABH.SOD1 mice did not occur to the same extent in EDL 
muscles from SOD1 .Faah -/- mice. However, ablation of the CBi receptor had no effect 
on the contractile characteristics and EDL muscles from SODl.Cwr/ -/- mice showed a 
fatigue trace equivalent to EDL muscles from ABH.SOD1 mice at 90 days of age. The 
scale of force is not indicated as the size of the initial tetanic recording was adjusted to 
maximally occupy the trace paper, to allow changes in contraction with time to be more 
easily visible.
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Figure 5.9 -  Fatigue index of EDL muscles from ABH.WT, ABH.SOD1, 
SODl.Faah -/- and SOD1.Cnrl -/- mice at 90 days of age
A fatigue index (F.I.) is a measure of the fatigability of a muscle. Repeated stimulation 
of EDL muscles over a 3 minute period elicited a fatigue trace (as shown in Figure 5.8). 
The decline in force over this period of time can be quantified by expressing the final 
force as a fraction of the initial tetanic tension of the muscle. Normally WT EDL 
muscles are fast fatigable muscles with an F.I. approaching 1.0, whereas fatigue 
resistant muscles have an F.I. approaching 0. By 90 days of age the EDL muscles from 
ABH.SOD1 mice had already undergone a phenotypic change as a consequence of 
disease progression and were largely fatigue resistant, as can be seen by the significant 
reduction in F.I. compared to ABH.WT EDL muscles. Ablation of the Faah enzyme 
lessened this reduction in F.I. in ABH.SOD1 EDL muscles, whereas ablation of the CBi 
receptor had no effect on the deleterious changes in contractile characteristics that 
occurred in EDL muscles from ABH.SOD1 mice at 90 days of age. Values are the mean 
± standard error of the mean. * p < 0.005, *** p < 0.005.
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in the contractile characteristics of hindlimb muscles had already occurred at this early 
stage of disease. However, the fatigue pattern of EDL muscles from SOD 1093A mice in 
which the Faah enzyme has been ablated resembled that of ABH.WT EDL muscles 
(Figure 5.8C), and had a F.I. of 0.43 (± 0.07 S.E.M.; n = 10), which was not 
significantly different from that of the WT EDL muscle (p > 0.05). In contrast, EDL 
muscles from SOD1G93a mice in which the CBi receptor had been ablated (Figure 
5.8D), showed significant fatigue resistance in response to repeated stimulation 
compared to EDL muscles from ABH.WT mice (p = 0.015), with a F.I. of 0.31 (± 0.07 
S.E.M.; n = 10), which was not significantly different from that of EDL muscles in 
ABH.SOD1 mice (p > 0.7). This observation suggested that ablation of the CBi receptor 
did not prevent the alterations in contractile characteristics that occur in SODlG93A mice 
as a consequence of disease progression. However, elevation of endocannabinoid levels 
by ablation of Faah, appeared to delay these deleterious changes in hindlimb contractile 
characteristics.
5.3.5. Muscle histochemistry
Histochemical staining of EDL muscle sections for SDH activity, an indicator of 
oxidative capacity, revealed patterns of staining as shown in Figure 5.10, which are 
consistent with the changes in contractile characteristics of EDL muscles described 
above. SDH staining of EDL muscle sections from ABH.WT mice (Figure 5.10A) 
revealed a mosaic pattern of lightly and darkly stained muscles fibres, with the majority 
of fibres staining lightly for SDH, indicating a low oxidative capacity. In contrast, a 
greater proportion of EDL muscle fibres from 90 day old ABH.SOD1 mice (Figure 
5.10B) stained more intensely for SDH. However, the pattern of SDH staining in EDL 
muscle fibres from SOD1 .Faah -/- mice (Figure 5.10C) resembled that of EDL muscles 
from ABH.WT mice, with the majority of fibres lightly stained. In contrast, ablation of
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Figure 5.10 -  SDH staining of EDL muscle sections from ABH.WT, ABH.SOD1, 
SOD1.Faah -/- and SODl.Cnrl -/- mice
EDL muscles from (A) ABH.WT, (B) ABH.SOD1, (C) SOD1.Faah -/- and (D) 
SOD1 .Cnrl -/- mice were cut on a cryostat and stained for SDH activity, an indicator 
of oxidative capacity. ABH.WT EDL muscles showed a mosaic pattern of SDH activity, 
with the majority of fibres staining lightly for SDH. In EDL muscles from ABH.SOD1 
mice, a greater proportion of muscle fibres were intensely stained for SDH, reflecting an 
increased oxidative capacity. Ablation of the Faah enzyme largely prevented this change 
in muscle fibre phenotype so that EDL muscles from 90 day old SOD1 .Faah -/- mice 
showed a pattern of SDH staining that was more characteristic of EDL muscles from 
WT mice, with a greater proportion of fibres lightly stained. In contrast, ablation of the 
CBi receptor had no significant effect on the oxidative capacity of EDL muscle fibres at 
90 days of age and the pattern of SDH staining in EDL muscle sections from 
SODl.C«r7 - / -  mice resembled that seen in ABH.SOD1 EDL muscle sections. Scale 
bar = 200pm.
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the CBi receptor had no effect on the oxidative capacity of the EDL muscle fibres and 
the pattern of SDH staining in SOD1 .Cnrl -/- mice (Figure 5.10D) resembled that of 
ABH.SOD1 EDL muscles fibres at 90 days of age, indicating increased oxidative 
capacity compared to muscles from ABH.WT mice.
5.3.6. Motoneuron survival
Motoneuron survival was assessed morphologically by counting the number of Nissl- 
stained motoneurons in a section of the sciatic motor pool in the lumbar spinal cord. 
Figure 5.11 shows examples of Nissl-stained motoneurons in spinal cord sections from 
(A) ABH.WT, (B) ABH.SOD1, (C) SOD1 .Faah -/- and (D) SODl.OW -/- mice. 
Figure 5.1 IE summarises the mean motoneuron survival for each genotype. It can be 
seen that significant motoneuron death had already occurred by 90 days of age in 
SOD1g93a mice. Only 245 (± 13.6 S.E.M.; n = 20) motoneurons survived in 
ABH.SOD1 mice compared to 358 (± 13.8 S.E.M.; n = 10) in their ABH.WT littermates 
(p < 0.001), a reduction of 32%. In the SOD1 .Faah -/- mice, however, genetic elevation 
of endocannabinoid levels delayed motoneuron loss at this stage of disease and 305 (± 
18.1 S.E.M.; n = 10) motoneurons survived, a reduction of only 14.8% compared to the 
ABH.WT mice (p = 0.04). However, in SOD LOW  -/- mice the absence of the CBi 
receptor did not affect motoneuron survival in SODlG93A mice and at 90 days only 217 
(± 12.8 S.E.M.; n = 10) motoneurons survived, which represents a reduction of 39.4%, 
compared to ABH.WT mice (p < 0.001).
In addition, the number of motoneurons surviving in the sciatic motor pool at the end- 
stage of disease in S0D1G93A mice on the ABH background was also assessed, and the 
results are summarised in Figure 5.12. In ABH.SOD1 mice, only 145 (± 8.2 S.E.M.; n 
= 6) motoneurons survived at disease end-stage. In S0D1G93A mice in which the Faah
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Figure 5.11 -  Sciatic motoneuron survival in ABH.WT, ABH.SOD1, SOD1 .Faah - 
/- and SODl.Otrf -/- mice at 90 days of age
Motoneuron survival at 90 days of age was assessed by counting the number of Nissl 
stained motoneurons in the sciatic motor pool (dotted areas) of (A) ABH.WT, (B) 
ABH.SOD1, (C) SOD1.Faah -/- and (D) SODl.CwT -/- mice at 90 days of age. The 
mean motoneuron survival is summarised in the bar chart (E). At 90 days of age, 
ABH.SOD1 mice (n = 20) had lost a significant proportion of their sciatic motoneurons 
compared with ABH.WT mice (n = 10). However, ablation of the Faah enzyme exerted 
neuroprotective effects and significantly more motoneurons survived in SOD1 .Faah -/- 
mice (n = 10) than in the ABH.SOD1 mice at 90 days of age. In contrast, ablation of the 
CBj receptor did not affect motoneuron survival in SOD 1093A mice (n = 10) and the 
number of motoneurons surviving in SODl.Oir/ -/- mice was not substantially 
different to ABH.SOD1 mice. Values are the mean ± standard error of the mean. Scale 
bar = 100pm. * p < 0.05, *** p < 0.005.
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Figure 5.12 -  Motoneuron survival in end-stage ABH.SOD1, SOD\.Faa1i -/- and 
SODl.Cnrl -/- mice
Motoneuron survival was assessed by counting the number of Nissl-stained 
motoneurons in the sciatic pool of ABH.SOD1, SOD1 .Faah -/- and SOD1.Cnrl-/- mice 
at the disease end-stage. It can be seen that ablation of either the Faah enzyme or CBi 
receptor had no effect on the number of sciatic motoneurons surviving at the end-stage 
of disease. Values are the mean ± standard error of the mean.
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enzyme had been ablated, there was no significant difference in the number of 
motoneurons surviving at disease end-stage and 136 (± 9.8 S.E.M.; n = 12) 
motoneurons survived (p > 0.7). Similarly, 135 (± 3.3 S.E.M.; n = 6) motoneurons 
survived in SOD1 .Cnrl -/- at end stage, which was not significantly different from that 
of ABH.SOD1 mice (p > 0.7).
5.3.7. Spinal cord immunocytochemistry
Spinal cord sections from (A) ABH.WT, (B) ABH.SOD1, (C) SOD1 .Faah -/- and (D) 
SODCnr l  -/- mice were stained for Glial Fibrillary Acidic Protein (GFAP), a marker 
of astrogliosis, as shown in Figure 5.13. GFAP is a measure of astrogliosis and its 
expression can therefore be used as an indicator of disease progression. At 90 days of 
age, there was a significant increase in GFAP immunoreactivity in the spinal cords of 
ABH.SOD1 mice compared to ABH.WT mice. However, in SOD1 .Faah -/- spinal 
cords, there was substantially less GFAP immunoreactivity, and therefore astrogliosis, 
at this stage of disease. In contrast, in the spinal cords of SOD\.Cnrl -/- mice, GFAP 
immunoreactivity appeared significantly elevated compared to spinal cords of ABH.WT 
mice.
5.3.8. The effect of Faah or CBi receptor ablation on the lifespan of ABH.SOD1 
mice
We next examined the effect of genetic manipulation of the endocannabinoid system on 
the lifespan of the S0D1G93A mice, and the results are summarised in Figure 5.14. In 
these experiments, S0D1G93A mice were bred onto the ABH background of the Faah -/- 
and Cnrl -/- mice and F2 generation animals were used in all experiments. In this 
colony the lifespan of the F2 generation ABH.SOD1 mice was reduced compared to that 
of SOD1G93a mice bred onto the traditional (C57BL/6 x SJL) Fj background. Thus, the
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Figure 5.13 -  The expression of GFAP in the spinal cords of ABH.WT,
ABH.SOD1, SOD1 .Faah -/- and SOD1 .Cnrl -/- mice
The photomicrographs show examples of cross sections of the lumbar spinal cord 
immunostained for GFAP, a marker of astrogliosis, and counterstained for Nissl, from 
(A) ABH.WT, (B) ABH.SOD1, (C) SOD1 .Faah -/- and (D) SODl.CwT -/- mice at 90 
days of age. It can be seen that there was a significant increase in GFAP 
immunoreactivity in the ventral horn of ABH.SOD1 mice compared to ABH.WT at 90 
days of age. However, GFAP immunoreactivity was significantly lower in the 
SOD1 .Faah -/- mice. In contrast, astrogliosis in SOD Cnrl -/- mice at 90 days of age 
resembled that in ABH.SOD1 spinal cord and was significantly increased compared to 
ABH.WT. Scale bar = 200pm.
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Figure 5.14 -  The effect of genetic manipulation of the endocannabinoid system on
the lifespan of ABH.SOD1 mice
The lifespan of SOD1 .Faah -/- and SODl. Cnrl -/- mice was recorded to determine 
whether genetic manipulation of the endocannabinoid system had any significant effects 
on the lifespan of ABH.SOD1 mice. The lifespan of F2 generation S0D1G93A mice bred 
onto the ABH background of the Faah -/- and Cnrl -/- mice was significantly less than 
SOD 1093A mice on the (C57BL/6 x SJL) Fi background (p = 0.01). Lifespan in this 
study was determined as the age when mice have lost > 20% of their body weight or 
when they can no longer right themselves within 30 seconds of being placed on their 
sides. Despite the significant amelioration of disease signs at 90 days of age achieved 
with ablation of the Faah enzyme, this was not reflected by an extension in lifespan of 
the SODl.Faah -/- mice (p = 0.4). In contrast, despite there being no significant 
improvements in disease signs at 90 days of age, SODl.Cnrl -/- mice had a 
significantly extended lifespan compared to ABH.SODl mice (p = 0.03). The value at 
each time point represents the mean survival of each group of experimental mice.
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F2 generation of ABH.SOD1G93a mice lived for 118 days (± 4.2 S.E.M.; n = 5) 
compared to 131 days (± 1.4 S.E.M.; n = 23) for SODlG93A mice on the (C57BL/6 x 
SJL) Fj background (p = 0.011). Surprisingly, despite the dramatic improvement in 
disease signs observed at 90 days of age in SODX.Faah -/- mice, ablation of the Faah 
enzyme had no significant effect on lifespan (p = 0.4) and SODl .Faah -/- animals lived 
on average for 114 days (± 1.5 S.E.M.; n = 12). Conversely, although we observed no 
difference in disease signs between ABH.SODl and SODl .Cnrl -/- at 90 days of age, 
ablation of the CBi receptor significantly increased lifespan and SODl .Cwr7 -/- mice 
lived for 133 days (± 5.9 S.E.M; n = 8; p = 0.03).
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5.4. DISCUSSION
The results presented in this Chapter show that genetic augmentation of endogenous 
levels of AEA, via ablation of the Faah enzyme, almost completely ameliorated disease 
signs in 90 day old SOD1G93a mice. However, the dramatic reduction in disease 
progression observed in SODl093A mice following genetic enhancement of the 
cannabinoid system, were not reflected in an increased lifespan. Interestingly, ablation 
of the CBi receptor had neither a positive or negative effect on disease progression in 
SODlG93A mice. However, in contrast to SODl .Faah -/- mice, in which AEA levels 
were augmented, or to SOD1G93a mice treated with WIN55,212-2, ablation of the CBi 
receptor significantly extended the lifespan of S0D1G93A mice.
Under various pathological conditions, such as excitotoxicity, inflammation and brain 
trauma, the synthesis of endocannabinoids is up-regulated in the CNS (Sugiura et al., 
2000; Baker et al., 2001; Hansen et al., 2001b ; Panikashvili et al., 2001; Marsicano et 
al., 2003; Muthian et al., 2004). This up-regulation may therefore constitute an 
endogenous protective mechanism that can be activated in response to a variety of 
pathological stimuli. The results presented in Chapter 4 (see Figure 4.1) show that 
both AEA and 2-AG, the two most widely studied endocannabinoids, are up-regulated 
in the spinal cords of symptomatic S0D1G93A mice. A similar pattern of 
endocannabinoid elevation has also been reported by Witting et al, (2004). Although, 
the pathogenic mechanisms underlying ALS are still far from understood there is 
substantial evidence that indicates that glutamate excitotoxicity, inflammation and 
oxidative stress are all involved (reviewed by Bruijn et al., 2004). The elevation in 
endocannabinoid levels observed in the spinal cord of the S0D1G93A mice may therefore 
be regarded as an adaptive response aimed at counteracting the pathological processes 
underlying ALS. However, this protective endogenous response is clearly not sufficient
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to counteract these pathological mechanisms in the long-term. Nevertheless, the results 
of this study show that genetic elevation of AEA levels, and therefore enhancement of 
the endocannabinoid-mediated protective response is neuroprotective, particularly in the 
early stages of disease and indicate that augmentation of this response may have 
therapeutic potential.
5.4.1. The effects of genetically manipulating the cannabinoid system on hindlimb 
muscle force
At 90 days of age, the MTT of both TA and EDL muscles are significantly reduced in 
ABH.SOD1 mice compared to the hindlimb muscles of ABH.WT littermates. Similar to 
results in SOD1G93a mice on the C57BL/6 x SJL Fi background, TA muscles from 
ABH.SOD1 mice are significantly more affected than EDL muscles even at this early 
stage of disease. Sharp et al, (2005) also reported a greater deficit in TA muscles than 
EDL muscles at 90 days of age in SODlG93A mice on the C57BL/6 x SJL Fi 
background. Therefore the MTT of TA and EDL muscles from ABH.SOD1 mice is 
only 41.3% and 71.1% of the MTT of these muscles in ABH.WT mice respectively.
Elevation of AEA levels, as a consequence of ablation of the Faah enzyme, prevents the 
loss in muscle force that occurs in SODlG93A mice during disease progression. Indeed, 
the TA and EDL muscles in SODFaah  -/- mice are as strong as the respective muscles 
in ABH.WT mice. Therefore, augmenting the increase in endogenous endocannabinoid 
levels that occurs in SOD 1093A mice during disease progression, by ablation of the Faah 
enzyme, prevents any loss in muscle force at an early stage of disease.
In contrast, ablation of the CBi receptor has no effect on the maximal hindlimb muscle 
force of SOD1G93a mice. The MTT of TA and EDL muscles in SOD1.Cnr/ -/- mice is
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similar to that in ABH.SOD1 mice, so that these muscles are significantly weaker than 
in their ABH.WT littermates. This result suggests that the beneficial effects of 
cannabinoids observed here following treatment with either WIN55,212-2 or following 
ablation of Faah, are not mediated by the CBi receptor. If the CBj receptor mediated the 
beneficial effects of endocannabinoids then ablation of this receptor subtype would be 
expected to result in an acceleration of disease progression. Therefore, the lack of effect 
seen following CBi receptor ablation implies that activation of this receptor subtype 
may not contribute to the protective effects mediated by cannabinoids.
5.4.2. The effect of genetically manipulating the cannabinoid system on muscle 
contractile characteristics
Normally, EDL muscles are fast, fatigable muscles. However, as a consequence of 
disease progression the EDL muscles in SOD 1093A mice become largely fatigue 
resistant as shown in Chapter 4.3.5. Interestingly, the results of this Chapter show that 
by 90 days of age, an early symptomatic stage of disease, EDL muscles from 
ABH.SOD1 mice are already largely fatigue resistant. This data is consistent with a 
previous study by Sharp et al, (2005), in which EDL muscles from S0D1G93A mice, on 
the C57BL/6 x SJL Fi background, have increased fatigue resistance compared to WT 
EDL muscles at 90 days of age. Thus, significant changes in the contractile 
characteristics have already occurred in SOD 1093A mice by this stage.
Consistent with the muscle force data, however, the fatigue pattern of EDL muscles 
from SODX.Faah -/- mice does not differ significantly from that seen in ABH.WT mice. 
Thus, elevation of AEA levels appears to delay the deleterious changes in contractile 
characteristics in EDL hindlimb muscles that occur in SOD1G93a mice at this early stage 
of disease. In contrast, EDL muscles from SODX.Cnrl -/- mice are fatigue resistant by
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90 days of age, similar to EDL muscles from ABH.SOD1 mice, implying that ablation 
of the CBi receptor does not alter the progression of changes occurring in muscle 
contractile characteristics in the SOD 1093A mice.
The pattern of SDH staining of EDL muscles fibres from ABH.WT, ABH.SOD1, 
SOD1.Faah -/- and SO D \.C nrl -/- is consistent with the EDL muscle fatigue data. 
Therefore, whereas ABH.WT EDL muscle fibres stain lightly for SDH, indicating a low 
oxidative capacity, EDL muscles from ABH.SOD1 mice at 90 days of age, in contrast, 
have a greater proportion of muscle fibres that are darkly stained suggesting that they 
have a higher oxidative capacity. EDL muscle fibres from SOD1 .Faah -/- mice 
resemble WT EDL, with the majority of fibres lightly stained, indicating that 
SOD1.Faah -/- EDL muscle fibres have not undergone the deleterious changes in 
muscle fibre phenotype that have already occurred in the EDL muscles of ABH.SOD1 
mice by this stage. This provides further evidence to suggest that elevation of 
endogenous AEA levels has a significantly beneficial effect on muscle function in 
SOD 1093A mice, as in SOD1.Faah -/- mice the EDL muscles remain fast, fatigable 
muscles with a relatively low oxidative capacity. The pattern of SDH staining of EDL 
muscles from SODl.Cwri -/- mice, in contrast, is similar to that seen in ABH.SOD1 
EDL muscles. Therefore, ablation of the CBi receptor has no effect on the changes in 
the muscle fibre phenotype of EDL muscles that occur by 90 days of age in the 
SODl093A mice.
5.4.3. The effect of genetically manipulating the cannabinoid system on the
i
survival of functional motor units in SOD1 mice
At 90 days of age, at the onset of observable disease symptoms, 32% of motor units 
have already been lost in ABH.SOD1 mice, compared to their ABH.WT littermates. In
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contrast, at this stage no motor unit loss occurs in SOD 1093A mice in which the Faah 
enzyme has been genetically ablated. Genetic ablation of the CBi receptor, however, 
has no effect on motor unit survival and at 90 days of age SOD LOW  -/- mice have lost 
39% of their functional motor units, which is similar to the motor unit loss that occurs in 
ABH.SOD1 mice. Therefore, consistent with the muscle function studies, ablation of 
the Faah enzyme has dramatic protective effects on motor unit survival, whereas 
ablation of the CBj receptor does not influence disease progression at 90 days of age in 
ABH.SOD1 mice.
5.4.4. The effect of genetic manipulation of the cannabinoid system on the survival 
of sciatic motoneurons
The increase in motor unit survival observed in SOD\.Faah -/- mice is reflected in a 
significant increase in survival of motoneurons in the spinal cord. Thus, in ABH.SOD1 
mice at 90 days of age, 32% of motoneurons have already died compared to their 
ABH.WT littermates. In contrast, in SOD1 .Faah -/- mice only 14.8% of motoneurons 
have been lost at this early stage of disease compared to ABH.WT mice. However, the 
survival of sciatic motoneurons in SOD l.O W  -/- mice at 90 days of age does not differ 
significantly from ABH.SOD1 mice, and 39.4% fewer motoneurons survive in 
SOD l.O W  -/- mice at 90 days of age compared to ABH.WT mice.
Surprisingly, the significant increase in motoneuron survival observed in SODl.Faah - 
/- mice at 90 days of age is not maintained, in the long-term. Thus, at the end-stage of 
disease there is no significant difference in motoneuron survival between ABH.SOD1, 
SODX.Faah -/- and SOD.OW -/- mice.
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5.4.5. The effect of genetically manipulating the cannabinoid system on the lifespan
of SOD1G93a mice on the ABH background
Both the ABH .Faah -/- and ABH .Cnrl -/- mice used in this study have a normal 
lifespan. However, it is interesting to note that the F2 generation of SOD 1093A mice on 
the ABH background show a significant reduction in lifespan compared to S0D1G93A 
mice on the C57BL/6 x SJL Fi hybrid background. This may result from a reduced level 
of BL/ 6  in the genetic background of these F2 generation ABH.SOD1 mice, due to 
backcrossing onto the ABH background. Previously, the genetic background of 
SOD 1G93A mice has been shown to have significant effects on their lifespan. Indeed, in a 
study by Heiman-Patterson et al, (2005), SOD1G93a mice on the C57BL/6 x SJL 
background live on average for 130.2 days (± 11.2) compared to 143.6 days (± 7.5) on 
the C57BL/6 background. The extension in lifespan in SOD1G93a mice on the C57BL/6 
background is related to a reduced level of SJL, which confers a less severe phenotype 
(Heiman-Patterson et al., 2005).
Surprisingly, despite the significant amelioration in disease progression in SOD1.Faah 
- / -  mice observed at 90 days, these effects are not reflected in an increase in the 
lifespan of SOD1.Faah -/- mice. This is consistent with the results shown in Chapter 4, 
whereby administration of an exogenous cannabinoid, WIN55,212-2, delays disease 
progression at 120 days of age, but does not significantly extend lifespan. Similarly, 
disease progression is delayed in SODlG93A mice treated with A9-THC or CBD, but 
there is no significant extension of lifespan (Raman et al., 2004; Weydt et al., 2005). 
Interestingly, it can be seen from the results in this Chapter that while ablation of the 
CBi receptor in SOD1g93A mice has no effect on disease progression at 90 days of age, 
there is a significant increase in the lifespan of these mice. Indeed, the lifespan of 
SOD1.Cnrl -/- mice is extended by 13%, similar to that of SOD1G93a mice treated with
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the anti-excitotoxic agents, riluzole and RPR119990, and the microglial inhibitor, 
minocycline (Gurney et al., 1998; Canton et al., 2001; van den Bosch et ah, 2002).
5.4.6. Why might ablation of the CBi receptor significantly extend lifespan?
The observation that CBi receptor ablation significantly extends lifespan without 
affecting disease progression at an early stage of disease suggests that CBi receptor 
activation does not play a role in the cellular defence mechanism of motoneurons in 
S0D1G93A mice. Furthermore, contrary to current opinion, the neuroprotective effects of 
cannabinoids, achieved either by treatment with WIN55,212-2 or elevation of 
endocannabinoids following ablation of Faah, may not be mediated by the CBi receptor. 
These results therefore suggest that inhibition or blockade of the CBi receptor may 
actually have a neuroprotective effect.
These results are therefore in contrast to studies in which an increase in neurological 
damage is seen in C nrl -/- mice after middle cerebral artery occlusion or NMDA 
injection, (Parmentier-Batteur et al., 2002). Furthermore, injection of KA into the CNS 
of Cnrl -/- mice produces a more extreme behavioural reaction and mortality than in 
WT mice (Marsicano et al., 2003; Pryce et al., 2003), therefore highlighting the role of 
this receptor in neuroprotection. However, other reports support the possibility that 
blockade of CBi receptors may be neuroprotective. Treatment with a CBi receptor 
antagonist alone reduces neurological damage following an intrastriatal NMDA 
injection in neonatal rats (Hansen et al., 2002). Similarly, neuroprotection in an animal 
model of permanent or transient middle cerebral artery occlusion is elicited via blockade 
of CBi receptors (Muthian et al., 2004). Interestingly in both of these models, similarly 
to the SOD1G93a mice, levels of AEA are elevated, suggesting that an underlying
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endocannabinoid-mediated toxic mechanism may be exerted by activation of CBi 
receptors.
Indeed, activation of CBi receptors has been reported to exert neurotoxic effects via the 
stimulation of an increased calcium influx (Chan et al., 1998; Netzeband et al., 1999; 
Klegeris et al., 2003). In vitro studies have also shown that AEA can induce apoptosis 
in many cell types (Zhu et al., 1998; Sarker et al., 2000), and it has been suggested that 
the immunosuppressive effects of AEA may result from the induction of apoptosis in 
immune cells (Zhu et al., 1998; Do et al., 2004), although the involvement of 
cannabinoid receptors in this effect is controversial (Movsesyan et al., 2004). 
Furthermore, Faah -/- mice are more susceptible to KA-induced seizures (Clement et 
al., 2003). Together these observations suggest a potentially neurotoxic role for elevated 
endocannabinoids, in contrast to their generally accepted neuroprotective role.
Nevertheless, the results here clearly show that elevated levels of cannabinoids are 
neuroprotective. However, the extended lifespan of S O D \.C nrl -/- mice suggests that 
these neuroprotective effects are not mediated via the CBi receptor. Therefore, it is 
possible that the beneficial effects observed with increased endocannabinoid levels are 
in fact mediated via the CB2 receptor. Other authors have demonstrated neuroprotective 
effects of cannabinoids in the presence of CBi receptor antagonism, also suggesting a 
non-CBi receptor mediated effect (Nagayama et al., 1999; van der Stelt et al., 2001; 
Klegeris et al., 2003). Activation of CB2 receptors may inhibit inflammatory processes 
and indeed, there is significant evidence to suggest that inflammation plays a role in 
ALS pathogenesis, as described in detail in Chapter 4.4.7.2.. Markers of inflammation, 
for example reactive astrocytes and microglia, are prevalent in the post-mortem spinal 
cords from ALS patients concurrent with elevated levels of inflammatory mediators
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(Alexianu et al., 2001; Yasojima et al., 2001; McGeer & McGeer, 2002; Maihofner et 
al., 2003). Similarly, in SOD1G93a mice there is a correlation between disease 
progression and the intensity of inflammation (Hall et al., 1998; Alexianu et al., 2001; 
Aimer et al., 2001). Interestingly, in post-mortem brains from Alzheimer’s disease (AD) 
patients, expression of CB2 receptors and the Faah enzyme are elevated in microglia and 
astrocytes associated with neuritic plaques (Benito et al., 2003). In a model of peripheral 
nerve injury, CB2 receptor expression is elevated in the rat spinal cord due to the influx 
of activated microglia (Zhang et al., 2003). Furthermore, another study reports a 
reduction in functional CBi receptors in the post-mortem brains of AD patients 
(Ramirez et al., 2005). Together with the findings of the present study, these 
observations suggest that pharmaceutical targeting of the CB2 receptor may be 
beneficial in neurodegenerative conditions where inflammation plays a significant role 
(Benito et al., 2003; Zhang et al., 2003; Ramirez et al., 2005).
5.4.7. How may CB2 receptor activation exert neuroprotective effects?
Cannabinoid-mediated activation of CB2 receptors located on microglia (Benito et al., 
2003; Klegeris et al., 2003) inhibits microglial activation (Arevalo-Martin et al., 2003) 
and reduces both mRNA expression and release of pro-inflammatory cytokines from 
microglia (Puffenbarger et al., 2000; Croxford & Miller, 2003; Facchinetti et al., 2003; 
Klegeris et al., 2003). Furthermore, an inhibitory effect of cannabinoids on microglia 
may also limit their release of glutamate and reactive oxygen species, therefore reducing 
the potential contribution of excitotoxicity and oxidative stress to disease pathogenesis 
(Molina-Holgado et al., 1997; Waksman et al., 1999; Tikka et al., 2002). Previously 
therapies targeting inflammation such as minocycline and NDGA, which are inhibitors 
of microglia, and selective COX2 inhibitors have had beneficial effects in mutant SOD1 
mice (Drachman et al., 2002; Kriz et al., 2002; Pompl et al., 2002; van den Bosch et al.,
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2002; Zhu et al., 2002; West et al., 2004). The present study provides evidence that 
elevated endocannabinoids, via Faah ablation, act to reduce inflammation as GFAP 
immunoreactivity, a marker of astro gliosis, is significantly reduced in SQDX.Faah -/- 
mice compared to ABH.SOD 1 mice. Therefore further investigation into the therapeutic 
potential of specific CB2 receptor agonists in ALS is warranted.
It is possible that other receptor subtypes may also contribute to the neuroprotective 
effects of elevated AEA observed in this study. For example, activation of the putative 
“CB3” receptor, characterised in the brains of Cnrl -/- mice, by AEA may contribute to 
the neuroprotection seen in SOD1 .Faah -/- mice (Di Marzo et al., 2000; Breivogel et al., 
2001; Monory et al., 2002). This receptor subtype may mediate cannabinoid-induced 
inhibition of glutamate neurotransmission (Hajos et al., 2001; Hajos & Freud, 2002) 
therefore reducing excitotoxicity. Alternatively, the ability of AEA to activate VR1 
receptors may also be involved (Zygmunt et al., 1999; Smart et al., 2000). VR1 
receptors are coupled to non-selective cation channels, thus receptor activation may 
induce neuronal excitability by increasing calcium influx. However, VR1 receptors are 
believed to undergo rapid desensitisation, therefore prolonged activation of VR1 
receptors by elevated endogenous AEA may induce receptor desensitisation and 
consequently reduce neuronal excitability (Zygmunt et al., 1999). Indeed, blockade of 
VR1 receptors has previously been shown to have neuroprotective effects in vivo 
(Veldhuis et al., 2003). Potentially AEA-mediated inhibition of sodium and T-type 
calcium channels, acting to reduce neuronal excitability may also contribute to the 
effects of AEA seen in the SOD1 .Faah -/- mice (Chemin et al., 2001; Nicholson et al.,
2003), whereas inhibition of the TASK-1 channel with excitatory consequences is 
unlikely to be involved (Maingret et al., 2001). Finally, a contribution of the oxidative 
products of AEA hydrolysis to the neuroprotective effects in this study must also be
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considered, in particular 1 2 -HAEA, which has exerted anti-oedematous effects in an 
animal model of excitotoxicity (Veldhuis et al., 2003).
5.4.8. The therapeutic potential of the Faah enzyme
The results of this study identify for the first time the Faah enzyme as a novel 
therapeutic target in ALS. In this study, genetic deletion of the Faah gene, which is 
known to bring about a 10 -  15 fold elevation of AEA levels in the CNS (Cravatt et al.,
2001), exerts a dramatic neuroprotective effect in S0D1G93A mice, at least at 90 days of 
age. Recently a class of highly selective and reversible O-arylcarbamate inhibitors of 
the Faah enzyme have been developed (Kathuria et al., 2003; Fegley et al., 2005), which 
will further aid research in this field. Within 2 hours of application, URB597, a member 
of the O-arylcarbamate inhibitor family, induces a 3-5 fold elevation in the CNS 
concentration of AEA and other NAEs hydrolysed by Faah, for example the non­
receptor binding endocannabinoids, OEA and PEA (Cravatt et al., 2003). Selective 
pharmaceutical (Baker et al., 2001) and genetic inhibition of Faah activity (Massa et al., 
2004) has been shown to ameliorate symptoms in an autoimmune rodent model of 
inflammation. Meanwhile, Faah inhibitors have also been proposed as potential 
therapies in the treatment of anxiety attacks (Kathuria et al., 2003)
In spite of the dramatic effects on disease signs observed in 90 day old SODl.Faah -/- 
mice, there is no increase in lifespan, suggesting that endocannabinoids may only be 
therapeutic in the early stages of disease. This effect may be related to the appearance of 
activated microglia from a presymptomatic stage in mutant SOD1 mice onwards (Hall 
et al., 1998; Alexianu et al., 2001; Elliott et al., 2001; Olsen et al., 2001; Weydt et al., 
2004). Therefore the protective effects mediated via endocannabinoid-induced 
activation of CB2 receptors on microglia may also be initiated at a presymptomatic
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stage. However, with further disease progression and the initiation of other pathological 
changes, the protective effects of endocannabinoids may then be overwhelmed. 
Nevertheless, ablation of Faah and the subsequent increase in endogenous AEA, does 
significantly delay disease onset. Therefore pharmacological inactivation of Faah may 
be particularly effective if used in combination with agents that act on mechanisms 
active during later stages of the disease such as heat shock protein co-inducers (Kieran 
et al., 2004) or glutamate inhibitors (Canton et al., 2001; Van Damme et al., 2003).
Recognition of the abundance of endocannabinoids in the CNS coupled with an 
increasing understanding of their physiological functions, has now established a role for 
endocannabinoids as modulators of neuronal activity. The precise elucidation of their 
mechanisms of synthesis, uptake and degradation has facilitated the development of 
pharmaceutical agents targeting particular steps of each pathway, in addition to 
permitting further assessment of the role of the endocannabinoid system. Therefore 
agents acting simultaneously to inhibit the hydrolysis or reuptake of several 
endocannabinoids may exert greater neuroprotective effects than observed with genetic 
inhibition of the Faah enzyme. Furthermore, the existence of different synthetic and 
degradative pathways for AEA and 2-AG may suggest a differential regulation of 
endocannabinoid functions in different areas of the CNS. Therefore, it is possible that 
the neuroprotective effects of 2-AG may be greater than those seen with AEA in this 
model of ALS.
5.5. CONCLUSION
In conclusion, the results from this Chapter show that increased tone of the 
endocannabinoid system obtained by ablation of the Faah enzyme, similar to that seen 
following treatment with synthetic cannabinoids such as WIN55,212-2, ameliorates
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disease symptoms, at least in the short term. These neuroprotective effects appear to be 
mediated by a non-CBi receptor dependent mechanism. Our results therefore identify 
the Faah enzyme and possibly the CB2 receptor as potential therapeutic targets in ALS. 
Manipulation of the endocannabinoid system alone or in combination with other 
therapeutic agents targeted at alternative mechanisms hypothesised to contribute to ALS 
pathogenesis is warranted in an attempt to further increase lifespan as well as quality of 
life.
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CHAPTER 6
THE SILENCING OF HUMAN MUTANT SODlG93A I N  
V I T R O  USING siRNA EXPRESSING LENTIVIRAL
VECTORS
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6.1. INTRODUCTION
In this Chapter, the ability of siRNA technology to successfully ablate human mutant 
SOD1 protein was investigated in primary mixed ventral horn SOD 1093A cultures. This 
project was carried out in collaboration with Dr Mimoun Azzouz from Oxford 
Biomedica (Oxford, UK). In these experiments the primary cell culture and viral 
transfection procedures were undertaken at the Institute of Neurology and the 
generation of lentiviral vectors and the protein analysis was carried by out by Dr 
Azzouz and colleagues at Oxford Biomedica.
6.1.1. ALS therapies
The mutant SOD1 transgenic mouse model of fALS provides the best available model 
of ALS in which to test neuroprotective strategies. Table 6.1 shows a selective list of 
potential neuroprotective agents that have been tested in mutant SOD1 mice. However 
to date, the translation of the positive effects observed in mutant SOD1 mice to humans 
has failed to materialise. There may be several reasons for this discrepancy. For 
example, it is possible that one major hurdle is the bioavailability of pharmacological 
agents and also the targeting of therapies to motoneurons within the human CNS. A 
recent attempt to overcome this problem has involved the use of viral vectors. Indeed, 
viral gene therapy is being extensively studied as a delivery method for therapeutic 
agents.
Viral vectors can infect non-dividing as well as dividing cells, therefore making them 
suitable candidates for the treatment of neurodegenerative disease. Replication deficient 
viruses can be manipulated to express a gene of interest that can be introduced directly 
into the patient. Alternatively, cells can be removed from patients, for example bone 
marrow cells, and injected with viral vectors ex vivo prior to transplantation back into
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Table 6.1 - Pharmacological therapies tested in mutant SOD1 mice for the 
treatment of ALS
In these studies, the onset of pharmacological treatment is at a presymptomatic stage in 
mutant SOD1 mice unless otherwise stated.
Pathogenic mechanism Mechanism of action Extension in Reference
targeted lifespan (%)
Drug name
Oxidative stress
d-penicillamine Copper chelator 8 Hottinger et al., 
1997
AR-R 17,477 Inhibits neuronal NOS 
activity
13 Facchinetti et al., 
1999
Excitotoxicity
Riluzole Inhibition of glutamate 
release, modulation of 
NMDA receptor function
10.5 Gumey et al., 1998
RPR 119990 AMPA receptor antagonist 12.7 Canton et al.,2001
NBQX
P-lactam antibiotics
AMPA/KA receptor 
antagonist
Upregulation of GLT-1
10
8
Van Damme et al., 
2003
Rothstein et al., 
2005
(treatment onset at early
symptomatic stage)
Mitochondrial dysfunction
Bcl-2 overexpression Inhibits caspase/apoptosis 
activation
15 Kostic et al., 1997
Creatine Stabilisation of 
mitochondrial creatine 
kinase
17.8
Klivenyi et al., 
1999
Protein aggregation
Arimoclomol HSP co-inducer 22
Kieran et al., 2004
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Inflammation
Celecoxib COX2 inhibitor 25 Drachman et al., 
2002
Minocycline Microglial inhibition, 
inhibition of cytochrome c 
release.
9-16 Kriz et al., 2002; van 
den Bosch et al., 
2002; Zhu et al., 
2002
NDGA (treatment onset at 
early symptomatic stage)
Inhibition of TNFa release 32
West et al., 2004
Other targeted
mechanisms
ICE inhibition Inhibits caspase 1 8
Friedlander et al., 
1997
WHI-PI3I Janus kinase inhibitor 49 Trieu et al., 2000
VEGF (in mutant SOD1 rats 
from 85d)
Growth factor 8
Storkebaum et al., 
2005
ZVAD-fmk Broad spectrum caspase 
inhibitor
22 Li et al., 2000
Combination therapy
Riluzole, minocycline and Inhibition of glutamate 13 Kriz et al., 2003
nimodipine -  targeting release, inhibition of
excitotoxicity and microglial activation and
inflammation inhibition of voltage-gated 
calcium channels
Viral therapies
AAV -  Bcl2
AAV-GDNF
Ad-GDNF
Inhibits apoptosis induction 
Neurotrophic factor 
Neurotrophic factor
0
14
12
Azzouz et al., 2000 
Wang et al., 2002 
Acsadi et al., 2002
AAV -  IGF -1 (treatment Neurotrophic factor and 18 Kaspar et al., 2003
onset at early symptomatic inhibits caspase activation
stage)
LV- VEGF (treatment onset Growth Factor 15 Azzouz et al., 2004
at early symptomatic stage)
LV -  shRNA to mutant Ablation of mutant SOD1 77 Ralph et al., 2005b
SOD1
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the patient. Several laboratories have attempted viral gene therapy in models of ALS. 
Lentiviral vectors expressing a recombinant GDNF transgene successfully transfect 
motoneurons in vitro and significantly increase their survival in the presence of 
exogenous trophic factor deprivation (Cistemi et al., 2000). Indeed, virus based GDNF 
is as effective in promoting survival as exogenous GDNF (Cistemi et al., 2000). In vivo, 
the local injection of lentivirus-encoding GDNF into the lumbar spinal cord of 
SOD 1093A mice at 35 days of age induces strong transgene expression that persists until 
120 days of age. However, despite maintained elevations in GDNF, no significant 
benefit is observed in terms of disease progression or lumbar motoneuron survival, 
although a significant protection of facial motoneurons occurs (Guillot et al., 2004). In 
contrast, intraspinal injection of recombinant adeno-associated vims (AAV) expressing 
Bcl2 significantly increases motoneuron survival in the lumbar spinal cord of SOD 1093A 
mice (Azzouz et al., 2000). Similarly, injection of Bcl2 expressing adenovims (Ad) into 
the tongue of SOD1G93a mice significantly protects motoneurons in the hypoglossal 
nucleus (Yamashita et al., 2002).
Intraspinal injection, however, is not likely to be an acceptable delivery route for human 
gene therapy due to the risks associated with such an approach. Instead the peripheral 
administration of viral vectors via intramuscular injection would have greater transfer to 
the clinic. In mutant SOD1 mice, following the intramuscular injection of a GDNF- 
expressing Ad or AAV vector, GDNF is retrogradely transported to the motoneurons of 
the spinal cord (Acsadi et al., 2002; Manabe et al., 2002; Wang et al., 2002; Lu et al.,
2003). Sustained expression of GDNF in the muscles and spinal cord significantly 
delays disease onset and extends survival of S0D1G93A mice by 12% or 14% following 
intramuscular delivery of Ad-GDNF (Acsadi et al., 2002) or AAV-GDNF respectively 
(Wang et al., 2002).
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Intramuscular viral therapies have also been shown to be effective if administered at the 
time of disease onset. Indeed, injection of AAV expressing insulin-like growth factor-1 
(IGF-1) induces significant expression and secretion of IGF-1 in spinal motoneurons, 
consequently delaying disease onset and extending lifespan of SOD1G93a mice by 18% 
(Kaspar et al., 2003). This neuroprotective effect is due to a combination of the trophic 
effects of IGF-1 and its anti-apoptotic actions. Furthermore, this effect is dependent on 
the retrograde transport of viral vectors encoding IGF-1 to the spinal cord in addition to 
IGF-1 expression in the muscle fibres (Kaspar et al., 2003). Similarly, retrograde 
transport of a lentiviral vector encoding VEGF from hindlimb and facial muscles of 
SOD1G93a mice significantly delays disease progression and is accompanied by a 15% 
extension in lifespan, despite treatment being initiated after disease onset, at 90 days of 
age (Azzouz et al., 2004).
6.1.2. Lentiviral-based therapy
The ability of viral vectors to infect non-dividing cells provides a mechanism to induce 
the expression of a gene of interest in non-mitotic, adult neuronal cells. This offers a 
significant advantage over other therapeutic strategies. Viral vectors can consist of 
either capsid virions, for example Ad and AAV, or envelope virions, for example 
lentiviruses and herpes simplex virus (Davidson & Breakefield, 2003). The individual 
attributes of the most commonly used viral vectors are listed in Table 6.2.
In the experiments in this Chapter, lentiviral vectors are used as the gene delivery agent. 
Lentiviral vectors are retroviral vectors that stably integrate the gene of interest into the 
host genome, via reverse transcription of the viral RNA. This provides stable, long-term 
expression of therapeutic molecules, circumventing the problem of maintaining 
treatment by repeated therapy. Indeed the expression of genes encoded by lentiviral
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Table 6.2. The attributes of commonly used viral vectors
Type of viral 
vector
Type of 
virus
Transgene
expression
Transgene
capacity
Immune
reaction
Transduction 
capacity of 
non-dividing 
cells
Recombinant
adenovirus
(Ad)
Capsid
virion
Long-term Large (up 
to 36kb)
Substantial 
immune 
response 
although 
reduced upon 
removal of 
Ad genomic 
sequences
Efficient and 
can be 
retrogradely 
transported
Adeno- 
associated 
virus (AAV)
Capsid
virion
Long-term
under
mammalian 
promoter 
although 
generally extra- 
chromosomal
Small (4- 
5kb)
Low Selective
neuronal
efficiency
Lentivirus Enveloped
virion
Long-term Moderate 
(up to 8kb)
Very low Efficient and 
can be 
retrogradely 
transported
Recombinant 
herpes 
simplex virus
Enveloped
virion
Long-term Large (up 
to 50kb)
Low but risk 
of expression 
of viral 
genes
Efficient and 
capable of 
retrograde and 
anterograde 
transport 
within the CNS
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vectors has been shown up to 1 year after transfection (Wong et al., 2003). Lentiviral 
vectors have a moderate cloning capacity (approximately 8 kb) and show a very high 
transduction efficiency of neuronal cells. The need for cell division is bypassed by 
lentiviruses via the formation of a preintegration complex, which docks at the nuclear 
membrane and passes through the nuclear pore in an ATP-dependent manner (Martin- 
Rendon et al., 2001). To avoid safety concerns over the use of HIV-based vectors, non­
primate vectors, for example equine infectious anaemia virus (EIAV), have been 
developed, which have also been rendered replication deficient and are therefore unable 
to replicate in human cells. These vectors also exert minimal inflammatory and 
immunological responses (Wong et al., 2003).
Another benefit of lentiviral vectors is the potential for manipulation of the glycoprotein 
components of the viral envelope. This manipulation can induce the interaction of viral 
vectors with specific receptors on the plasma membrane of target cells, therefore 
potentially allowing the targeting of selective populations of cells for gene therapy. For 
example, after intramuscular injection, viral vectors pseudotyped with a Rabies-G viral 
envelope will be retrogradely transported from muscles to the innervating motoneurons 
in the spinal cord. In contrast, viral vectors that are pseudotyped with the vesicular 
stomatitis virus-G envelope protein (VSV-G) will be confined to the muscle and are not 
retrogradely transported to the spinal cord (Martin-Rendon et al., 2001; Mazarakis et al., 
2001; Kaspar et al., 2003). Therefore, their low toxicity combined with the ability to 
target motoneurons after intramuscular injection, suggests that lentiviral vectors may be 
an ideal vector for the treatment of ALS.
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6.1.3. Small interfering RNA technology
RNA interference refers to the ability of small, endogenous or exogenous RNA 
molecules to induce specific, post-translational silencing of selective, sequence-matched 
mRNAs (Fire et al, 1998). Endogenous RNA interference is involved in the regulation 
of gene expression, the maintenance of genome stability and possibly as a defence 
mechanism against RNA viruses (Denli & Hannon, 2003). However, the treatment of 
Caenorhabditis elegans with double stranded RNA (dsRNA), which initiated the 
degradation of endogenous, sequence-matched mRNA, indicated that this endogenous 
system could be successfully manipulated to induce specific gene silencing (Fire et al, 
1998). It was subsequently discovered that the silencing effect in vivo is mediated by 
small interfering RNA (siRNA) duplexes of 21-23 nucleotides in length, which are 
formed by the cleavage of exogenous dsRNA (Zamore et al., 2001). This initiated the 
development of synthetic siRNA duplexes, 21 base pairs in length, which upon direct 
transfection of mammalian cell lines induce specific down-regulation of sequence 
specific genes (Elbashir et al., 2001). More recently, short hairpin RNAs (shRNA), 
which consist of a sense and anti-sense strand, joined by a loop region and under the 
control of an RNA polymerase III promoter, have been developed. In vivo transcription 
of shRNAs from expression vectors generates siRNA and subsequently induces specific 
gene silencing (Brummelkamp et al., 2002). The mechanism underlying siRNA- 
mediated gene silencing is proposed to involve the cytoplasmic cleavage of shRNA by 
an RNase III enzyme (DICER), therefore generating siRNA molecules. Following 
degradation of the sense strand, the anti-sense strand associates with an RNA-induced 
silencing complex (RISC). The RISC complex is subsequently targeted to the siRNA 
sequence-matched mRNA, and this mRNA is then cleaved and degraded (Ralph et al., 
2005a). This mechanism is summarised in Figure 6.1.
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Figure 6.1 -  Mechanism of action of siRNA
The intracellular mechanism of siRNA-induced selective gene silencing is summarised 
in the diagram, which is adapted from Ralph et al (2005a). Following viral delivery of 
targeted shRNA molecules, they are cleaved intracellularly to form specific siRNA 
molecules, which can subsequently associate with RISC and induce degradation of 
sequence-matched mRNA.
RISC - RNA-induced silencing complex; shRNA - short-hairpin RNA; siRNA -  small 
interfering RNA.
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The use of siRNA technology to induce long-term gene silencing may therefore provide 
a novel mechanism for the development of a therapy for dominantly inherited 
neurodegenerative conditions. Furthermore, the use of viral vectors to express siRNA 
overcomes the problem of transfecting non-mitotic, adult neurons. Indeed, injection of 
AAV expressing siRNA targeted against the human mutant form of ataxin-1 
significantly reduces the cerebellar pathology and improves motor co-ordination in a 
mouse model of spinocerebellar ataxia type 1 (Xia et al., 2004). Moreover, specific 
targeting of siRNA against a mutation in the APP gene implicated in a Swedish form of 
Alzheimer’s disease successfully ablates expression in Cos-7 cells in vitro, although the 
in vivo effects remain to be elucidated (Miller et al., 2004).
siRNA technology may therefore prove to be an effective therapy in ALS as although 
ALS is a predominantly sporadic disorder, approximately 10% of cases have a family 
history consistent with mendelian inheritance. Currently 11 candidate genes have been 
identified in familial ALS, although the existence of further causative genes is likely. 
Therefore, siRNA technology may prove to be a suitable approach for the treatment of 
some cases of familial ALS, by reducing the expression of specific genes known to be 
involved. In mutant SOD 1-mediated ALS, the mutant SOD1 enzyme acquires a toxic 
gain of function and therefore ablation has the potential to exert significant beneficial 
effects. Indeed, in contrast to the ubiquitous expression of mutant SOD1, selective 
expression in either astrocytes or motoneurons, does not initiate motoneuron 
degeneration in transgenic mice (Gong et al., 2000; Pramatarova et al., 2001; Lino et al.,
2002). Selective ablation of mutant SOD1 in vitro has previously been shown by 
transfection of siRNA targeted to mutant SOD1 (Ding et al., 2003; Maxwell et al.,
2004). Furthermore, selective ablation of mutant SOD1 protein significantly protects 
SODlG37R expressing N2a cells from cyclosporine-induced toxicity (Maxwell et al.,
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2004). Therefore, potentially ablation of mutant SOD1 in vivo may have 
neuroprotective effects in transgenic mutant SOD1 mice.
6.1.4. Hypothesis to be tested
In this study the potential capability of EIAV lentiviral vectors to transfect primary 
motoneurons is tested in vitro. Furthermore, the ability of siRNA to ablate mutant 
SOD1 protein in SODlG93A mixed ventral horn cultures is assessed. This project formed 
part of a pilot study to ensure specific in vitro ablation of mutant SOD1, before the 
initiation and completion of an in vivo study by Oxford Biomedica (Ralph et al., 2005b).
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6.2. METHODS
6.2.1. pONY8.7-H 1 SOD 1KO vectors
The design and construction of the pONY8.7-HlSODlKO vectors, which encode 
siRNA targeted to mutant SOD1, was undertaken at Oxford Biomedica. The lentiviral 
vectors used were non-primate lentiviruses derived from EIAV. To optimise safety all 
viral proteins had been removed from EIAV except gag  and pol, and the accessory 
gene, rev, which represent the minimal requirement for gene transfer. Furthermore, the 
virus had been rendered replication defective by deletions from the 5’ and 3’ long 
terminal repeats. Finally, the EIAV virus was pseudotyped with a vesicular stomatitis 
virus-G envelope protein (VSV-G), which permits transduction of neuronal cells and 
long-term expression of the transgene (Martin-Rendon et al., 2001), and reduces the 
probability of reformation of replication competent EIAV (Mitrophanous et al., 1999). 
Viral titres were estimated by real time quantitative reverse transcriptase PCR by 
comparison with a previously quantified vector, pONY8.0GFP (Mazarakis et al., 2001), 
and then normalised for viral RNA (Martin-Rendon et al., 2002). Viral titres used in
Q Q
these experiments were in the range of 5x10  - 1 x 10  transducing units/ml.
To determine transfection capability of EIAV vectors in mixed ventral horn cultures, 
lentiviral vectors expressing green fluorescent protein (GFP) or lacZ were constructed 
initially, which permitted the calculation of transfection efficiency.
Putative small interfering RNA (siRNA) target sequences were designed against the 
human SOD1 gene using online algorithms (Dharmacon, Lafayette, CO, USA). 
Sequences were determined to be unique to the human SOD1 gene by BLAST 
searching of the GenBank database. The target sequence of the siRNA used in this study 
was 5’-GCATTAAAGGACTGACTGA-3’. Subsequently, oligonucleotide primers were
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designed corresponding to the sense and antisense sequences of the siRNA target site of 
interest and separated by a hairpin loop sequence (Brummelkamp et ah, 2002). The 
primers were annealed and cloned into the EIAV vector downstream of a ribonuclease P 
RNA component HI (RPPH1) promoter, which had been amplified from human 
embryonic kidney cell 293T (HEK293T) cell line. Figure 6.2 provides a diagrammatic 
representation of the vector used including the mutant SOD1 specific siRNA sequence.
6.2.2. Mixed ventral horn cultures
Mixed motoneuron cultures were prepared using a protocol adapted from that described 
by Camu & Henderson (1994). The genotype of each embryo was determined prior to 
culturing, using PCR as described in Chapter 2.3, and the spinal cords were pooled 
according to genotype, either WT or SOD1G93a, and each genotype was cultured 
separately, as detailed in Chapter 2.5. Cells were maintained at 37°C in a 5% CO2 
humidified incubator and media replaced twice a week.
6.2.3. Viral transfection
At 1DIV, SOD 1093A mixed ventral horn cultures were incubated with VSV-G 
pseudotyped EIAV vectors expressing either GFP, lacZ, shRNA to mutant SOD1 or an 
empty vector. The volume of virus added to each well of a 24 well plate (5 x 105 cells), 
was calculated according to the following equation:
Multiplicity of infection (MOI) x Number of cells
Volume = ...................................................................................
Titre
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Figure 6.2 -  EIAV lentiviral vector encoding siRNA to mutant SOD1G93a
Putative small interfering RNA (siRNA) target sequences were designed against the 
human SOD1 gene. Oligonucleotide primers were designed corresponding to the sense 
and antisense sequences of the siRNA target site of interest (EIAV-SOD1HP1) and 
separated by a hairpin loop sequence. The primers were annealed and cloned into the 
EIAV vector downstream from RPPH1 (encoding ribonuclease P RNA component HI) 
promoter, as shown. Following transcription shRNA molecules targeted to mutant 
S0D1G93A were generated. LacZ was incorporated to enable detection of the vector and 
therefore successful transfection (in some experiments this was replaced with GFP). 
Control vectors were also constructed containing an empty expression cassette. 
SIN-LTR, self-inactivating long terminal repeat; 'F, EIAV packaging signal; CMV, 
cytomegalovirus promoter; EIAV-SOD1HP1 treated.
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sPPT
EIAV-S0D1HP1
GATCCCC GCATTAAAGGACTGACTGA TTCAAGAGA TCAGTCAGTCCTTTAATGC TTTTT GGAAA
GGG CGTAATTTCCTGACTGACT AAGTTCTCT AGTCAGTCAGGAAATTACG AAAAA CTTTGATC
Sense Loop Antisense
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The viral titre ranged from 5 x 108 -  1 x 109 transducing units/ml, and was consistent 
within each viral batch. Initially, using lacZ encoding EIAV vectors, the MOI was 
varied (between 0.5 and 5) and transfection efficiency calculated for each MOI to allow 
optimisation of the transfection, as described in Chapter 2.12 and 6.2.5. The required 
volume of virus was diluted into 0.5ml complete neurobasal media and added to the 
cells via media replacement. Mixed ventral hom cultures were incubated for 5 hours at 
37°C in a 5% CO2 humidified incubator and then the media was replaced with fresh 
complete neurobasal media. Cells were left for a further 7DIV before processing.
6.2.4. Immunocytochemistry
EIAV-lacZ transfected cultures were double immunostained with primary antibodies to 
P-galactosidase (1:500, AbCam, Cambridge, UK) and the motoneuron specific marker 
choline acetyltransferase (ChAT; 1:100, Chemicon, Temecula, CA, USA), according to 
the protocol detailed in Chapter 2.8.
6.2.5. Calculation of transfection efficiency
EIAV-lacZ transfected cultures were processed for Xgal, as described in Chapter 2.12. 
Successful transfection was indicated by the formation of a blue product due to p- 
galactosidase (the lacZ gene product) mediated hydrolysis of Xgal. The number of 
motoneurons that stained blue was expressed as a percentage of the total number of 
motoneurons present. Following calculation of the transfection efficiency, in the 
remainder of the experiments, cells were transduced with VSV-G pseudotyped vectors 
using an MOI of 2.5 transducing units/cell.
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6.2.6. Protein extraction
Following transfection at 1DIV, mixed ventral horn cultures were left for a further 
7DIV before processing. SOD1G93a motoneurons transfected with either lentiviruses 
expressing shRNA targeted to mutant SOD1 or an empty vector, were lysed and the 
protein extracted, as described in Chapter 2.13. Samples were then frozen at -80°C and 
sent to Oxford Biomedica on dry ice for analysis of S0D1G93A protein levels.
6.2.7. Statistical analysis
Statistical significance was assessed using a Mann-Whitney U test (Sigma Stat, version
2.03, Erkrath, Germany). Values are expressed as the mean ± standard error of the mean 
(S.E.M). Significance was set at p < 0.05.
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6.3. RESULTS
In this Chapter, lentiviral vectors expressing shRNA targeted to human mutant SOD1 
were assessed in their ability to ablate SOD 1093A protein in mixed ventral horn cultures.
6.3.1. Assessment of transfection
Initially, it was necessary to determine the ability of EIAV lentiviral vectors to 
transduce primary motoneurons in culture. Therefore, GFP encoding EIAV vectors were 
incubated with mixed ventral horn cultures, with GFP expression indicating successful 
transfection. The photomicrograph in Figure 6.3 shows primary motoneurons 
successfully transfected with GFP-encoding EIAV vectors. In a separate set of 
experiments, cultures were transfected with lacZ-encoding EIAV vectors and double 
immunolabelling was performed to confirm that the cells transfected were motoneurons. 
Therefore, cultures were immunostained for ChAT, a marker of cholinergic neurons that 
can be used to identify motoneurons, and p-galactosidase, the lacZ gene product, which 
indicated successful transfection. Indeed, double labelling of motoneurons was 
observed, as shown in Figure 6.4.
6.3.2. Transfection efficiency
Mixed ventral horn cultures were transfected with lacZ-encoding EIAV vectors and 7 
days later were processed for Xgal, as described in Chapter 2.12. The formation of a 
blue product indicated successful transfection and the number of transfected 
motoneurons, identified by the morphological criteria listed in Chapter 2.7, were 
calculated as a percentage of the total number of motoneurons. The photomicrographs 
in Figure 6.5 show transfected motoneurons in which Xgal has been hydrolysed to a 
blue product. The percentage of transfected motoneurons at differing MOIs are shown
404
Figure 6.3 - Motoneurons successfully transfected with GFP-encoding EIAV
lentiviral vectors
The photomicrograph shows primary motoneurons in culture that have been transfected 
with GFP-encoding EIAV vectors. The expression of GFP indicates that the 
motoneurons have been successfully transfected with the lentiviral vector.
Scale bar = 20pm
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Figure 6.4 -  Double-immunolabelling of motoneurons in culture
The photomicrographs show a primary motoneuron in culture that has been stained for
(A) ChAT, a marker of ACh synthesis and therefore motoneurons, and (B) P- 
galactosidase, the lacZ gene product. The overlay between the immunostaining for 
ChAT and P-galactosidase is shown in image C. The merged image shows a complete 
overlap of ChAT and p-galactosidase immunostaining, which therefore indicates that 
motoneurons have been successfully transfected with lacZ-encoding EIAV vectors. 
Scale bar = 20pm
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Figure 6.5 -  Motoneurons transfected with lacZ-encoding EIAV vectors
The photomicrographs show motoneurons at different magnifications (using the x20 
and x40 objective lenses), successfully transfected with lacZ-encoding EIAV vectors, 
which is indicated by the formation of a blue product. It can be seen in (A) that many 
neurons in the mixed ventral horn cultures are successful transfected. Transfected 
motoneurons, with significant nuclear staining, are shown at higher magnification in
(B). The processing of mixed ventral horn cultures for Xgal staining was used to 
determine the transfection efficiency.
Scale bar = 50pm
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in Table 6.3.. However, the decision regarding the optimal MOI was based not only on 
the percentage of motoneurons that had been successfully transfected but also required 
an assessment of the viability of the motoneurons after transfection. Thus in random 
fields of neurons, the general health of motoneurons was assessed and for example, 
signs of membrane blebbing and underdeveloped neurites were taken to represent 
reduced motoneuron viability. An individual MOI was therefore deemed toxic in vitro if 
greater than 10% of motoneurons in a particular culture showed signs of reduced 
viability. Using these criteria, an MOI of 2.5, which successfully transfected 69% of 
motoneurons, was chosen for the remaining experiments. In contrast, an MOI of 5, 
which produced higher transfection efficiency, also produced signs of motoneuron 
toxicity in vitro.
6.3.3. Ablation of mutant SOD1
At 1 DIV, mixed ventral horn SOD1G93a cultures were transfected with either EIAV 
vectors-encoding siRNA targeted to mutant SOD1 or an empty vector (MOI 2.5). At 7 
days post-transfection, cells were lysed and protein was extracted. The analysis of 
protein levels was undertaken at Oxford Biomedica. Figure 6.6A gives an example of a 
typical Western blot measuring mutant SOD1 protein levels in the SOD1G93a cultures, 
and the densities are quantified in the bar chart in Figure 6.6B. Transfection with EIAV 
expressing an empty vector did not significantly lower mutant SOD1 protein levels in 
mixed ventral horn cultures (p = 0.142). In contrast, transfection with shRNA targeted 
to mutant SOD1 significantly ablated the expression of the mutant SOD1 protein (p < 
0.02). Indeed, mutant SOD1 protein levels were reduced by 70% (± 0.06 S.E.M.) 
compared to untransfected mixed ventral horn cultures.
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Table 6.3 -  Transfection efficiency of EIAV vectors in motoneurons
The Table summarises the number of motoneurons successfully transfected with lacZ- 
encoding EIAV vectors, expressed as a percentage of the total number of motoneurons 
in the cultures. To optimise the transfection procedure, varying multiplicities of 
infection (MOI) were used. An MOI of 2.5 was finally chosen for the remainder of the 
experiments due to the high transfection efficiency and a lack of side effects achieved 
using this MOI.
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Multiplicity of Infection (MOI) Percentage of motoneurons successfully 
transfected
0.25 23.6
0.5 44.0
0.75 48.8
1 60.8
2.5 69.0
5 77.8
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Figure 6.6 -  Ablation of mutant SOD1 protein by siRNA-expressing EIAV vectors
Following transfection with either siRNA targeted to mutant SOD1, or an empty vector, 
cultures were processed for protein extraction and western blot analysis. An example of 
a typical western blot is shown in A, where the levels of mutant SOD1 protein were 
measured in mixed ventral horn cultures, either untransfected, or transfected with either 
an empty vector or shRNA. p-actin protein levels were also calculated to correct for 
loading. The bar chart (B) quantifies the ablation of mutant SOD1 protein by the 
shRNA-expressing lentiviral vectors. It can be seen that transfection with a lentivirus 
expressing an empty vector did not reduce mutant SOD1 protein levels. However, 
siRNA targeted to mutant SOD1, ablated protein levels by approximately 70%. Values 
are the mean of 3 experiments ± standard error of the mean. * p < 0.05.
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6.4. DISCUSSION
The results presented in this Chapter show that primary motoneurons can be 
successfully transfected by EIAV lentiviral vectors in vitro. Furthermore, transfection 
with shRNA targeted to mutant SOD1 successfully ablates the expression of SOD 1093A 
protein in mixed ventral horn cultures.
6.4.1. Ablation of mutant SOD1 protein by siRNA
The ablation of mutant SOD1 protein has previously been shown by in vitro transfection 
of siRNA targeted to specific mutant SOD1 sequences in both a neural and a HEK cell 
line (Ding et al., 2003; Maxwell et al., 2004). However, the data presented in this 
Chapter represents part of an initial investigation into the development of EIAV vectors 
as a method of therapeutic delivery to ALS patients (Ralph et al., 2005b). Indeed, EIAV 
vectors have a high safety profile and elicit a minimal immune reaction. Furthermore, 
previous studies have shown that EIAV vectors, injected intramuscularly are 
retrogradely transported to motoneurons of the spinal cord (Mazarakis et al., 2001; 
Martin-Rendon et al., 2001; Azzouz et al., 2004). Therefore the in vitro capabilities of 
EIAV vectors-encoding shRNA targeted to mutant SOD1 have been assessed in the 
experiments in this Chapter, to ensure efficient transfection of primary motoneurons, the 
main target cells in ALS, and also to determine whether the effects induced by siRNA 
treatment are specific. These in vitro results proved to be very promising. Indeed, using 
this approach, 69% of primary motoneurons are successfully transfected and 
approximately 70% of the mutant SOD1 protein is ablated. These results indicate that 
administration of siRNA can effectively silence mutant SOD1 expression in primary 
motoneurons in vitro. The percentage of mutant SOD1 protein ablated in our mixed 
ventral horn cultures using lentiviral vectors is equivalent to that obtained in other
416
studies. Raoul et al, (2005) similarly use lentiviral vectors expressing shRNA to mutant 
SOD1, and report a 70% protein ablation in purified motoneurons.
6.4.2. Ablation of mutant SOD1 in vivo
In mutant SOD 1-mediated ALS, the mutant SOD1 enzyme acquires a toxic gain of 
function. However, it has been shown that expression of mutant SOD1 enzyme is 
necessary in both motoneurons and astrocytes for the disease to manifest. Indeed, 
transgenic mice expressing mutant SOD1 selectively in either motoneurons or 
astrocytes fail to develop motoneuron disease (Gong et al., 2000; Pramatarova et al., 
2001; Lino et al., 2002). This implies that ablation of mutant SOD1 in vivo potentially 
may have therapeutic value in mutant SOD 1-mediated ALS.
The success of siRNA-mediated ablation of mutant SOD1 in vitro has been extended in 
an in vivo study carried out by Dr Mimoun Azzouz and colleagues at Oxford 
Biomedica, to examine the ability of siRNA to silence mutant SOD1 in S0D1G93A mice 
(Ralph et al., 2005b). In this study, SOD 1093A mice receive an intramuscular injection of 
siRNA-encoding EIAV vectors into the diaphragm, intercostal, facial, tongue and 
hindlimb muscles at 7 days of age. Modification of the vectors from the in vitro study 
includes the replacement of the VSV-G envelope with a pseudotyped Rabies-G 
envelope, which allows retrograde transport of the viral vector from muscle fibres to 
motoneurons in the spinal cord. Indeed, over 50% of ventral horn motoneurons are 
transfected for more than 7 months (the duration of the study; Ralph et al., 2005b). 
Ablation of mutant SOD1 protein (40% ablation after 2 weeks) exerts significant 
neuroprotective effects in SOD1G93a mice, in which disease onset is delayed by 115% 
and survival extended by 77% (Ralph et al., 2005b). This is the greatest extension in 
lifespan observed with any therapeutic manipulation in mutant SOD1 mice to date.
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Indeed, it has actually been suggested that the death of the shRNA treated SOD 1093A 
mice may not have been a consequence of motoneuron degeneration, due to the 
significant increase in motoneuron survival at disease end-stage compared to untreated 
SOD1G93a mice (Ralph et al., 2005b). A concurrent study by Raoul et al, (2005) 
similarly demonstrates ablation of mutant SOD1 in SOD l093A mice via bilateral 
intraspinal injection of an HIV-derived lentiviral vector encoding siRNA to mutant 
SOD1. 15 days post-injection, mutant SOD1 protein levels are reduced by 52% and this 
translates to a 20% delay in disease onset, with significant neuroprotection and 
preservation of motor function. This method results in the transfection of both 
motoneurons and glial cells (Raoul et al., 2005), whereas the retrograde transfer of 
EIAV vectors only transfects motoneurons (Ralph et al., 2005b). Potentially therefore, 
modification of EIAV vectors to also infect non-neuronal cells might exert further 
beneficial effects. Intramuscular injection of SODl093A mice with AAV-expressing 
siRNA, shown in a subsequent study, similarly ablates mutant SOD1 protein in spinal 
motoneurons and preserves motor function (Miller et al., 2005).
6.4.3. Potential relevance to the clinical situation
The development of a viral vector system that can be injected intramuscularly to apply 
treatment to motoneurons in the spinal cord may be a significant advance in the 
development of therapies for ALS. Indeed, EIAV vectors pseudotyped with a Rabies-G 
envelope can specifically target motoneurons innervating the injected muscles and they 
can induce stable, efficient and long-term expression of the transgene in motoneurons 
and muscle fibres (Mitrophanous et al., 1999; Mazarakis et al., 2001; Azzouz et al., 
2004; Ralph et al., 2005b). A study by Kaspar et al, (2003) highlights the importance of 
retrograde transport of the viral vector to the motoneurons. Expression of IGF-1 in 
motoneurons and muscle fibres following intramuscular injection extends lifespan of
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SOD1G93a mice by 22%, whereas IGF-1 expression localised only to muscle fibres 
extends lifespan by only 7% (Kaspar et al., 2003). Furthermore, an intramuscular 
injection would be significantly less risky than an intraspinal injection. The ability to 
target selective neuronal populations will also reduce the risk of adverse side effects due 
to non-specific drug application (Ralph et al., 2005b). Interestingly, EIAV vectors 
encoding VEGF are currently in clinical development for the treatment of ALS (Ralph 
et al., 2005b). However, there are several hurdles to overcome before siRNA targeting 
mutant SOD1 can be used in patients. For example, over 100 mutations are known to 
exist in the SOD1 gene, therefore to provide a cost effective strategy, an siRNA targeted 
to both mutant SOD1 and endogenous SOD1 would probably be necessary to ensure 
ablation of all mutant forms of SOD1. However, the detrimental effects of ablating 
endogenous SOD1 are unknown in patients, although no phenotype is evident in mice 
(Reaume et al., 1996). Indeed, it may be necessary to incorporate a replacement 
endogenous SOD1 transgene in the same therapy (Ralph et al., 2005b).
6.5. CONCLUSION
In this Chapter, the successful transfection of primary motoneurons in vitro has been 
shown with an EIAV lentiviral vector. Furthermore, the transfection of an EIAV vector 
encoding shRNA targeted to mutant SOD1 significantly ablates the mutant S0D1G93A 
protein in mixed ventral horn cultures. This study has since been extended in an in vivo 
study, which demonstrates that ablation of the S0D1G93A protein significantly delays 
disease onset and extends the survival of S0D1G93A mice by 77% (Ralph et al., 2005b). 
Potentially, this therapy may prove to be suitable for use in ALS patients.
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CHAPTER 7
GENERAL DISCUSSION
420
7.1. Aims of this Thesis
The aim of the experiments described in this Thesis using both in vitro and in vivo 
models, was to investigate mechanisms that may play a role in the disease pathogenesis 
of ALS and to evaluate potential neuroprotective agents. Indeed, in Chapter 3, a co­
culture model of spinal cord motoneurons and astrocytes was developed to investigate 
the role of astrocytes in ALS. Confocal fluorescence microscopy was used to study the 
influence of expression of mutant SOD1 in astrocytes on the resting cellular properties 
of motoneurons. Furthermore, the effect of mutant SOD1 expression on the cellular 
response of motoneurons to excitotoxic conditions was also explored.
Currently, the only available therapy for ALS is riluzole, an anti-excitotoxic agent. 
However, riluzole extends patient lifespan by only 2-4 months, and so the development 
of alterative and more effective therapies is essential. Cannabinoids have been shown to 
exhibit anti-excitotoxic, anti-inflammatory and anti-oxidant actions, all of which are 
neuroprotective mechanisms that may have relevance to the treatment of ALS. This 
suggests that cannabinoids may exert greater benefits in ALS than therapies that target 
excitotoxicity alone. Therefore in Chapter 4, the neuroprotective effects of 
WIN55,212-2, a synthetic cannabinoid, were evaluated in the S0D1G93A mouse model 
of ALS. In Chapter 5, the endocannabinoid system was genetically augmented to 
establish whether this would have a greater impact on disease than pharmacological 
treatment. Therefore SOD1G93a mice were bred with mice in which the endogenous 
Faah enzyme, which is responsible for the hydrolysis of the endocannabinoid 
anandamide (AEA), was genetically ablated thereby increasing AEA levels. In addition, 
in an attempt to elucidate the mechanism of action of cannabinoids, S0D1G93A mice 
were also bred with mice lacking the CBi receptor in Chapter 5. The consequences of
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these pharmacological and genetic manipulations were assessed in S0D1G93A mice in 
terms of muscle function and motoneuron survival in addition to lifespan.
The potential of lentiviral vectors to deliver therapeutic agents to motoneurons was 
investigated in Chapter 6, in collaboration with colleagues from Oxford Biomedica. 
The experiments described in this Chapter were designed to test the ability of EIAV 
vectors to transfect motoneurons. Furthermore, the ability of siRNA to ablate mutant 
SOD1 protein in primary SOD 1093A motoneurons was investigated. These experiments 
formed the basis of a study undertaken at Oxford Biomedica to investigate the ability of 
these vectors to ablate mutant SOD1 expression in vivo in SOD1G93a mice. 
Furthermore, the consequences of mutant SOD1 ablation were investigated on disease 
progression and lifespan in SODlG93A mice.
7.2. Does the expression of mutant SOD1 in astrocytes influence the cellular 
properties of motoneurons?
There is increasing evidence that suggests that ALS is a non-cell autonomous disorder. 
In contrast to the ubiquitous expression of mutant SOD1, selective expression of mutant 
SOD1 in either astrocytes or motoneurons alone does not result in motoneuron 
degeneration in transgenic mice (Gong et al., 2000; Pramatarova et al., 2001; Lino et al., 
2001). Therefore, in Chapter 3 the effect of mutant SOD1 expression in astrocytes was 
investigated on both the basal cellular properties of motoneurons and their response to 
excitotoxic stimulation in an in vitro co-culture model.
Under basal conditions, the expression of mutant SOD1 protein in spinal cord astrocytes 
induced impairment of the electron transport chain in co-cultured motoneurons. This 
defect in combination with an elevation in mitochondrial calcium loading at rest,
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induced by the expression of mutant SOD1 in either motoneurons or astrocytes, 
stimulated depolarisation of mitochondria in the co-cultured motoneurons. Therefore, 
the presence of mutant SOD 1-expressing astrocytes was sufficient to significantly alter 
the cellular homeostasis of motoneurons under basal conditions.
In response to acute excitotoxic stimulation, the influence of mutant SOD 1-expressing 
astrocytes on motoneurons was less clear. Indeed, cultures expressing mutant SOD1 
protein were more vulnerable to excitotoxicity, in terms of mitochondrial depolarisation 
and superoxide generation. However, this effect was not specific to mutant SOD1 
expression in astrocytes, and the expression of mutant SOD1 protein in motoneurons 
was also sufficient to induce increased susceptibility to an acute excitotoxic insult.
These results therefore suggest that mutant SOD 1-expressing astrocytes induce 
functional deficits in mitochondria in motoneurons under basal conditions. It is possible 
that these defects increase the vulnerability of motoneurons to the progressive, 
accumulative neurotoxicity that occurs in ALS.
A
7.3. Are cannabinoids neuroprotective in the SOD1 mouse model of ALS?
Cannabinoids have been shown to exert neuroprotective effects in several in vivo and in 
vitro models, and in Chapter 4 their potential to protect motoneurons in SOD1g93A 
mice was investigated. In SOD1G93a mice, an up-regulation of endocannabinoids in the 
spinal cord occurs during disease progression and it is possible that this represents an 
endogenous cellular defence mechanism to protect neurons from damage. However, this 
was not sufficient to halt disease progression in SODlG93A mice. Therefore in order to 
boost this endogenous protective mechanism, SODlG93A mice were treated with 
WIN55,212-2, a synthetic CBi and CB2 receptor agonist, in Chapter 4.
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The results of the experiments in Chapter 4 demonstrated that treatment with 
WIN55,212-2, even after the onset of disease, prevented the decline in muscle function 
that occurs with disease progression. Moreover, this treatment improved motoneuron 
survival in SOD1G93a mice at 120 days of age, a relatively late stage of disease. 
However, despite these significant improvements observed at 120 days of age, 
WIN55,212-2 did not extend the lifespan of SOD1g93A mice. Cannabinoids are known 
to have anti-excitotoxic actions, via activation of the CBi receptor or putative ‘CB3 ’ 
receptor, anti-inflammatory actions via the CB2 receptor, as well as receptor- 
independent antioxidant actions. It is likely that the neuroprotective actions of 
WIN55,212-2 observed in the study presented in Chapter 4 are exerted through 
activation of CBi or CB2 receptors, since WIN55,212-2 does not exert antioxidant 
actions (Hampson et al., 1998).
7.4. Does enhancement of the endocannabinoid system exert neuroprotection in 
SODlG93A mice?
In the experiments described in Chapter 4, the endocannabinoid system was augmented 
by pharmacological manipulation. However, despite significant improvements in 
disease signs, WIN55,212-2 did not increase the lifespan of S0D1G93A mice. Therefore 
in Chapter 5 the endocannabinoid system was augmented by genetic ablation of the 
Faah enzyme to establish whether this would have a greater impact on disease than 
pharmacological treatment. The Faah enzyme is responsible for the hydrolysis of the 
endocannabinoid AEA. Therefore mice in which the Faah enzyme has been ablated 
have a 10-15 fold increase in AEA levels in the CNS. Therefore in Chapter 5, 
SOD 1093A mice were crossed with Faah knock-out mice and the effects of the 
consequential ablation of Faah on SOD1G93a mice was investigated at 90 days of age, an 
early symptomatic stage of disease.
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Ablation of Faah had significant beneficial effects in SOD 1093A mice. Indeed, at 90 days 
SQDX.Faah -/- mice were almost indistinguishable from WT mice in terms of muscle 
function and motoneuron survival. However, as observed following pharmacological 
enhancement of the endocannabinoid system, ablation of the Faah enzyme did not 
extend the lifespan of SOD1G93a mice.
Therefore, the results of Chapters 4 and 5 together show that enhancement of the 
endocannabinoid system has neuroprotective effects in S0D1G93A mice, and may indeed 
significantly improve the quality of life of these mice. This may therefore prove to be a 
valuable therapy in ALS patients. However, it appears that cannabinoid treatment is 
most effective at the early symptomatic stages of disease and therefore may have greater 
therapeutic effects if used in combination with agents that act on mechanisms active 
during later stages of the disease such as heat shock protein co-inducers (Kieran et al., 
2004) or glutamate inhibitors (Canton et al., 2001; Van Damme et al., 2003).
7.5. Are the neuroprotective effects of cannabinoids in SOD1G93a mice mediated 
through the CBi receptor?
The neuroprotective effects of pharmacological and genetic augmentation of the 
endocannabinoid system are likely to be mediated primarily through CBi or CB2 
receptors. To investigate this neuroprotective effect further, in Chapter 5 the effects of 
breeding SOD 1093A mice with mice in which the CBi receptor had been ablated, were 
examined. Activation of the CBi receptor can exert anti-excitotoxic actions via 
inhibition of the presynaptic release of glutamate and also by reducing postsynaptic 
calcium influx via an inhibition of voltage-gated N- and P-/Q- type calcium channels. 
Therefore, it was proposed that this mechanism would significantly contribute to the
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neuroprotective effects of cannabinoids in S0D1G93A mice, so that in SOD1.Cnrl -/- 
mice, an acceleration in disease might be predicted.
Since it was possible that disease progression would be much more rapid in these mice 
the effects of ablating the CBi receptor in S0D1G93A mice were assessed at 90 days of 
age, usually an early symptomatic stage of disease. Surprisingly, ablation of the CBi 
receptor had no significant effect on disease progression in S0D1G93A mice at this stage. 
Indeed, SOD1 .C nrl-/- mice did not differ significantly from SODlG93A mice in terms of 
muscle function or motoneuron survival at 90 days of age. Moreover, despite the lack of 
improvement in disease signs at 90 days of age, ablation of the CBi receptor 
significantly extended the survival of SODlG93A mice, increasing lifespan by 13%.
These results suggest that activation of the CBi receptor may actually exert deleterious 
effects in SODlG93A mice. Therefore, inhibition of the CBi receptor may have beneficial 
effects in this model. Furthermore, these results also suggest that the neuroprotection 
exerted by WIN55,212-2 and Faah enzyme ablation may not be mediated via activation 
of the CBi receptor and suggest a role for CB2 receptor activation in mediating the 
observed neuroprotective effects. Activation of CB2 receptors, located on microglia, is 
known to reduce microglial activation. Thus, the pharmacological targeting of the CB2 
receptor may be a valid approach to reduce inflammation. Therefore, the results of 
Chapter 5 identify the CB2 receptor as a potential therapeutic target in ALS.
7.6. Are lentiviral vectors encoding siRNA targeted to mutant SOD1 able to 
successfully ablate human mutant SOD1 protein in vitro?
In mutant SOD 1-mediated ALS, the mutant SOD1 enzyme acquires a toxic gain of 
function, therefore ablation of mutant SOD1 may have therapeutic value in ALS. To
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investigate this, a collaborative project was initiated with Dr Mimoun Azzouz and 
colleagues at Oxford Biomedica. As described in Chapter 6, the ability of EIAV 
vectors to successfully transfect motoneurons in vitro was first evaluated. Furthermore, 
EIAV vectors encoding siRNA targeted to mutant SOD1 were then tested for their 
ability to ablate mutant SOD1 in vitro.
The results described in Chapter 6 show that 69% of primary motoneurons were 
successfully transfected with EIAV vectors. Furthermore, siRNA targeted to mutant 
SOD1 successfully ablated mutant SOD1 protein, to 30% of the original levels. The 
success of these in vitro experiments subsequently initiated an in vivo study at Oxford 
Biomedica to investigate the effect of ablation of mutant SOD1 in SOD1G93a mice. This 
study showed that ablation of mutant SOD l in vivo increased motoneuron survival and 
extended the lifespan of SOD1G93a mice by 77% (Ralph et al., 2005b).
7.7. Conclusions
In summary, the results from this Thesis suggest that:
i) Mutant SOD1 expression in astrocytes has a significant influence on the 
mitochondrial function of motoneurons, suggesting that astrocytes play a 
significant role in motoneuron degeneration in ALS.
ii) Enhancement of the endocannabinoid system, either by pharmacological or 
genetic manipulation, can delay the disease-associated decline in muscle 
function and motoneuron survival, therefore potentially improving quality of 
life.
iii) Blockade of the CBi receptor, or stimulation of the CB2 receptor may have 
significant therapeutic benefit in ALS
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iv) Viral-mediated delivery of therapeutic agents may obviate the need for 
repeated treatments and minimise side effects by targeting specific neuronal 
populations. Furthermore, the ablation of mutant SOD1 using siRNA 
technology represents a novel therapy for the treatment of ALS.
These results highlight the role of non-neuronal cells in ALS pathogenesis and suggest 
that targeting of both astrocytes and microglia may be beneficial as a therapeutic 
approach in ALS.
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